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Abstract  
In this thesis I used of a range of genetic methodologies and strategies to unravel the 
genetic bases of Parkinson disease (PD), myoclonus-dystonia (M-D), and chorea. 
First, I detail the work I performed in PD, including (1) the screening of GBA in a 
cohort of early-onset PD cases, which led to the identification of the allele E326K 
(p.Glu365Lys) as the single most frequent, clinically relevant, risk variant for PD; (2) a 
detailed genetic analysis in a large cohort of PD cases who underwent deep-brain 
stimulation treatment and a longitudinal comparison of the phenotypic features of 
carriers of mutations in different genes; (3) the observation that rare GCH1 coding 
variants, known to be responsible for the childhood-onset disorder DOPA-responsive 
dystonia, are a novel risk factor for PD.  
Then, I describe the work I performed to identify novel causes of M-D, including (1) the 
discovery of the missense p.Arg145His mutation in KCTD17 as a novel cause of 
autosomal dominant M-D; (2) the identification of tyrosine hydroxylase deficiency as a 
novel treatable cause of recessive M-D; and (3) the conclusive disproof of the 
pathogenic role of the p.Arg1389His variant in CACNA1B as a cause of M-D. 
Finally, I detail my work in the field of choreic syndromes, including (1) the genetic 
screening of NKX2-1 in the Queen Square cohort of benign hereditary chorea (BHC) 
cases; (2) the identification of ADCY5 mutations, the gene thought to be responsible for 
the condition familial dyskinesias with facial myokymia, as an important cause of BHC; 
and (3) the identification of de novo mutations in PDE10A as a novel genetic cause of 
chorea. 
These findings are discussed in light of the recent literature. Following my analysis, I 
suggest future directions for the identification of novel genetic causes of movement 
disorders, in light of my recent findings and ongoing research.  
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Chapter 1. General Introduction 
1.1 Thesis Aim 
Movement disorders comprise a large group of clinically and genetically heterogeneous 
conditions, which may be subdivided into various clinical entities, including Parkinson 
disease (PD), tremor, dystonia, myoclonus and chorea. Mendelian disorders are 
disorders in which inheritance of one (dominant) or two (recessive) mutations in a 
single gene leads to the development of a disease phenotype.  
Many movement disorders, such as Huntington’s disease (HD) or spinocerebellar 
ataxias (SCAs), are transmitted as Mendelian diseases. Furthermore, a small but 
significant percentage of patients with diseases traditionally considered sporadic (e.g. 
PD or dystonia) are inherited as Mendelian traits. Despite their rarity, Mendelian 
diseases provide fertile ground for understanding a large number of essential biological 
processes that are critically involved in the pathogenesis of these complex disorders and 
represent fitting targets for the development of future treatments. 
Although, overall, monogenic causes are rare, more than 200 genes are known to cause 
either an isolated movement disorder or a syndromic form of movement disorder when 
mutated (Klein, 2014, Spatola and Wider, 2014, Gardiner et al., 2015). However, in 
total, mutations in these genes only explain a small proportion of cases, suggesting that 
mutations in more genes await discovery. 
The introduction and diffusion of ‘next generation’ sequencing (NGS) technologies, in 
particular whole-exome sequencing (WES) and micro-array based genotyping, has 
made the time and cost-effective generation of vast amounts of sequencing data 
increasingly easy, allowing an exponential increase in the understanding of the genetic 
bases of human diseases. 
In the work outlined in this thesis, I used a combination of various genetic techniques 
and strategies to try and identify novel disease-causing genes or risk factors for familial 
and sporadic forms of PD, dystonia and chorea. The results of this work represent an 
example of how genetics can both guide the clinical practice and facilitate the 
understanding of the cellular pathways implicated in the pathogenesis of these diseases, 
paving the way for the development of future treatments.  
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1.2 Summary of Relevant Techniques in Genetics 
What follows is a summary of the genetic techniques that I used for the work detailed in 
this thesis.  
1.2.1 Dideoxynucleotide Sequencing 
Dideoxynucleotide sequencing, commonly referred to as Sanger sequencing, named 
after Frederick Sanger who pioneered this technique in 1977, has been the most widely 
used sequencing method for the last three decades (Sanger et al., 1977).  
Sanger sequencing still represents the most reliable and accurate method for variant 
detection and relevant NGS results are regularly validated by Sanger sequencing for the 
exclusion of artefacts (Pittman and Hardy, 2013). 
The method relies on the principle of random inhibition of the DNA polymerase, 
creating newly synthesised DNA strands of different lengths that can be subsequently 
separated by capillary electrophoresis depending on the size. The DNA chain elongation 
is randomly inhibited by the inclusion in the reaction mix of a small quantity of 
dideoxynucleotides (ddNTPs). These differ from the normal deoxyribonucleotide 
 dNT   as they lack the hydroxyl grou  at the 2’ and 3’ carbon  ositions. This feature 
prevents the formation of a phosphodiester bond with the subsequent dNTP, stopping 
DNA from extending the chain elongation any further.   
The input DNA sample for Sanger sequencing is a population of identical molecules of 
DNA obtained by polymerase chain reaction (PCR) amplification. PCR primers are 
designed to target and amplify individually the portions of the genome of interest, such 
as the coding exons and the exon-intron boundaries. 
Each of the fragments  roduced during the sequencing reaction  ill ha e a common 5’ 
end  determined by the sequencing  rimer  but a different 3’ end  de ending on the 
insertion of the appropriate ddNTP into any one of the different positions that will 
match that base). As the different ddNTPs are combined with fluorescent dyes with 
different emission wavelengths, automated DNA sequencing machines, which use laser 
excitation during electrophoresis, are able to construct the DNA sequence from the 
intensity profiles of the four different fluorophores.   
  22 
1.2.2 Next Generation Sequencing 
In the last 5-10 years NGS technologies have completely transformed the hunt for 
Mendelian disease genes due to a dramatic reduction in cost and commensurate increase 
in the speed of DNA sequencing (Bras et al., 2012).  
NGS is applied to three main techniques: whole-genome sequencing (WGS; for 
sequencing all coding and non-coding portions of the genome), WES (for sequencing 
only the coding portions of the genome) and targeted gene sequencing (for capturing 
and sequencing of a more limited set of genes or specific genomic regions). 
Although WGS certainly represents the most comprehensive approach, so far its use has 
been limited by some important factors, including the cost and the capacity required to 
store the data. Furthermore, interpreting variants in the non-protein-coding portion of 
the genome is extremely challenging.  
Protein-coding genes, which constitute approximately 1-2% of the human genome (the 
‘exome’ , harbor the majority of disease-causing mutations. For this reason WES has 
become the most widely used NGS technique for the identification of genes underlying 
Mendelian disorders. 
Differently from Sanger sequencing, which is based on conventional capillary-based 
sequencing, NGS relies on massively parallel sequencing of DNA molecules, which are 
spatially separated in a flow cell. This enables the automated processing of millions of 
sequence reads and hundreds of gigabases of nucleotide-sequence output in parallel in a 
time and cost-effective manner. Different NGS chemistries, technologies and platforms- 
differing in specific technical details with respect to cost, accuracy, read length and 
multiplexing capability- are currently available (Metzker, 2010), but the details of this 
are beyond the scope of this chapter.  
The main technical steps of the NGS process are summarised in Figure 1-1. In brief, 
genomic DNA is first broken up into small fragments. Then, sequence adaptors, which 
are platform-specific and allow each fragment to be hybridized to the flowcell where the 
sequencing occurs, are added to both ends of each fragment. WES protocols proceed 
with the hybridization of the fragments to probes that are complimentary to all the 
known exons in the genome, which are then captured while the remaining DNA is 
washed away, leaving a pool of fragments containing exons. WGS requires no extra 
steps following the addition of adaptors and the library is ready to be sequenced at that 
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point. The raw sequencing data is subsequently analysed through a bioinformatic 
pipeline, composed of a series of software tools, which allow the production of the 
sequence reads, quality score assessment of the reads, alignment of the reads to the 
reference genome, variant calling and annotation of the called variants. 
 
 
Figure 1-1 Schematic representation of the main technical steps of NGS 
Reproduced from (Bras et al., 2012) 
  24 
One of the first steps and most important aspects for understanding and interpreting the 
results of WES is the definition of the ‘exome’.  ndeed, considerable uncertainty still 
exists regarding which portions of the human genome truly encode for proteins. Initially, 
exome-capture kits used the CCDS (Consensus Coding Sequence Project) definition 
(Pruitt et al., 2009), which is subset of genes determined to be coding with high 
confidence. Currently, most of the available commercial kits target all of the genes 
contained in Refseq (Pruitt et al., 2014) and an increasingly large number of intronic 
promoter regions, hypothetical proteins and non-coding RNAs. This aspect is 
particularly important as mutations may be missed if they are located in portions of the 
genome not targeted by the used exome-capture kit. 
1.2.3 Linkage Analysis 
As I will discuss in the next sections of this chapter, even in the age of NGS, linkage 
analysis, which enables the identification of areas of the genome where the causal 
variants are more likely to lie, remains of invaluable importance to narrow down the 
number of possible candidate variants under consideration. 
Briefly, genetic linkage analysis is a statistical method that is used to associate a 
phenotype and the chromosomal location of the causative mutation (Dawn Teare and 
Barrett, 2005). Linkage analysis relies on the principle that genes or genetic markers, 
which are located proximal to each other on a chromosome, tend to be inherited 
together during meiosis. The greater the frequency of recombination between two 
genetic markers, the further apart they are likely to be. Conversely, the lower the 
frequency of recombination of two markers, the closer they are. Therefore the position 
of a disease gene can be inferred by finding markers that tend not to recombine in all 
affected individuals.   
The markers generally assessed in linkage analysis are, on the one hand, the detectable 
phenotypes of interest, and, on the other, DNA markers evenly spread throughout the 
genome.  
In the past microsatellites, tracts of repetitive DNA in which certain DNA motifs 
(ranging in length from 2–5 base pairs) are repeated, used to be the most widely adopted 
genetic markers for linkage analysis. However, sizing of hundreds of microsatellites is a 
time-consuming and laborious process. Consequently, the use genome-wide arrays, 
which enable the simultaneous detection of thousand of single-nucleotide 
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polymorphisms in an automated way, has become the most popular way to generate 
genetic markers for linkage analysis.  
Linkage analysis may be either parametric (if the pattern of transmission of the trait of 
interest is known) or non-parametric. Parametric linkage analysis is the traditional 
approach in the study of pedigree with Mendelian diseases. 
The proportion of offspring in which two parental alleles are separated by 
recombination is the recombination fraction  θ . The recombination fraction varies from 
0 (for adjacent loci) to 0.5 (for distant loci) and may serve as a measure of the distance 
between the loci. The probability that a causative gene is linked to a genetic marker is 
assessed through the LOD score (logarithm -base 10- of odds), which is a function of θ. 
The LOD score is a value that results from comparing the likelihood of obtaining the 
data if the two loci are indeed linked, to the likelihood of observing the same data by 
chance. In order to calculate the LOD score, a model for disease must be specified, 
which includes the frequency of the disease allele and mode of inheritance (dominant 
versus recessive), marker allele frequencies, and a full marker map for each 
chromosome.   
Large positive scores are evidence for linkage, and negative scores are evidence against 
it. By convention, a LOD score greater than 3.0 (equivalent to p=0·001) is considered 
significant evidence for linkage. On the other hand, a LOD score < -2.0, indicating a 
probability against linkage of 100 to 1, is considered enough evidence to exclude 
linkage. 
A monogenic mode of inheritance established by segregation analysis and a correct 
phenotypic designation of affected and unaffected status are the two essential 
requirements for successful genetic mapping using linkage analysis. 
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1.3 Models and Strategies to Study the Genetic Architecture 
of Diseases  
Three main models are thought to describe the genetic basis of human diseases and, 
depending on the postulated underlying model, different sets of genetic tools and 
strategies are necessary to unravel the architecture of a disease (Singleton et al., 2010). 
 
Figure 1-2 Scheme illustrating the necessary methods for gene discovery depending on the 
hypothesised underlying architecture of disease. 
Image reproduced from (Singleton et al., 2010) 
 
Mendelian Disease Model 
Mendelian diseases are caused by very rare and highly penetrant variants (minor allele 
frequency [MAF] far below 1%) that often, but not always (i.e. sporadic cases with 
recessive or de novo mutations) affect multiple individuals in a family. The most 
effective way of identifying these types of mutations is based on mapping strategies (e.g. 
linkage analysis or homozygosity mapping). However, as I will discuss more in the next 
section, WES has revolutionised this field, introducing a series of potential new 
approaches.  
Common Disease-Common Variant Model 
Genetically complex diseases may be influenced by single variants or by a combination 
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of variants that are common in the general population (MAF > than 5%), but exert only 
a small role in increasing the disease risk. Genome-wide association studies (GWAS) 
have been shown to be an excellent resource for identifying these types of variants. 
Common Disease-Rare Variant Model 
Genetically complex diseases may also be caused or influenced by rare variants that 
exert a moderate effect on disease risk.  
Detection of these types of variants is notoriously difficult because they do not have a 
strong enough effect to be transmitted as Mendelian traits and therefore elude mapping 
strategies, such as linkage analysis. Furthermore, multiple variants at the same locus 
may contribute to disease risk in a cumulative way and individual variants tend not be 
frequent enough to be detected through GWAS and association strategies. For these 
reasons, rare variants with intermediate effect represent a major challenge for genetic 
studies currently and in the near future.  
Currently, there are two main approaches for the detection of these types of variants: 
1) A candidate gene approach, whereby researchers assess the role of variants in genes 
that are plausibly involved in the biology of a disease. Interestingly, most of the genes 
identified to date through this approach had initially been suspected thanks to astute 
clinical observations (e.g. GBA mutations in PD or TREM2 variants in Alzheimer 
disease) (Sidransky and Lopez, 2012, Guerreiro et al., 2013).  
(2) A hypothesis-free exome (or genome)-wide approach, based on the comparison of 
NGS data obtained from large cohorts of cases and controls. This approach requires the 
assembly of very large cohorts of cases and controls and, to date, no novel risk genes 
for movement disorders have been identified. However, this approach has recently led 
to the identification of TUBA4A and TBK1 mutations in amyotrophic lateral 
sclerosis/fronto-temporal dementia (Smith et al., 2014, Cirulli et al., 2015). 
The architecture of complex diseases, such as PD, may be composed of a combination 
of various types of causative variants, and some genes may contain multiple types of 
variants contributing to the disease risk (pleomorphic gene loci). 
For the purposes of this thesis, I have elected to focus only on the discovery of rare 
Mendelian variants and rare variants with intermediate effect. 
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1.4 Strategies for Gene Identification in Mendelian Diseases 
When attempting to identify pathogenic variants, researchers should select the correct 
technological and analytical approach based on the most likely genetic architecture of 
the disease of interest, the suspected type of variants, the frequency of the disease of 
interest, the inheritance pattern, and the penetrance of the mutations. The strategies for 
gene identification in the NGS era are schematically summarised in Figure 1-3. 
 
Figure 1-3 NGS strategies for gene identification 
Reproduced from (Olgiati et al., 2016). 
 
The identification of mutations causing Mendelian diseases has traditionally relied on 
the use of mapping strategies (e.g. linkage analysis or homozygosity mapping), 
followed by gene identification through positional cloning or candidate gene approach 
(i.e. prioritising genes for Sanger sequencing within the mapped genomic region, based 
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on the biological plausibility or possible relevance to the disease of interest).  
While in theory the power of NGS would not be absolutely necessary for this approach, 
NGS has made gene discovery tremendously easier when used in combination with 
traditional mapping strategies. When informative families with several affected 
individuals from the same family are available, the disease locus can be narrowed down 
significantly and then NGS can be used to interrogate all the coding exons and splicing 
regions of the genes contained within the locus for the presence of the causative 
mutations. 
For dominant traits, linkage analysis (discussed in detail in section 1.2.3) represents the 
gold standard for genetic mapping (Figure 1-3A). However, families that are genetically 
informative enough for linkage analysis are exceedingly rare. Thus, application of this 
approach for gene discovery is becoming harder by the day, as there are not many 
families left which may be suitable for this analysis.  
For the study of recessive disorders where a homozygous variant is suspected (e.g. 
study of consanguineous families), NGS can be complemented by the use of 
homozygosity mapping (Figure 1-3B), which relies on the identification of regions that 
are identical by descent in affected individuals only (Alkuraya, 2013).  
As discussed previously, NGS can be also used to rapidly screen candidate disease-
causing or predisposing genes, selected based on their biological plausibility or on 
grounds of clinical observations hinting towards a possible genetic association (Figure 
1-3C). 
As discussed in more detail in the next chapter, applications of these traditional 
strategies in combination with NGS has been already successfully used in multiple 
occasions for the discovery of novel genes causing movement disorders. 
Besides facilitating traditional mapping strategies, NGS has also offered the opportunity 
to identify novel disease-causing gene mutations in ways that simply were not possible 
before the advent of NGS (Olgiati et al., 2016). 
For the study of dominant families that are too small for the application of linkage 
analysis, one novel approach is sequencing the exomes (or genomes) of several distant 
affected individuals belonging to the same family (Figure 1-3D) and look for shared 
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variants after applying filtering criteria to prioritise the likely pathogenic variants (see 
next section for details of prioritisation strategies). Depending on the number of family 
members available for sequencing and their distance in the pedigree, this approach can 
result in the identification of relatively small lists of candidate variants that can be then 
used for replication studies in additional families or cohorts of similarly affected 
subjects.  
For the study of recessive families where homozygosity mapping is not applicable (e.g. 
non-consanguineous pedigrees), the double hit strategy (Figure 1-3E) may be applied to 
look for compound heterozygous mutations. Here, the exomes of siblings affected by 
the same condition are interrogated for the presence of at least two separate, likely 
pathogenic, mutations in the same gene. With this strategy, when the number of affected 
individuals is small (i.e. only two affected siblings), it is useful to sequence also the 
DNA of the healthy parents, as this makes it possible to exclude genes carrying multiple 
mutations inherited from the same parent (and therefore located on the same allele), a 
mode of inheritance not compatible with a recessive disease. 
Another important novel approach is the study of family trios by NGS, looking for the 
presence of de novo mutations (Figure 1-3F). These are mutations present in the DNA 
of the affected subject, but not in the DNA of the parents. This type of approach is 
generally used for individuals without a family history with severe neurological 
phenotypes that reduce the fitness to procreate. To date, this approach has been 
incredibly successful for the study of autism-spectrum disorders, schizophrenia and 
intellectual disability (Rauch et al., 2012, Xu et al., 2012, Gulsuner et al., 2013, 
Genome of the Netherlands Consortium, 2014, Iossifov et al., 2014). 
Finally, NGS can also be used to study a cohort of unrelated patients, looking for the 
presence of causative mutations in the same gene (Figure 1-3G). This strategy is more 
likely to be effective for identifying the disease-causing gene when the disease of 
interest is rare and highly specific (e.g. presence of radiological hallmarks), as this 
would significantly reduce the possibility of genetic heterogeneity (i.e. multiple genes 
responsible for the same phenotype). This approach has been proven to be successful 
even with relatively small cohort of carefully characterised patients (Haack et al., 2012, 
Simons et al., 2013). 
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1.5 Identifying Causal Alleles: How to Prioritise Variants? 
The key challenge in NGS is the interpretation of the large number of variants that are 
routinely detected. An a erage ‘exome’  ould re eal the  resence of ~24,000 coding 
and splice-site variants in individuals of African origin and ~20,000 variants in 
individuals of European origin (Bamshad et al., 2011). Of these, on average, ~ 98% are 
known benign polymorphisms, and about ~50-60% are synonymous variants, meaning 
that they not lead to an amino acid change. However, hundreds of novel non-
synonymous variants are found in the exome of each individual. Among these, only one 
(in case of dominant disease) or two (in recessive diseases) variants will be causative in 
most families with a Mendelian disease. Therefore, the crucial and more challenging 
step in the search of THE disease-causing mutation is recognising and differentiating 
the true disease-related alleles among the myriad of benign common and rare/novel 
variants and sequencing artefacts.  
I will describe in the next section the strategies that are commonly used to filter and 
reduce the number of possible pathogenic variants, schematically summarised in Figure 
1-4. 
 
Figure 1-4 Prioritization of NGS candidate variants.  
Image reproduced from (Olgiati et al., 2016) 
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1.5.1 Filtering Based on the Inheritance Mode and Pedigree 
Information 
In the case of Mendelian disorders, a correct understanding of the mode of inheritance 
can effectively reduce the search space for candidate pathogenic changes. As previously 
explained, the pattern of inheritance of a monogenic disorder will greatly influence both 
the experimental design (e.g. the number of cases to sequence and the most informative 
cases to select for sequencing) and the analytical approach.  
Generally, family studies will examine variants that are shared between multiple 
affected relatives and consequently, it is preferable to select for sequencing subjects that 
are as distantly related as possible, as they will share a smaller number of genes. Where 
a dominant mode of inheritance is suspected, only shared heterozygous variants are 
considered, unless there is the suspicion that recessive mutations are transmitted in a 
pseudo-dominant way due to multiple loops of consanguinity in the pedigree. When a 
recessive inheritance is suspected, homozygous or compound heterozygous variants 
should be considered. Recessive inheritance or de novo dominant mutations should be 
suspected in sporadic cases. However, an increasing number of reports indicate that de 
novo mutations can also be inherited by multiple individuals in the same family due to 
germinal mosaicism in one of the unaffected parents, leading to pseudo-recessive 
presentations (Kancheva et al., 2015). 
Segregation of candidate variants, usually by Sanger sequencing, in other affected 
family members can further refine the list of variants. Unaffected individuals can be 
also of great help in reducing the number of candidate variants, as variants carried by 
these subjects are less likely to be responsible for the phenotype. However, two caveats 
should be kept in mind when using unaffected subjects to filter out variants: (i) 
pathogenic variants may be associated with incomplete penetrance (meaning that 
carriers of the variants may not manifest the disease); (ii) carriers of pathogenic variants 
may be too young at the time of the genetic study to firmly exclude that they will not 
develop the disease.   
Importantly, segregation analysis alone in a single family cannot definitively implicate a 
variant as disease-causing, as there is the possibility that a separate, unobserved 
pathogenic mutation may lie on the same haplotype as the candidate variant.  
Finally, it is important to mention that phenocopies, cases with the familial phenotype or 
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closely mimicking it but not carrying the causative variant, may be present in pedigree, 
greatly complicating the correct interpretation of the pedigree structure. 
In summary, a substantial number of benign variants can be excluded from the list of 
disease-causing candidates using as filters the pedigree structure and the assumed mode 
of inheritance of the disease.  
1.5.2 Filtering Based on Rarity  
Filtering the list of variants against a variety of publicly available datasets, which 
contain NGS data from thousands of individuals originating from different human 
populations, is essential to removing common benign variations and narrowing the 
fraction of candidate variants down to a workable number.  
The list of the most widely used datasets of genetic variations includes the Exome 
Aggregation Consortium (ExAC; http://exac.broadinstitute.org/), dbSNP version 129 
and 137 (www.ncbi.nlm.nih.gov/projects/SNP), 1000 Genomes project (1kGP; 
www.1000genomes.org), NHLBI Exome Variant Server (EVS; evs.gs.washington.edu) 
and Complete Genomics 69 (www.completegenomics.com/public-data/69-Genomes). 
Furthermore, variants should also be filtered against data from large cohorts of 
individuals sequenced in-house. This step is particularly important for excluding 
sequencing artifacts and false positive calls, which tend to be specific for the 
sequencing chemistry and the pipeline used in the analysis of the NGS data. 
The population frequency of a variant is particularly important as it would be expected 
that Mendelian disease causing alleles are extremely rare, if not absent, in the general 
population. For dominant disorders, it is sensible to consider only novel or extremely 
rare variants. Alleles causative for recessive diseases are usually present in the 
population at MAF of < 0.01. However, it is essential to remember that these are largely 
arbitrary cut-offs. The frequency filter should be set depending on the frequency of the 
disease of interest in the general population, the clinical presentation (i.e. early 
onset/aggressive versus late onset/indolent phenotype), and the expected penetrance of 
the putatively disease-causing variants.  
There are other two important issues that should be considered during this crucial step. 
First, the frequency of both benign and pathogenic variants can vary substantially 
among different ethnicities and certain variants are found exclusively in certain specific 
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populations. This means that variants that are completely absent in one population could 
be much more frequent in another. Therefore, it is essential to filter the WES results 
against data derived from ethnicity-matched populations. 
Secondly, it is important to consider that well-established pathogenic mutations (e.g. the 
LRRK2 mutations p.Gly2019Ser causing autosomal dominant PD) may be present in 
population variant databases, although at low frequencies. Being too strict with filtering 
based on MAF may therefore sometimes result in the exclusion of pathogenic alleles 
from the analysis. This is particularly true for diseases such as PD, which tend to 
manifest later in life and thus non-manifesting carriers of pathogenic alleles may be 
present in large control populations.  
1.5.3 Filtering Based on Deleteriousness and Conservation 
Further stratification of variants can be undertaken based on predictions of their 
deleteriousness. Synonymous variants are generally excluded from the analysis, as it is 
expected that causative alleles for Mendelian diseases will be missense, nonsense, 
frameshift or splice site variants. Importantly, although in rare instances, synonymous 
variants can potentially affect splice sites and therefore result in loss-of-function alleles 
(Korvatska et al., 2013). In addition, variants located in deep intronic and in other non-
coding genomic regions are generally removed from the list of candidates under the 
assumption that disease causing-mutations would affect the coding region of the 
genome. However, one should be aware that this assumption is based on the fact that, as 
a matter of feasibility, in the Sanger sequencing era only the coding portion of the genes 
were screened. It is hence plausible that a significant proportion of the missing 
variability responsible for Mendelian diseases is located in the intronic region. 
Greater importance may be given to loss-of-function variants (i.e. frameshift, stop 
codons and variants disrupting canonical splice sites), than to missense variants. 
Additional strategies can be used to further prioritize the remaining candidate variants, 
especially if they are missense. A powerful approach uses the quantitative estimates of 
mammalian evolution at the nucleotide level. This approach relies on the principle that 
deleterious mutations generally present high sequence conservation as a result of 
purifying selection. Therefore, highly conserved nucleotides and amino acids are likely 
to be very relevant for the function of the gene and the encoded protein. Examples of 
tools used in this thesis for assessment and quantification of evolutionary conservation 
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are PhiloP (Pollard et al., 2010) and GERP++ (Davydov et al., 2010). 
The predicted deleteriousness of amino acid substitutions can also be assessed using in 
silico tools such as SIFT (http://sift.jcvi.org/) (Kumar et al., 2009), PolyPhen2 
(http://genetics.bwh.harvard.edu/pph2/) (Adzhubei et al., 2010), Provean 
(http://provean.jcvi.org/) (Choi et al., 2012), MutationTaster 
(http://www.mutationtaster.org/) (Schwarz et al., 2014) and CADD 
(http://cadd.gs.washington.edu/home) (Kircher et al., 2014).  
Some of these tools (e.g. SIFT or Provean) rely on specific biological aspects of 
deleterious mutations (often conservation) to classify variants in discrete classes of 
pathogenicity (first-principles approaches). Another group (e.g. Polyphen-2 or 
MutationTaster) consists of classifiers that are trained to distinguish between a set of 
known deleterious mutations against a set of benign polymorphisms (trained classifiers). 
Importantly, these methods are particularly useful when assessing the pathogenicity of 
putatively loss-of-function variants, either causing recessive diseases or causing 
dominant diseases through haplo-insufficiency or dominant negative effects. However, 
the in silico tools are less reliable for the assessment of dominant variants that are 
pathogenic through a gain-of-function mechanism. 
1.6 Limitations of Next-Generation Sequencing 
Despite many successful reports of disease-associated novel genes identified by WES, it 
is not precisely known how often this approach fails, as negative results are not reported 
most of the times. The experience in our department teaches that failure in the analysis 
of kindreds with suspected Mendelian diseases is unfortunately not uncommon.  
NGS bears a number of important limitations, which have to be kept in mind when the 
causative variant is not identified.  
1. Current NGS technologies easily detect single nucleotide variants or small deletions 
are, but there remain significant issues with the identification of large deletions and 
copy number variants (CNVs). 
2. The currently used short read libraries (~250bp) lead to particular problems with the 
detection of repeat expansions, which not uncommonly are the responsible cause for 
neurodegenerative diseases, such as the dominant SCAs or HD.  
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3. Variable coverage of the targeted regions, as mutations may be missed if they are 
located in poorly covered areas.  
4. The causative gene is not in the exome capture kit target definition (for instance, it is 
not a known gene, or there is a failure in the design) 
Finally, even once a single or few promising candidate variant are found in a given 
pedigree, the significant genetic heterogeneity that exists for many inherited 
neurological conditions, can hamper the confirmation of the finding, which generally 
relies on the identification of other mutations in the same gene in unrelated pedigrees. 
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Chapter 2. Overview on Genetics of Selected 
Movement Disorders 
2.1 The Genetics of Parkinson disease 
2.1.1 Introduction  
PD is the second most common neurodegenerative disease after Alzheimer disease, 
affecting >2% of those over 75 years (Mayeux et al., 1995).  
The main clinical features of PD and clinical diagnostic criteria include bradykinesia 
and at least one other sign amongst muscular rigidity, rest tremor, or postural instability 
(Figure 2-1). A progressive course, unilateral presentation with asymmetrical signs, a 
classic pill rolling tremor, good sustained response to levodopa (L-DOPA) and a number 
of non-motor symptoms accompanying or preceding the motor onset (eg. hyposmia, 
constipation, genito-urinary symptoms, REM-behavioural sleep disorders) generally 
support the diagnosis (Lees et al., 2009, Noyce et al., 2016).  
 
Figure 2-1 Typical appearance of a patient with Parkinson disease. 
Reproduced from (Lees et al., 2009) 
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The pathological signature of PD is a selective loss of pigmented dopaminergic neurons 
from the pars compacta of the substantia nigra (Figure 2-2A). Nigral neuron 
degeneration and consequent decrease in dopaminergic striatal innervation result in 
classic PD motor symptoms. This nerve cell loss is accompanied by three distinctive 
intraneuronal inclusions: Lewy bodies (LBs; Figure 2-2B), the pale body, and the Lewy 
neurite.  
α-synuclein  α-syn) is the main component of LBs (Spillantini et al., 1997). According 
to the model  ro osed by Braak and colleagues, α-syn pathology may spread ascending 
from the dorsal motor nucleus of the vagus and involving progressively, the lower 
brainstem, the olfactory bulb, the midbrain and finally the cortex (Braak et al., 2003). 
 
Figure 2-2 Pathological features of Parkinson disease 
(A) Cross section of the midbrain showing the pigmented substantia nigra in a normal brain (bottom) and 
depigmented nigra in a brain with PD (upper). (B) Microscopic section of a substantia nigra pigmented 
neuron containing neuromelanin (white arrow) and a Lewy body (black arrow) within the cytoplasm of 
the neuron. The Lewy body has a dense core and a lighter halo. 
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The aetiology of PD is poorly understood and, similarly to other neurodegenerative 
conditions, age is the major risk factor. However, 10% of people with the disease are 
younger than 45 years of age (early-onset PD). 
PD was long thought to be a sporadic disorder without genetic causation with most of 
the research interest focused on the identification of environmental risk factors 
(reviewed in (Noyce et al., 2012). 
Several studies estimating the genetic contribution to PD pathogenesis using twins have 
shown low concordance rates in monozygotic and dizygotic twins (Duvoisin et al., 1981, 
Ward et al., 1983, Marttila et al., 1988). However, in studies based on PET scan data, 
rather than simple cross-sectional observance of the phenotype, the concordance rate 
was significantly higher for monozygotic twins, than for dizygotic twins (55% versus 
18%), suggesting a substantial genetic contribution to the PD pathogenesis (Piccini et 
al., 1999). It is estimated that approximately 5-10% of people with PD have a positive 
family history in a first degree-relative. 
Over the last 25 years, since the identification of the a-synuclein (SNCA) locus, the 
views on the aetiology of PD have profoundly changed. Mutations in a growing list of 
genes have been incontrovertibly linked to monogenic forms of PD (recently reviewed 
in (Hernandez et al., 2016). Furthermore, genome-wide-association studies (GWAS) 
have succeeded in identifying many common, low risk variants that are likely to play a 
direct role in the aetiology of the common sporadic disease as well (Nalls et al., 2014). 
In addition, rare variants with intermediate-effect have been identified as important risk 
factors (e.g. GBA). A schematic overview of the frequency and penetrance of the genes 
linked to PD is shown in Figure 2-3. 
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Figure 2-3. Schematic representation of the frequency and penetrance of the Parkinson disease 
genes 
*Pleiotropic loci. Figure adapted from (Verstraeten et al., 2015) 
2.1.2 Monogenic Causes of Parkinson Disease 
The genes associated with monogenic forms of PD are listed in Table 2-1.  
Mendelian forms of PD are overall rare and generally have an earlier disease 
manifestation than sporadic PD. Mutations in genes identified as causing Mendelian 
forms of PD explain 30% of familial PD and only 3%-5% of patients with sporadic 
disease occurrences (Kumar et al., 2011). In the next section I will describe the main 
clinical and biological features of the most relevant Mendelian genes that have been 
shown to cause PD. 
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Table 2-1 Monogenic causes of Parkinson disease 
Locus Gene Features Inheritance Mutational spectrum Pathology 
PARK1/PARK4 SNCA Early and late-onset, fast progression, severe dementia, AD 
Missense and gene 
dosage 
Synucleinopathy 
PARK2 Parkin Juvenile- or young-onset parkinsonism, slow progression AR 
Missense, truncating and 
gene dosage 
Synucleinopathy 
(occasionally) 
PARK6 PINK1 Early-onset parkinsonism, slow progression AR 
Missense, truncating and 
gene dosage 
Synucleinopathy 
(occasionally) 
PARK7 DJ-1 
Early-onset parkinsonism, psychiatric features, 
slow progression 
AR 
Missense, truncating and 
gene dosage 
Synucleinopathy 
PARK8 LRRK2 Late onset parkinsonism, slow progression AD Missense 
Synucleinopathy, 
tauopathy 
PARK9 ATP13A2 Juvenile and early onset, atypical, fast progression AR Missense, truncating Not known 
PARK14 PLA2G6 Juvenile and early onset, atypical, fast progression AR Missense, truncating Synucleinopathy 
PARK15 FBX07 Juvenile and early onset, atypical, fast progression AR Missense, truncating Not known 
PARK17 VPS35 Late onset parkinsonism, slow progression AD Missense Not known 
PARK17 DNAJC6 Juvenile and early onset, atypical, fast progression AR Missense, truncating  Not known 
PARK20 SYNJ1 Juvenile and early onset, atypical, fast progression AR Missense, truncating  Tauopathy 
NA DNAJC13 Late-onset, typical, slow progression AD Missense  Synucleinopathy 
NA RAB39B Early onset, intellectual disability X-linked 
Missense, truncating and 
gene dosage 
Synucleinopathy 
NA CHCHD2 Late onset parkinsonism, slow progression AD Missense Synucleinopathy? 
NA VPS13C Early onset, fast progression AR Truncating Synucleinopathy 
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Autosomal Dominant Parkinson Disease 
SNCA (PARK1, PARK4) 
The identification in 1997 of the p.Ala53Thr missense mutation in SNCA as a cause of 
autosomal dominant PD in families of Greek and Southern Italian origin was the first 
proof for a genetic aetiology in a subset of PD cases (Polymeropoulos et al., 1997). 
Furthermore soon after the identification of SNCA mutations in familial PD cases it was 
disco ered that α-Syn is the major component of LBs, the pathological hallmark of PD, 
therefore linking familial to sporadic PD (Spillantini et al., 1997).  
Subsequently, whole-locus duplication and triplication of SNCA were identified, 
pro ing that not only structurally altered α-synuclein, but also simple overexpression of 
the wild-type protein is pathogenic (Singleton et al., 2003, Kara et al., 2014). The 
p.Ala30Pro and p.Glu46Lys mutations have been detected in a single family of German 
and Spanish ancestry, respectively (Kruger et al., 1998, Zarranz et al., 2004). Only 
recently, three additional SNCA point mutations (p.His50Gln, p.Gly51Asp and 
Ala53Glu) have been discovered (Kiely et al., 2013, Proukakis et al., 2013, Pasanen et 
al., 2014).  
The missense mutations are pathogenic through a toxic gain of function, whereby they 
increase the tendency of α-Syn to form β-pleated sheets, which, in turn, are thought to 
 redis ose α-Syn to form the aggregates that are localised in LBs (Devine et al., 2011).  
Patients with SNCA missense mutations usually have EOPD with initial good response 
to L-DOPA. The disease tends to be aggressive, with dementia often complicating early 
on the clinical picture.  
  dose relationshi  bet een α-Syn levels and severity of the clinical phenotype is 
observed. In SNCA multiplications families, duplications (three copies of SNCA) are not 
fully penetrant and lead to late-onset dopa-responsive PD, as seen in typical sporadic 
PD (Ibanez et al., 2009); triplications (four copies of SNCA) are conversely fully-
penetrant and cause a much more aggressive phenotype with earlier onset and severe 
rapidly progression, almost inevitably complicated by early dementia and additional 
features such as dysautonomia (Farrer et al., 2004, Fuchs et al., 2007).  
Brain pathology in patients with SNCA mutations is characterized by abundant α-Syn-
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positive neuronal inclusions.  
LRRK2 Mutations (PARK8) 
The PARK8 locus was first mapped on chromosome 12p11.23-q13.11 in a large 
Japanese family with autosomal dominant PD (Funayama et al., 2002). A few years 
later two independent groups identified the causative mutations underlying the PARK8 
locus in the LRRK2 gene (Paisan-Ruiz et al., 2004, Zimprich et al., 2004).  
Mutations in LRRK2 have been since then recognized as the most common Mendelian 
cause of PD. A large number of variants have then been described in PD cases. However, 
based on segregation with disease in families and frequency in population controls, only 
few of these variants are firmly considered pathogenic: p.Arg1441Gly, p.Arg1441Cys, 
p.Arg1441His, p.Tyr1699Cys, p.Gly2019Ser and p.Ile2020Thr (Di Fonzo et al., 2005, 
Gilks et al., 2005, Zabetian et al., 2005).  
The most frequent mutation is by far the c.6055G>A; p.Gly2019Ser which is found in 
up to 40% of cases of PD in North African populations (Lesage et al., 2006), in about 
20% of Ashkenazi Jewish patients (Ozelius et al., 2006) and 1-7% of PD patients of 
European origin (Di Fonzo et al., 2005, Clark et al., 2006, Zabetian et al., 2006).  
The p.Arg1441Cys is the second most common mutation and has been identified 
worldwide (Nuytemans et al., 2008). Conversely the p.Arg1441Gly and the 
p.Ile2020Thr are very rare and population-specific, being the first mainly found in the 
Basques (Simon-Sanchez et al., 2006) and the second in the Japanese population 
(Tomiyama et al., 2006).  
The penetrance of the LRRK2 p.Gly2019Ser mutation has been established to be ~28% 
in subjects younger than 60 years of age, but increases up to 74% at 79 years of age 
(Healy et al., 2008). Of note, there has been a recent report of two monozygotic twins in 
their 70s with the p.Gly2019Ser but discordant for the presence of PD, suggesting that 
the variability in onset and penetrance between LRRK2, maybe largely non-genetic in 
origin (e.g. stochastic; environmental) (Xiromerisiou et al., 2012). Furthermore, a recent 
report suggested that the penetrance in the Ashkenazi Jewish population could be as low 
as 25% by the age of 80, a figure much lower than in other ethnic background, 
suggesting the existence of genetic or environmental factors which affect the penetrance 
of the p.Gly2019Ser mutation in this population (Marder et al., 2015). 
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The majority of patients with LRRK2 mutations presents with late-onset asymmetric L-
DOPA responsive tremor-predominant PD, clinically indistinguishable from PD (Healy 
et al., 2008). Neuropathological findings showed pleiomorphic pathologies overlapping 
with other neurodegenerative diseases, including LBs, tau- and ubiquitin-containing 
inclusions and pure nigral degeneration without LBs (Zimprich et al., 2004, Giasson et 
al., 2006). 
LRRK2 is a large gene that consists of 51 exons and encodes the 2527-amino acid 
protein leucine-rich repeat kinase 2. The physiological and pathological functions of 
LRRK2 have not yet been fully characterized. Several pathogenic LRRK2 mutations 
cluster in functionally important domains and impair their function: p.Arg1441Cys, 
p.Arg1441Gly, and p.Arg1441His reduce protein GTPase activity, whereas the 
p.Gly2019Ser and p.Ile2020Thr mutations in the kinase domain have been shown to 
increase its activity (Simon-Sanchez et al., 2006). 
VPS35 (PARK17)  
A single missense mutation in VPS35, p.Asp620Asn, has been identified by two groups 
through WES as an important cause of autosomal-dominant PD (Vilarino-Guell et al., 
2011, Zimprich et al., 2011). Several other studies in which the sequencing of the entire 
VPS35 coding region was performed has disclosed a handful of other missense 
mutations (p.Gly51Ser, p.Met57Ile, p.Thr82Arg, p.Ile241Met, p.Pro316Ser, 
p.Arg524Trp, and p.Leu774Met). However, none of these additional mutations have 
been proven to be pathogenically relevant (Lesage et al., 2012, Sharma et al., 2012, 
Nuytemans et al., 2013). Overall, VPS35 the p.Asp620Asn mutation is a rare cause of 
PD accounting for only about 1% of familial parkinsonism and 0.2% of sporadic PD. 
VPS35 encodes a highly-conserved component of the retromer, a complex that mediates 
reterograde transport of transmembrane cargo from endosomes back to the trans-Golgi 
network (Seaman, 2005, Bonifacino and Rojas, 2006). Clinically VPS35-related PD 
appears to be similar to idiopathic PD (Sheerin et al., 2012). 
DNAJC13 
WES and linkage analysis identified the missense mutation p.Asn855Ser in DNAJC13 
in a Saskatchewan autosomal-dominant family affected by multi-generational PD with 
evidence LB pathology. Subsequent genotyping in 2928 patients and 2676 control 
subjects from Canada, Norway, Taiwan, Tunisia, and the USA identified four additional 
   45 
patients carrying the same mutation, of which two had familial parkinsonism, but none 
in controls (Vilarino-Guell et al., 2014). DNAJC13 regulates the dynamics of clathrin 
coats on early endosomes. Cellular analysis shows that the mutation confers a toxic 
gain-of-function and impairs endosomal transport. Subsequent studies have shown that 
the DNAJC13 p.Asn855Ser substitution is not a common cause of PD among Caucasian 
populations (Gustavsson et al., 2015, Lorenzo-Betancor et al., 2015). 
CHCHD2 
Funayama and colleagues used linkage analysis and WES to successfully identify in a 
Japanese dominant PD family a missense variant in the CHCHD2 gene, encoding the 
mitochondrial protein coiled-coil-helix-coiled-coil-helix domain-containing 2 
(Funayama et al., 2015). Screening of a further 340 index patients with autosomal 
dominant PD identified three additional pathogenic missense and splice-site mutations, 
p.Thr61Ile, p.Arg145Gln, and c.300+5G>A. Subsequently, other independent groups 
have confirmed that coding mutations in CHCHD2 represent a rare genetic cause of 
autosomal dominant PD and may also represent a risk factor for sporadic PD and other 
synucleinopathies (Jansen et al., 2015, Ogaki et al., 2015, Koschmidder et al., 2016, Shi 
et al., 2016, Zhang et al., 2016). 
Autosomal Recessive Parkinson Disease 
PARK2 
Mutations in PARK2, firstly identified by positional cloning in Japanese families 
(Matsumine et al., 1997, Kitada et al., 1998), are the most common cause of autosomal 
recessive, EOPD. PARK2 mutations are detected in up to ~50% of cases with recessive 
familial EOPD (Lucking et al., 2000), as well as ~10% of sporadic cases with onset 
before the age of 45 (Klein and Lohmann-Hedrich, 2007). A range of loss-of-function 
variants are detected, including missense, truncating mutations and whole-exon 
deletions or duplications, most commonly in the compound heterozygous state.  
Whether heterozygous mutations in PARK2 represent a risk factor for PD is still a matter 
of debate (Klein et al., 2007) and circumstantial evidence suggests that copy-number 
variants may increase the disease risk (Huttenlocher et al., 2015), but not point 
mutations (Kay et al., 2007, Kay et al., 2010).  
PARK2-related disease usually shows a slowly progressive course with a dramatic 
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response to dopaminergic treatment. No specific features differentiate PARK2 mutation 
carriers from other EOPD forms; however, symmetrical onset, dystonia at onset, 
hyperreflexia, slower progression of the disease, a tendency toward a better response 
to L-DOPA, and preservation of olfaction might be more frequent among patients 
with PARK2 mutations (Khan et al., 2003, Alcalay et al., 2011). 
Post-mortem examination of PARK2-mutated cases shows a more restricted distribution 
of the pathology than in classic sporadic PD, with severe but selective ventral nigral 
degeneration and absent or scarce LB pathology (Doherty et al., 2013).  
PARK2 encodes parkin, a protein that functions as an E3 ubiquitin ligase in the process 
of ubiquitination, a form of post-translational modification that conjugates ubiquitin 
proteins to lysine residues of target proteins, in order to address them towards 
proteosomal degradation. Most PARK2 mutations lead to loss of its E3 ligase function. 
Disturbed elimination of damaged mitochondria, which is an important cellular process 
called mitophagy, appears to be one of the most important mechanisms for neuronal 
death in parkin deficiency (Deas et al., 2011).  
PINK1 (PARK6) 
Mutations in phosphatase and tensin homolog-induced putative kinase 1 (PINK1) are 
the second-most common cause of autosomal recessive EOPD, accounting for ~1% to 8% 
of recessive familial EOPD and ~1% of sporadic EOPD cases (Healy et al., 2004, 
Rogaeva et al., 2004, Valente et al., 2004, Bonifati et al., 2005). Mutations are found 
across different populations and one mutation with a founder effect is particularly 
frequent in the Philippines (Bonifati et al., 2005). 
PINK1 is a 581 amino acid ubiquitously expressed protein kinase. It consists of an 
amino-terminal mitochondrial targeting motif, a conserved serine-theonine kinase 
domain, and a carboxy-terminal autoregulatory domain. Two-thirds of the reported 
pathogenic mutations determine a loss-of-function of the PINK1 kinase domain, 
supporting the relevance of PINK1 enzymatic activity in the pathogenesis of PD. More 
than 90% of the reported mutations in PINK1 are missense mutations, whereas the 
remaining are copy number mutations or truncating mutations. Similarly to PARKIN, the 
role of heterozygous PINK1 mutations is debated (Abou-Sleiman et al., 2006). 
Clinically, PINK1 mutation carriers present with early-onset, slowly progressive L-
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DOPA-responsive parkinsonism, initial gait impairment and often psychiatric symptoms, 
such as depression and anxiety. Cognitive involvement is rare. Differently from PARK2 
mutated cases, olfactory dysfunction is common in PINK1 (Ferraris et al., 2009). 
The first post-mortem analysis in a case with PINK1-linked PD showed neuronal loss in 
the substantia nigra and the presence of LBs (Samaranch et al., 2010). However, a more 
recent report showed absence of LB pathology (Takanashi et al., 2016). 
PINK1 and Parkin function in a common pathway for detecting mitochondrial damage 
and selectively eliminating corrupted mitochondria. PINK1 is stabilized on 
mitochondria with lower membrane potential and recruits Parkin from the cytosol. Once 
recruited to mitochondria, Parkin becomes enzymatically active and initiates the 
autophagic clearance of mitochondria by lysosomes (i.e., mitophagy) (Youle and 
Narendra, 2011).  
DJ-1 (PARK7) 
Bonifati and colleagues identified mutations in DJ-1 as an additional cause of EOPD 
(Bonifati et al., 2003). DJ-1 mutations are more rare than PARK2 and PINK1, being 
found in only ~1% of EOPD cases (Abou-Sleiman et al., 2003, Pankratz et al., 2006). 
The clinical phenotype is similar to that of PARK2- and PINK1-related EOPD (Abou-
Sleiman et al., 2003). Dementia and features of motorneuron disease have been 
described in individual cases with bi-allelic DJ-1 mutations (Annesi et al., 2005, 
Hanagasi et al., 2016). 
DJ-1 encodes for a protein working as a cellular sensor of oxidative stress (Canet-Aviles 
et al., 2004, Junn et al., 2005). Recently, the first neuropathological assessment of a DJ-
1 mutated case has been reported, indicating that DJ-1 mutations are associated  ith α-
syn aggregation and deposition (Taipa et al., 2016). 
RAB39B 
Genetic analysis of an Australian and of an American family with a combination of 
EOPD and intellectual disability with an X-linked pattern of inheritance identified a 
large deletion and a missense mutation (p.Thr168Lys) in the RAB39B gene (Wilson et 
al., 2014). All affected cases initially presented in childhood with various degrees of 
intellectual disability, including developmental delay, cognitive impairment, 
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macroencephaly, and, seizures. EOPD appeared later on, with tremor as the first 
symptom. Post-mortem studies show that RAB39B mutations causes extensive nigral 
dopaminergic neuronal loss with widespread LB pathology.  
Other groups have subsequently replicated this finding and found RAB39B mutations in 
individuals affected by classic EOPD, in absence of the atypical signs observed in the 
families where the gene was first identified (Lesage et al., 2015, Mata et al., 2015).  
Interestingly, previous work had identified RAB39B as a cause of X-linked intellectual 
disability in absence of parkinsonian signs (Giannandrea et al., 2010), indicating that 
RAB39B mutations cause a spectrum of overlapping syndromes. Furthermore, this 
suggests that shared pathogenic mechanisms may exist linking PD to developmental 
disorders. Rab proteins are small molecular weight guanosine triphosphatases involved 
in the regulation of vesicular trafficking (Cheng et al., 2002). 
VPS13C  
Very recently, VPS13C loss of function variants have been recognised as a novel cause 
of autosomal-recessive EOPD (Lesage et al., 2016). Homozygous or compound 
heterozygous truncating mutations were detected in three isolated PD subjects. The 
phenotype associated with VPS13C mutations is characterised by rapid and severe 
disease progression and early cognitive decline. Neuropathological assessment showed 
evidence of diffuse LB pathology. Functional work demonstrated that VPS13C knock-
down leads to a severe mitochondrial pathology and exacerbation of PINK1/Parkin-
dependent mitophagy. 
Complex Forms of Autosomal Recessive Parkinsonism 
Mutations in the genes described in this section are generally associated with more rare 
and aggressive forms of recessive parkinsonism, characterised by very early-onset (<30 
years) and usually additional, atypical features (pyramidal, dystonic, ocular movement, 
and cognitive disturbances). However, in spite of the different phenotypic presentation, 
several biological evidences link the pathogenic mechanisms of these conditions to that 
of PD. Furthermore, several recent observations indicate that mutations in most of these 
genes can lead to more typical forms of autosomal recessive EOPD. 
ATP13A2 (PARK9) 
Recessive loss-of-function of ATP13A2 cause Kufor-Rakeb syndrome, a rare, juvenile-
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onset disorder characterized by severe parkinsonism, dementia, pyramidal signs and 
supranuclear gaze palsy (Ramirez et al., 2006). Subsequently, ATP13A2 recessive 
mutations have been detected in cases with a broader phenotype, including isolated 
juvenile-parkinsonism (Di Fonzo et al., 2007, Martino et al., 2015), parkinsonism with 
brain iron accumulation (Schneider et al., 2010) and, more recently, also neuronal 
ceroidal lipofuscinosis (a severe infantile neurodegenerative disorder) (Bras et al., 2012).  
ATP13A2 is a large gene encoding for a protein normally located in the lysosomal 
membrane (Ramirez et al., 2006). Loss of ATP13A2 leads to lysosomal dysfunction and 
subsequent α-Syn accumulation (Tsunemi and Krainc, 2014).  
PLA2G6 Mutations (PARK14) 
A broad range of truncating recessive mutations in the phospholipase A2 group VI 
(PLA2G6) gene, encoding for a phospholipase involved in metabolism of phospholipids 
to free fatty acids, were first described as the cause of infantile neuroaxonal dystrophy 
and neurodegeneration associated with brain iron accumulation (Kurian et al., 2008).  
PLA2G6 mutations were subsequently detected also in subjects with a different 
presentation, featuring L-DOPA-responsive dystonia-parkinsonism, pyramidal signs and 
cognitive/psychiatric features, with onset in early adulthood, without evidence of iron 
accumulation (Paisan-Ruiz et al., 2009). More recently, bi-allelic missense mutations, 
more likely to have a milder effect on protein function, have also been identified in 
cases with uncomplicated EOPD (Xie et al., 2015, Giri et al., 2016).  
LBs have been described in association with PLA2G6 mutations (Paisan-Ruiz et al., 
2012). Functional work performed in a Drosophila model of PLA2G6 deficiency shows 
that loss of normal gene activity leads to lipid peroxidation and mitochondrial 
dysfunction (Kinghorn et al., 2015). 
FBOX7 (PARK15) 
FBXO7 mutations were first described in a Persian family and then in an Italian family 
with severe juvenile-onset parkinsonism associated with spasticity and prominent 
pyramidal signs (Najim al-Din et al., 1994, Di Fonzo et al., 2009). More recently a 
homozygous FBXO7 missense mutation was described also in a family with more 
classic EOPD (Lohmann et al., 2015). FBXO7, like Parkin, is part of an E3 ubiquitin 
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ligase complex necessary for the correct initiation of the mitophagy process (Laman, 
2006, Burchell et al., 2013).  
SYNJ1 
The same homozygous mutation in SYNJ1 (p.Arg258Gln) was identified by WES, in 
t o unrelated consanguineous kindred’s, as a cause of a com lex autosomal recessi e 
parkinsonian syndrome (Krebs et al., 2013, Quadri et al., 2013). The phenotype 
includes aggressive parkinsonism with severe levodopa-induced dystonia. Additional 
features are generalized seizures, cognitive decline, dysarthria, eyelid apraxia and 
supranuclear gaze palsy.  
SYNJ1 encodes synaptojanin 1, a phosphoinositide phosphatase protein involved in 
clathrin-mediated endocytosis in the adult brain (Drouet and Lesage, 2014). A recent 
report showed that bi-allelic loss of synaptojanin 1 cause severe infantile epileptic 
encephalopathy with brain accumulation of tau protein (Dyment et al., 2015, Dyment et 
al., 2015). 
DNAJC6  
Recessive truncating mutations in DNAJC6 cause juvenile onset parkinsonism with 
rapid progression. Associated features include dysarthria, generalised seizures and brain 
atrophy on MRI (Edvardson et al., 2012, Koroglu et al., 2013). The group of Bonifati 
recently described DNAJC6 mutations in cases with a milder presentation, consistent 
with classic EOPD (Olgiati et al., 2016). DNAJC6 encodes the protein auxilin, which is 
a clathrin-associated protein enriched in nerve terminals and may play a role in synaptic 
vesicle recycling (Ahle and Ungewickell, 1990). 
2.1.3 Rare Variants Predisposing to PD 
 GBA  
Homozygous or compound heterozygous loss-of-function mutations in GBA are the 
genetic abnormality underlying Gaucher’s disease  GD , the most common lysosomal 
storage disorder. GD has a prevalence of 1/40,000 to 1/50,000 in all ethnicities and is 
particularly frequent in the Ashkenazi Jewish population, where it affects 1/800 to 
1/1,000 live births (Cox, 2001, Grabowski, 2008). 
GD is an autosomal recessive disorder and more than 300 different causative GBA 
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mutations spanning the entire coding region have been described (Figure 2-4), including 
insertions, deletions, point mutations and complex alleles resulting from recombination 
events with the neighbouring pseudogene GBAP (Hruska et al., 2008).  
 
Figure 2-4 GBA gene structure and distribution of pathogenic mutations across the coding exons 
Image reproduced from (Hruska et al., 2008) 
 
GD is caused by an insufficient activity of glucocerebrosidase (GCase), the lysosomal 
enzyme coded by GBA.  athogenic mutations affect the enzyme’s catalytic function, 
cellular stability and/or subcellular trafficking, resulting in intracellular build-up of 
GCase’s main substrate, glucosylceramide. mainly in the cells of the reticuloendothelial 
system of the spleen, liver and bone marrow, and often resulting in organomegaly 
(Grabowski, 2008).  
Clinically, GD presents with a spectrum of manifestations, the severity of which 
partially depend on the deleteriousness of the mutation on GCase activity: type 1 GD, 
the non-neuronopathic, most common and mildest form of GD; type 2 (GD2) the acute 
neuronopathic, most severe form associated with a complete deficiency in GCase 
activity and short life-expectancy; and type 3 (GD3) the chronically neuronopathic form 
which has a later onset and longer life-expectancy than GD2.  
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The main clinical features of GD are summarised in the panel below taken from 
(Sidransky and Lopez, 2012). 
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In the past decade a previously unexpected link between GD and PD has been 
recognised. The first findings were based on isolated clinic observations of GD cases 
presenting a parkinsonian picture with clinical features very similar to those classically 
seen in patients with sporadic PD (Neudorfer et al., 1996, Tayebi et al., 2001, Tayebi et 
al., 2003). These observations were subsequently extended to the GD first-degree 
relatives, obligate carriers of GBA heterozygous mutations (Goker-Alpan et al., 2004).  
Then, many independent case-control studies, performed in PD cases from different 
ethnical backgrounds (reviewed in (Sidransky and Lopez, 2012), have then consistently 
observed a higher frequency of GBA mutations in PD patients (Figure 2-5), indicating a 
causal relationship between GD and PD. 
GBA mutations are now considered the most relevant genetic risk factors for PD 
(Neumann et al., 2009, Sidransky et al., 2009). Among Ashkenazi Jewish subjects, GBA 
mutation are found in ~15% of patients and among non-Ashkenazi Jewish subjects 
mutations are identified in ~7%, with an odds ratio for any GBA mutation in patients 
versus controls of ~5.  
Neuropathological analysis of brains from parkinsonian patients with GD or carriers of 
heterozygous GBA mutations re ealed the  resence of abundant α-syn positive LBs 
(Bembi et al., 2003, Neumann et al., 2009). 
Clinically, patients with PD and GBA mutations (both homozygous and heterozygous 
carriers) present with a classic clinical picture, indistinguishable from that of sporadic 
PD. Patients are characterized by asymmetric resting tremor, rigidity and bradykinesia 
and a good response to L-DOPA treatment. Most series of patients with GBA mutations 
report a lower mean age at onset and a higher incidence of cognitive and behavioural 
symptoms, such as dementia and visual hallucinations, compared to wild type cases 
(Alcalay et al., 2012, Winder-Rhodes et al., 2013).  
Importantly, the replacement therapy used to treat GD cases does not modify the risk of 
PD. It is not clear though whether the drug simply does not cross the blood-brain barrier 
or whether enzyme replacement is not targeting the pathogenic mechanisms critical for 
PD (Rosenbloom et al., 2011). 
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Figure 2-5 Map showing the countries where the frequency of GBA mutations in Parkinson disease patients was assessed  
Image taken from (Sidransky and Lopez, 2012) 
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Despite the numerous investigations that followed from the discovery of this association, 
the molecular nature of the link between GBA mutations,  D and α-syn aggregation 
remains largely unexplained. Furthermore there exists a deepening debate as to whether 
the mutant GBA protein acts by a loss- or toxic-gain-of-function mechanism (Goldin, 
2010).  
As previously mentioned, GD is caused by a drastic reduction in the activity of the 
encoded lysosomal enzyme β-glucocerebrosidase (GCase) and a consequent 
accumulation of substrates, mainly glucosylceramide and glucosysphingosine, in the 
tissues where GD is associated with lysosomal storage dysfunction.  
However, while it would seem likely that GCase loss of enzymatic activity contribute to 
the risk of PD, many elements argue against this view, suggesting the mutant GBA 
could instead increase the risk of PD through other mechanisms. 
Most patients with GBA mutations and PD are heterozygous carriers, which implies that 
at least 50% of residual enzymatic activity is conserved. This is largely sufficient to 
avoid the pathogenic build up of substrates, as enzymatic activity needs to be reduced 
by at least 70-90% before substrate accumulation occurs. However, it is possible that 
GBA has other distinct unidentified regulatory functions of lysosomal activity the loss 
of  hich could fa our α-syn aggregation and neuronal cell death. Furthermore, studies 
assessing age-specific penetrance and estimated life cumulative risk for PD in GD 
patients and heterozygous carriers have demonstrated that the risk is similar in the two 
groups (from 9 to 12% by the age of 80), thus arguing against the presence of a gene 
dosage effect, which is a typical of pure loss-of-function-mutations (Rosenbloom et al., 
2011, McNeill et al., 2012, Rana et al., 2013, Alcalay et al., 2014). 
On the other hand, there is growing evidence of a direct relationship between the 
severity of the mutation, in terms of GCase activity reduction, and PD risk. For instance, 
Gan-Or et al. found that carriers of severe mutations had a considerably higher disease 
risk and reduced age at onset compared to carriers of mild mutations (Gan-Or et al., 
2008, Gan-Or et al., 2015). Moreover, Lesage et al. found that the PD onset tended to 
occur earlier in carriers of severe GBA mutations (Lesage et al., 2011). Finally, recent 
work by Barrett and colleagues determined in a cohort of relatives of GD1 patients that 
non-N370S mutations (severe or null mutations) conferred a higher risk for PD 
compared to the mild N370S mutation (Barrett et al., 2013).  
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Different investigations carried out in cell and animal models of GD and 
synucleinopathies support the idea that both mechanisms, toxic gain of function due to 
misfolded mutant proteins and loss of enzymatic activity, are likely to equally contribute 
to the com lex lysosomal dysfunction that leads to aberrant α-syn aggregation and 
ultimately to nigral neuronal death (Cullen et al., 2011, Mazzulli et al., 2011, Sardi et 
al., 2011).  
SPMD1 
SMPD1 encodes sphingomyelin phosphodiesterase 1, a lysosomal enzyme that cleaves 
the phosphocholine head group of sphingomyelin to generate ceramide. Bi-allelic 
mutations in the gene are the cause of Niemann-Pick type A, another multi-systemic 
lysosomal disorder, particularly frequent in the Ashkenazi Jewish population 
(Schuchman, 2007).  
Gan-Or and colleagues recently suggested that a heterozygous missense mutation in this 
gene, p.Leu230Pro, could be a risk factor for the development of PD in the  Ashkenazi 
Jewish population, with an odds ratio of ~9 (Gan-Or et al., 2013). Importantly, other 
groups have subsequently replicated this finding in populations of different ethnical 
background (Foo et al., 2013, Wu et al., 2014), strongly supporting the view that 
dysfunctional lysosomal acti ity is critical to α-syn accumulation and PD pathogenesis. 
2.1.4 Common Low-Risk Variants Predisposing to PD 
Candidate gene association studies have been used in the past to try and identify 
common loci that increase the risk for PD. Through this approach common variability at 
the SNCA locus (Kruger et al., 1999) and at the MAPT locus were shown to contribute 
to the risk of disease (Golbe et al., 2001).  
However, it is mainly thanks to unbiased GWAS that in recent years a growing number 
of susceptibility genes and risk loci have been undoubtedly associated with increased 
risk of PD. These studies rely on the common-disease-common variant hypothesis, 
according to which common genetic variants of small effect size can increase the risk of 
diseases, such as PD, that are frequent in the general population. GWAS have been 
made possible by the development of platforms that allow the assessment of genetic 
variability (usually single-nucleotide polymorphisms; SNPs) across the genome with 
the disease on the order of 500,000 to 1 million variants (Hardy and Singleton, 2009).  
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While the first GWAS in PD were underpowered and therefore yielded negative results 
(Fung et al., 2006), larger GWAS identified that common variability in several loci, 
including SNCA, MAPT, LRRK2, PARK16, BST1, HLA-DRB5, and GAK, increase PD 
risk in independent populations (Pankratz et al., 2009, Satake et al., 2009, Simon-
Sanchez et al., 2009, Edwards et al., 2010, Saad et al., 2011, Spencer et al., 2011, 
Sharma et al., 2012) 
Subsequently, thanks to imputation of variants and a meta-analysis of different GWAS 
datasets, additional genes were identified, including ACMSD, STK39, MCCC1/LAMP3, 
SYT11, and CCDC62/HIP1R (Nalls et al., 2011).  
The largest and most recent meta-analysis of all existing GWAS, which includes a total 
of ~13,000 PD cases and ~95,000 controls, showed that 24 risk loci containing 28 
independent risk variants are associated with an increased risk of PD (Nalls et al., 
2014). The Manhattan plot showing the results of this meta-analysis is represented in 
Figure 2-6.  
Importantly, most of the SNPs associated with increased PD risk are non-coding and the 
functional role of the vast majority of them is far from being understood. Furthermore, 
the effect size of the individual risk variants is low, although initial evidence suggests 
that the risk conferred by the combination of multiple risk variants may be more 
substantial. 
It is of interest to note that some of the most robustly associated SNPs are located in 
close proximity of genes that also contain high penetrant mutations causing Mendelian 
forms of familial PD, such as SNCA, LRRK2 and VPS13C. Importantly, this suggests 
that there could be a substantial overlap in the pathogenic mechanisms underlying rare 
Mendelian forms of PD and the more common sporadic forms, reinforcing the crucial 
importance of dissecting the bases of PD with Mendelian transmission. 
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Figure 2-6 Manhattan plot from the latest GWAS meta-analysis for Parkinson disease 
Image reproduced from (Nalls et al., 2014)
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2.2  Overview on the Genetics of Dystonia 
2.2.1 Introduction 
The dystonias are a clinically and genetically heterogeneous group of movement 
disorders. In 2013, an international panel of experts provided a consensus update on 
definition, phenomenology and classification of dystonia (Albanese et al., 2013). 
Dystonia was defined as a “movement disorder characterized by sustained or 
intermittent muscle contractions causing abnormal, often repetitive, movements, 
postures, or both. Dystonic movements are typically patterned, twisting, and may be 
tremulous. Dystonia is often initiated or worsened by voluntary action and associated 
with overflow muscle activation”.  
Dystonia is the third most common movement disorder worldwide and approximately 
70,000 people are affected by dystonia in the UK alone (Paudel et al., 2012). 
Dystonia has been traditionally classified based on the four main features (Table 2-2): (1) 
age of onset (early onset vs. adult onset), (2) distribution of affected body parts (focal, 
segmental or generalised), (3) aetiology (primary vs secondary dystonia) (4) special 
clinical features (paroxysmal, exercise-induced, task-specific or dopa-
responsive)(Albanese et al., 2011). Given the existence of several problems and 
confusion with this system, a new classification has been recently proposed, which uses 
two axes to define dystonia. (Albanese et al., 2013).  
Axis I describes the clinical features of dystonia and includes age at onset, body 
distribution, temporal pattern, coexistence of other movement disorders and other 
neurological manifestations.  
Axis II focuses on the presumed aetiology; the two classifying criteria are the presence 
of nervous system pathology (evidence of degeneration vs structural lesions vs absence 
of any pathology) and a differentiation among inherited dystonia (when a precise 
genetic cause is recognized) and acquired dystonia (e.g. perinatal brain injury, infections, 
drugs among others) or idiopathic dystonia. The old and the new classification are 
shown and compared in the figure Figure 2-7. 
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Table 2-2 Traditional clinical classification of dystonia 
A) Aetiology 
1. Primary dystonia 
No underlying structural, pharmacological or metabolic cause can be 
identified 
1.1) Primary isolated 
dystonia 
Dystonia is the only clinical sign (apart from tremor) and there is no 
identifiable exogenous cause or other inherited or degenerative disease 
1.2) Primary plus 
dystonia 
Dystonia is a prominent sign but is associated with another movement 
disorder, e.g. myoclonus or parkinsonism.  
1.3) Primary paroxysmal 
dystonia Torsion dystonia occurs in brief episodes with normalcy in between. 
2. Heredodegenerative 
dystonia 
Dystonia is a feature, among other neurological signs, of a genetically 
determined neurodegenerative disorder 
3. Secondary dystonia 
Dystonia is a symptom of an identified neurological condition, e.g. a focal 
brain lesion, exposure to drugs or chemicals 
B) By age at onset 
1.  Early onset  
(<30 years of age) 
Usually starts in a leg or arm and frequently progresses to involve other 
limbs and the trunk 
2.  Late onset 
Usually starts in the neck (including the larynx), the cranial muscles or one 
arm. Tends to remain localized with restricted progression to adjacent 
muscles 
C) By distribution of affected body parts 
1. Focal Single body region  e.g.  riter’s cram , ble haros asm  
2. Segmental Contiguous body regions (e.g. cranial and cervical, cervical and upper limb) 
3. Multifocal 
Non-contiguous body regions (e.g. upper and lower limb, cranial and upper 
limb) 
4. Generalised Both legs and at least one other body region (usually one or both arms) 
5. Hemidystonia 
Half of the body (usually secondary to a lesion in the contralateral basal 
ganglia) 
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Figure 2-7 Schematic comparison of the old and the new classification system of dystonia 
Table reproduced form (Balint and Bhatia, 2014). 
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The pathophysiology basis of dystonia is poorly understood. It has been proposed that 
dystonia may derive from a functional impairment of the neural circuits underlying the 
control and coordination of voluntary movements (Figure 2-8). These include the basal 
ganglia, the cerebellum, the sensorimotor cortex, and the interactions between these 
regions of the brain (Neychev et al., 2011). The impairment of these circuits may occur 
as a consequence of structural lesions of these brain areas (either focal lesions or 
degeneration), as a consequence of a pharmacological treatment altering the activity of 
the neurons constituting these pathways (e.g L-DOPA treatment in PD patients or 
antipsychotic treatments blocking the dopamine receptors), or, most frequently, in 
absence of any overt brain pathology, which defines the primary dystonias. This last 
group of conditions is thought to derive from anatomically preserved, but functionally 
abnormal, basal ganglia and cerebellar circuits. 
 
 
Figure 2-8 The circuits of dystonia 
Reproduced from (Berman and Jinnah, 2015) 
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2.2.2 Overview of Monogenic Forms of Dystonia 
Genetic factors largely contribute to the pathogenesis of dystonia. A positive family 
history in first-degree family members is reported in a very high proportion of patients 
with primary dystonia, ranging from 18 to 50% of cases (Rubio-Agusti et al., 2013). 
Moreover, in a small but defined subset of families, dystonia can be transmitted across 
generations as a clear Mendelian trait.  
Mutations in a growing number of genes are responsible for the Mendelian forms of 
dystonia. Importantly, the identification of these genes has allowed the initial 
recognition of different cellular pathways that could be involved in the molecular 
pathogenesis of primary dystonia, including perturbed synaptic transmission and 
plasticity (in particular of the dopamine system), abnormal transcription and cell-cycle 
regulation and endoplasmic reticulum (ER) dysfunction (Ledoux et al., 2013).  
The genes that have been associated with dystonia are summarised in Table 2-3.  
This overview will only focus on genes that cause primary dystonia. 
The Primary Isolated Dystonias 
This term defines a group of syndromes in which dystonia is the only clinical feature 
(except for tremor of the arms or head and neck), without any evidence of 
neurodegeneration or any obvious secondary cause.  
TOR1A Mutations (DYT1-related Dystonia)  
In 1997 an in-frame 3 base pairs (CAG) deletion in exon 5 of the TOR1A gene, was 
identified as the genetic abnormality underlying the DYT1 locus (Ozelius et al., 1997). 
This mutation is responsible for approximately 50% of cases with early onset 
generalized dystonia across different ethnicities (Kramer et al., 1994). Due to a founder 
mutation, the DYT1 mutation is particularly frequent among Ashkenazi Jewish 
population, where it accounts for 80% of early onset dystonia.  
Clinically, TOR1A-related dystonia would present in childhood with dystonic posturing 
of lower limbs and subsequent generalisation. Dystonia can nevertheless begin in any 
part of the body, with usual sparing of the neck and face. Late onset forms and atypical 
presentation of the disorder are not infrequently recognised (Jamora et al., 2006, 
Stamelou et al., 2013).  Most cases would report a family history consistent with 
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autosomal dominant inheritance. However, the penetrance of the mutation is markedly 
reduced (~30%), which explains the frequent observation of pseudo-sporadic cases 
(Hjermind et al., 2002). A small number of other variants have been described in 
sporadic cases with various forms of dystonia, but none of them has been convincingly 
shown to be pathogenic due to lack of clear segregation in other family members 
(Leung et al., 2001, Kabakci et al., 2004, Vulinovic et al., 2014). 
TorsinA is a member of the AAA+ superfamily (ATPases associated with different 
cellular activities) with multiple functions in the cell. TOR1A is exclusively expressed in 
neurons and the protein localizes in the endoplasmic reticulum (ER). Cellular models 
have demonstrated that mutant torsinA is displaced from the ER to the nuclear envelope 
(Goodchild and Dauer, 2004). The abnormal localisation may result in dysfunction of 
the secretory pathway and synaptic vesicle machinery (e.g. transportation of dopamine 
vesicles and/or dopamine receptors to the pre- and post-synaptic membrane, 
respectively) (Warner et al., 2010).  
Recently the first mouse model of DYT1-dystonia, exhibiting a motor phenotype 
closely resembling the human disease, has been described (Liang et al., 2014). 
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Table 2-3 Monogenic causes of dystonia  
Locus Gene locus Features Inheritance 
Mutational 
spectrum 
DYT1 TOR1A Early-onset primary torsion dystonia 
AD with reduced 
penetrance 
Only an in-frame 
3 base pairs 
(CAG) deletion 
in exon 5 is 
pathogenic 
DYT2 HPCA 
Early-onset primary dystonia with prominent 
cranio-cervical involvement 
AR Missense 
DYT4 TUBB4A 
Whispering dystonia (adult onset spasmodic 
dysphonia)  ith generalisation and ‘hobby horse’ 
gait. Hypomyelination of basal ganglia and 
cerebellum (H-ABC). Spastic paraparesis 
AD/De novo Missense 
DYT5a GCH1 Dopa-responsive dystonia AD/AR 
Missense, 
truncating and 
large deletions or 
duplications 
DYT5b TH Dopa-responsive dystonia 
AR 
Missense and 
truncating 
NA SPR Dopa-responsive dystonia AR 
Missense and 
truncating 
DYT6 THAP1 
Adult-onset torsion dystonia with prominent 
cranio-cervical and laryngeal involvement 
AD with reduced 
penetrance 
Missense and 
truncating 
DYT8 MR1 Paroxysmal non-kinesigenic dyskinesia AD Missense 
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DYT10 PRRT2 Paroxysmal kinesigenic dyskinesia AD 
Mainly 
truncating and 
large deletions 
DYT11 SGCE 
Myoclonic dystonia (often with alcohol 
responsiveness) 
AD 
Mainly 
truncating and 
large deletions 
DYT12 ATP1A3 
Rapid onset dystonia parkinsonism and 
alternating hemiplegia of childhood 
AD/de novo Missense 
DYT16 PRKRA Early-onset dystonia-parkinsonism AR Missense 
DYT18 SLC2A1 
Paroxysmal exercise-induced dyskinesia +/- 
epilepsy 
AD 
Missense and 
truncating 
DYT23 CIZ1 Adult onset cervical dystonia AD Missense 
DYT24 ANO3 
Tremulous cranio-cervical dystonia 
+/- upper limb tremor 
AD Missense 
DYT25 GNAL Adult onset cervical dystonia 
AD with reduced 
penetrance /de 
novo 
Missense and 
truncating 
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THAP1 mutations (DYT6) 
In 2009 mutations in the THAP1 gene, coding for the thanatos-associated protein 
domain-containing apoptosis-associated protein 1, were identified in two Mennonite 
families as the genetic abnormality responsible for the DYT6 locus (Almasy et al., 1997, 
Fuchs et al., 2009). A range of missense, nonsense and frameshift mutations spread 
throughout the coding portion of the gene are associated with disease in several 
genetically diverse populations. The inheritance of DYT6-related dystonia is autosomal 
dominant with a penetrance of ~60% (Saunders-Pullman et al., 2007, Fuchs et al., 2009, 
Houlden et al., 2010).  
Clinically, mutation carriers tend to develop symptoms later than DYT1-positive 
patients, with an onset in adolescence or adulthood. DYT6-positive patients usually 
present with a predominant involvement of the upper body, in particular severe 
oromandibular, cranio-cervical, laryngeal or upper limbs involvement, and subsequent 
generalisation (Xiromerisiou et al., 2012).   
THAP1 is an atypical zinc finger protein with DNA binding properties, involved in the 
regulation of gene transcription (Roussigne et al., 2003). One hypothetical mechanism 
whereby THAP1 substitutions could lead to dystonia is by dysregulated transcription of 
strategic genes. Mutations in THAP1 have been shown to disrupt binding to the TOR1A 
promoter and result in decreased TOR1A gene expression, suggesting that under normal 
conditions TOR1A is negatively regulated by THAP1 (Kaiser et al., 2010).  
TUBB4A (DYT4-related Dystonia)  
The DYT4 family is a large kindred of British origin characterised by onset in the third 
decade of a severe form of dominantly inherited generalized dystonia (Parker, 1985). 
Several affected family members spread across five generations have been described. 
Affected members would present with a laryngeal dysphonia which progresses to a 
generalized dystonia. Some patients displayed a unique ‘hobby horse’ gait (Wilcox et al., 
2011). To date, no other pedigree with similar clinical features has been published. 
Through a combination of linkage analysis and exome sequencing, the missense 
mutation p.Arg2Gly in the TUBB4A gene was independently identified as causal in the 
DYT4 kindred by our and Klein’s grou  (Hersheson et al., 2012, Lohmann et al., 2012).   
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TUBB4A encodes β-tubulin-4a, a constituent of axonal microtubules. The mutation lies 
in the highly conserved autoregulatory MREI (Methionine–Arginine–Glutamic acid–
Isoleucine) domain of the protein. The MREI tetrapeptide sequence at the start of the N-
terminal domain is kno n to be necessary for the autoregulation of the β-tubulin mRNA 
levels and in vitro studies using site-directed mutagenesis have previously shown that 
mutations in this domain abrogate the autoregulatory ability (Yen et al., 1988, Yen et al., 
1988).  
Screening of the gene in a cohort of 394 unrelated dystonia patients revealed one further 
possibly pathogenic variant (p.Ala271Thr) in an individual who exhibited autosomal 
dominant spasmodic dysphonia (Lohmann et al., 2012). We could not detect other 
mutation carriers in a cohort of ~200 dystonia cases with prominent laryngeal 
involvement (Hersheson et al., 2013). A more recent study investigating 575 subjects 
with primary laryngeal, segmental or generalized dystonia failed to detect any further 
TUBB4A mutations (Vemula et al., 2014), indicating overall that TUBB4A mutations are 
an exceptionally rare cause of dystonia. 
Importantly, it was subsequently recognised that de novo mutations in TUBB4A are also 
the cause of hypomyelination with atrophy of the basal ganglia and cerebellum (H-ABC 
syndrome) (Simons et al., 2013, Hamilton et al., 2014). H-ABC is a rare 
neurodegenerative disorder with onset in infancy and childhood, characterised by the 
specific combination of hypomyelination, cerebellar atrophy, and absence or 
disappearance of the putamen (van der Knaap et al., 2002). Clinically, H-ABC cases 
show a combination of severe dystonia, cerebellar ataxia, and variable degrees of 
intellectual disability. There is ongoing debate about whether DYT4-dystonia and H-
ABC are distinct allelic conditions (brain imaging of members of the DTY4 kindred 
does not show the classic H-ABC findings) or whether the DYT4-phenotype simply 
represents a milder clinical presentation of the same disease, possibly questioning 
TUBB4A as a primary dystonia gene (Erro et al., 2015). 
CIZ1 mutations (DYT23) 
Linkage analysis and WES were recently used to identify a missense mutation in CIZ1 
(c.790A>G p.Ser264Gly) as the possible causal variant in a large Caucasian kindred 
with adult-onset autosomal dominant cervical dystonia (Xiao et al., 2012). Screening of 
other unrelated cases with adult-onset dystonia identified 2 additional missense 
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mutations in 3 individuals (p.Pro47Ser and p.Arg672Met; segregation not confirmed for 
any of these mutations), but also a similar number of novel variants in matched controls. 
Two subsequent studies have failed to identify additional mutations in CIZ1 (Ma et al., 
2013, Dufke et al., 2015). This finding is still awaiting independent confirmation and 
several concerns have been raised questioning the real contribution of CIZ1 mutations 
to the pathogenesis of dystonia (Klein et al., 2012). 
CIZ1 encodes Cip1-inderacting zinc finger protein 1 and is a p21
Cip1/Waf1
-interacting zinc 
finger protein, expressed in brain and involved in DNA synthesis and cell-cycle control. 
The work detailing the features of a CIZ1 knock-out mouse model has been recently 
published (Xiao et al., 2016). Ciz1 showed the highest expression in the cerebellum and 
Ciz1-/- mice did not display features of dystonia, but exhibited mild motoric 
abnormalities on balance, open-field activity, and gait. Whole-genome gene expression 
analysis based on RNA extracted from cerebellum suggests that CIZ1 may be involved 
in the post-mitotic differentiation of neurons in response to external signals (Xiao et al., 
2016). 
ANO3 mutations (DYT24) 
Our group identified a segregating missense mutation in ANO3 in a three-generation 
British family with autosomal dominant cranio-cervical dystonia (Charlesworth et al., 
2012).  Five further novel variants were detected by a subsequent screening of the gene 
in 188 probands with dystonia (Charlesworth et al., 2012). 
Clinically, patients with ANO3 mutations exhibit focal or segmental tremulous dystonia, 
variably affecting the cranio-cervical, laryngeal and brachial regions. Some individuals 
showed isolated upper limb tremor and had been misclassified as essential tremor. 
Furthermore two patients exhibited myoclonic jerks of the head or the arms (Stamelou 
et al., 2014).  
A recent screening in a large German cohort of sporadic cases with cervical dystonia 
identified two novel mutations in cases, but also a similar number of novel variants in 
controls, indicating that caution should be posed when assigning pathogenicity of 
individual variants (Zech et al., 2014). However, a screening conducted in the Chinese 
population identified two additional dominant families with cranio-cervical dystonia 
that carried a segregating ANO3 mutation (Ma et al., 2015), confirming the contribution 
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of ANO3 to dystonia pathogenesis. 
ANO3 is very high and selectively expressed in the striatum, a key brain region in 
dystonia pathogenesis. ANO3 encodes a protein called anoctamin 3 and belongs to a 
family of closely related genes (ANO1-10) with different tissue expression patterns. 
ANO1 and ANO2 encode for Ca
2+
-activated chloride channels. Hence, it is postulated 
that ANO3 may function in the same way and regulate striatal neurons excitability 
(Caputo et al., 2008).  
GNAL mutations (DYT25-related dystonia) 
In 2012 heterozygous mutations in GNAL were identified in two unrelated dominant 
families as a novel cause of familial adult-onset cervical dystonia (Fuchs et al., 2013). 
Screening of further 39 families revealed 6 additional segregating novel mutations, 
suggesting that GNAL mutations could be a relatively common cause for familial 
dystonia.  
However, a number of subsequent mutational screening have shown a much lower 
mutational yield with a reported frequency across different populations of around 0.5-
1%.  Several loss-of-function mutations have been described, including missense and 
truncating mutations, (Dobricic et al., 2014, Dufke et al., 2014, Kumar et al., 2014, 
Zech et al., 2014). GNAL mutations are most frequently transmitted as a dominant trait, 
although de novo mutations have been found in sporadic cases (Dobricic et al., 2014, 
Kumar et al., 2014, Ziegan et al., 2014, Carecchio et al., 2016). More recently a family 
with severe childhood-onset dystonia harboring a recessive homozygous GNAL 
mutation has also been reported (Masuho et al., 2016).  
Clinically, most GNAL mutation carriers present the first symptoms in the cervical 
region. Progression to other body segments is observed in ~50% of cases, although a 
frank generalisation of dystonia is rare (Fuchs et al., 2013).  
GNAL encodes Golf, the alpha subunit of triheteromeric G protein Golf, a striatal 
protein involved in dopamine (D1) signalling. Golf is responsible for coupling D1 
receptors to adenylyl cyclase 5 in striatal neurons and Golf is required for D1-mediated 
behaviour and biochemical effects (Herve et al., 1993, Zhuang et al., 2000, Corvol et al., 
2001).  
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HPCA-related dystonia (DYT2) 
Our group has recently identified homozygous and compound heterozygous HPCA 
mutations in two pedigrees with autosomal recessive generalised dystonia. HPCA were 
initially identified through homozygosity mapping and WES in a pedigree with three 
affected subjects, product of a consanguineous marriage (parents are first cousins), 
presenting with early-onset generalised dystonia (Charlesworth et al., 2015). 
Subsequently, compound-heterozygous mutations in HPCA were also identified in a 
second independent kindred affected by AR isolated dystonia.  
HPCA are likely to represent an extremely rare cause of dystonia, as a recent study 
assessing HPCA mutation frequency in large cohort of primary dystonia cases, failed to 
identify any additional mutation (Dobricic et al., 2016). 
HPCA encodes hippocalcin, a neuronal calcium sensor protein present almost 
exclusively in the brain and expressed at particularly high levels in the striatum 
(Charlesworth et al., 2015). 
Primary Dystonia-plus 
The dystonia-plus syndromes (also known as combined dystonias, according to the most 
recent nomenclature system) represent a heterogeneous group of non-neurodegenerative 
diseases, where additional neurological features (non-epileptic myoclonus or 
parkinsonism) accompany dystonia (Asmus and Gasser, 2010).  
DOPA-responsive dystonia (DYT5) 
The term DOPA-responsive dystonia (DRD) defines a group of rare conditions, which 
share the clinic characteristic of a dramatic improvement in symptoms in response to 
treatment with oral L-dopa (Kurian et al., 2011). Mutations in three genes have 
incontrovertibly been shown to cause DRD: GCH1 (GTP Cyclohydrolase 1), TH 
(Tyrosine Hydroxylase) and SPR (Sepiapterin Reductase) (Ichinose et al., 1994, 
Brautigam et al., 1998, Bonafe et al., 2001). All three genes encode enzymes that are 
critically involved in the biosynthesis of dopamine in nigrostriatal cells and pathogenic 
mutations result in a dramatic decrease in dopamine synthesis (Figure 2-9).  
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Figure 2-9 Schematic illustration of the cellular pathway involved in dopamine synthesis in nigral 
neurons 
Reproduced from (Charlesworth et al., 2013). 
 
Heterozygous GCH1 mutations are by far the most common cause of DRD, accounting 
for 60-80% of autosomal dominant DRD pedigrees (Furukawa, 2004). Penetrance is 
incomplete being lower for males (~40-50%) than females (~80%) (Wider et al., 2008).  
Clinical presentation is typically with lower limb dystonia and gait disturbance, with a 
variable degree of generalisation over time (Nygaard et al., 1990). The response even to 
low doses of L-DOPA is excellent, sustained and not generally associated with 
dyskinesias that often follow chronic use of L-DOPA in PD (Clot et al., 2009). As I will 
discuss in more detail in chapter 4.4, parkinsonism may occur in the later stages of the 
disease. 
TH and SPR mutations are associated with autosomal recessive DRD (Ludecke et al., 
1996, Blau et al., 2001). Typically, patients with mutations in these two genes present 
with a severe combination of dystonia, parkinsonism, ptosis, seizures and truncal 
hypotonia in infancy. The clinical picture is overall more severe than in GCH1-related 
DRD and response to L-DOPA treatment is often less satisfactory.  
Recently mutations in ATM, the gene usually mutated in ataxia- telangiectasia, have 
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been identified in an Indian pedigree with recessive DOPA-responsive cervical dystonia 
(Charlesworth et al., 2013). The mechanisms whereby ATM mutations may lead to this 
phenotype are unknown. 
SGCE-related Myoclonus-Dystonia (DYT11) 
M-D clinical and genetic aspects will be discussed in detail in chapter 5.2. 
ATP1A3 Mutations (DYT12) 
Mutations in ATP1A3 were initially reported as the cause of rapid-onset dystonia-
parkinsonism (RDP), a rare autosomal dominant condition characterized by abrupt onset 
in adolescents or young adults of fixed dystonic and parkinsonian symptoms (de 
Carvalho Aguiar et al., 2004, Brashear et al., 2007).  
It was subsequently recognized that de novo ATP1A3 mutations are also responsible for 
alternating hemiplegia of childhood (AHC) (Heinzen et al., 2012, Rosewich et al., 
2012). AHC is an infantile disorder characterized by a fluctuating course and recurrent, 
and alternating, hemiplegic or hemidystonic episodes, followed in most cases by the 
development of permanent neurological symptoms (i.e. epilepsy, neurodevelopmental 
delay with intellectual disability, chorea, dystonia, parkinsonism, bulbar symptoms and 
cerebellar ataxia) (Heinzen et al., 2014).   
More recently, a single missense mutation was shown to cause another distinct 
autosomal dominant condition, featuring progressive cerebellar atrophy with relapsing 
episodes of cerebellar ataxia, areflexia, pes cavus, optic atrophy, and sensori-neural 
deafness (CAPOS) (Demos et al., 2014).  
Importantly, a growing number of cases with overlapping RDP/AHC (Roubergue et al., 
2013, Rosewich et al., 2014, Rosewich et al., 2014, Panagiotakaki et al., 2015, 
Termsarasab et al., 2015) and CAPOS/AHC (Rosewich et al., 2014) have been reported 
in the literature.  
ATP1A3 encodes the catalytic unit of the sodium pump that uses ATP hydrolysis to 
exchange Na+ and K+ across the cell membrane to maintain ionic gradients.  
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PRKRA Mutations (DYT16) 
Mutations in PRKRA a rare cause of autosomal recessive dystonia-parkinsonism, were 
initially identified in two apparently unrelated consanguineous Brazilian families 
featuring young onset generalised dystonia with additional parkinsonian features 
(Camargos et al., 2008).  Autozygosity mapping and subsequent mutational screening 
revealed the PRKRA homozygous missense mutation p.Pro222Leu in both families 
(Camargos et al., 2008). Only recently three more families with bi-allelic PRKRA 
mutation have been reported (Zech et al., 2014, de Carvalho Aguiar et al., 2015, Quadri 
et al., 2016), confirming the contributory role of PRKRA to dystonia pathogenesis. Two 
European families (one Italian and one Polish) carried the same homozygous missense 
change, while the third family carried two novel mutations, p.Cys77Ser and p.Cys213Ph,  
in the compound heterozygous state.  
PRKRA encodes protein kinase, interferon-inducible double-stranded RNA-dependent 
activator, a protein involved in signal transduction, cell differentiation, cell proliferation, 
antiviral response and apoptosis (Patel et al., 2000).     
The Primary Paroxysmal Dystonias 
The paroxysmal dystonias are a clinically and genetically heterogenous group of 
movement disorders characterized by temporally defined dyskinetic episodes with 
interictal neurological normality. Paroxysmal dyskinesia can be subdivided into three 
main clinical syndromes: paroxysmal kinesigenic dyskinesias (PKD), paroxysmal 
exercise-induced dyskinesias (PED), and paroxysmal non-kinesigenic dyskinesias 
(PNKD) (Erro et al., 2014).  
Paroxysmal kinesigenic dyskinesias  
Mutations in PRRT2, encoding for the synaptic protein proline-rich transmembrane 
protein 2, were identified as the cause of PKD in 2011 (Chen et al., 2011, Wang et al., 
2011).  
Affected individuals have frequent (up to 100 times per day) and short (seconds to 
minutes) dyskinetic attacks, triggered by sudden movements. PKD attacks respond 
dramatically to anticonvulsant therapy with carbamazepine.  
PRRT2 mutations have also been described as the cause of benign familial infantile 
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epilepsy and of other childhood-onset movement disorders (i.e. episodic ataxia, 
paroxysmal torticollis of childhood), headache disorders, and intellectual disability 
(Ebrahimi-Fakhari et al., 2015). 
Most PRRT2 pathogenic mutations are truncating and by far the most common mutation 
is the recurrent frameshift c.649dupC, which is present in ~80-90% of the cases 
described to date (Cao et al., 2012, Friedman et al., 2012, Hedera et al., 2012, Steinlein 
et al., 2012).   
The PRRT2 protein is highly expressed in the developing nervous system and localised 
to the synapse (Lee et al., 2012).  Truncating mutations result in a protein lacking the 
transmembrane domain, leading to altered subcellular localization. The subsequent 
reduction of PRRT2 protein may lead to altered synaptic neurotransmitter release and 
dysregulated neuronal excitability (Chen et al., 2011).  
More recently, a single missense mutation (p.Glu1483Lys) in SCN8A, encoding a 
voltage gated Na-channel subunit widely expressed in the CNS, has recently been 
linked to paroxysmal kinesigenic dyskinesia and benign familial infantile seizures 
(Gardella et al., 2016). This observation expands the phenotypic spectrum associated 
with mutations in this gene, which also includes severe epileptic encephalopathy and a 
neurodevelopmental disorder (Larsen et al., 2015). 
Paroxysmal non-kinesigenic dyskinesia  
Paroxysmal non-kinesigenic dyskinesia (PNKD) symptoms classically starts in the first 
two decades of life, featuring attacks of dystonic and choreatic dyskinesias, often 
triggered by stress or alcohol and/or caffeine consumption (Bruno et al., 2007). PNKD 
episodes usually last from minutes to hours and occur with a frequency that can vary 
between 20 attacks per day to only few attacks per year.  
PNKD is caused by heterozygous mutations in the myofribillogenesis regulator (MR-1) 
gene and mutations are inherited as an autosomal dominant trait.  Only three mutations 
have been described to date, all clustered in the N-terminus of the protein:  p.Ala7Val, 
p.Ala9Val and p.Ala33Pro (Lee et al., 2004, Rainier et al., 2004, Chen et al., 2005, 
Djarmati et al., 2005, Hempelmann et al., 2006, Ghezzi et al., 2009).  
PRRT2 mutations have been found in small number of patients with a PNKD 
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presentation (Gardiner et al., 2015). 
Paroxysmal exercise-induced dyskinesia 
Mutations in the SLC2A1 gene, which codes for the glucose transporter GLUT1, cause 
paroxysmal exercise-induced dyskinesia (PED). PED is characterized by attacks of 
combined chorea, athetosis, and dystonia, which tend to last from a few minutes to an 
hour (Bruno et al., 2004). GLUT1 is the main glucose transporter in the brain and PED 
may be caused by reduced glucose transport into the brain, particularly when energy 
demand is high after prolonged exercise.  
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2.3 Genetics of Choreas 
2.3.1 Introduction 
Chorea  from the Greek  ord χορεία =dance  is a hy erkinetic mo ement disorder 
characterized by continuous and brief involuntary movements. Chorea can affect any 
body segment, including limbs, trunk, neck, face, and mouth. Typically choreic 
movements flow from one body part to another and are unpredictable in terms of timing, 
speed and direction. Different from dystonia, choreic movements are not repetitive or 
patterned. Chorea is usually worsened by anxiety and execution of voluntary 
movements, and it is absent during sleep. When chorea is accompanied by athetosis, a 
term defining slower and continuous writhing involuntary movements, it is referred to 
as choreo-athetosis. Chorea is commonly observed in combination with other 
hyperkinesias, such as dystonia (Donaldson et al., 2012).  
Focal lesions of the striatum and degeneration and/or functional dysregulation of 
medium spiny neurons (MSNs), which constitute ~95% of the striatal cells and form the 
striatal output projections, are considered to underlie the pathophysiology of choreic 
movements [2]. 
Chorea is a major feature of several neurological disorders that can be either genetically 
inherited or acquired.  
There are many non-inherited causes of chorea. These include focal lesions of the 
striatum (e.g. strokes, occupying-space lesions), infection/immune-related conditions 
 e.g. Sydenham’s chorea, systemic lu us erythematosus or anti-phospholipid syndrome), 
use of drugs such as L-DOPA, neuroleptics, antiemetics and oral contraception, and 
several metabolic, haematological, or endocrinological disorders (e.g. polycythaemia 
rubra vera, hyperthyroidism, hypo/hyperparathyroidism and hypo/hyperglycemia) (Wild 
and Tabrizi, 2007). Acquired causes of chorea will not be further discussed in this 
chapter. 
Clinically, inherited choreas may be classified according to the age at onset of 
symptoms, as mutations in different genes tend to cause disease with onset either in 
childhood/juvenile years (< 20 years) or in adulthood. A further important distinction 
can be made between progressive (i.e. neurodegenerative) and non-progressive causes 
of inherited chorea.  
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From a clinical point of view, it is also important to establish whether chorea is the only 
or the predominant neurological feature or whether other accompanying features are 
present. This is essential for guiding genetic diagnostic testing. Other neurological 
features that should be looked for in patients with chorea are cognitive impairment, 
ataxia, epilepsy, myoclonus, dystonia, peripheral neuropathy, spasticity, and eye 
movement disorders.  
Of relevance, a number of childhood-onset metabolic (e.g. Lesch-Nyhan Syndrome, 
glutaric aciduria, propionic acidemia) or mitochondrial disorders (e.g. Leigh syndrome, 
MELAS) can present with a movement disorder (most frequently dystonia, followed by 
chorea), though typically in the context of a complex multi-systemic neurologic 
presentation (Hermann and Walker, 2015). 
The genes that have been associated with choreic syndromes are summarized in Table 
2-4. Mitochondrial diseases and inborn errors of metabolism associated with a choreic 
presentation are not listed in the table.   
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Table 2-4 Monogenic causes of chorea 
Gene Main associated phenotype Gene product Inheritance Age of onset Diagnostic clues 
HTT Huntington disease Huntingtin AD (CAG expansion) 
Childhood to 
late adulthood 
Cognitive decline, psychiatric disturbances 
Progressive course 
MRI: caudate nucleus head atrophy 
PRNP 
HDL1/ 
Prion disease 
Prion protein 
AD (octapeptide coding repeat 
expansion) 
Adulthood 
Dementia, seizures and psychiatric features 
Possible parkinsonism at onset and longer survival 
than HD 
JPH3 HDL2 Junctophilin 3 AD (CAG/CTG expansion) Adulthood 
Parkinsonism may be first manifestation 
High frequency in people with black African ancestry 
TBP 
HDL4/ 
Spinocerebellar ataxia type 
17 
 
TATA box-binding 
protein 
AD (CAG expansion) 
Childhood to 
adulthood 
Ataxia, epilepsy and cognitive decline  
Frequent parkinsonism 
MRI: cerebellar atrophy 
ATN1 
Dentato-rubral-pallido-
luysian atrophy 
Atrophin-1 AD (CAG expansion) 
Childhood to 
adulthood 
Seizures, myoclonus and cognitive decline 
MRI: Cerebellar and brainstem atrophy (especially 
pons) 
High frequency in Japan 
C9orf72 FTD/MND 
Chromosome 9 
Open Reading 
Frame 72 
AD (GGGGCC expansion) 
Childhood to 
adulthood 
Prominent cognitive and psychiatric features 
Pyramidal signs 
MRI: diffuse cerebral atrophy 
FTL Neuroferritinopathy Ferritin light chain AD 
Teenage to 
late adulthood 
Action-specific facial dystonia 
Reduced ferritin plasma levels 
MRI: iron deposition in basal ganglia and cortical 
pencil lining 
VPS13A Chorea-acanthocytosis Chorein AR 
Early 
adulthood 
Severe oromandibular dystonia with lip and tongue 
biting 
Head drops 
Peripheral axonal neuropathy 
Elevated serum CK 
MRI: caudate nucleus head atrophy 
XK Macleod syndrome 
Kell blood group 
protein 
X-linked recessive Adulthood 
Peripheral sensorimotor neuropathy 
Cardiomyopathy 
Elevated serum CK 
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ATM Ataxia-telangiectasia 
Ataxia-
telangiectasia 
mutated gene 
AR 
Childhood to 
adulthood 
Oculocutaneous telangiectases 
Sensorimotor neuropathy 
Elevated serum alpha-fetoprotein 
Predisposition to malignancy 
MRI: cerebellar atrophy 
APTX 
 
SETX 
 
Ataxia with oculomotor 
apraxia (AOA) type 1, 2 
Aprataxin 
 
Senataxin 
 
 
AR 
Childhood to 
adulthood 
Sensorimotor neuropathy 
Hypoalbuminemia in AOA1 
Hypercholesterolemia in AOA1  
Elevated alpha-fetoprotein in AOA2  
MRI: cerebellar atrophy 
FRDA Friedreich’s ataxia Frataxin AR 
Childhood to 
adulthood 
Cardiac involvement, diabetes, skeletal deformities 
Pyramidal signs 
RNF216 Gordon-Holmes syndrome 
Ring finger protein 
216 
AR Adulthood 
Behavioural problems, and severe dementia 
Hypogonadism 
MRI: white matter lesions and cerebellar atrophy 
NKX2-1 
NKX2-1-related chorea 
(Benign Hereditary Chorea) 
Thyroid 
transcription factor 
1 
AD/De novo Infancy 
Non-progressive course 
Hypotonia and early falls 
Learning difficulties 
Frequent pulmonary and thyroid involvement 
AD: autosomal dominant; AR: autosomal recessive; BFIS: Benign familial infantile seizures; HDL: Huntington’s disease-like. 
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2.3.2 Huntington’s disease 
HD is by far the most common cause of chorea and represents the archetype of 
progressive forms of chorea.  
HD is a fatal neurodegenerative disorder inherited as an autosomal dominant trait and is 
caused by heterozygous expansion of a CAG trinucleotide repeat in the HTT gene 
(encoding the huntingtin protein). In healthy individuals the CAG repeat ranges between 
10 and 29 copies on normal chromosomes, whereas is expanded to 36–121 in HD 
patients. CAG repeats equal or above 40 are fully penetrant, whereas expansion between 
36 and 39 are associated with reduced penetrance.  
Clinically, HD features a triad of relentlessly progressive motor, cognitive and 
psychiatric symptoms, generally with onset in adult years, and inevitably leading to 
death after ~15-20 years of disease (Ross and Tabrizi, 2011). Onset of disease is 
typically in adult years, with less than 10% of patients presenting at an age below 20 
(Koutsis et al., 2013). Juvenile HD (Westphal variant) tends to be associated with little 
choreic movements, while rigidity, parkinsonism, dystonic features, myoclonus and 
cognitive impairment would dominate the phenotype (Quinn and Schrag, 1998).  
Most of the current research efforts in HD genetics are aimed at identifying disease 
modifiers, which may influence the disease progression and determine the age at onset 
(AAO) of motor symptoms (Gusella et al., 2014). The length of the CAG expansion is 
well known to be the most relevant determinant of the age at onset, with longer repeats 
associated with an earlier onset (Andrew et al., 1993). However, the CAG repeat size 
accounts for only ~50% of the variation in age at onset (Langbehn et al., 2004) and a 
substantial portion of the remaining variance in age at onset is highly heritable, strongly 
indicating the existence of other critical genetic determining factors (Gusella et al., 
2014). Neither the size of the non-expanded HTT allele, nor the presence of a second 
smaller CAG pathological expansion, is able to significantly influence age at onset (Lee 
et al., 2012). A recent study showed that a variant (rs13102260; G>A) in the HTT 
promoter, located in the site that regulates binding of the transcription factor NF-κB, 
exerts a bidirectional effect on HD age at onset (Becanovic et al., 2015). The authors 
showed in vitro and in vivo that the presence of the A allele determined a lower NF-κB-
mediated HTT transcriptional activity, resulting in delayed age at onset when inherited 
on the same allele of the pathological expansion (reduced expression of the pathological 
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allele). On the contrary, the A allele was associated with an earlier age at onset when 
located on the non-expanded allele (reduced expression of the normal HTT). An 
important corollary of these results is that therapeutic strategies aimed at lowering the 
expression of the pathological CAG expansion should take into account that non allele-
specific silencing of HTT could bear undesired effects by decreasing the expression of 
the normal allele. The most relevant advance toward the discovery of HD genetic 
modifiers is the recent publication of GWAS performed by the Genetic Modifiers of 
Huntington Disease (GeM—HD) Consortium (Lee et al., 2015). The authors identified 
two GWAS-significant loci, one on chromosome 15 and one on chromosome 8 that 
significantly modified the age at onset of motor symptoms as predicted solely by the 
CAG expansion length. Other suggestive associations, though not passing the stringent 
GWAS-significance threshold, were observed on chromosomes 3, 5 and 21. Genes 
located on chromosome 15 locus are MTMR10 and FAN1 and on the chromosome 8 
locus are RRM2B and UBR5. Pathway analysis of the GWAS results indicates that HD 
modifiers may be involved in control of DNA handling and repair mechanisms. 
Supporting this view, the chromosome 3 locus centred on MLH1, a gene previously 
identified in a HD mouse model as a modifier of somatic instability of the CAG repeats 
(Pinto et al., 2013).  
2.3.3 Huntington’s disease-like syndromes 
~1% of families with a HD-like clinical presentation do not carry pathogenic expansion 
in the HD gene and are therefore labelled as HD phenocopies or HD-lookalike (HDL) 
disorders (Schneider et al., 2007).  
Importantly, HD phenocopies are clinically and genetically heterogeneous and a 
conclusive genetic diagnosis is currently possible in only a small minority of cases. In 
the Queen Square series, a genetic diagnosis could be achieved in only 8/285 HDL cases 
(2.8%) (Wild et al., 2008). Other studies report even lower diagnostic yields (Stevanin 
et al., 2003, Keckarevic et al., 2005, Costa Mdo et al., 2006, Koutsis et al., 2012). 
HDL1 
HDL1 is an exceptionally rare autosomal dominant neurodegenerative disorder, caused 
by an 8-octapeptide repeats expansion in the prion protein (PrP) gene (PRNP) (Moore et 
al., 2001).  
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The clinical features of carriers of the PRNP octapeptide repeats are indistinguishable 
from classic HD and include chorea, personality changes, psychiatric symptoms and 
cognitive decline. Moreover, few members of a very large British pedigree with a PRNP 
6-octapeptide repeats expansion presented with a combination of chorea and cognitive 
decline, mimicking HD (Mead et al., 2006). In the Queen Square series only one HDL 
case was found to carry a PRNP mutation, and was subsequently recognized to be a 
member of the large family previously reported by Mead and colleagues (Wild et al., 
2008).  
HDL2 
HDL2 is caused by a CTG-CAG triplet repeat expansion in the junctophilin 3 (JPH3) 
gene (Holmes et al., 2001). The expansion is virtually absent in Caucasian population 
(Margolis et al., 2004), but is common in patients of black South Africans of sub-
Saharan descent, where the expansion is responsible for up to ~50% of patients with a 
HDL presentation (Stevanin et al., 2003, Krause et al., 2015). Abnormally expanded 
repeat expansions range from 40 to 59 triplets and the penetrance of the expansion is 
high (Govert and Schneider, 2013). Most HDL2 patients are clinically indistinguishable 
from HD cases (Margolis et al., 2001). However, Schneider and colleagues reported a 
large African-American kindred carrying a JPH3 expansion and presenting with a 
progressive akinetic-rigid syndrome and severe dementia but very little chorea. This 
indicates that JPH3 should be considered in the differential diagnosis of early-onset 
dementia and hypokinetic-rigid syndromes in individuals of African descent (Schneider 
et al., 2012) 
HDL3  
The HDL3 locus was mapped to 4p15.3 in a single consanguineous pedigree from Saudi 
Arabia with a recessive HDL presentation (Kambouris et al., 2000). However no other 
pedigrees mapping to this locus have been subsequently identified and the causative 
gene has not been reported as yet. 
HDL4 
HDL4 is caused by heterozygous CAG triplet repeat expansions in the TATA box-
binding protein (TBP) gene located on chromosome 6q27 (Stevanin and Brice, 2008). 
The same triplet expansion is also responsible for SCA type 17 (SCA17) (Stevanin et al., 
2003). SCA17 expansions account for approximately 1% of the HDL cases, which 
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makes it one of the most important genetic mutations found in HDL Caucasian subjects 
(Wild and Tabrizi, 2007). However, chorea is present only in 20% of SCA17 patients, 
with ataxia, seizures, dementia and parkinsonism being the most frequently detected 
features (Zuhlke and Burk, 2007). Interestingly, within given SCA17 positive pedigrees, 
homogenous HDL presentation can be observed in multiple individuals, suggesting that 
other co-inherited genetic factors may influence he presentation (HDL vs ataxic) 
(Schneider et al., 2006). 
Global cortical atrophy, putaminal enhancement or cerebellar atrophy can be 
inconsistently found in SCA17-associated HDL. Importantly, other SCA expansions, in 
particular those associated with SCA1, SCA2, and SCA3, can cause hyperkinetic 
movement disorders that can sometimes include chorea (Schols et al., 2000, van Gaalen 
et al., 2011). 
Dentato-rubral-pallido-luysian atrophy 
Dentato-rubral-pallido-luysian atrophy (DRPLA) is an autosomal dominant 
neurodegenerative disease. DRPLA is caused by CAG triplet repeat expansions in the 
gene encoding atrophin-1 (Nagafuchi et al., 1994). DRPLA is particularly frequent in 
Japan, where it is almost as frequent as HD, but is exceptionally rare in other ethnicities. 
Clinically, DRPLA presents with a variable combination of chorea, ataxia, cognitive 
decline, and, especially in young individuals with larger expansions, progressive 
myoclonic epilepsy (Becher et al., 1997).  
C9orf72-Related HDL 
A hexanucleotide repeat expansion in a non-coding portion of the C9orf72 gene was 
recently shown to be the most important cause of familial and sporadic frontotemporal 
lobar degeneration and amyotrophic lateral sclerosis (DeJesus-Hernandez et al., 2011, 
Renton et al., 2011). Hensman Moss and colleagues recently screened a cohort of 514 
HDL patients for the presence of the C9orf72 expansion and 10 subjects (1.95%) 
carrying the expansion, making this mutation the most common identified cause of HDL 
syndromes in a UK cohort (Hensman Moss et al., 2014). Not surprisingly, a movement 
disorder was a prominent feature in these cases, with 3 exhibiting chorea, 4 dystonia, 4 
myoclonus, and 3 tremor. Furthermore, 6 cases had rigidity and 5 bradykinesia. 
Although, none of the cases had been formally diagnosed with fronto-temporal 
dementia, behavioural, psychiatric and cognitive difficulties were observed in most of 
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the carriers. Upper motorneuron signs were present in 4 of the 10 subjects, while lower 
motorneuron signs were not detected. 
Other groups have been subsequently confirmed C9orf72 expansions to be a relevant 
cause of HDL in other populations (Kostic et al., 2014, Koutsis et al., 2015).  
Chorea-Acanthocytosis  
Bi-allelic mutations in VPS13A, coding for the large protein chorein, are responsible for 
the neurodegenerative condition chorea-acanthocytosis (CA) (Rampoldi et al., 2001). 
CA is mainly characterized by orofacial and cervical dyskinesias (chorea, dystonia and 
tics) combined with abnormal erythrocyte morphology (acanthocytosis) that can be 
detected with blood film microscopic examination. Highly classical neurological signs 
are tongue protrusion, biting of the tongue and lips and neck and trunk flexion drops and 
extension spasms (Schneider et al., 2010). Progressive cognitive decline and psychiatric 
features are often prominent as in HD. Seizures, ataxia, and a peripheral neuropathy 
with distal amyotrophy and increased serum creatine kinase are also common features 
that should prompt a diagnosis of CA (Schneider et al., 2007).  
Macleod Syndrome 
Macleod syndrome is a recessive X-linked neuro-acanthocytosis syndrome caused by 
mutations in XK encoding Kell antigen (Wiethoff et al., 2014). Clinical presentation is 
similar to CA, though often with a later onset and milder and longer course. Dystonia 
tends to be less pronounced than in CA and cardiomyopathy and haemolytic anaemia 
may be relevant distinctive features (Walker et al., 2007). 
Neurodegeneration with Brain Iron Accumulation 
Neurodegeneration with brain iron accumulation (NBIA) is a group of inherited 
neurological disorders in which iron accumulates in the basal ganglia, which classically 
present with movement disorders and cognitive decline (Kara et al., 2013). Brain 
magnetic resonance imaging (MRI) usually shows the presence of iron deposition in the 
basal ganglia allowing the diagnosis. Most of the NBIA syndromes are recessive and 
start early in life and therefore are easily distinguishable from HD.  
However, mutations in the FTL1 gene, encoding ferritin light chain, are an exception to 
this rule as they cause a late-onset dominant disease, called neuroferritinopathy, which 
may be often misdiagnosed as HD (Curtis et al., 2001). So far, only a small number of 
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FTL1 mutations have been reported and the frameshift insertion c.460InsA by far the 
most common in UK cohorts.  
Neuroferritinopathy typically presents with chorea and/or dystonia. Other clinical 
features are variably reported, including parkinsonism, cerebellar signs, dysarthria, 
frontal lobe syndrome and dementia. An action-specific facial dystonia is reported in 
~65% of the patients (Chinnery et al., 2007). Our group has recently shown that cortical 
pencil lining, which reflecting excessive cortical iron deposition, is a useful radiological 
sign of neuroferritinopathy (Batla et al., 2015). 
Other recessive NBIAs (in particular aceruloplasminemia) should be considered too, 
although chorea alone is rarely a sole prominent feature of these conditions (Walker, 
2016). 
Chorea in Patients with Mutations in Cerebellar Ataxia-Related Genes 
Hyperkinetic movement disorders, including both chorea and dystonia, are frequently 
observed in a range of genetic neurodegenerative disorders usually presenting with 
predominant cerebellar ataxia (other than the aforementioned SCA17 and DRPLA).   
Ataxia-telangiectasia (A-T) is an autosomal recessive multi-system disorder caused by 
mutation in the ataxia-telangiectasia mutated gene (ATM). A-T is usually characterized 
by progressive cerebellar ataxia, oculocutaneous telangiectasia, oculomotor apraxia, 
immunodeficiency with recurrent lung infections, and increased risk for cancer. Patients 
with bi-allelic ATM mutations, the cause of ataxia-telangiectasia (A-T), may present 
with a broad spectrum of movement disorders, including chorea (Klein et al., 1996, 
Hardy and Singleton, 2009, Worth et al., 2013), isolated dystonia (Saunders-Pullman et 
al., 2012, Claes et al., 2013), DOPA-responsive dystonia (Charlesworth et al., 2013), 
and myoclonus-dystonia (Cheng et al., 2002, Cummins et al., 2013, Termsarasab et al., 
2015). Meneret and colleagues recently reported a total of 14 consecutive adults with 
variant A-T and compared them to patients with typical A-T (Meneret et al., 2014). 
Patients with variant A-T have milder mutations, which allow a degree of residual 
protein activity (Gilad et al., 1998), and clinically present with a later age at onset, a 
milder disease course and longer survival. Dystonia and subcortical myoclonus were the 
most common movement disorders observed (84%), followed by tremor (48%) 
(Meneret et al., 2014). Of relevance, patients with ATM-related chorea and dystonia 
may completely lack the classic clinical features of A-T (Kuhm et al., 2015).  
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Friedrich ataxia (FA) is the most common form of recessively inherited ataxia. FA is 
caused by mutations in the frataxin gene; 98% of cases have homozygous expansions of 
a GAA trinucleotide in intron 1 of the frataxin gene (Parkinson et al., 2013). Rarely, 
chorea can be observed in bi-allelic carriers of frataxin mutations, sometimes preceding 
the onset of frank cerebellar symptoms (Hanna et al., 1998, Zhu et al., 2002, Wild et al., 
2008). Chorea has been rarely described also in cases with ataxia with oculomotor 
apraxia type 1 and 2, caused respectively by mutation in the genes encoding aprataxin 
and senataxin (Salvatore et al., 2008, Anheim et al., 2009) 
Recessive mutations in RNF216 have recently been found in families with 
hypogonadotropic hypogonadism and cerebellar ataxia (Margolin et al., 2013). 
Expanding the phenotype of RNF216 mutations-associated diseases, Santens and 
colleagues identified bi-allelic mutations in the RNF216 in 2 recessive pedigrees with a 
HDL presentation, including chorea, behavioural problems, and severe dementia. In the 
affected cases rain imaging showed white matter lesions and subclinical evidence of 
hypogonadotropic hypogonadism was detected (Santens et al., 2015). 
2.3.4 Benign Hereditary Chorea 
Clinical and genetic aspects of benign hereditary chorea will be discussed in detail in 
chapter 6.2. 
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Chapter 3. Materials and Methods 
3.1 DNA Extraction 
3.1.1 Extraction from Whole Blood  
Genomic DNA was extracted from whole blood (taken in ethylenediaminetetraacetic 
acid bottles) in the Diagnostic Genetics Laboratory in the UCL Institute of Neurology 
using a FlexiGene© kit (Qiagen), according to manufacturer instructions.  
 n brief, 300μl of  hole blood is mixed  ith 750μl of buffer  FG1 ,  hich lyses the 
cells. The sample is centrifuged for 20 seconds at 10,000xg and then the supernatant 
 as discarded. 150μl of Buffer  FG2 – which contains a protease) is added to the pellet 
and the tube vortexed until the pellet was homogenized. The sample is subsequently 
centrifuged for 5 seconds and then placed for 5 minutes in a heating block at 65°C. 
150μl of iso ro anolol  100%  is then added and the tube inverted several times, 
allowing the DNA to precipitate. The sample is centrifuged for 3 minutes at 10,000xg 
and then the supernatant was discarded. 150μl of 70% ethanol is added and the sample 
vortexed for 5 seconds and centrifuged for 3 minutes at 10,000xg. The supernatant is 
discarded and the pellet air dried. 200μl of Buffer  FG3  is added and the sample 
vortexed at 5 seconds. The DNA is then dissolved by heating the sample at 65°C in a 
heating block.  
3.1.2 Extraction from Saliva  
Genomic DNA was extracted from saliva samples using the Oragene© DNA kit 
according to the manufacturers’ instructions.  
Briefly, the saliva sample and Oragene solution are incubated at 50°C in an air incubator 
for 2 hours. Then, 500μl of the solution is transferred to a 1.5mL microcentrifuge tube 
and 20μl of Oragene DN   urifier is added and then vortexed for a few seconds. The 
sample is then incubated on ice for 10 minutes and subsequently centrifuged at room 
temperature for 15 minutes at 13,000 rpm. The clear supernatant is transferred into a 
fresh microcentrifuge tube and the  ellet containing im urities discarded. 500μl of 100% 
ethanol is added to the solution and inverted 10 times. The sample is then left at room 
temperature for 10 minutes allowing the DNA to precipitate. The sample was then 
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centrifuged at room temperature for 2 minutes at 13,000 rpm and the supernatant is 
removed and discarded. 250μl of 70% ethanol  as added. The sam le is allowed to 
stand at room temperature for 1 minute. The ethanol is then removed, taking care not to 
disturb the  ellet. 100μl of DN  buffer  as then added to dissol e the DN   ellet. 
After extraction, the concentration of DNA samples was then measured using the 
Nanodrop (Thermo Scientific). 
3.2 Polymerase-Chain Reaction  
PCR primers were designed using Primer3 (http://primer3.ut.ee/). The nucleotide 
sequence form each exon, along with flanking ~200 down and up-stream intronic base 
pairs, was inputted in the program. DNA sequence of each exon was obtained from a 
suitable transcript (generally the longest coding transcript available with a consensus 
CDS (CCDS) identifier) downloaded from UCSC Genome Browser 
(https://genome.ucsc.edu/). 
 CR  as  erformed using 10 μl Faststart  CR Master  Roche    lied Sciences , 2 μl of 
for ard and re erse  rimers at a dilution of 5  mol/μl, 5 μl of double distilled water and 
genomic DNA at a final concentration of 20-30ng. DMSO was added to the mix for 
amplification of amplicons GC-rich. Each PCR reaction was performed using a program 
that had been demonstrated to optimally amplify the product. 
3.3 Agarose Gel Electrophoresis 
Agarose gel electrophoresis was used to check whether the PCR reaction was successful 
and verify the quality and size of PCR amplification product. 10x TBE (tris-borate-
EDTA solution) solution was prepared using 121.1g of Trizma base (Sigma), 61.8g 
Boric Acid (Sigma), 7.4g of Ethylenediaminetetraacetic acid (EDTA) (Sigma) and 
dissolved in 1 litre of distilled water. A 1.5% gel was prepared using Ultrapure Agarose 
(Invitrogen) and TBE 1X buffer and stained  ith gel red  Cambridge bioscience . 3μl of 
 CR  roduct and 3μl of X6 Orange DN  loading dye  Thermo scientific   ere mixed 
together and loaded into one well of the gel. A DNA ladder (Midrange 100-2000 bp) 
(Qiagen) was run alongside each lane of the gel and then the samples were run at 100 
mV for 45 minutes. DNA fragments are visualized using UV light. 
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3.4 PCR Purification 
PCR cleanup was performed using an enzymatic method. The enzymatic cleanup 
solution  as  re ared mixing 200μl of Fast-Alkaline phosphatase (Thermo scientific), 
 hich remo es unused dNT s, 50μl Exonuclease    Thermo scientific ,  hich remo es 
single strand DN  from  CR  roducts, and 750μl of  urified  ater. 5μl of  CR  roduct 
 as added to 2μl of the enzymatic solution and then run on a thermal cycler at 37°C for 
30 minutes followed by 80°C for 15 minutes. 
3.5 Sanger Sequencing 
The sequencing Reaction mix  as  re ared combining 0.5μl BigDye Terminator  3.1 
    lied Biosystems , 2μl 5x Sequencing Buffer     lied Biosystems , 1μl for ard or 
re erse  rimers at 5  mol/μl and 3μl of  urified  CR  roduct and 2.15μl of  CR grade 
water. The standard thermo-cycler program recommended by Applied Biosystems was 
used to run the Sequencing reaction. Sequencing purification was performed through 
the Sephadex method. A hydrated solution of Sephadex was prepared mixing 40ml of 
autoclaved water and 2.9 grams of Sephadex G-50 powder (Sigma-Aldrich). It was then 
vigorously mixed and allowed to hydrate, resting for at least 30 minutes at room 
temperature. Next, 350μl of the Se hadex solution  as  laced into each  ell of a 
Corning FiltrEXTM 96 well filter plates (0.66 mm glass fibre filter). The Corning 
FiltrEXTM filter plate was placed on top of an empty collection plate and centrifuged 
for 3 minutes at 750xg. The Corning FiltrEXTM was then placed on top of a new PCR 
plate. The entire sequencing reaction volume was then pipetted onto the Sephadex 
columns and the plates were then centrifuged again for 5 minutes at 910xg. 
Sanger sequencing reaction products were then read on a 3730 DNA analyser (Applied 
Biosystems, Foster City, CA, USA) and electropherograms were visualised using 
Sequencher software (Gene Codes Corporation, MI, USA, version 5.0.1). 
3.6 Multiplex Ligation-Dependent Probe Amplification  
Multiplex Ligation-Dependent Probe Amplification (MLPA) analysis is is a multiplex 
PCR method used to determine exon copy number of genes of interest.  
In this thesis I used the MLPA probemix P051-D1 (MRC-Holland, Amsterdam, the 
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Netherlands), which screens for the presence of exon deletions and duplications in 
SNCA, PARK2, PINK1, PARK7 (Djarmati et al., 2007). In addition, it contains probes 
that will only generate a signal when the SNCA p.Ala30Pro and LRRK2 p.Gly2019Ser 
mutation are present. 
 
Figure 3-1 Steps of the MLPA reaction 
Reproduced from mlpa.com 
 
The MLPA reaction can be divided in five major steps (Figure 3-1): 1) DNA 
denaturation and hybridisation of MLPA probes. During this step, the DNA of the 
probands is first denatured at 98°C and then incubated overnight with a mixture of 
MLPA probes and MLPA buffer. MLPA probes consist of two separate oligonucleotides, 
each containing one of the PCR primer sequences. 2) Ligation reaction; this reaction can 
occur only if the two probe oligonucleotides are both hybridised to their adjacent targets. 
3) PCR reaction; because only ligated probes will be exponentially amplified during this 
reaction, the number of probe ligation products is a measure for the number of target 
sequences in the sample. 4) Separation of PCR amplification products, after combining 
it with a mix of Hi-Di Formamide (Thermo Fisher Scientific) and marker Liz500 
(Thermo Fisher Scientific) by electrophoresis on the 3730 DNA analyser. 5) Data 
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analysis; the results of the analysis are checked and interpreted using Genemarker 
software (Softgenetics). 
3.7 Analysis of Microsatellites  
Microsatellites are DNA sequences located in non-coding genomic regions and formed 
by mono, di, tri or tetra-nucleotides repeated in multiple tandem copies. Microsatellites 
are abundant and dispersed through the genome. The number of repeats is highly 
variable amongst different individuals in a population, whereas they tend to be stable 
between generations and are transmitted in a Mendelian fashion. Microsatellites are 
therefore widely used as genetic markers in genetic familial study. In this thesis 
microsatellites were used to define and compare the haplotype surrounding specific 
mutations in different families.  Microsatellites were selected in UCSC genome browser. 
Primers to amplify the regions containing the microsatellite of interest were designed 
using Primer3. One primer for each reaction was labelled with a fluorescent dye (6-
F M .  CR reactions  ere  erformed as  re iously described. 0.5μl of undiluted  CR 
 roduct  as mixed  ith 12 μl of Hi-Di Formamide and 0.3μl of Liz500, denaturated at 
98°C for 3 minutes and analysed by electrophoresis on the 3730 DNA analyser. The size 
of the microsatellites was assessed using the GeneMapper software (Thermo Fisher 
Scientific). 
3.8 DNA Array SNP Analysis 
Two types of DNA array SNP beadchips were used. For whole genome linkage analysis, 
I used Human CytoSNP beadchips (Illumina), which contains probes for ~220,000 
markers. For detection of copy number variants or small chromosomal rearrangements, 
I used HumanOmni2.5-8 BeadChips (Illumina), which contains probes for ~2,500,000 
markers. 
For each sam le, 10 μl of DNA at a concentration of ~75 ng/μl  ere  re ared. Sam les 
were processed, hybridized and scanned in accordance with the manufacturers 
instructions at UCL Genomics. Clustering, normalization and genotype calls were 
performed using Genome Studio 2010.3 Genotyping module (Illumina). 
A Genome Studio project was created for each family project with default parameters.  
CNVs analysis was performed using the plugin CNV partition 2.4.4 und results were 
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applied as bookmarks in genome viewer. PLINK output files, to be used for whole-
genome linkage analysis, were created in Genome Studio through the PLINK report 
plug-in. 
3.9 Genome-Wide Parametric Multipoint Linkage Analysis 
Quality control checks were performed through PLINK. SNPs with low call rates 
(<90%) and monomorphic SNPs (MAF <0.5%) were removed using the commands –-
maf 0.05 –-geno 0.1. ~6000 single nucleotide polymorphisms (SNP) equally distributed 
across the genome were then randomly selected using the command –-thin.  
Linkage analysis was performed using the software MERLIN 
(http://www.sph.umich.edu/csg/abecasis/merlin/tour/linkage.html) (Abecasis et al., 
2002).  
A .ped, .dat, .map and .model files were generated following the instructions. The .ped 
file contains information about the affection status of each individual included in the 
analysis (specified with a number: 1=unaffected and 2=affected 0=unknown), the sex of 
the individual (1=male, 2=female). Furthermore, the .ped file contains information 
about the pedigree structure, indicated by assigning every individual a unique number 
and specifying for each subject the identifiers of his/her father and mother. The .map 
files contains the list of SNP markers used for the linkage analysis and their genetic 
position expressed in centimorgans (cM). The model file contains information regarding 
the assumed mode of inheritance (autosomal dominant vs recessive) together with the 
estimated disease allele frequency and the probability of being affected for individuals 
with 0, 1 and 2 copies of the disease allele (penetrances). 
The PEDSTATS function (http://csg.sph.umich.edu//abecasis/PedStats/) was used to 
validate the input formats and pedigree consistency using the command:  
pedstats –d file.dat –p file.ped 
To identify Mendelian errors (genotyping errors), which can lead to misleading 
inferences about gene flow in pedigrees and reduce the power of pedigree analysis, I 
used the command:  
merlin -d file.dat -p file.ped -m file.map –error 
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 Then, to erase from the input files the genotypes flagged as problematic I run the 
command:  
pedwipe -d error.dat -p error.ped  
MERLIN was then used to perform genome wide parametric linkage analysis using the 
command:  
merlin –d file.dat –p file.ped –m file.map –model file.model –markernames –-pdf –-
tabulate 
This produces an output file containing LOD scores for each marker and a PDF 
graphical representation of the results. At least three randomly generated sets of markers 
were generated to perform linkage analysis. 
Haplotype analysis allows to reconstructing the haplotype of a region of interest and 
checking segregation in the pedigree of the disease-associated haplotypes with disease 
status. Furthermore, it allows to possibly identifying recombination event, which could 
further narrow down the genomic intervals (fine mapping). 
Fine mapping and haplotype reconstruction were performed for chromosomal loci 
identified by linkage analysis with LOD scores >0. First, for each locus, a list of SNPs 
spanning the linked region was compiled and this was used to generate a new of input 
files  (.ped, .map, and .dat) using PLINK.  
Haplotype analysis was then performed using the MERLIN command:  
merlin -d haplo.dat -p haplo.ped -m haplo.map –-best –-horizontal 
3.10 Whole-Exome Sequencing  
WES was performed using the next-generation sequencing platform at Institute of 
Neurology. WES experiments were performed by Deborah Hughes and preliminary 
bioinformatics analysis by Dr Alan Pittman. The Truseq Exome Enrichment Kit 
(Illumina) was used for WES and run on an Illumina Hiseq 2000. This kit targets 64Mb 
of genomic sequence, including exons, exons-introns boundaries and UTRs and micro-
RNAs. This kit offers on average more than 90% coverage of the exons, as defined in 
the latest version of the CCDS and Refseq database.  
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The first of WES is the library preparation (Figure 3-2 .  n brief, 3μg of genomic DN  
must be sheared to form fragments, either by mechanical (Covaris) or enzymatic 
methods. This was followed by blunting of ragged ends of the DNA fragments and 
binding of the sequencing adapters. The latters contain unique indexes, which are 
unique for each sample and are essential in the next steps of the data analysis. After a 
series of PCR amplification, purification steps (to eliminate leftover adapters, enzymes 
and primers) and normalization (to ensure equal coverage of each sample in the total 
data), the libraries are ready for the enrichments stage. 
 
Figure 3-2 Scheme of the library preparation using the Truseq Illumina kit 
Reproduced from (http://tucf-genomics.tufts.edu/home/faq) 
 
The first step of enrichment is hybridization, during which the DNA fragments are first 
denatured to single strands and then bound to biotin-labelled probes specific for the 
target exome region. This is flowed by a series of capture and washing steps through a 
magnetic beads system and then the library is amplified through a final PCR step.  After 
a last washing step, the libraries are ready for cluster generation, which is completed 
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within the Illumina cBOT. To form the clusters, the single-stranded, single-molecule 
template are primed and extended and subsequently the immobilized templates undergo 
bridge amplification with immediately adjacent primers (Figure 3-3). 
A flow cell consists of eight lanes and is covered with a lawn of specific oligos to 
capture libraries as they are passed through the flow cell. Multiple samples can be 
pooled together and loaded in the same lane. The more libraries are pooled together the 
poorer will be the coverage.  
 
Figure 3-3 Cluster generation, bridge amplification and imaging 
Reproduced from Openwetware.org 
 
Following cluster generation and bridge amplification, the flow cell is loaded into the 
HiSeq 2000 for sequencing and imaging. After sequencing and imaging are terminated, 
the individual sample reads are de-multiplexed based on their unique indexes (Casava 
1.8.2). 
3.11 Bioinformatic Analysis of Whole-Exome Sequencing  
In order to obtain a final list of variants the WES raw data was run and analysed through 
a bioinformatics pipeline, constructed by Dr. Vincent Plagnol and optimized by Dr Alan 
Pittman. The pipeline is schematically represented in Figure 3-4. 
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The WES data generated by the HiSeq 2000 is stored in a FASTQ file, a text-based 
format for storing nucleotide sequence.  
Paired-end sequence reads are aligned with Novoalign (www.novocraft.com) against the 
reference human genome (UCSC hg19). Generation of duplicate DNA sequencing reads, 
which are due to PCR-induced duplication, is one of the most relevant technical 
artifacts of the capture-sequencing procedure. Duplicate read needs to be removed so 
that they do not influence variant calling and this step is performed with Picard software 
package (http://picard.sourceforge.net/).  
 
Figure 3-4. Bioinformatic pipeline for WES analysis. 
 
Information regarding the project, the genome and an alignment section, which includes 
mapping position and information on mismatches, are contained into tab-delimitated 
text files, called SAM files (.sam). A BAM file (.bam) is the binary version of a SAM 
file. BAM files, rather than SAM, are the recommended format for visualisation 
software.   
After the alignment is completed, variant calling is performed comparing at each 
genomic position the aligned SAM/BAM file to the reference genome. SAMTOOLS 
package (http://samtools.sourceforge.net/) is used to recalibrate base quality scores, 
perform local realignments around possible indels, and to call and filter the variants. 
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The outcome of the analysis is a Variant Call Format (VCF) file, which holds the list of 
identified genetic variants and the associated quality scores that take into account both 
base calling and mapping scores. 
ANNOVAR software is used to perform functional annotation the variants (Wang et al., 
2010). Annotated variant files are generated including a comparison to several publicly 
available reference databases of genetic variation, including the Exome Aggregation 
Consortium (ExAC; http://exac.broadinstitute.org/), dbSNP version 129 and 137 
(www.ncbi.nlm.nih.gov/projects/SNP), 1000 Genomes project (1kGP; 
www.1000genomes.org), NHLBI Exome Variant Server (EVS; evs.gs.washington.edu) 
and Complete Genomics 69 (www.completegenomics.com/public-data/69-Genomes).  
In silico prediction of pathogenicity is assessed using SIFT (http://sift.jcvi.org/) (Kumar 
et al., 2009), PolyPhen2 (http://genetics.bwh.harvard.edu/pph2/) (Adzhubei et al., 2010), 
Provean (http://provean.jcvi.org/) (Choi et al., 2012), MutationTaster 
(http://www.mutationtaster.org/) (Schwarz et al., 2014) and CADD 
(http://cadd.gs.washington.edu/home) (Kircher et al., 2014). Evolutionary conservation 
of nucleotides involved by variants is score using PhiloP (Pollard et al., 2010) and 
GERP++ (Davydov et al., 2010). 
Copy number variants (CNV) were called in WES data using the Exome depth 
algorithm (Plagnol et al., 2012). 
3.12 Regional Gene Expression Profiling in Brain Tissue 
To add further support to the causal role of newly identified gene variants, regional gene 
expression profile across various brain regions in humans was assessed using an in-
house and other publicly available datasets. The in-house dataset originated from the 
work of Dr Mina Ryten and Dr Daniah Trabzuni. This dataset was generated using 
Affymetrix Exon 1.0 ST Arrays and brain tissue originating from 134 control 
individuals, collected by the Medical Research Council (MRC) Sudden Death Brain and 
Tissue Bank, Edinburgh, UK, and the Sun Health Research Institute (SHRI), an affiliate 
of Sun Health Corporation, USA. Ten brain regions were analyzed: putamen (PUTM), 
frontal cortex (FCTX), temporal cortex (TCTX), hippocampus (HIPP), substantia nigra 
(SNIG), medulla (specifically inferior olivary nucleus, MEDU), intralobular white 
matter (WHMT), thalamus (THAL), and cerebellar cortex (CRBL). A full description of 
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the samples used and the methods of RNA isolation and processing can be found in 
(Trabzuni et al., 2011).  
As described therein, all arrays were preprocessed using Robust Multi-array Average 
(RMA) quantile normalisation with GC background correction and log2 transformation 
in  artek’s Genomics Suite  6.6   artek  ncor orated, US  . Regional differences in 
gene-level expression were investigated using Partek's mixed-model ANOVA with 
gender and batch effects (date of hybridization and brain bank) included as co-factors. 
RNA expression changes during the course of human brain development were assessed 
accessing the data available through the Human Brain Transcriptome (HBT) database 
(Johnson et al., 2009, Kang et al., 2011). The brain regions analyzed are the striatum 
(STR), amygdala (AMY), neocortex (NCX), hippocampus (HIP), mediodorsal nucleus 
of the thalamus (MD), and cerebellar cortex (CBC). The data is publicly available 
accessing the HBT website (http://hbatlas.org/). 
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Chapter 4. Exploring the Genetics of 
Parkinson Disease 
4.1 Outline Of The Chapter  
This chapter describes the work I conducted to expand our knowledge of the genetic 
basis of PD.    
The specific aims of the study were:  
1) To assess the contribution of genetic variation in GBA in the Queen Square cohort of 
early-onset PD 
 2) To characterise genetically the Queen square cohort of PD patients who underwent 
treatment with DBS and assess whether the genetic status influence the outcome of the 
treatment and disease progression;  
3) To assess the relationship between mutations in GCH1, the gene responsible for the 
childhood-onset disease DOPA-responsive dystonia, and PD. 
4.2 GBA Mutational Analysis In Early Onset Parkinson 
Disease  
4.2.1 Statement Of Contribution  
I participated to the design of this study and ascertained the cases to be included in this 
study. I performed the GBA sanger-sequencing analysis in the PD cases. Dr Raquel 
Duran performed the GBA sanger-sequencing analysis in the Gaucher disease (GD) 
cohort and in control samples. 
4.2.2  Background 
Patients with EOPD, in comparison to patient with late-onset PD (LOPD) tend to 
progress more slowly in terms of motor features and generally have a longer disease 
course, often with preservation of cognitive function. On the other hand, L-DOPA 
induced complications, including motor fluctuations and dyskinesias, tend to appear 
earlier and be more severe (Schrag and Schott, 2006).  
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As previously discussed in this thesis, mutations in several genes have been associated 
with EOPD, in particular autosomal recessive genes, including PARK2, PINK1 and 
PARK7 (Bonifati, 2012). PARK2 is by far the most commonly mutated gene in EOPD, 
whereas mutations in PINK1 and PARK7 are significantly more rare (Abou-Sleiman et 
al., 2003, Healy et al., 2004, Alcalay et al., 2010).  
PARK2 mutations are particularly common (frequency ~50%) in familial cases and in 
patients with very early onset (e.g. onset at age < 30), whereas their frequency drops 
(frequency ~10-15%) in sporadic cases and patients with later onset (e.g. onset at age > 
30 and < 50) (Lucking et al., 2000). 
The different clinical course of EOPD, together with pathological reports showing in 
most PARK2 mutations carriers the absence of the characteristic LBs (Doherty et al., 
2013), suggest that EOPD may represent a distinct clinical and pathological entity. 
Loss-of-function mutations in the acid β glucocerebrosidase gene  GBA), which are 
responsible for the autosomal recessive lysosomal disorder GD (Grabowski, 2008), 
represent the most prevalent genetic risk factor for PD identified to date (Sidransky et 
al., 2009).  So far genetic analysis has suggested that all GBA mutations causing GD 
can equally predispose to PD, the assumption being that variants that do not cause GD 
in the homozygous would not predispose to PD.  
In this this study, a complete sequence analysis of the open reading frame of GBA was 
performed in a cohort of 185 PD cases with early onset PD (EOPD; defined by an age at 
onset of ≤50 years . These data were compared with those obtained from 283 controls 
and 73 patients with type 1 GD from the same geographic region (Duran et al., 2012).  
This study had two main aims; first, to assess and quantify the contribution of GBA 
mutations in EOPD; second, to compare the spectrum of GBA mutations found in PD 
cases versus that of GD cases. Indeed, possible differences in the type of mutations 
found in the two disease groups may shed light onto the underlying pathogenic 
mechanisms responsible for PD and GD. 
4.2.3 Subjects, Materials and Methods  
Subjects 
The cohort included in this study was formed by 185 unrelated PD cases with an onset 
age ≤ 50  ho attended the Mo ement Disorders clinics at the National Hos ital Queen 
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Square. They were all diagnosed with PD following the UK Brain Bank Clinical 
Criteria, presenting with at least 2 of 3 cardinal signs of tremor, rigidity, and 
bradykinesia, as well as a positive response to L-DOPA therapy (Hughes et al., 1992).
 
The age-at-onset was on average 40 ± 7.2 years (range 16 – 50). A positive family 
history compatible with PD in at least a first or second-degree relative was reported in 
27.5% of patients (51/185) reported.  
Controls were age-matched subjects. This series of controls has been previously 
described (Neumann et al., 2009)
 
with the addition of twenty-six age-matched spouse 
controls. Controls were neurologically intact. All cases and controls were of UK 
Caucasian origin with no reported Jewish Ashkenazim background. GD patients were 
73 unrelated subjects, affected with the type 1 form of the disease (non-neuronopathic), 
attending the National GD clinics at the Royal Free and Addenbrookes Hospitals. 16 
were Ashkenazi Jewish (22%) and 4 had Eastern European ancestry (5.7%); the 
remainder were white UK citizens without Ashkenazi ancestry. The results of the GBA 
mutational screening of this cohort have been published independently (Duran et al., 
2012). Written informed consent was taken from each participant. 
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Genetic Analysis 
The open reading frame (11 exons) of the GBA gene (RefSeq accession number 
NM_000157.3) was entirely sequenced in cases and controls.
 
For PCR amplification of 
GBA, three different long-range PCR reactions were performed. To avoid amplification 
of the pseudogene, primers were designed to bind to DNA regions exclusively present 
within GBA. Primer sequences are listed in the appendix. Allele names refer to the 
processed protein, excluding the 39-residue signal peptide.  
Statistical Analysis 
Frequencies of coding and splice-site GBA variants in cases and controls were compared 
by means of Fisher’s exact  statistical significance set at    alue < 0.05 using a t o-
tailed test) and odds ratios (OR) and 95% confidence intervals (CI) were calculated. 
Analyses were performed using the statistical analysis program R (http://www.r-
project.org/). 
4.2.4 Results 
The results of the genetic analysis are summarised in Table 4-1. In this population of 
early-onset PD, a surprisingly high proportion of cases carried a GBA variant (25.94 %; 
48/185 individuals; odds ratio for carriers of any variant in cases versus controls: 7.9, 95% 
confidence interval 4.1 - 15.4, P < 0.0001). 14 of the GBA mutation carriers (29.7%) 
had a positive family history for PD, though we could not check segregation of the 
mutations in other affected family members due to unavailability of genetic material. 
Among the GBA mutation carriers, 22 cases had a known GD-causing pathogenic 
mutation (20 carried one mutation and two each carried two mutations), a proportion 
significantly higher than in a late-onset PD cohort from the same population reported by 
our group (11.9%; 22/185 individuals versus 3.8%; 30/790, p = 0.0001) (Neumann et al., 
2009).  
The most frequent GD-causing mutations found in the PD cohort was the N370S 
(p.Asn409Ser) that was observed in 5 cases, followed by R463C (p.Arg502Cys) and the 
recombinant allele RecNciI (L444P [p.Leu483Pro] + A456P [p.Ala495Pro] + V460V 
[p.Val499Val]), which were each present in 3 cases, and by L444P (p.Leu483Pro) and 
R131C (p.Arg170Cys), each found in 2 cases. All the other GD-causing mutations were 
each found in single individuals. In the control group the N370S (p.Asn409Ser) and the 
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R257Q (p.Arg314Gln), each found in 1 subject, were the only GD-causing mutations 
detected.  
Of relevance, one PD case carried the N370S (p.Asn409Ser) mutation in the 
homozygous state and, although this genotype is known to cause GD, he did not display 
any feature of GD. This is not entirely surprising, as the clinical spectrum in GD is wide 
and there are studies suggesting that patients homozygous for mild mutations, such as 
N370S, may actually never develop the disease (Cormand et al., 1997).
 
Furthermore, 
individuals with two pathogenic GBA variants, presenting with typical PD but showing 
no signs of GD, have already been reported in the literature (Lesage et al., 2011). 
The second important finding is that the single most common mutation in the PD group 
was E326K (p.Glu365Lys), which was detected at a frequency of 7.57% in cases 
(14/185 individuals; 12 were heterozygote, including one in combination with L444P 
and 2 homozygote) versus 2.47% in controls (7/283 individuals). To confirm this 
observation, a further 202 controls were screened for this variant and the frequency in 
this new cohort was 2.97 % (6/202). Taking into account both sets, the total frequency 
in controls was 2.68% (13/485 individuals), indicating a significant association of this 
variant with PD (p = 0.0059, odds ratio 2.97, 95 % confidence interval 1.3 -6.4).  
However, despite the high frequency in both PD and control groups, E326K 
(p.Glu365Lys) was not detected at all in the GD cohort (Duran et al., 2012). Consistent 
with previous reports (Park et al., 2002), this finding clearly indicates that this variant 
does not cause GD. Further supporting this conclusion, the two PD cases homozygote 
for the E326K did not have any of the clinical or haematological features of GD and 
their white blood cell GCase enzymatic activity was at the lower limit of normal range. 
Interestingly, a number of other variants, not present in GD group and never associated 
with GD, were also detected in the PD cohort. Of these E388K (p.Glu427Lys), G113A 
(p.Gly152Ala), T369M (p.Thr408Met), S465P (p.Ser504Pro) have been previously 
reported in both PD cases or controls, whereas L(-14)V (p.Leu25Val), V172L 
(p.Val211Leu), S177T (p.Ser216Thr), L217P (p.Leu256Pro), L354P (p.Leu393Pro), 
V375G (p.Val414Gly), c.1506-4 C>T, c.1506-12 C>T are novel. Collectively, these 
variants of undetermined clinical significance were more frequent in cases than in 
controls (OR 7.0 - confidence interval 1.8-31.6; p = 0.001).  
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Table 4-1 Proportion of cases and controls with GBA mutations 
GBA variants 
% in PD 
(n=185) 
% in controls 
(n=283) 
% in type 1 
GD (n=73) 
OR      
(95%CI)* 
N370S 2.70 (5) 0.35 (1) 86.30 (63) 
7.8              
(0.9-67.6) 
RecNciI 
(L444P+A456P+V460V) 
1.6 (3) 0 (0) 10.96 (8) Ø 
R463C 1.62 (3) 0 (0) 5.48 (4) Ø 
L444P 1.08 (2) 0 (0) 24.66 (18) Ø 
Other Gaucher’s causing 
mutations 
5.4 (10) 
2
 0.35 (1)
3
 45.2 (33) 
16.1          
(2.04-126.97) 
E326K 7.57 (14) 2.47 (7)
1 
0 (0) 
3.2              
(1.2-8.1) 
Other variants with unproven 
pathogenicity 
7.03 (13)
4
 1.06 (3)
5
 0 (0) 
7.0              
(1.8-31.6) 
Total 25.94 (48) 4.24 (12) 100 (100) 
7.9              
(4.1-15.4) 
The number of carriers for each GBA variant is in brackets  
*OR: Odds ratio calculated for PD patients versus controls.  CI: confidence interval. Ø: OR cannot be 
calculated, as all carriers were cases  
1Additionally further 202 individuals were screened for just this variant and the frequency in these 
additional samples was 2.97 % (6/202). The total frequency, taking into account both sets of controls, was 
2.68% (13/485 individuals).  
2 IVS2+1 (1), R131C (2), W184R (1), N188S (1), H255Q (1), R257Q (1), D409H (2), RecTL (1) 
3 R257Q (1) 
4 E388K (1), G113A (2), T369M (1), S465P (1), L(-14)V (1), V172L (2), S177T (1), L217P (1), L317L 
(1), L354P (1), V375G (1), IVS10-4 C>T(1), IVS10-12 C>T(1). 
5 E340A (1), T369M (1) and V458L (1). 
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4.2.5 Discussion  
This study reports the largest series of early-onset PD cases in which the GBA gene was 
entirely sequenced and shows that the frequency of GBA mutations is much higher than 
in late-onset patients from the same geographic area. Prior to this work, only one study 
had screened the entire GBA open-reading frame in EOPD cases, but in a much smaller 
cohort (Clark et al., 2007). Consistent with the results of this project, Clark and 
colleagues found that the frequency of GBA mutations was 22.2% in subjects with 
EOPD, compared with 9.7% in cases with classic LOPD. This indicates that GBA 
mutations represent by far the most common genetic alteration in EOPD, in particular in 
subjects with an onset of symptoms at ages between 30 and 50 years. As will be 
discussed more extensively in the next chapter, this finding bears important clinical 
consequences. It has been reported that EOPD cases often have a more benign disease 
course, in particular with regard to the risk of developing dementia (Schrag et al., 1998). 
However, this may not be true for carriers of GBA mutations, as it is now recognized 
that the risk of progression both to dementia and major motor difficulties (i.e. balance 
loss) is significantly greater in GBA mutation carriers (Alcalay et al., 2012, Winder-
Rhodes et al., 2013). 
Importantly, the GBA variant E326K was by far the most common variant found in this 
cohort (7.5% of cases screened), indicating that in north European populations this 
mutation may be the single most frequent predisposing factor for PD.  
The possibility that the E326K could be a risk factor for PD was raised before, but 
discarded as in previous studies it was a priori considered a benign polymorphism or 
the association with PD was not as robust as we describe in this study (Nichols et al., 
2009, Lesage et al., 2011).
 
These data confirm those initial observations and put 
uncertainty beyond doubt, demonstrating that indeed this variant does increase the risk 
of PD. Consistent with this results, similar data were presented by Pankratz and 
colleagues as part of a large meta-analysis of the existing available PD GWAS datasets, 
in which the E326K reached genome-wide significance (OR=1.71; p=5 × 10
-8
) and 
hence was highlighted as a susceptibility allele for PD (Pankratz et al., 2012). 
These results are in apparent contrast with the large meta-analysis of GBA in PD 
performed by Sidransky et al., which failed to demonstrate this association (Sidransky 
et al., 2009). This difference could be due to the heterogeneity of populations included 
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in that study. Indeed, it was enriched with subjects from populations (e.g. Asian, Jewish, 
Portuguese) in which the E326K is absent or very rare (Clark et al., 2007, Bras et al., 
2009, Mitsui et al., 2009).  
Although biochemical observations have demonstrated that the E326K is a subtle loss-
of-function variant (Montfort et al., 2004, Horowitz et al., 2011),
 
this reduction of the 
activity is clearly not severe enough to lead to disease in the tissues where GD is 
associated with lysosomal storage dysfunction. However, when E326K is detected on 
the same allele with another mutant variant (e.g. L444P, N188S, or N370S), it does not 
act as a neutral allele, and instead contributes to GD severity by further reducing the 
residual enzymatic activity (Grace et al., 1999, Chabas et al., 2005, Rozenberg et al., 
2006, Liou and Grabowski, 2012). 
The association of the E326K with PD and its absence in the GD cohort, together with 
the presence of many other novel rare GBA variants in the PD group not associated with 
GD, may suggest a possible dissociation of the pathogenic molecular mechanisms that 
underlie these two diseases. 
However, it is not clear whether the mild loss-of-function of the allele E326K is the 
cause of the increased risk for PD or whether other, still undetermined, effects of the 
mutation on lysosomal function are contributing to nigral neuron degeneration. Recent 
studies suggest that heterozygous GBA mutations may contribute to the pathogenesis of 
PD through a gain of function effect that may include endoplasmic reticular stress 
(Gegg et al., 2012). 
Interestingly, an overall enrichment of variants of undetermined clinical relevance was 
detected in the PD group. Although further population studies and functional analyses 
are warranted to substantiate this observation, these data indicate that there may be other 
GBA variants that predispose to PD but are not associated with GD. It is also possible 
that, as PD is a frequent disorder and a higher number of PD cases, compared to GD, 
are screened for GBA mutations, some of these variants are actually GD-causing 
mutations, simply not observed yet in GD cases.
 
In conclusion, this study shows that GBA mutations are the most common genetic 
abnormality in patients with PD with an age at onset below 50. These results strongly 
link the pathogenesis of EOPD to that of LOPD and suggest that both forms are part of 
the disease spectrum associated with the same underlying pathogenic process. 
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Furthermore, these results incontrovertibly establish a pathogenic role for the allele 
E326K. The latter extends the relevance of GBA dysfunction to a much larger number of 
PD patients than previously thought, bearing crucial implications for the development 
and application of future treatment targeting lysosomal dysfunction in PD. Finally, these 
data reflects the need to accurately explore the contribution of all GBA rare variants to 
the increased risk of PD and not just alleles that have been previously associated to GD. 
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4.3 Genotype-Phenotype Correlation in A Cohort Of 
Parkinson Disease Patients Treated With Deep-Brain 
Stimulation 
4.3.1 Statement of Contribution  
I performed all the genetic experiments and analysed the genetic data. Dr Aikaterini 
Angeli performed the clinical assessment and Dr Thomas Foltynie performed the 
clinical data analysis. 
4.3.2 Background 
Patients with PD may present significant heterogeneity in their clinical features, in 
particular with relation to their motor phenotype, their rate of disease progression and 
the development of non-motor symptoms (e.g. cognitive decline) (Foltynie et al., 2002). 
From a clinical viewpoint, the purpose of identifying PD subtypes is to aid individually 
tailored prognosis and to understand whether different subtypes of PD may show 
different responses to treatments.  
Previous authors have attempted to classify subgroups of PD patients based on clinical 
features, such as “Tremor Dominant  D” or “ kinetic-Rigid  D” (Jankovic et al., 1990).  
However, despite the recognition of the existence of PD heterogeneity, there has been 
little translation of theories into practice, largely because of the lack of consensus 
regarding how best to sub-classify PD based on clinical phenotype. Techniques other 
than clinical examination have been used to help explore PD heterogeneity, including 
neuro-physiological techniques (Morgante et al., 2006), CSF examination (Jellinger, 
2012), structural (Jubault et al., 2011) & functional imaging (Brooks and Pavese, 2011) 
biomarkers as well as clinico-pathological correlations have all been explored 
(Selikhova et al., 2009). However, to date there have been no convincing 
demonstrations that any of these methods can reliably distinguish subtypes of disease. 
It is possible that some features of PD phenotype heterogeneity could depend on the 
underlying genetic background, with superimposed effect of other environmental or 
stochastic inter-individual modifiers. A number of studies have described the phenotype 
of specific genetic mutations carriers and compared it to non-carriers (Lesage et al., 
2011, Marras et al., 2011), but a direct comparison of PD phenotype between carriers of 
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mutations in different genes are few (Gan-Or et al., 2010).  
Functional neurosurgery has embraced PD heterogeneity in day-to-day practice for 
many years. PD tremor responds very well to Deep Brain Stimulation (DBS) of the 
motor thalamus (Benabid et al., 1993), severe disabling dyskinesia responds very well 
to Globus Pallidum pars interna (GPi) DBS (Krack et al., 1998), whereas the Akinesia/ 
Rigidity of PD is best relieved through targeting the Subthalamic nucleus (STN) 
(Limousin et al., 1995). Given that the risks of neurosurgery become higher with 
advancing age, patients undergoing DBS are a very skewed group of PD patients, 
necessarily having had many years of PD but nevertheless still remaining young and 
judged fit enough to undergo neurosurgery. Consequently PD patients undergoing DBS 
tend to have relatively young onset disease and may contain an over-representation of 
genetic forms of PD. Furthermore, as part of the pre-operative workup, patients undergo 
a systematic evaluation of PD severity both in the absence and presence of medication, 
as their drug responsiveness is a helpful predictor of subsequent DBS response. 
I performed an extensive genetic characterization of a series of patients with PD 
undergoing DBS surgery in a single centre. Cases were screened for point mutations in 
PARK2, GBA, for exonic rearrangements in SNCA and PARK2 and for the presence of 
the LRRK2 variants c.6055 G>A; p.Gly2019Ser. 
The clinical phenotype among the carriers of different genetic mutations both on and off 
dopaminergic medication, as well as assessing the range of responses to DBS, was 
compared. In addition, a subgroup of these patients with complete longitudinal follow 
up assessments allows us to evaluate the natural history of PD following DBS according 
to genotype with respect to, perhaps the most important long term outcome, cognitive 
decline. 
4.3.3 Subjects, Materials and Methods  
Subjects 
94 patients who underwent DBS for PD were included in the study. The mean age at PD 
onset of the cohort was 40.4±8.2 (range 7-58). Of these 31 (32.9%) had a positive 
family history for PD in a first or second degree relative. 
Clinical assessment 
All patients included in this series were followed-up at the National Hospital for 
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Neurology and Neurosurgery (NHNN), Queen Square. As part of their routine 
assessment, details were recorded regarding their basic demographics such as age at 
onset, initial symptoms and disease duration. The L-DOPA equivalent dose was derived 
using standard formulae (Tomlinson et al., 2010). 
As part of the decision making process regarding appropriateness of DBS, all patients 
underwent detailed assessments including a formal L-DOPA challenge comparing 
scores on motor  art of the Unified  arkinson’s disease rating scale  U DRS  in the 
 ractically defined “Off state”- (overnight free from dopaminergic medication) and the 
“On state” after a L-DOPA challenge (250mg of oral dispersible L-DOPA). Additional 
assessments included a detailed battery of Neuropsychological assessments including 
the Mattis Dementia Rating Scale (DRS-2). From the UPDRS motor scale, sub-scores 
were derived to quantify tremor (based on the sum of items 20 and 21), akinesia and 
rigidity (based on the sums of items 22-26 and 31), and axial features (based on the sum 
of Items 18, 19, & 27-30). Part 4 of the UPDRS was divided into 2 sub-scores; items 32 
to 34 for dyskinesia and items 35-39 to reflect OFF periods.  
The optimal DBS target was chosen according to the frequency and severity of OFF-
symptoms, dyskinesias, tremor, speech-intelligibility, and cognition. STN was targeted 
in the majority of patients requiring DBS. However, the presence of severe dyskinesias 
was an indication to target the bilateral internal globus pallidus (GPi), whereas severe 
tremor, especially if unresponsive to L-DOPA and in the absence of other disabling PD 
symptoms, is an indication for DBS of motor thalamus (VIM DBS).  
Post-operative assessments were performed at 12 months after DBS implantation. A 
subgroup of patients with longer follow-up after DBS surgery was recruited to repeat 
cognitive assessment, including the DRS-2. Their mean annual change in cognitive 
performance between baseline and follow up was calculated as follows (DRS-2 score at 
baseline – DRS-2 score at follow up)/ number of years between assessments. 
Genetic analysis 
The coding regions and the flanking intronic sequences of PARK2 and GBA were 
analysed by PCR amplification and subsequent direct Sanger sequencing, as described 
in Materials and Methods. Primer sequences are listed in the appendix. Exonic 
rearrangements (deletions/duplications) in SNCA, PARK2, PINK1, PARK7 and the 
presence of the p.Gly2019Ser mutation in LRRK2 were screened using a multiplex 
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ligation-dependent probe amplification (MLPA), as described in Materials and Methods. 
Patients found by MLPA to be positive for LRRK2 p.Gly2019Ser mutation had this 
result confirmed by Sanger sequencing.  
Statistical analysis 
Chi-squared test was used to make comparisons between categorical data. Continuous 
data were checked for normality using Shapiro-wilk test. For normally distributed 
variables, one way analysis of variance (ANOVA) was used to compare genetic 
subgrou s.  ost hoc  air  ise com arisons  ere  erformed using Sidak’s method. For 
non-normally distributed variables, Kruskal-Wallis & non-parametric post hoc pair wise 
comparisons were used. Analyses were performed using the statistical analysis program 
R (http://www.r-project.org/). 
4.3.4 Results  
Genetic results 
27 out 94 patients included in the study (29%) carried at least one mutation in the genes 
I tested. The results of the genetic screening are summarised in Table 4-2. 
Eight individuals (8.5% of the cohort) had at least one pathogenic mutation in PARK2. 
Of these six had homozygous or compound heterozygous mutations (phase of the 
mutations unknown), while two patients had a single mutation only (one of whom also 
had a GBA T369M mutation). Given the controversial role of single heterozygous 
PARK2 mutations (Klein et al., 2007), only patients with bi-allelic PARK2 mutations 
were included in the phenotypic analysis.  
Eighteen patients (19.1% of the cohort) had at least one mutation in the GBA gene. 
Amongst the GBA mutation carriers, ten carried GD-causing mutations (of these one 
had the L444P combined with E326K) and five carried the pathogenic common risk 
factor E326K (four heterozygotes and one homozygote; see previous section of this 
chapter for further discussion about this variant). One case carried the novel variant 
L271P, predicted pathogenic by in silico prediction scores and therefore likely to be a 
deleterious variant. Two cases carried the variants T369M and E388K, respectively. 
Given the uncertainty regarding the clinical relevance of the two variants (Walker et al., 
2003) (Paciotti et al., 2012), these two cases were excluded as well from further 
phenotypic analysis.  
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Five patients (5% of the cohort) carried the common pathogenic mutation in LRRK2 
p.Gly2019Ser. One of the cases with p.Gly2019Ser also carried the E326K GBA 
mutation. This patient developed PD symptom at age 35, the youngest age at onset from 
the group of LRRK2 positive patients reported in this study and overall much earlier 
than the average age at onset of the LRRK2 mutation carriers (Healy et al., 2008).
 
This 
finding possibly suggests a synergistic effect of the two variants on the onset 
anticipation.  
The remaining 67 patients had no mutation detected using the genetic tests performed.  
Phenotypes 
The mean age at onset of the bi-allelic PARK2 carriers (26.6 years) was significantly 
lower than GBA mutation carriers (p=0.0009), LRRK2 p.Gly2019Ser mutation carriers 
(p=0.0008) and gene negative (p=0.006) patients (Table 4-3). There was no significant 
difference in the age at onset between the other groups. 
The mean duration of PD in patients undergoing DBS surgery was 15.0±6.6 years 
(range 3.8-38.0 years). Patients with PARK2 mutations had a longer duration of disease 
at the time of surgery than all other subgroups (p=0.007). On the contrary, GBA 
mutation carriers had a significantly shorter mean duration of disease at the time they 
needed DBS surgery compared to all other sub-groups (p=0.001) (Table 4-3). There was 
no difference in duration of disease between the LRRK2 p.Gly2019Ser and gene 
negative groups. 
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Table 4-2 Description of the genetic mutations in PARK2, GBA and LRRK2 in a cohort of PD 
patients with DBS surgery. 
Genetic test results n Description 
Age at symptom 
onset ± SD 
PARK2 
(Compound heterozygotes/ 
homozygotes) 
 
6 
Homozygous c.101_102delAG 
p.Gly430Asp+p.Arg275Trp 
c.337_376del+c.465_466del 
Homozygous del exons 3-4 
p.Arg275Trp+het dup of exon 6 
c.337_376del +p.Ala82Glu 
30 
20 
36 
27 
7 
39 
   (Mean  26.5±11.6) 
PARK2 
(Single mutation carriers) 
2 
p.Arg334Cys 
p.Pro437Leu + GBA T369M
a 
41 
39 
GBA* 
 
16 
R463C 
L444P+E326K 
N370S 
D409H 
recNcil 
R463C 
N188S 
R275Q 
IVS2+1 G>A 
L444P 
E326K/E326K 
E326K 
45 
34 
45 
39 
40 
45 
49 
42 
41 
45 
42 
36 
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E326K 
E326K 
E326K+LRRK2 p.Gly2019Ser
a
 
L217P
 
 
51 
58 
35 
39 
(Mean 42.9±6.2) 
LRRK2  5 
p.Gly2019Ser 
 p.Gly2019Ser 
p.Gly2019Ser 
p.Gly2019Ser 
p.Gly2019Ser +GBA E326K
a
 
 
40 
36 
49 
55 
35 
(Mean 43±8.7) 
No mutation found 67  (Mean 40.8±7.2) 
Numbers add up to 96 since 2 individuals marked with 
a 
are represented twice in the table in view of their 
carrying 2 mutations. 
* Allele names refer to the processed protein, excluding the 39-residue signal peptide 
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As part of the preoperative assessment for DBS, all patients underwent an L-DOPA 
challenge. All patients in this series had a good response to L-DOPA (mean UPDRS part 
3 improvement of 68% in the group as a whole), independently from the mutational 
status. This is not surprising, as a positive L-DOPA challenge represents an essential 
part of the basis for predicting a beneficial response from DBS surgery and therefore 
only patients with an excellent L-DOPA responsiveness were included in the cohort.  
Dyskinesia scores were higher in the PARK2 bi-allelic mutations carriers, in spite of the 
lower doses of L-DOPA they were taking.  
All patients in this series had baseline neuropsychological performance that was judged 
to be clinically acceptable for DBS surgery.  
During pre-operative assessment in the off phase, there were no overt differences in the 
motor phenotype according to mutational status. Tremor was present in all subgroups, 
and the proportion of tremor compared with akinesia/rigidity or axial features was 
similar in each group. 
Chi-squared
 
analysis showed a significant difference in targeted brain region for DBS 
according to mutational status (p<0.001), with an excess of PARK2 and GBA patients 
that received bilateral GPi DBS rather than STN DBS.  
There were no significant differences in the level of improvement obtained with STN 
DBS between gene negative patients and patients with PARK2, GBA or LRRK2 
mutations. 
Longitudinal 5-year follow up data regarding cognitive performances were available for 
35 subjects, all treated with STN DBS, and amongst them six were GBA mutations 
carriers. The mean reduction in Mattis DRS-2 scores in patients with GBA mutations 
was 4.4±7.3 points per year, compared with 0.5±0.9 points per year among gene 
negative patients, although this did not reach threshold for significance. 
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Table 4-3 Pre-operative UPDRS scores and response to L-dopa according to genetic subgroup 
Genetic results 
Duration of 
PD at DBS 
assessment yrs 
(SD) 
L-dopa 
Equivalent 
Dose;  
mg (SD) 
UPDRS 
part 1 
(SD) 
UPDRS 
part 2 
OFF 
meds 
(SD) 
UPDRS 
part 2 On 
meds 
(SD) 
UPDRS 
Part 3 Off 
meds 
(SD) 
UPDRS 
part 3 On 
meds 
(SD) 
Percentage 
improvement 
UPDRS part 3 
with L-dopa 
UPDRS    Part 
4 Dyskinesia 
score (SD) 
UPDRS 
Part 4 
Off Score 
PARK2 (N=6) 25.2 (12.8) 960 (611) 1.7 (2.0) 24.3 (4.0) 6 (6.2) 
57.0 
(11.2) 
21.0 (6.4) 61.0 (18.3) 5.3 (3.9) 3.5 (1.3) 
GBA (N=16) 11.2 (5.0) 1143 (540) 1.5 (1.5) 
24.6 
(11.3) 
10.9 
(12.3) 
51.3 
(14.0) 
18.0 
(15.4) 
66.9 (18.6) 3.2 (2.7) 4.9 (1.9) 
LRRK2 (N=5) 12.1 (1.8) 1317 (803) 1.3 (1.3) 26.8 (7.9)  4.5 (4.3) 
65.4 
(14.9) 
10.8 (5.1) 84.9 (5.5) 3.5 (3.1) 4.8 (0.9) 
No mutations found 
N=67 
15.1 (5.5) 1280 (548) 2.0 (1.7) 22.7 (7.9) 8.0 (7.3) 
47.4 
(14.7) 
15.6 
(11.3) 
68.5 (19.3) 3.2 (2.3) 4.5 (1.2) 
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4.3.5 Discussion  
This study shows the usefulness of studying a cohort of cases undergoing DBS as a 
valuable resource for detecting genetic forms of PD. DBS is usually performed in 
patients with advanced PD that has been refractory to non-invasive therapies, and yet 
patients are also selected on the basis that they are still young enough to tolerate 
invasive neurosurgery. Therefore, it is not surprising that EOPD are over-represented in 
this cohort.  
While some of the Mendelian forms of PD can present in later decades, it is indeed well 
established that, overall, mutations in most Mendelian genes tend to be associated with 
an earlier onset of symptoms (Alcalay et al., 2010). This could explain in part why the 
frequency of PD genes mutation carriers is much higher in this cohort (27/94 patients; 
29%), than in population representative cohorts of PD (Winder-Rhodes et al., 2013). 
Although it is widely known that both GBA mutations (Sidransky et al., 2009) and 
LRRK2 mutations (Ozelius et al., 2006) are more common in Jewish populations, this 
was not the reason for the high rate of gene positive subjects in our cohort. 
While the use of DBS cohorts represents a clear advantage in terms of facilitating a 
rapid identification of gene positive patients, there are some biases to consider that may 
impact on the relevance of these data to the broader PD population. Patients with major 
cognitive, main psychiatric problems or lack of L-DOPA response are excluded during 
the selection process, and therefore this limits the ability to comment whether these 
features are more or less frequent according to mutational status. However, in this study 
it was therefore possible to explore the underlying PD phenotype and disease 
progression in patients undergoing with DBS with different genetic forms of PD, 
without the major bias of dopamine replacement. Patients were indeed routinely 
systematically evaluated On and Off medication as part of their DBS work-up, and thus 
it was possible to observe and evaluate their Off medication phenotype. 
Apart from confirming the known PARK2-related feature of younger age at onset and 
earlier and more severe L-DOPA induced dyskinesias (Doherty et al., 2013), any 
consistent phenotypic difference between carriers of mutations in different genes and 
gene negative cases were not identified at a single time point. This includes evaluating 
the relative distribution of tremor, akinesia/rigidity and axial features as well as the 
degree of L-DOPA responsiveness.  
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However, a number of interesting observations were made through analysis of the 
longitudinal data. Duration of disease at time of needing DBS surgery was significantly 
different between genetic subgroups. As mentioned, PARK2 mutation carriers had an 
earlier age at onset of disease and earlier dyskinesias, however they also have a longer 
duration until requiring DBS, which indicates a more benign form of disease. As 
observed in this study, PARK2 patients have been previously reported to respond well to 
DBS (Capecci et al., 2004, Romito et al., 2005, Lohmann et al., 2008, Moro et al., 
2008), though these series restricted their reports to response to STN DBS. In this series 
the GPi target was favoured, given the greater severity of dyskinesias in PARK2 cases. 
Importantly, PD patients carrying GBA mutations needed DBS significantly earlier in 
their disease course than any other mutation group. At the time of needing DBS, GBA 
mutations carriers presented off-medication comparable clinical features to other groups, 
while with a significantly shorter duration of disease. This suggests a more aggressive 
form of the disease in PD patients with GBA mutations. This is in keeping with data 
obtained from an unselected population of PD cases from the UK showing that PD 
patients with GBA mutations have a faster rates of progression to major motor end-
points (Hoehn and Yahr stage 3) in cases followed longitudinally (Winder-Rhodes et al., 
2013). At one-year follow-up, the response to both STN DBS and GPi DBS was not 
different between GBA patients and the other groups. However, longer follow up 
showed that patients undergoing STN DBS with GBA mutations may develop far 
greater cognitive impairment than any other group. This possibly suggests there may be 
an interaction between GBA status and risk of subsequent decline following DBS. 
Consistent with this observation, a previous report of three GBA patients undergoing 
STN DBS also identified a more aggressive process that lead to both cognitive 
impairment and axial impairments (Weiss et al., 2012).  
Patients with LRRK2 mutations have been previously shown to have a good response to 
STN DBS (Schupbach et al., 2007, Gomez-Esteban et al., 2008, Breit et al., 2010). 
Consistent with previous data, this study confirms that G2019S mutation carriers have 
indeed an excellent response to STN DBS, without risk of major cognitive decline. The 
particular suitability of LRRK2 G2019S mutation carriers to DBS treatment may explain 
the surprisingly high frequency of the mutation in this cohort (~5%), compared to 
unselected PD case from the UK (~1%) (Healy et al., 2008).  
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In conclusions, from a longitudinal perspective, differences in phenotype between 
carriers of mutations in different genes appear to clearly emerge. PARK2 mutation 
carriers have a younger onset of disease and more severe dyskinesias, but overall a more 
indolent disease course. On the other hand, patients with GBA mutations have a more 
aggressive motor disease needing earlier intervention with therapies such as DBS and 
are likely to have more rapid cognitive impairment following STN DBS implantation. 
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4.4  Mutational Analysis of the GTP cyclohydrolase-1 Gene in 
Parkinson Disease 
4.4.1 Statement of Contribution  
I designed the research, performed the genetic analysis and collected the clinical 
information concerning the four pedigrees reported in the first section of the study, 
performed clinical assessment and DNA and RNA analysis in family 1, and analysed the 
whole-exome sequencing data, generated and provided by the International Parkinson 
Disease Genetic Consortium (IPDGC) and UCL-exomes. Dr Ioannis Isaias performed 
the analysis and quantification of the dopaminergic imaging data.  
4.4.2 Background 
GTP cyclohydrolase 1 (GTPCH), encoded by the GCH1 gene (14q22.1-q22.2; OMIM 
600225), is the enzyme controlling the first and rate-limiting step of the biosynthesis of 
tetrahydrobiopterin (BH4), the essential cofactor for the activity of tyrosine hydroxylase, 
and for dopamine production in nigrostriatal cells (Kurian et al., 2011). 
Mutations in GCH1 are the commonest cause of dopa-responsive dystonia (DRD) (Clot 
et al., 2009), a disorder that presents typically in childhood with lower limb dystonia 
and subsequent generalisation (Nygaard, 1993). An excellent and sustained response to 
small doses of L-DOPA, generally without the occurrence of motor fluctuations 
generally observed in patients with PD, is the classic hallmark of the disease (Trender-
Gerhard et al., 2009).  
The diagnosis of GTPCH-deficiency may be supported by low cerebrospinal fluid (CSF) 
levels of pterins, dopamine and serotonin metabolites (Assmann et al., 2003) or by an 
abnormal phenylalanine-loading (PLT) (Bandmann et al., 2003).  
Inheritance is usually autosomal dominant with incomplete penetrance (Furukawa et al., 
1998), though recessive cases have been described (Opladen et al., 2011). Dominant 
GCH1 mutations result in a significant reduction of GTPCH activity through a 
dominant negative effect of the mutant protein on the normal enzyme (Hwu et al., 2000). 
Neuropathological examination, in a limited number of DRD cases, revealed marked 
reduction of melanin pigment and dopamine content in nigrostriatal neurons, but no 
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evidence of nigral cell loss or degeneration (Furukawa et al., 1999). 
Parkinsonian features are common in patients with DRD (Tassin et al., 2000) and 
carriers of GCH1 mutations may develop adult-onset parkinsonism in absence of 
dystonia (Nygaard et al., 1990). Based on previous studies, the prevailing hypothesis 
was that parkinsonism represented an atypical, age-specific, presentation of DRD 
without nigral degeneration (Nygaard and Wooten, 1998). 
The aim of this work was to explore the relationship between GCH1 mutations and 
parkinsonism and investigate whether adult GCH1 mutation carriers are actually at 
increased risk of developing true neurodegenerative PD. 
4.4.3 Subjects, Materials and Methods  
Family Study 
Pedigrees 
DRD pedigrees were included in the study, where family members affected with adult-
onset parkinsonism were available for clinical and genetic examination and in whom 
dopaminergic studies had been performed. Local ethics committees approved the study 
and informed consent for genetic testing was obtained in all cases.  
Genetic Analysis 
Probands were screened for GCH1 mutations (NCBI transcript NM_000161.2) by 
standard bi-directional Sanger sequencing of all 6 coding exons and exon-intron 
boundaries. Dosage analysis for GCH1 exonic deletions and duplications was 
performed by MLPA. Sanger sequencing and MLPA were performed as described in the 
Materials and Methods.  
To test the effect of the splice-site variant c.343+5G>C identified in family-A, 
messenger RNA (mRNA) was extracted from peripheral blood of individuals II-1 and 
III-1 using the PAXgene Blood RNA System (Qiagen/PreAnalytix). Following RNA 
extraction, complementary DNA (cDNA) was synthesized using the Applied 
Biosystems High-Capacity cDNA reverse transcription kit. The GCH1 transcript was 
amplified using exonic primers in exon 1 and exon 3 in both cases and two controls 
(supplementary Fig. 1A). Following separation by agarose gel electrophoresis, the 
mutant bands from the patient samples were extracted and sequenced. 
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Transcript PCR primers 
GCH1_exonic_1F GGGAGTGTGATCTAAGCAG 
GCH1_exonic_3R AAGTTTGCTGAGGCCAAGG 
 
A SYBR Green PCR assay was designed to establish if the c.343+5G>C mutation 
caused retention of GCH1 intron 1. Two PCRs were employed, each using the same 
reverse primer in exon 3 (GCH1_rt_Exon3_R), and a forward primer in either intron 1 
(GCH1_rt_Intron1_F) or exon 1 (GCH1_rt_Exon1_F).  
rtPCR primers 
GCH1_rt_Intron1_F catgttactaaagcaagcctctga 
GCH1_rt_Exon1_F TCTTCACCAAGGGCTACCAG 
GCH1_rt_Exon3_R AAGTTTGCTGAGGCCAAGG 
 
Real-Time PCR was performed on a RotorGene 6000, measuring product accumulation 
after each amplification cycle. All PCRs for the standard curves and samples were 
performed in triplicate, the results for sample replicates were averaged. Serial dilutions 
of control cDNAs were prepared for each PCR over a 27- 490 fold range. Standards and 
patient samples were amplified on the same experimental run. Rotor-Gene 6000 Series 
Software 1.7 was used to calculate the cycle threshold (Ct) at which exponential 
amplification was occurring in the PCRs and a standard curve was plotted for each PCR 
(log DNA concentration vs. Ct) from the serial dilutions. The relative concentration of 
each transcript was then calculated for all samples by interpolating from the standard 
curves. The ratio of immature/mutant transcript : Wild-Type transcript abundance was 
then derived for each sample.  
Dopamine transporter imaging studies 
Dopaminergic striatal innervation was evaluated as dopamine reuptake transporter 
(DAT) density by means of Single Photon Computed Tomography (SPECT) and 
[
123
I]N-ω-fluoropropyl-2β-carbomethoxy-3β-(4-iodophenyl) tropane ([123I]FP-CIT). 
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SPECT data acquisition and reconstruction has been described in details elsewhere 
(Isaias et al., 2010). To obtain comparable measurements among different centers, 
[
123
I]FP-CIT binding values for the caudate nucleus and putamen were calculated by 
means of the Basal Ganglia Matching Tool (Nobili et al., 2013). 
Whole-exome sequencing study 
Participants and study design 
The study initially involved 1337 unrelated subjects with PD and 1764 controls of 
European origin or North American of European descent that underwent whole-exome 
sequencing. 
Patients, originating mainly from the USA, UK, Holland and France, were recruited by 
the IPDGC). A further 190 PD cases were recruited through a community-based 
epidemiological study of PD in Estonia (University of Tartu, Estonia). 
Patients with PD were clinically diagnosed according to the UK Parkinson disease 
Society Brain Bank (UKPDSBB) criteria (Hughes et al., 1992).  
Control samples were collected by the UCL-exomes. Controls had no diagnosis of PD, 
DRD or any other movement disorder. Whole-exome sequencing data from additional 
4300 North American individuals of European descent were analysed from the publicly 
available from the NHLBI Exome Sequencing Project Exome Variant Server (EVS) 
database. 
Procedures 
Whole exome-sequencing was performed as described in the Materials and Methods. 
Statistical analysis 
Frequencies of coding and splice-site GCH1 variants in cases and controls were 
com ared by means of Fisher’s exact  statistical significance set at P value < 0.05 using 
a two-tailed test) and odds ratios (OR) and 95% confidence intervals (CI) were 
calculated. Analyses were performed using the statistical analysis program R 
(http://www.r-project.org/). 
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4.4.4 Results 
Family study 
Family A  
The proband (III-1, Figure 4-1A) is a British 18-year-old man who had a difficult 
caesarean birth, with perinatal distress and subsequent developmental delay. At 18 
months he developed inward turning of his feet with walking difficulties and frequent 
falls. He was diagnosed clinically with DRD at the age of 3 and administration of L-
DOPA (300mg/day) markedly improved his symptoms. [
123
I]FP-CIT SPECT, performed 
at the age 17, was normal. The  roband’s father    -1), who was initially thought to have 
cerebral palsy due to a birth injury, was subsequently diagnosed at age 42 with DRD. 
The  roband’s grandfather   -1) is a 65 year-old man with a six-year history of 
progressive asymmetric rest tremor in the right upper limb. Examination showed signs 
of typical PD with hypomimia, unilateral rest tremor and asymmetric bradykinesia. He 
did not present signs of dystonia. [
123
I]FP-CIT SPECT showed bilateral reduced tracer 
uptake more marked on the left, consistent with nigrostriatal dopaminergic denervation. 
He responded well to L-DOPA therapy (300mg/day). 
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Figure 4-1 Pedigrees and [
123
I]FP-CIT SPECT scan images of the four families with GCH1 mutations involved in this study 
P=Parkinson disease. D=DOPA-responsive dystonia
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GCH1 analysis revealed a heterozygous splice site mutation (c.343+5G>C) in the three 
affected individuals. We previously detected c.343+5G>C in a recessive pedigree, 
carried by the unaffected mother of two very severely affected children who also 
inherited the K224R mutation from their unaffected father (Bandmann et al., 1996, 
Trender-Gerhard et al., 2009). However the c.343+5G>C mutation has not been 
previously described in DRD dominant pedigrees, making its pathogenicity uncertain.  
To test the pathogenic effect of this variant on splicing, messenger RNA (mRNA) was 
extracted from peripheral blood of individuals II-1 and III-1 and the GCH1 transcript 
was amplified using exonic primers in exon 1 and exon 3 in both cases and two controls 
(Figure 4-2A). Following separation by agarose gel electrophoresis, the mutant bands 
from the patient samples were extracted and sequenced. Sequencing of the upper mutant 
band (352 bp) revealed a mutant transcript whereby exon 2 is spliced to base c.50 of 
exon 1, splicing-out 293 bp of exon 1 that would be predicted to cause a premature 
truncation of the protein after 8 out-of-frame amino acids (Figure 4-2A and B). 
Sequencing of the second mutant transcript at ~200 bp failed. 
The low intensity of the mutant bands in Figure 4-2A prompted us to consider other 
possible effects of this mutation. A SYBR Green PCR assay was designed to establish if 
the c.343+5G>C mutation caused retention of GCH1 intron 1. As illustrated in figure 1, 
the Intron 1 – Exon 3 PCR captured any transcripts in which at least some splicing had 
occurred (exon 2 to exon 3), but in which intron 1 had not been spliced-out. This is 
referred to as 'immature/mutant transcript'. The ratio of the abundance of the transcripts 
was derived and indicates that the mutant/immature transcript is significantly more 
abundant relative to WT transcript in the patients than controls (Figure 4-2C), 
confirming that the c.343+5G>C mutation abolishes splicing of intron 1 and is therefore 
likely to lead to haploinsufficiency. 
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Figure 4-2 RNA analysis performed in family-A 
A) Transcript PCR: PCR from GCH1 exon 1 to exon 3 revealed additional bands in the patients carrying 
the c.343+5G>C mutation compared to controls (Con1 and Con2) at 352 bp and ~200 bp. (B) Mutant 
Transcript Sequencing: Sequencing electropherogram screenshot showing mutant GCH1 transcript from 
patient III-1 whereby exon 2 is aberrantly spliced to c.50 of exon 1. If translated, this would result in 16 
in-frame amino acids, followed by 8 out-of-frame amino acids before a premature stop codon. (C) Intron 
1 Retention: Two GCH1 cDNA PCRs each used a common reverse primer in exon 3 and a forward 
primer either in intron 1 (to detected incompletely-spliced or mutant transcript) or exon 1 (to detect wild-
type (WT) transcript). Transcripts are shown with exons 1 to 6 alternately shaded and numbered, the 
translational start (ATG) and stop (X) sites are indicated with vertical lines. Each SYBR Green PCR was 
performed on cDNA from patients II-1 and III-1 (two independent extractions from each) and 6 controls. 
The ratio of the abundance of the transcripts was derived and indicates that the mutant/immature 
transcript is significantly more abundant relative to WT transcript in the patients than controls (Mean +/- 
SE; Student's t-test). 
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Family B  
The proband (III-1; Figure 4-1B) is a 12-year-old right-handed female of German origin 
with DRD, with an onset at age 11 with writing and foot dystonia. Her mother (II-1) 
presented at age 39 with progressive loss of dexterity and slowness in her right arm and 
dystonic posturing of the right foot. Examination showed an asymmetric rigid-akinetic 
parkinsonian syndrome without tremor and severe right foot fixed dystonia. L-DOPA 
therapy resulted in marked improvement of both dystonic and parkinsonian symptoms. 
[
123
I]FP-CIT SPECT revealed an asymmetric bilateral reduced tracer uptake, more 
marked in the left striatum. There was sustained response to L-DOPA therapy although 
there was an increase in dose requirement (up to 800mg/day). L-DOPA -induced 
dyskinesias developed 6 years after initiation of L-DOPA. Examination of the  roband’s 
66-year-old grandmother (I-1) revealed oromandibular dyskinesias and upper limb 
dystonic features. She declined a trial of L-DOPA. Her [
123
I]FP-CIT SPECT displayed 
border-line reduced DAT values in both putamens.  
GCH1 screening in this family revealed two variants: c.68C>T; p.Pro23Leu (carried by 
III-1 and II-1) and c.312C>A;p.Phe104Leu (carried by II-1 and I-1). There were no 
GCH1 exonic rearrangements. F104L is absent in public control datasets and has been 
previously reported in association with DRD (Clot et al., 2009). p.Pro23Leu 
(rs41298432) is a benign polymorphism present in population controls at a frequency of 
1-2% (Jarman et al., 1997, Hauf et al., 2000). 
To confirm GTPCH deficiency, PLT (100 mg/kg) was performed in individuals I-I and 
II-I and showed pathologically elevated phenylalanine/tyrosine ratios in both cases 
(Figure 4-3). CSF analysis, performed in individual III-I, displayed low levels of BH4 
(13 nmol/l; 18-53 nmol/l) and neopterin (6nmol/l; 10-31 nmol/l), consistent with 
GTPCH deficiency. Given the benign nature of p.Pro23Leu, we hypothesize that the 
GTPCH deficiency confirmed in this patient may be the result of an as yet unidentified 
non-coding causative mutation. 
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Figure 4-3 Phenylalanine-loading test performed in family B 
Abnormally elevated ratios of phenylalanine (Phe) and tyrosine (Tyr) plasma levels at 1, 2, 4, and 6 hours 
after oral loading with phenylalanine (100mg/kg) in individual I-1 (c.312C>A;p.Phe104Leu), II-1 
(c.68C>T;p.Pro23Leu and c.312C>A;p.Phe104Leu) of family B compared to healthy subjects (HS). 
 
Family C  
The proband (II-1, Figure 4-1C) is a German 41-year-old lady, affected by DRD, who 
presented at age four with bilateral foot inversion on walking. Her father (I-1) is a 67-
year old man with a one-year history of typical PD with left hand rest tremor, bilateral 
rigidity and bradykinesia and mild gait difficulties. There was no dystonia. [
123
I]FP-CIT 
SPECT examination revealed asymmetrically reduced DAT-density in the striatum. 
Rasagiline and pramipexole were started with good response. The mother (I-2), aged 62, 
had a normal neurological examination. 
The proband was compound heterozygous for two GCH1 missense variants, c.610G>A; 
p.Val204Ile, inherited from the asymptomatic mother, and the novel variant c.722G>A; 
p.Arg241Gln, which was paternally inherited. p.Arg241Gln is absent in all public 
control datasets, is predicted deleterious by all in silico prediction tools and involves an 
amino acid residue conserved down to invertebrate species. Furthermore a pathogenic 
mutation at the same residue has already been reported (Bandmann et al., 1998).  
CSF analysis in the parkinsonian case supported a pathogenic effect of the p.Arg241Gln 
mutation on GTPCH activity: pterin analysis revealed low BH4 (8 nmol/L; 18-53), but 
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normal neopterin (24 nmol/L; 10-31); neurotransmitter analysis showed low 
homovanillic acid (95 nmol/L; 115-455) and 5-hydroxyindolacetic acid (59 nmol/L; 61-
204), which are metabolites of dopamine and serotonin respectively. 
Family D  
The proband is an Italian 58-year-old lady (II-1, Figure 4-1D), who developed 
progressive tremor and clumsiness in the right arm at age 44. Clinical examination 
showed typical PD with hypomimia, hypophonia and asymmetrical bradykinesia and 
rigidity. Action dystonic tremor (right>left), poor postural reflexes and slow gait were 
also evident and there was a sustained response to L-DOPA. The dose was gradually 
increased up to 400 mg/day after which rotigotine 4 mg/day was added. Dyskinesias 
and wearing-off symptoms developed 6 years after L-DOPA initiation. [
123 
I]FP-CIT 
SPECT revealed asymmetrically reduced DAT binding values in the striatum. 
Her sister (II-2; Figure 4-1D), aged 60, had a childhood onset of mild walking 
difficulties. At age 55, she developed exercise-induced left foot dystonia and dystonic 
tremor in both arms. She had no bradykinesia or other parkinsonian signs. Low-dose L-
DOPA (100mg alternate days) was started with excellent symptom control. [
123
I]FP-CIT 
SPECT was normal. Their father was reported to have a tremulous condition but was 
not available for clinical or genetic examination. GCH1 sequencing revealed that both 
sisters were heterozygous for the previously reported pathogenic mutation c.626+1G>C 
(Garavaglia et al., 2004). 
The structure of the four pedigrees is shown in Figure 4-1. DAT binding values are 
reported in Table 4-4.. The main clinical features of the GCH1 mutation carriers with 
adult-onset parkinsonism and abnormal [
123
I] FP-CIT SPECT imaging are summarized 
in Table 4-5. Their clinical features fully met the UKPDSBB criteria for definite PD 
diagnosis. None of these cases presented significant diurnal fluctuations, worsening of 
symptoms in the evening or substantial sleep benefit, features often recognised in DRD 
cases (Kurian et al., 2011). 
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Table 4-4 DAT binding values of GCH1 mutation carriers evaluated in this study 
Subject Phenotype L-putamen R-putamen L-caudatus R-caudatus 
Family A/ I-1 PD 2.08 
b
 2.74
 a
 3.51 4.28 
Family B/ II-1 PD 2.63
 b
 3.73
 a
 4.72 4.94 
Family B/ I-1 DRD 2.85 
a
 2.96
 a
 3.95 3.95 
Family C/ I-1 PD 1.86
 b
 1.64
 b
 2.52
 b
 2.19
 b
 
Family D/ II-1 PD 1.53
 b
 2.63
 b
 3.29
 a
 4.5 
Family D/ II-2 DRD 5.38 5.27 5.71 5.82 
Values are expressed as the ratio of [
123
I]FP-CIT specific uptake in the region of interest/background. 
[
123
I]FP-CIT binding values for the caudate nucleus and putamen were calculated by means of the Basal 
Ganglia Matching Tool. 
a 
Value
 
below 97% inferior confidence limit of healthy controls
 
b 
Value
 
below 90% inferior confidence limit of healthy control 
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Table 4-5 Characteristics of PD cases with GCH1 pathogenic variants and abnormal dopaminergic imaging described in this study and present in the 
literature 
Origin Sex/Age at 
scan/Age at 
onset (y) 
Mutation Relatives 
with 
DRD 
Age at 
L-DOPA 
start (y) 
Current treatment 
dose (mg/day) 
Parkinsonian 
features 
Dystonic 
features 
L-DOPA-
induced 
complications 
Scan Result Reference 
UK M/65/59 c.343+5G>C/w Son and 
grandson 
60 L-dopa 300 Hypomimia, R hand 
rest and re-emergent 
postural tremor, and 
bilateral rigidity and 
bradykinesia (R>L) 
No No Bilateral 
(L>R) 
reduced 
DAT density 
Present 
study 
(Family A) 
Germany F/47/39 p.Phe104Leu/ 
p.Pro23Leu 
Daughter,  
mother 
(?) 
41 L-dopa 800 Hypomimia, 
bilateral rigidity, 
bradykinesia, 
reduced arm 
swinging (R>L), 
and mild gait 
difficulties 
R foot 
dystonia 
Dyskinesias 
after 6 y of 
therapy 
Bilateral 
(L>R) 
reduced 
DAT density 
Present 
study 
(Family B) 
Germany M/67/66 p.Arg241Gln/w Daughter / Rasagiline 1 
Pramipexole 0.375 
Hypomimia, L hand 
rest tremor, bilateral 
bradykinesia and 
rigidity (L>R), and 
mild gait difficulties 
No No Bilateral 
(R>L) 
reduced 
DAT-density 
Present 
study 
(Family C) 
Italy F/58/44 c.626+1G>C/w Sister 53 L-dopa 400 
Rotigotine 4 
Hypomimia, 
bilateral rigidity and 
bradykinesia (R>L), 
mild postural 
instability, and gait 
difficulties 
Bilateral 
(R>L) upper 
limb 
dystonic 
tremor 
Dyskinesias 
after 6 y of 
therapy 
Bilateral 
(L>R) 
reduced 
DAT density 
Present 
study 
(Family D) 
Japan M/54/39 p.Arg184His/w No 40 L-dopa 600 Cogwheel rigidity, 
akinesia, and 
postural instability 
Dystonic 
posture in 
the four 
limbs (R>L) 
Wearing-off 
and dyskinesias 
after 10 y of 
therapy 
Bilateral 
reduced  FD 
intake 
Kikuchi et 
al. 
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Denmark M/38/28 p.Pro199Ser/w Brother 33 L-dopa 350 
Entacapone 
Selegiline 5 
Bradykinesia and 
rigidity in the L arm 
Dystonia of 
neck, trunk 
and four 
limbs, action 
tremor 
(L>R) 
Dyskinesias 
after 2 y of 
therapy 
Bilateral 
(R>L) 
reduced 
DAT density 
Hjermind et 
al. 
Germany F/65/50 Complete 
deletion of the 
GCH1 gene/w 
Daughter 60 (for 
10 y on 
dopamine 
agonist 
only) 
L-dopa 200 
Selegiline 5 
Tremor in the R 
hand, reduced 
dexterity and mild 
gait disturbance 
No No Bilateral 
(L>R) 
reduced 
DAT density 
Eggers et al. 
Italy M/59/NA Deletion of 
exons 5-6/w 
Son with 
DRD, 
sister 
with 
MSA 
NA NA Hypomimia, L hand 
rest tremor. 
bradykinesia (L>R), 
mild gait difficulties 
No Dyskinesias 
after 10 y of 
therapy 
Bilateral 
reduced 
DAT density 
Ceravolo et 
al. 
NA=not available; DRD=dopa-responsive dystonia; H&Y=Hoehn and Yahr; F=female; M=male L=left; R=right; MSA=multiple-system atrophy; y=years; w=wild-
type. 
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Whole-exome sequencing study 
To investigate if pathogenic variants in GCH1 could be found in PD subjects without a 
family history for DRD, I analysed whole-exome sequencing data of a large cohort of 
patients predominantly affected by early-onset or familial PD and controls.  
After quality control checks (removal of gender mismatches, duplicate, related and non-
Caucasian samples, samples with low call rate or excess of heterozygosity), 1318 PD 
cases and 1635 controls remained. Additional control data (n = 4300) were obtained 
from the publically available EVS dataset. 
In total 1318 cases and 5935 controls were analysed for the presence of GCH1 coding 
(including small insertions/deletions, missense and stop-gain changes) or splice-site 
variants (± 5 base pairs from the coding exons). 
The mean age of subjects with PD was 55.7 ± 13.9 years (range 17-101; data available 
for 970 cases) and the mean age at onset was 46.7 ± 13.8 years (range 6-98; data 
available for 1194 cases). 423/1194 (35.4%) were early-onset cases (age at onset ≤ 40 
years) and ~630 were familial cases (positive family history for PD in a first or second 
degree relative). 
Coverage of the six GCH1 coding exons (NCBI transcript NM_000161.2) was similar 
in the three datasets as shown in Table 4-6. 
Coverage of exon 1 was sub-optimal, being the average read depth only 12 in the 
IPDGC data, 17.9 in the UCL-ex data and 6 in the EVS data. Visual inspections of 
aligned reads of IPDGC and UCL-ex data (BAM files opened with Genome Browse 
software, Golden Helix) revealed that the first ~150 coding nucleotides of exon 1 were 
barely covered (average depth 1-2 reads) in the majority of samples. Similar coverage 
data were evident for the EVS data (Figure 4-4). The coverage of the rest of the exon 
 as good  read de th ≥ 8 . No common  ariants  frequency >1%   ere identified. The 
benign polymorphisms p.Pro23Leu (rs41298432) and p.Pro69Leu (rs56127440), 
detected at similar frequencies in cases and controls, were not included in the analysis. 
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Table 4-6 Average exome sequencing coverage of the six GCH1 exons. 
Exon Genomic coordinates 
IPDGC 
(n=1318) 
UCL-ex 
(n=1645) 
EVS 
(n=4300) 
1 chr14:55369016-55369405 12 (65.4%) 18 (61.8%) 6 (59.1%) 
2 chr14:55332045-55332154 89 (99.6%) 48 (87.4%) 98 (99.7%) 
3 chr14:55326326-55326528 58 (99.6%) 45 (97.1%) 85 (86.3%) 
4 chr14:55313798-55313934 14 (81.8%) 35 (77.3%) 20 (83.3%) 
5 chr14:55312427-55312630 94 (100%) 114 (98.9%) 93 (95%) 
6 chr14:55310683-55310913 53 (99.2%) 22 (80%) 133 (99.5%) 
IPDGC=International PDGenetic Consortium; UCL-ex= University College of London exomes 
consortium; EVS= NHLBI Exome Variant Server; chr=chromosome 
Data are expressed as the average read depth per region of interest. In brackets is the percentage of 
samples that had a read de th ≥8 reads. 
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Figure 4-4 Visual representation of coverage depth for GCH1 exon 1 
NHLBI exome variant server sample average coverage depth, showing significantly reduced co erage is e ident at the 5’ end of the exon, most likely due to the high 
GC content (greater than 70%)
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The main results of the GCH1 analysis are summarized in Table 4-7. 
Combining cases and controls, 11 unique heterozygous GCH1 variants (ten missense 
and one stop-gain mutation) were identified in 16 individuals. Six variants were found 
only in PD cases (p.Gln110*, p.Gln110Glu, p.Ala120Ser, p.Asp134Gly, p.Gly217Val 
and p.Met230Ile), three in controls alone (p.Thr112Ala, p.Ile154Val and p.Arg198Gln) 
and two were detected in both groups (p.Val204Ile, p.Lys224Arg).  
The frequency of GCH1 variants was significantly higher in PD cases (10/1318; 0.75%) 
than in individual (UCL-ex controls 1/1635; 0.06%; P = 0.003; OR 12.4 95% CI 1.7-
541.1; EVS database 5/4300; 0.11%; P = 0.0004; OR 6.5, 95% CI 2.0-24.5) and 
combined datasets of controls (6/5935; 0.1%; P = 0.0001; OR 7.5, 95% CI 2.4-25.3). 
All carriers of variants in GCH1 were negative for pathogenic mutations in all known 
genes associated with Mendelian forms of parkinsonism. The presence of copy number 
variants in the SNCA, PARK2, PARK7, and PINK1 genes was excluded by MLPA in all 
cases. One case carried the GBA mutation E326K. 
The main features of the ten PD cases with pathogenic or possibly pathogenic GCH1 
variants are listed Table 4-8. The age at onset of GCH1-mutated cases was 43.2 ± 13.4 
years (range 17-61). Seven had a positive family history of PD. DNA of other family 
members was available for only one case and we showed segregation of the same GCH1 
mutation (p.Gln110*) in the affected sister of the index case. All cases exhibited a 
variable combination of asymmetrical bradykinesia, rigidity, rest and postural tremor, 
walking difficulties, postural instability and excellent response to dopaminergic 
treatment, consistent with a clinical diagnosis of PD (Lees et al., 2009).  
The two subjects with the youngest age at onset of symptoms (case 4 and 9, who 
developed symptoms at age 32 and 17 respectively) presented with dystonic features in 
the lower limbs at onset, a well-recognised characteristic of young-onset PD cases (Bozi 
and Bhatia, 2003). One case (case 5) developed lower limb dystonia in off periods over 
the course of the disease. The remainder did not present with any symptoms or signs of 
dystonia. 
Detailed information about treatment was available for eight cases: the two cases (case 
1 and 7   ith the shortest disease duration  ≤ 5 years   ere treated only  ith a 
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dopamine-agonist, whereas the other cases were taking a combination of L-DOPA and 
other anti-parkinsonian drugs. 
Mean disease duration was 17.6 ± 15.4 years (range 4-56). Patients with longer disease 
duration displayed a more severe clinical picture with some degree of postural 
instability  Hoehn and Yahr score ≥ 3 , indicating disease  rogression in s ite of the 
dopaminergic treatment. 
In those patients taking L-DOPA and for whom follow up information was available (n 
= 7), all developed clinically relevant motor complications of chronic L-DOPA 
treatment, including wearing off, motor fluctuations and dyskinesias. Dyskinesias in 
case 4 were so disabling that he required treatment with deep brain stimulation of the 
subthalamic nuclei at age 60.  
Most cases exhibited some of the typical non-motor features often recognised in PD, 
such as cognitive difficulties (case 5), hyposmia (case 3, 4, 5, 6 and 10) constipation 
(case 4 and 10), urinary problems (case 5, 6 and 9), fatigue (case 2 and 5) and sleep 
disturbances (case 4, 5, 6 and 10). 
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Table 4-7 List of GCH1 variants identified by exome sequencing in patients with PD and controls
a
 
Mutation Exon dbSNP 
Prediction 
scoreb 
Previously 
described in 
DRD? 
PD 
patients 
(n=1318) 
UCL-ex 
controls 
(n=1635) 
OR (95% 
CI) 
p-
value 
EVS controls 
(n=4300) 
OR (95% 
CI) 
p-value 
Total 
controls 
(n=5935) 
OR     
(95% CI) 
p-value 
All variants     10 (0.75%) 1 (0.06%) 
12.4     
(1.7-541.1) 
0.003 5 (0.11%) 
6.5 (2.0-
24.5) 
0.0004 6 (0.1%) 
7.5       
(2.4-25.3) 
0.0001 
c.328C>T; 
p.Gln110* 
1  NA 
Yes, in 
dominant and 
recessive 
pedigrees 
1 0   0   0   
c.328C>G; 
p.Gln110Glu 
1  2 No 1 0   0   0   
c.334A>G; 
p.Thr112Ala 
2 
rs1999
90434 
2 No 0 0   1   1   
c.358G>T; 
p.Ala120Ser 
2  4 No 1 0   0   0   
c.401A>G; 
p.Asp134Gly 
2  4 No 1 0   0   0   
c.460A>G; 
p.Ile154Val 
3  2 No 0 1   0   1   
c.593G>A; 
p.Arg198Gln 
5 
rs2012
38926 
0 No 0 0   1   1   
c.610G>A; 
p.Val204Ile 
5 
rs2008
91969 
 
4 
Yes, in 
sporadic and 
recessive 
cases 
3 0   1   1   
c.650G>T; 
p.Gly217Val 
6  4 No 1 0   0   0   
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c.671A>G; 
p.Lys224Arg 
6 
rs4129
8442 
2 
Yes, in 
dominant and 
recessive 
pedigrees 
1 0   2   2   
c.690G>A; 
p.Met230Ile 
6  4 
Yes, in a 
sporadic case 
1 0   0   0   
NA=not applicable; DRD=dopa-responsive dystonia; PD=Parkinson disease; UCL-ex= University College of London exomes consortium; EVS=Exome Variant Server; OR=odds 
ratio; CI=confidence intervals. p- alues  ere calculated by means of Fisher’s exact test 
 a 
NCBI transcript NM_000161.2.
.
This count includes all detected coding and splice-site variants at any frequency, but the two benign variants P23L and P69L  
b 
This score, ranging from 0 to 4, indicates the number of tools (Polyphen-2, SIFT, LRT and Mutation Taster) predicting a pathogenic effect on the protein function 
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Table 4-8 Clinical features of PD cases with GCH1 variants identified in the exome-sequencing study 
Case 
Sex/Age
/ Age at 
onset (y) 
GCH1 
mutation 
Family 
history 
of PD 
Age at 
L-
dopa 
start 
(y) 
Current treatment 
(mg/day) 
Parkinsonian features 
H&Y 
score 
Cognitive 
symptoms 
Other non-
motor features 
Dystonia 
Levodopa-
induced 
complications 
1 F/47/43 p.Met230Ile No / Pramipexole 0.75 
Asymmetric onset, bilateral involvement 
with rest and postural tremor, 
bradykinesia and rigidity, mild gait 
difficulties 
2 No No No No 
2 M/55/37 p.Lys224Arg 
Yes 
(father) 
NA NA 
Asymmetric onset, moderate bilateral 
involvement with rest tremor, 
bradykinesia and rigidity, postural 
instability and gait difficulties 
3 No Fatigue No 
Dyskinesias and 
wearing-off 
3 M/49/35 p.Gly217Val No 43 
L-dopa 600, 
Tolcapone 400, 
Pramipexole 3.15 
Asymmetric onset, slurred speech, mild L 
arm rest and postural tremor, moderate 
bilateral bradykinesia and rigidity, 
postural instability 
3 
Subjective 
loss of 
memory 
(MMSE 
29/30) 
Hyposmia, ICD No 
Initial dyskinesias 
and wearing-off 
4 M/63/32 p.Val204Ile 
Yes (1st 
degree 
cousin) 
36 
DBS, L-dopa 200 
Amantadine 100 
Rotigotine 8 
Asymmetric onset, hypomimia, slurred 
speech, hypophonia, marked bilateral rest 
and postural tremor, moderate bilateral 
rigidity and bradykinesia, postural 
instability 
4 No 
Hyposmia, 
constipation, 
RBD 
Right foot 
exercise-
induced 
dystonia 
at onset 
Disabling 
dyskinesias and 
on-off fluctuations 
5 M/75/61 p.Val204Ile 
Yes 
(mother) 
61 
L-dopa 400, 
Pramipexole 3.15 
Asymmetric onset, rest and postural 
tremor (R>L), bradykinesia and rigidity, 
mild gait disorder, hypomimia 
3 
Mild 
cognitive 
impairme
nt 
Hyposmia, 
fatigue, sleep 
and bladder 
disorder 
Lower 
limb off-
dystonia 
On-off 
fluctuations (30% 
of waking day in 
off-state) 
6 M/72/59 p.Val204Ile 
Yes 
(mother) 
65 
L-dopa 600 
Entacapone 800 
Asymmetric onset, bilateral bradykinesia 
and rigidity (L>R), no tremor. Mild gait 
difficulties and postural instability 
3 No 
Hyposmia, sleep 
and bladder 
disorder 
No 
Dyskinesias (30-
40% of waking 
day), wearing-off 
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7 M/57/52 p.Asp134Gly 
Yes 
(father 
and 
paternal 
aunt) 
/ Ropinirole 14 
Asymmetric onset, unilateral left arm rest 
tremor, bradykinesia and rigidity. 
Reduced arm swing 
1 No NA No No 
8 F/59/51 p.Ala120Sera 
Yes 
(mother) 
NA NA 
Asymmetric onset, bilateral bradykinesia 
and rigidity. No tremor. Mild gait 
difficulties 
2 No NA No NA 
9 F/73/17 p.Gln110X* 
Yes 
(sister; 
father 
had 
tremor) 
49 
L-dopa 600 
Trihexyphenidyl 6 
Bilateral rest and postural tremor (L>R), 
bilateral rigidity and bradykinesia. Some 
postural instability 
3 
No 
 
Urinary urgency 
Lower 
limb 
dystonia 
at onset 
Marked limb and 
truncal 
dyskinesias, off 
phases in the 
morning 
10 M/58/45 p.Gln110Glu No 55 
L-dopa 400 
Entacapone 800 
Rasagiline 1 
Amantadine 300 
Bilateral severe bradykinesia and rigidity, 
postural instability, mild tremor, 
hypomimia 
3 No 
Hyposmia, 
constipation, 
fatigue, sleep 
disorder 
No 
Mild dyskinesias 
and wearing-off 
NA=information not available; M=male; F=female; PD=Parkinson disease, y=years, ICD=Impulse control disorder, DBS=deep brain stimulation, RBD=REM behavioural sleep 
disorder, H&Y=Hoehn and Yahr. 
a
This case also carries in the heterozygous state the GBA E326K variant 
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4.4.5 Discussion 
Family study 
I report here four unrelated DRD pedigrees in which loss-of-function GCH1 mutations 
(two splice-site mutations and two missense mutations, confirmed to be pathogenic by 
metabolic or CSF studies) were found in individuals, asymptomatic for DRD during 
childhood, who developed adult-onset parkinsonism. They all met the UKPDSBB 
clinical criteria for a definite diagnosis of PD and had imaging evidence of a PD-like 
nigrostriatal dopaminergic denervation.  
A parkinsonian syndrome in the absence of dystonia has been reported in adults who are 
first-degree relatives of children with DRD. In a series of 21 families, Nygaard showed 
that 7/50 (14%) individuals older than 40 years had parkinsonism (Nygaard, 1993) and 
Hagenah and colleagues reported that 8/23 (34.7%) patients of their series had a positive 
family history for PD (Hagenah et al., 2005). GCH1 mutations have also been shown to 
segregate in pedigrees with multiple individuals affected by isolated parkinsonism (Irie 
et al., 2011). 
This study provides evidence that in most of the cases the parkinsonian phenotype in 
adult GCH1 mutation carriers is likely due to nigrostriatal degeneration, rather than 
being part of the phenotypic spectrum of metabolic GTPCH-related striatal dopamine 
deficiency. This is consistent with other previous isolated reports of adult-onset 
parkinsonism in GCH1 mutation carriers with abnormal nigrostriatal imaging (features 
summarized in table 1) (Kikuchi et al., 2004, Hjermind et al., 2006, Eggers et al., 2012, 
Ceravolo et al., 2013). 
Our imaging findings are however in apparent contrast to a previous report by Nygaard 
and colleagues (Nygaard et al., 1992). The authors described a large DRD pedigree, in 
which three subjects had a late-onset benign parkinsonism, two of which had normal 
nigrostriatal dopaminergic function determined by means of 
18
F-fluorodopa (FD) PET.  
Compensatory mechanisms at the presynaptic level (e.g. increased dopamine-intake and 
dopamine-decarboxylation activity) may result in relatively higher striatal FD uptake in 
the initial phase of PD, underestimating the degree of nigral cell decrease (Nandhagopal 
et al., 2011). DAT values are therefore a more precise indicator of dopaminergic 
innervation loss (Ito et al., 1999). I speculate that GCH1-parkinsonian cases with 
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normal FD-PET scan could have up-regulated compensatory dopaminergic activity at 
the presynaptic level, possibly masking the presence of striatal denervation.  
In agreement with these findings, Gibb and Lees reported a case that presented with 
juvenile-onset parkinsonism and dystonia with good response to L-DOPA (commenced 
at the age of 30) and occurrence of disabling dyskinesias after one year of treatment. 
The patient died at 39 years and pathological examination showed a striking 
combination of low melanin content in nigral neurons and devastating neuronal loss 
with reactive gliosis. Furthermore, LBs were found in surviving nigral cells and in the 
locus coeruleus (Gibb et al., 1991). This case was subsequently demonstrated to be 
carrier of a heterozygous mutation in GCH1 (c.276delC) (Segawa et al., 2004).  
Whole-exome sequencing study 
I subsequently showed, in a large cohort of PD patients without family history of DRD, 
that rare GCH1 coding variants are associated with PD and increase the disease risk by 
seven-fold on average.  
Among the GCH1 variants identified by exome sequencing, two (p.Gln110* and 
Lys224Arg) have been shown to cause GTPCH deficiency and DRD in dominant 
pedigrees (Leuzzi et al., 2002, Saunders-Pullman et al., 2004) and two (p.Val204Ile and 
p.Met230Ile) have been reported in heterozygous sporadic or in recessive cases with 
DRD (Segawa et al., 2004, Trender-Gerhard et al., 2009, Opladen et al., 2011).  
The other heterozygous variants identified in this study could not be functionally 
investigated (e.g. PLT or CSF analysis), therefore their effect on GTPCH activity 
remains undetermined. However, three of the four novel variants (p.Ala120Ser, 
p.Asp134Gly and p.Gly217Val) detected in PD cases were located at amino acid 
positions that are fully conserved through species down to invertebrates and were 
predicted to be pathogenic by all in silico prediction tools, whereas this was not the case 
for any of the novel mutations present in controls.  
Nevertheless, the limitations of prediction tools in reliably distinguishing benign from 
pathogenic missense changes are well known and therefore we did not exclude any 
variant from the association test based on predictions scores, possibly underestimating 
the effect size of GCH1 pathogenic variants. 
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The p.Pro23Leu (rs41298432) and p.Pro69Leu (rs56127440) variants were excluded 
from the exome sequencing analysis as several data argue against their pathogenic role.  
p.Pro23Leu has been reported in population controls at a frequency of 1-2% (Jarman et 
al., 1997, Hauf et al., 2000), it affects a non-conserved amino acid residue and 
functional studies have shown that it does not affect GCH1 enzymatic activity 
(Furukawa et al., 1999). It was also shown not to segregate with the clinical phenotype 
in a large dominant dystonia kindred and GTPCH deficiency was excluded in affected 
carriers by CSF analysis (Hauf et al., 2000). In this study it was detected in only 1/1318 
(0.07%) cases and 4/5915 controls (0.06%; difference not significant), due to very poor 
sequencing coverage of the first part of exon 1. 
The p.Pro69Leu variant, despite its relatively high frequency in the general population, 
has been described only in two published DRD cases; Clot et al. detected it in the 
heterozygous state in a sporadic case, but in the same study it was also found at a 
similar frequency in controls (Clot et al., 2009); it was also found in an apparently 
recessive pedigree, in trans with a pathogenic frameshift mutation, but the phenotype of 
the carriers was not as severe as usually reported in recessive GTPCH deficient cases 
(Furukawa et al., 2004). In this study it was detected in 3/1318 (0.22%) cases and 
10/5935 controls (0.17%; difference not significant). Among the three cases identified 
in this study with p.Pro69Leu, two had a positive family history for PD. Segregation 
analysis was performed in one pedigree for which DNA of multiple affected members 
was available. The mutation did not segregate with the clinical phenotype and no 
carriers presented features of DRD. 
Previous studies investigating the contribution of rare coding GCH1 variants in small 
cohorts of PD cases have reported negative results although these were insufficiently 
powered to draw conclusions (Bandmann et al., 1996, Hertz et al., 2006, Cobb et al., 
2009).  
The association between GCH1 variants and PD is further strengthened by the recent 
identification, through the meta-analysis of GWAS data deriving from approximately 
13,000 cases and 95,000 controls, that GCH1 is also a low-risk susceptibility locus for 
PD (Nalls et al., 2014). This finding potentially extends the role of GTPCH deficiency 
in the pathogenesis of PD beyond carriers of rare deleterious coding mutations. 
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The mechanism whereby GCH1 mutations could predispose to nigral cell degeneration 
is a matter of speculation. Biochemical evidence of GTPCH deficiency and reduced 
dopamine production has been reported in asymptomatic carriers of GCH1 mutations 
(Takahashi et al., 1994, Furukawa et al., 2004). It is therefore possible that GTPCH 
deficiency and the consequent chronic dopamine deficiency could directly predispose to 
nigral cell death. This would suggest that normal levels of dopamine exert a protective 
role on the survival of nigral neurons. There is increasing evidence that L-DOPA is not 
toxic to nigral neurons as was previously thought (Parkkinen et al., 2011). Furthermore, 
activation of dopamine receptors may have a strong antiapoptotic effect and increase 
survival of dopaminergic neurons (Nair et al., 2003, Vaarmann et al., 2013) (Nair et al., 
2003, Vaarmann et al., 2013). In animal models, L-DOPA has been shown to promote 
recovery of nigrostriatal denervation (Datla et al., 2001).  
Another possibility is that GCH1 mutation carriers who do not develop symptoms of 
DRD in childhood may have compensatory mechanisms that allow for normal 
nigrostriatal dopaminergic transmission. The maintenance of these mechanisms may 
increase nigral cell vulnerability to aging or other environmental and genetic factors, 
favouring degeneration. 
It is also possible that the reduced striatal basal dopamine levels found in GCH1 
mutation carriers may simply lower the threshold of nigral cell loss before parkinsonian 
symptoms are exhibited.  
Lastly, we cannot exclude that other yet unrecognized cellular pathways, not related to 
dopamine synthesis, may be disrupted by GTPCH and BH4 deficiency.  
With this regard, Ryan and colleagues have recently proposed that different cellular 
mechanisms secondary to BH4 deficiency, other than reduced dopamine levels, could be 
contributing to the death of nigral dopaminergic neurons (Ryan et al., 2015). BH4 acts 
as an antioxidant itself (Milstien and Katusic, 1999) and is an essential cofactor for 
nitric oxide synthases (NOS) activity (Crabtree et al., 2009). Furthermore decreased 
BH4 levels have been demonstrated to lead to NOS uncoupling which results in 
increased oxidative and nitrative stress (Chen et al., 2014). In addition to these 
mechanisms, Ryan and colleagues ha e recently demonstrated that α-synuclein 
modulates cellular BH4 levels by regulating GTPCH activity (Ryan et al., 2014). This 
supports the compelling hypothesis that a pathogenic cascade may occur in nigral 
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neurons, whereby increased levels of α-synuclein and mitochondrial dysfunction lead to 
decreased GTPCH activity and BH4 levels, which in turn may result in increased 
oxidative stress and cell death.  
There are some important limitations in this study that need to be acknowledged. 
Firstly, dopamine transporter imaging was not available for the PD cases with GCH1 
variants identified in the exome sequencing study. It remains a possibility therefore that 
some of these cases (in particular case 9, who presented at age 17, with lower limb 
dystonia and parkinsonism) may represent DRD cases with a parkinsonian phenotype, 
which may have been misdiagnosed as PD.  
However, removal of the aforementioned case from the statistical analysis did not 
change substantially the significance of the association (P = 0.0003). Furthermore, most 
of the patients for whom clinical follow-up data were available showed a progressive 
disease course with increasing L-DOPA requirements, emergence of motor 
complications due to chronic treatment with L-DOPA and presence of classic non-motor 
features of PD, strongly supporting nigrostriatal cell loss as the underlying pathology. 
Although dyskinesias have been very rarely described also in DRD cases, these are 
significantly different from the ones generally observed in PD. Indeed they tend to 
appear at the beginning of the treatment and subside after dose reduction without 
reoccurring with subsequent slow dose increase (Furukawa et al., 2004, Lee et al., 
2013). 
Secondly, the effect of the GCH1 variants detected in the exome sequencing study on 
pterin and dopamine metabolism could not be determined at the individual level. 
Reduced penetrance of GCH1 pathogenic variants for the DRD phenotype is a well-
established feature. Nevertheless it has been repeatedly reported, through analysis of 
brain tissue (Furukawa et al., 2002), CSF (Takahashi et al., 1994) and urine (Leuzzi et 
al., 2013), that even completely asymptomatic carriers of GCH1 mutations have 
abnormal metabolism of biopterins and dopamine, although to a lesser extent than DRD 
cases. This indicates the existence of a metabolic endophenotype, which we speculate 
could be the pathogenic mechanism underlying the increased risk for PD. 
Thirdly, a cohort enriched with early-onset and familial PD cases was evaluated. Thus 
the frequency of detected GCH1 variants may not reflect the frequency in late-onset 
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sporadic cases.  
Finally, I did not assess our samples for the presence of GCH1 copy number variants, 
possibly underestimating the frequency of GCH1 mutations. 
In conclusion, I demonstrate that rare GCH1 coding variants should be considered as a 
risk factor for PD. This is derived both from imaging evidence of striatal dopaminergic 
denervation in GCH1 pathogenic variant carriers with a clinical diagnosis of definite PD 
(in DRD pedigrees) and from exome sequencing data which show a significant 
association between GCH1 coding variants and an increased risk for the disease.  
These findings expand the clinical and biological relevance of GTPCH deficiency, 
suggesting a role not only in biochemical dopamine depletion and DRD, but also in 
nigrostriatal degeneration. The question as to how the same variants known to cause a 
Mendelian disease may also exist as risk alleles in PD may be explained by the well-
known reduced penetrance of GCH1 pathogenic variants. Whether additional genetic or 
epigenetic factors play a role in determining the clinical phenotype of GCH1 variant 
carriers should be addressed by future studies. 
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Chapter 5. Exploring the Genetics Basis of 
Myoclonus-Dystonia  
5.1 Outline of the Chapter 
This chapter describes my efforts to identify novel genetic causes responsible for 
Myoclonus-Dystonia (M-D). 
The chapter begins with an overview of the clinical and genetic features of M-D. The 
specific aims of the study were:  
1) To identify the underlying causative mutation in a pedigree with genetically 
unexplained autosomal dominant M-D;  
2) To identify the genetic cause in a recessive pedigree with genetically unexplained M-
D;  
3) To assess the role of the missense variant p.Arg1389His in CACNA1B, a newly 
identified M-D genetic cause, in a large international cohort of patients with M-D. 
5.2 Overview of Myoclonus-Dystonia  
M-D is a very rare condition with a suggested prevalence about 2 per million in Europe. 
M-D is clinically characterized by a variable combination of non-epileptic myoclonic 
jerks and dystonic movements (Asmus and Gasser, 2004).  
The first locus for autosomal dominant M-D (DYT11) was mapped on chromosome 
7q21-q31 (Nygaard et al., 1999). Heterozygous mutations (including nonsense, missense, 
deletions, and insertions) in the SCGE gene (MIM 604149) were subsequently 
identified as the genetic cause responsible for DYT11 and represent a major cause of 
inherited autosomal dominant M-D (Zimprich et al., 2001). Usually SGCE mutation 
carriers manifest the first symptoms in childhood with brief lightning-like myoclonic 
jerks affecting the upper body often being the most prominent symptom (Asmus et al., 
2002). Dystonia,  resenting as cer ical dystonia or  riter’s cram , generally a  ears 
later and is generally of mild to moderate intensity. Cranial, laryngeal and lower limb 
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dystonia are conversely more rarely reported (Roze et al., 2008). Additional features 
such as alcohol responsiveness of jerks and psychiatric co-morbidities (depression, 
anxiety and obsessive-compulsive disorder, alcohol addiction and attention deficit and 
hyperactivity disorder) are frequently present in SGCE-mutation carriers (Peall et al., 
2013).  
Asmus and colleagues recognised that large heterozygous deletions of SGCE, 
undetectable by direct Sanger sequencing, may account for a substantial portion (~25%) 
of the genetically unexplained cases with familial M-D (Asmus et al., 2005). Large 
deletions on the 7q21.13-21.3 region, encompassing not only SGCE but also other 
neighbouring genes (e.g. KRIT1, COL1A2, SHFM1, DLX6 and DLX5), are associated 
with a M-D plus presentation, which include other clinical features, such as hearing loss, 
short stature, joint laxity and microcephaly, skeletal deformities and cavernous cerebral 
malformations on cranial MRI (Asmus et al., 2007, Grunewald et al., 2008, Saugier-
Veber et al., 2010, Peall et al., 2014). Penetrance of mutations in the SGCE is reduced 
and related to maternal imprinting. Transcription occurs almost exclusively from the 
paternal allele, whilst transcription from the maternal allele is silenced by promoter 
methylation (Grabowski et al., 2003). Individuals with paternally inherited loss-of-
function SGCE mutations exhibit M-D, whereas individuals with maternally inherited 
mutations are asymptomatic. This particular pattern of inheritance explains why patients 
with M-D due to SGCE-mutations may lack a positive family history. 
The SGCE gene encodes the 438-aminoacid protein -sarcoglycan, member of the 
sarcoglycan gene family. In the brain SGCE mutations are thought to lead to 
mislocalisation of the protein from the plasma membrane to the endoplasmic reticulum 
and to promotion of its degradation by the proteasome (Esapa et al., 2007). 
SGCE mutations, including both point mutations and large deletions, are detected in 
only ~30-50% of familial cases, suggesting genetic heterogeneity and the existence of 
other still unidentified disease-associated genes (Schule et al., 2004, Tezenas du 
Montcel et al., 2006, Carecchio et al., 2013, Peall et al., 2014). An additional locus on 
chromosome 18p11 (DYT15; MIM 607488) has been linked to M-D in a single large 
Canadian family, but the causative mutation has not been identified as of yet (Han et al., 
2007). A frameshift mutation in TOR1A and a missense mutation in the DRD2 gene 
have been proposed as possible causes for M-D in single pedigrees, but then dismissed 
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as in both pedigrees pathogenic SGCE were subsequently detected (Klein et al., 2002).  
Other autosomal dominant M-D syndromes include some cases of benign hereditary 
chorea due to NKX2-1 mutations, with additional signs such as delayed motor 
milestones and later chorea (Armstrong et al., 2011) and one family with GCH1 
mutations, which presented with L-DOPA-responsive M-D and later developed 
parkinsonism (Leuzzi et al., 2002). With regard to AR disorders, M-D is described in 
one case with Vitamin E deficiency (Angelini et al., 2002), that later developed ataxia. 
When myoclonus and dystonia are only part of the phenotype a number of 
mitochondrial (Hanna and Bhatia, 1997, Garcia-Cazorla et al., 2008) or neurometabolic 
disorders (e.g. Lafora body disease, GM2 gangliosidosis, Niemann-Pick disease) should 
be considered in the differential diagnosis (Gouider-Khouja et al., 2010). 
Recently, Groen and colleagues identified two missense variants, p.Arg1389His 
(rs184841813) in CACNA1B and p.Thr1904Met (rs114190729) in RELN, each in a 
single autosomal dominant Dutch pedigree with M-D lacking mutations in SGCE, as the 
likely causative mutations (Groen et al., 2015, Groen et al., 2015). However, the 
pathogenic role of these variants is not confirmed as yet. 
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5.3  Linkage Analysis and Exome Sequencing Identify A 
Novel Cause Of Familial Myoclonus-Dystonia 
5.3.1 Statement of contribution 
The index case of the family described in this chapter was recruited in Professor Kailash 
Bhatia’s clinic at the National Hos ital for Neurology, London.   examined and 
recruited all other available family members. I performed all the genetic analysis and 
the functional studies in fibroblasts. I performed stable transfection of SH-SY5 cell lines 
and immunocytochemistry, in collaboration with Dr Anselm Zdebik. The WGCNA 
analysis was performed by Dr Conceicao Bettencourt based on the data generated by Dr 
Paolo Foraboschi, Dr Mina Ryten and Dr Trabzuni.  
5.3.2 Introduction 
I describe here the work that resulted in the identification of the genetic cause in a large 
British four-generation pedigree affected with autosomal dominant M-D, without 
mutations in SGCE. Through a combination of linkage analysis and WES, I identified a 
single missense mutation in KCTD17 as a novel cause for M-D. 
5.3.3 Subjects, Materials and Methods 
Index Family 
The clinical characteristics of the patients and the family pedigree are described in the 
Results. Out of 19 living family members from the index family, 13 subjects were 
assessed and recruited. Six children of unaffected individuals were not examined. 
Assessment included a detailed medical interview and a full videotaped neurological 
examination, with focus on movement disorders. All videos were subsequently blindly 
reviewed by two experts in movement disorders (Professor Kailash P. Bhatia and Dr 
Tom Foltynie). After obtaining informed consent, a blood sample was collected and 
DNA was extracted from 13 family members and 4 spouses. Samples were collected 
with the written consent of participants and formal ethical approval by the relevant 
research ethics committee (UCLH Project ID number 06/N076). 
Linkage Analysis 
Genome-wide linkage analysis was performed in a standard manner as described in the 
Materials and Methods section.  
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Whole-Exome Sequencing 
WES (TruSeq SBS chemistry sequenced on the Illumina HiSeq 2000) was performed in 
the two most distantly related affected individuals (V-3 and IV-14), as described in the 
Materials and Methods chapter.  
Sanger Sequencing 
Sanger sequencing was performed to validate WES results, check variants segregation 
in the index family and screen other M-D cases. Sanger sequencing was performed as 
described in Materials and Methods section. Primers were designed the entire coding 
region of KCTD17 (9 exons; transcript NM_001282684.1). The primers used are listed 
in the Appendix. 
Selection of Additional Cases for Mutational Screening 
A cohort of M-D cases was selected to search for further confirmatory mutations in 
candidate genes. Cases were selected from a bank of DNA samples donated with 
research consent, which are held at NHNN Neurogenetics Department. Additional cases 
were provided by international collaborators (Prof. Thomas Gasser, University of 
Tubingen; Prof. Christine Klein, University of Lubeck; Prof. Nardo Nardocci, Istituto 
Neurologico Carlo Besta). All selected cases fulfilled the proposed diagnostic criteria 
for M-D (Kinugawa et al., 2009). All samples included in this project had previously 
undergone diagnostic testing for mutations in SGCE (both point mutations and copy 
number variants) and were negative. In total 87 unrelated probands with familial M-D 
(defined by a family history of M-D in at least a first or second degree relative) and 358 
sporadic cases of British, German and Italian origin were selected. The study was 
approved by the relevant local ethics committees and informed consent was provided by 
all participants in accordance with local guidelines. 
Expression Profiling of KCTD17 In Brain Tissue  
Brain expression profiling data was collated for KCTD17 as described in Materials and 
Methods section.  
Generation of stably transfected SH-SY5 cell lines  
To assess subcellular distribution of KCTD17, a major splice variant from mouse brain 
was cloned. Total RNA was isolated from TRIZOL lysate, which was purified using the 
Zymo Direct-zol RNA mini kit (Cambridge Bioscience, UK) and quality assessed by 
non-denaturing agarose gel electrophoresis. Following poly-dT primed transcription 
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using Superscript III (Invitrogen, UK) on 5 ug total RNA, we amplified the full-length 
cDNA with primers containing unique restriction sites. The mutation c.434 G>A 
p.Arg145His was inserted by recombinant PCR. Either N- or C-terminal HA tagged 
wild-type and mutant cDNAs were inserted with a 1-step recombinant PCR into 
pcDNA3.1 constructs for expression in mammalian cells. Stable SH-SY5 cells were 
generated by electroporating 5 µg linearized tagged wild-type and mutant plasmids into 
~1 million cells and G418 (InvivoGen) selection at 250 mg/l over at least 4 weeks and 
at least 6 passages. A control cell line expressing the empty vector was obtained in 
parallel. 
Immunocytochemistry 
Immunocytochemistry was performed on cells seeded on glass coverslips (13 mm 
diameter) coated with Cultrex basement membrane extract (R&D systems, USA). After 
fixation with either 4% PFA in PBS or ice-cold 50% methanol/50% acetone, cells were 
blocked in PBS+2% BSA%, 3% normal goat serum, 1% NP-40, 0.5% 
sodiumdesoxycholate for 30 minutes and primary antibodies. The Roche 3F10 or 12Ca5 
monoclonal antibodies were used for detection of the HA tag, at 1:1000 or 1:300 
dilutions, respectively. Subcellular marker antibodies were used at 1:1000 dilution. 
After washing, secondary detection used Alexa-dye labelled, highly cross-absorbed anti-
rat (Invitrogen, UK) in 0.5x block, with 1 mg/l DAPI. Coverslips were mounted using 
Prolong Gold (Invitrogen, UK) after 4 washes with PBS. Microscopy was performed on 
a Zeiss confocal microscope.  
Weighted Gene Co-expression Network Analysis 
Weighted Gene Co-expression Network Analysis (WGCNA) was performed based on 
the UKBEC human brain mRNA expression data. In brief, this systems biology analytic 
approach uses brain regional whole-transcriptome gene expression data and establishes 
the degree of gene neighbourhood sharing, as defined on the basis of co-expression 
relationships. This approach allows to identify in an unsupervised and unbiased manner 
modules of genes that are highly co-expressed and co-regulated and therefore likely to 
be functionally related (Oldham et al., 2006). Microarray data on 19152 transcripts 
(corresponding to 17247 genes), generated from 788 brain samples obtained from 101 
neuropathologically healthy individuals was used for weighted gene co-expression 
network analysis (WGCNA). The WGCNA network was constructed for each brain 
region to achieve a scale-free topology, as previously described (Forabosco et al., 
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2013). A dissimilarity matrix based on topological overlap measure was used to identify 
gene modules (i.e., densely interconnected and co-expressed genes) through a dynamic 
tree-cutting algorithm. A detailed description of the methods used to generate the 
dataset is available in the manuscript of Forabosco and colleagues. 
 Calcium Imaging in Fibroblasts  
After obtaining informed consent, fibroblasts were isolated from a skin biopsy taken 
from a carrier of the KCTD17 Arg145His mutation (index family, III-2). Two unrelated 
age- and passage-matched controls were selected from in-house cell lines. The 
fibroblasts  ere cultured in Dulbecco’s modified Eagle’s medium GlutaM X 
supplemented with 10% heat-inactivated fetal bovine serum and 1% penicillin-
streptomycin. They were maintained at 37°C in a humidified atmosphere of 5% CO2 
and 95% air, media changed twice a week. Calcium homeostasis was assessed using the 
ratio-metric calcium (Ca
2+
) dye, Fura-2, AM (Molecular Probes, Paisley, UK), which 
indicates intracellular Ca
2+
 concentration and allows recordings of Ca
2+
 fluxes upon 
application of different pharmacological stimuli. Fibroblasts were loaded at room 
temperature for 30 minutes with 5mM fura-2 AM and 0.005% Pluronic in HBSS 
composed of (mM): 156 NaCl, 3 KCl, 2 MgSO4, 1.25 KH2PO4, 2 CaCl2, 10 glucose and 
10 HEPES (pH adjusted to 7.35 with NaOH). Fluorescence measurements were 
obtained on an e iﬂuorescence in erted microsco e equi  ed  ith a 20x ﬂuorite 
objective. Analysed areas were randomly chosen, and at least three independent 
experiments were performed for each condition. Ca
2+ 
was monitored in single cells 
using excitation light provided by a Xenon arc lamp, with the beam passing 
monochromator centred at 340 and 380 nm (Cairn Research, Kent, UK). Emitted 
ﬂuorescence light  as reﬂected through a 515 nm long- ass ﬁlter to a cooled CCD 
camera (Retiga, QImaging, Surrey, BC, Canada). All imaging data were collected and 
analysed using software from Andor (Belfast, UK). ATP (100 mM) was used for 
stimulating Ca
2+ 
signals in fibroblasts via purinoceptors and for releasing calcium from 
the endoplasmic reticulum (ER) via IP3 receptors. In a second round of experiments 
thapsigargin (1 mM), in Ca2+-free medium (plus 0.5 mM EGTA), was used for inducing 
the release of calcium from the ER to the cytosol and thus for estimating the size of the 
reticular Ca2+pool. After stimulation with thapsigargin, Ca2+ (2mM) was added to the 
medium for stimulating the plasma membrane store-operated Ca2+ channels and 
assessing the store-operated calcium entry.   
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5.3.4 Results 
Clinical phenotype of the index family 
The family pedigree is shown in Figure 5-1. The 71-year-old index case (subject III-2) 
was first seen in clinic at age 56. She was born without complications after an 
uneventful pregnancy and had a normal development as a child. Her symptoms started 
during childhood with involuntary jerky movements of her arms. She always felt 
clumsier than other children. In her fifties, she developed constant head jerks and head 
deviation to the left. In her sixties her speech became involved, with changes of tone 
and stops during conversation. She also noticed that her balance was not as good as 
before. Involuntary movements worsened while performing voluntary actions, 
particularly while walking, and improved when relaxed. Touching her chin or the back 
of her head reduced the jerks markedly. Occasional use of alcohol did not have an 
impact on symptoms. On examination she had spasmodic dysphonia, perioral 
myoclonus and blepharospasm. She had a left torticollis and frequent irregular head 
myoclonic jerks. There was dystonic posturing of the hands with some writhing 
movements of the fingers and occasional low amplitude jerks. When she walked her 
trunk was slightly tilted to the left and backwards and she presented bilateral foot 
dystonia with feet turning inwards. She walked with a wide base and felt that walking 
backwards was easier. While standing she developed jerks in her legs. 
A broad range of genetic investigations resulted negative, including testing for SCA 
1,2,3,6 and 7, HD, DRPLA, DYT1, DYT6 and DYT11 (including sequencing of all 
coding exons and adjacent intronic regions and MLPA to detect copy number variants). 
Her brain MRI showed minor age-linked atrophy and some non-specific high signal 
spots in subcortical areas. She also had normal EEG, nerve conduction studies, EMG 
and central motor and sensory conduction times. She had a trial of oral L-DOPA (up to 
600 mg/day for at least a month) without improvement. She was treated with local 
Botulinum Toxin injections for her cervical dystonia, with some improvement. Because 
of progressive worsening of her symptoms she was considered for globus pallidus 
internus (GPi) deep brain stimulation and, after the appropriate assessment, she was 
operated, at the age of 70. Following surgery her cervical dystonia improved 
considerably but her other symptoms, particularly her gait problems, remained 
unchanged. 
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Six other family members displayed signs of dystonia and/or myoclonus, and were 
accordingly categorized as affected (see Table 5-1). Age of onset of movement disorder 
symptoms ranged from 5 to 20 years. All affected family members initially presented 
with jerks or a jerky tremor, with mild dystonic features presenting later in life. All 
cases fulfilled the currently proposed clinical criteria for a definite diagnosis of M-D 
(Kinugawa et al., 2009), except individual IV-3, who upon examination displayed 
isolated cervical dystonia, although she reported intermittent jerky arm tremor. 
Myoclonus involved predominantly the arms. Dystonia predominantly affected the 
cranio-cervical region and upper limbs. Older individuals (>60 years; III-2 and III-5) 
were more severely affected and also showed laryngeal involvement. None of the 
affected subjects reported improvement of symptoms with alcohol. No other individuals 
presented with psychiatric symptoms. Case IV-12 aged 42 when clinically assessed, was 
considered to be unaffected with the family condition by both Professor Bhatia and Dr 
Foltynie. He had strabismus and benign congenital nystagmus. He showed no 
myoclonus or dystonia, but exhibited a mild bilateral postural hand tremor, consistent 
with a diagnosis of essential tremor. A similar tremor was also observed in his father, 
spouse of the affected individual III-5, suggesting that this feature is likely to be 
unrelated from the condition affecting the other family members. The remaining 
individuals were asymptomatic and had an entirely normal neurological examination. 
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Figure 5-1 Pedigree of the index family where the KCTD17 c.434 G>A p.Arg145His mutation was identified.   
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Table 5-1 Clinical features of cases carrying the KCTD17 c.434 G>A p.Arg145His mutation 
Subject III-2 III-5 IV-2 IV-3 IV-14 V-1 V-3 
II.2 
(Germany) 
Sex F F M F M F M M 
Age at last examination (y) 70 65 46 44 35 20 19 62 
Age at onset (y) 10 6 10 20 10 5 5 10 
Presenting symptoms Jerks; Arms Jerks; Arms Jerks; Arms 
Jerky tremor; 
Arms 
Jerky tremor; 
Arms 
Jerks; Arms Jerks; Arms Jerks, Arms 
Dystonic features Yes Yes Yes Yes Yes Yes No Yes 
Involved areas 
Cranial, Cervical, 
Brachial, Truncal, 
Crural 
Cranial, 
Cervical, 
Brachial 
Brachial Cervical 
Cervical, 
Brachial 
Brachial NA 
Cranial, 
Cervical, 
Brachial, 
Truncal 
Myoclonus Yes Yes Yes No Yes Yes Yes Yes 
Involved areas 
Cranial, Cervical, 
Brachial 
Cranial, 
Brachial 
Brachial NA 
Cranial, 
Brachial 
Brachial 
Cervical, 
Brachial 
Brachial 
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Linkage analysis  
Genotype from seven affected individuals (III-2, III-5, IV-2, IV-3, IV-14, V-1 and V-3), 
five unaffected (III-4, IV-6, IV-8, IV-12 and V-4) and four spouses (III-1, III-6, IV-1, IV-
4) was included in the analysis. The unaffected subject V-2 was not included as she was 
too young (17 when last examined) to exclude or confirm disease status. Linkage was 
performed under the assumption of an autosomal dominant inheritance with 90% 
penetrance and a disease allele frequency of 0.0001%. One single locus with a LOD 
score > 2 was identified on chromosome 22q13 (LOD score 2.4, the maximal expected 
value given the pedigree size; Figure 5-2). Fine mapping identified a segregating 
haplotype delimitated by SNP markers rs926543 and rs3213584 and spanning 6.7Mb 
(chr22: 36989327-43716324; UCSC hg19 Genome Build), which contained 132 
protein-coding genes. In addition, 5 other regions presented with uninformative 
multipoint LOD scores, ranging from -0.9 to +0.14 (see Table 5-2), but haplotype 
analysis excluded co-segregation of these regions with the disease.  
Table 5-2 Summary of position, size and genetic content of the regions with a LOD score > -2 
Chromosome Start position (Hg19) Stop position (Hg19) LOD score 
3 100410724 101569726 -0.8111 
12 58842292 60028954 0.1474 
12 70112707 70517723 -0.7314 
12 70422480 71099936 -0.9131 
12 72641784 73373089 -0.7143 
22 36989327 43716324 2.4082 
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Figure 5-2 Linkage analysis results 
LOD score plot for genome-wide linkage analysis in the British index pedigree showing a single linkage peak on chromosome 22q13 with a maximum LOD score of 2.4. An 
autosomal dominant model was specified with an estimated allele frequency of 0.00001 and 90% penetrance. The chromosome is indicated across the top of the plot; chromosomal 
distance in centiMorgans (cM) is indicated on the x-axis; and the LOD score is indicated on the y-axis.  
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Whole-exome sequencing 
To identify the disease-causing variant, WES was performed in the two most distantly 
related affected individuals (V-3 and IV-14). In total, 83,572,847 (V-3) and 81,527,162 
(IV-14) unique reads were generated. According to the Consensus Coding Sequences 
hg19 definition of the ‘TruSeq exome’, the a erage read de th of both exomes  as > 
70, > 95% of the target bases were covered at a read depth of 2x and > 90% at a depth 
of 10x. A total of 22,857 (V-3) and 22,946 (IV-14) exonic/splicing variants were 
detected. A summary of the WES metrics can be found in Table 5-3. 
Table 5-3 Summary of results from exome sequencing 
 
 
 
 
 
 
 
 
 
 
 
All synonymous changes and those not shared by the two affected individuals were 
filtered out. Then, under the assumption that the mutation causing this rare autosomal 
dominant disease is extremely rare and not present in the general population, I also 
excluded variants that are present in databases of sequence variations publicly available 
databases of sequence variations (dbSNP version 129, 1000 Genomes project, NHLBI 
Exome Variant Server and Complete Genomics 69). Furthermore, I excluded variants 
found in our own in-house exomes (n=200) from individuals with unrelated diseases. 
Patient V-3 IV-14 
Unique reads 83,572,847 81,527,162 
Aligned Reads (%) 87.6 87.2 
Mean depth 73 71 
Target covered at least 2x 96 95 
Target covered at least 10x 92 91 
Total variants 22,857 22,946 
Excluding synonymous variants 11,710 11,737 
Novel variants 154 140 
Shared novel variants 4 4 
Shared  novel variants within the linkage peak on 22q 1 1 
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After applying filtering criteria, only four novel missense variants shared by the two 
affected individuals were left (see Table 5-4): c.10976 C>T; p.Ser3659Phe in FLG 
(filaggrin; RefSeq NM_002016.1), c.1055 T>G; p.Phe352Cys in OBSCN (obscurin; 
RefSeq NM_052843.3), c.1076 A>C; p.Lys359Thr in LRRC6 (leucine rich repeat 
containing 6; RefSeq NM_012472.4) and c.434 G>A; p.Arg145His in KCTD17 
(potassium channel tetramerisation domain containing 17; RefSeq NM_001282684.1). 
Of these variants, only the missense change in KCTD17 was located within the linked 
chromosomal locus on chromosome 22q. No shared rare copy number variants in 
exome sequencing data were detected using the Exome depth algorithm.  
Sanger sequencing of the KCTD17 variant (see Figure 5-3) in all available family 
members confirmed perfect co-segregation of the variant with the disease-phenotype, 
being the nucleotide change present in all affected individuals and absent in all 
unaffected (including subject V-2, initially excluded from the linkage analysis). 
Segregation analysis of the other three novel variants, shared by individuals V-3 and IV-
14 but located outside the identified linkage peak, was also performed. As expected, 
none of them fully segregated: the LRRC6 variant was not carried by affected 
individuals (IV-2 and V-1) and the OBSCN and FLG variants were carried by unaffected 
subjects V-4 (OBSCN and FLG) and IV-12 (FLG), aged 20 and 40 respectively when 
last examined. Although the KCTD17 p.Arg145His substitution falls in a functionally 
uncharacterized portion of the protein, it lies in an extremely conserved amino acid 
motif, not only completely conserved down to invertebrate species, but also identical in 
the KCTD17 human paralogs KCTD2 and KCTD5 (see Figure 5-4). 
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Figure 5-3 Sanger sequencing confirmation of the KCTD17 c.434G>A p.Arg145His mutation. 
 
The variant is absent in over 3,700 individuals of European origin without movement 
disorders, who were exome sequenced by the UCL-exomes consortium, and in a further > 
61,000 individuals listed in the Exome Aggregation Consortium database (last accessed 
in March 2016). All in silico tools consistently predicted a deleterious effect of the 
substitution (see Table 5-4). 
 
Figure 5-4 Interspecies protein sequence alignment 
Multiple-sequence alignment showing complete conservation of protein sequence across species and 
human paralogs (KCTD2 and KCTD5) in the region of KCTD17 where the disease-segregating mutation 
p.Arg145His was identified. The amino acid involved by the mutation is marked in red. The residues that 
are not completely conserved are highlighted in yellow. In blue the residues completely conserved. 
 166 
 
 
Table 5-4 Summary of novel variants detected by whole-exome sequencing and shared by individuals V-3 and IV-14. 
Chr 
Position 
(hg19) 
Gene (Transcript) Variant 
GERP 
score
a
 
CADD 
C-score
b
 
SIFT Provean 
PolyPhen-2 
HumVar 
Mutation 
Taster 
Gene previously 
associated with 
disease? 
Linkage 
analysis     
(LOD score) 
1 152276386 
FLG 
(NM_002016.1) 
c.10976 C>T; 
p.Ser3659Phe 
2.48 11.15 
T 
(0.06) 
N          
(-0.8) 
D         
(0.78) 
P    (0.99) 
Yes, skin diseases 
(e.g. ichthyosis 
vulgaris, and/or 
eczema) 
< -2 
1 228401208 
OBSCN 
(NM_052843.3) 
c.1055 T>G; 
p.Phe352Cys 
5.58 21 
D   
(0) 
D          
(-3.8) 
D         
(0.94) 
D    
(0.99) 
Hypertrophic 
cardiomyopathy 
< -2 
8 133622476 
LRRC6 
(NM_012472.4) 
c.1076 A>C; 
p.Lys359Thr 
3.5 15.74 
D 
(0.01) 
D          
(-3.1) 
B         
(0.39) 
D (0.99) 
Recessive primary 
ciliary dyskinesia 
< -3 
22 37453460 
KCTD17 
(NM_001282684.1) 
c.434 G>A; 
p.Arg145His 
4.46 28.8 
D   
(0) 
D          
(-4.8) 
D         
(0.53) 
D     
(0.99) 
No 2.4 
B=benign; D=deleterious/damaging/disease-causing; N=neutral; P=polymorphism; T=tolerated 
a 
Positive scores represent a substitution deficit and indicate that a site may be under evolutionary constraint. Negative scores indicate that a site is probably evolving neutrally. 
Positive scores scale with the level of constraint, such that the greater the score, the greater the level of evolutionary constraint inferred to be acting on that site. 
b 
C-scores greater or equal 10 indicates that the variant is predicted to be the among the 10% most deleterious substitutions that you can do to the human genome; a score of greater or 
equal 20 indicates the 1% most deleterious 
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Sanger Sequencing of KCTD17 in a Cohort of Phenotypically Similar Myoclonus-
Dystonia Cases 
The entire coding region of KCTD17 was subsequently sequenced by Sanger 
sequencing in a further 87 unrelated probands with familial SGCE-negative M-D. Exon 
4 only (containing the c.434 G>A mutation) was sequenced in a further 358 sporadic M-
D cases. This analysis revealed the presence of the same KCTD17 mutation, c.434 G>A 
p.Arg145His, in the index case of a German family with autosomal dominant M-D 
(Figure 5-5). No further pathogenic mutations in KCTD17 were identified.  
 
Figure 5-5 Pedigree of the German families with the KCTD17 c.434 G>A p.Arg145His mutation.  
 
The clinical presentation of this case closely resembled that of III-2 and III-5, the older 
affected subjects from the British family. He reported arm jerks and difficulty writing, 
starting in childhood. Right torticollis and a jerky head tremor appeared around age 40, 
becoming progressively debilitating. There was no response to alcohol or psychiatric 
comorbidities. He underwent surgery for bilateral pallidal deep brain stimulation at age 
58, which resulted in marked improvement of cervical dystonia and myoclonus of the 
upper limbs. Clinical examination at age 62 showed generalized dystonia, with 
prominent cranio-cervical involvement, and myoclonic jerks involving the upper limbs.  
His father was also affected with a movement disorder, presenting with perioral 
dyskinesia in his forties. The  roband’s brother had M-D, with similar clinical features, 
including generalized jerks, cervical dystonia and dysarthria. Unfortunately, DNA 
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samples of the deceased father and brother were not available for segregation analysis. 
The 25-years old  roband’s only son,  ho had no signs u on examination, refused 
genetic testing.  
To determine whether the KCTD17 c.434 G>A; p.Arg145His occurred on the same 
haplotype in the British and in the German kindreds, SNP markers located 0.5 Mb up- 
and down-stream the mutation were compared (see Table 5-5). In the British family, the 
haplotype of the identified KCTD17 mutation was reconstructed. The German case was 
genotyped using the same array. In the German case SNP phasing was possible only for 
homozygous alleles, due to lack of genetic data on other family members. Different 
alleles were located at markers rs5756477 and rs228924 (45.9 kb upstream and 53 kb 
downstream of KCTD17, respectively), delimitating a small region of approximately 99 
kilobases (Kb) of a possibly shared haplotype. Further analysis with a highly 
polymorphic microsatellite (19xAG; chromosomal position 22:37,446,300-37,446,339), 
located only 1.4 Kb u stream of the 5’ end of the KCTD17 open reading frame, revealed 
that the two pedigrees had different alleles.  
Table 5-5 Disease haplotype of the families with the KCTD17 c.434 G>A; p.Arg145His 
Marker Chromosomal position (hg19) 
Genotype         
UK family 
Genotype 
German family 
rs5756370 37242476 A A 
rs6000449 37251377 A A 
rs4821542 37252918 G G 
rs909483 37260474 A A 
rs2413429 37289869 G A 
rs4821558 37308785 G A 
rs11705394 37329676 A A 
rs9622506 37338286 A G 
rs8137446 37347959 G G 
rs9622521 37350881 G G 
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rs4821576 37357169 G G 
rs8142593 37363121 A A 
rs877166 37369148 C C 
rs5756437 37375668 G G 
rs1157557 37381674 G G 
rs5756477 37407527 G A 
rs5756492 37424991 G G 
Microsatellite 19xAG 37446300 17
a
 18/14
a
 
KCTD17 c.434G>A 37453460 A A 
rs2160906 37493178 G G 
rs228924 37507250 A G 
rs11914132 37509087 G G 
rs228942 37524619 C C 
rs3218258 37544245 A G 
rs229483 37553619 G A 
rs12167757 37567490 G G 
rs229518 37577872 A A 
rs11913300 37580627 A A 
rs5756540 37582205 G G 
rs5756546 37589805 G G 
rs64547 37592504 A A 
rs9610680 37621951 A G 
rs8137698 37624236 G A 
  170 
rs739042 37625419 G G 
rs2285110 37628145 G G 
rs9607431 37629938 C A 
rs5995404 37632938 C C 
All alleles where the haplotype of the UK family differs from that of the German family are 
highlighted in yellow. 
a
These values indicate the number of AG repeats 
 
Brain expression analysis 
KCTD17 gene expression was evaluated in 10 brain regions from 134 normal 
individuals using our in-house data from the UK Brain Expression Consortium. 
KCTD17 mRNA expression throughout the course of human brain development was 
assessed using the data available in the Human Brain Transcriptome (HBT) database. 
KCTD17 mRNA expression was high across all brain regions, but it was highest in the 
putamen followed by the thalamus (Figure 5-6A). There was a 3.2-fold difference (p 
value < 3.5
-71
) between the striatum and the cerebellum, the regions with respectively 
the highest and lowest expression. These findings are consistent with the data available 
in the HBT database, showing increasing KCTD17 brain mRNA levels in the striatum 
and the thalamus from early midfetal development (between 21 and 25 post-conception 
weeks of age) to adolescence (between 12 and 20 years of age) in the striatum and the 
(Figure 5-6B). 
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Figure 5-6 KCTD17 brain regional mRNA expression data 
(A) Box plot of mRNA expression levels for KCTD17 in 10 adult brain regions, based on exon array experiments and plotted on a log2 scale (y axis). The plot shows significant 
variation in KCTD17 transcript expression across the 10 CNS regions analysed. “N” indicates the number of brain samples analysed to generate the results for each CNS region. 
KCT17 expression is higher in the putamen, followed by the thalamus. Whiskers extend from the box to 1.53 the interquartile range. (B) Graph to show mRNA expression levels for 
KCTD17 in 6 brain regions during the course of human brain development, based on exon array experiments and plotted on a log2 scale (y axis).  
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Immunocytochemistry 
Stably transfected SH-SY5 cells were generated by incorporating either N- or C-
terminally HA-tagged wild-type and mutant KCTD17 cDNAs. KCTD17 staining with 
anti-HA primary monoclonal antibodies showed that the protein is diffusely distributed 
in the cytosol with fine reticular pattern and does not localize at the plasma membrane 
(Figure 5-7). We did not observe significant changes in subcellular localization of 
mutant versus wild-type KCTD17, indicating that the amino acid substitution does not 
lead to cellular mislocalisation of the protein. 
 
Figure 5-7 Immunocytochemistry in stably transfected SH-SY5 cells 
These experiments show no difference between wild-type and mutant KCTD17 subcellular localization. 
HA-tagged KCTD17 is shown in green. Cellular nuclei are stained with DAPI and are shown in blue. 
Weighted Gene Co-expression Network Analysis 
KCTD17, in common with other dystonia genes (e.g. ANO3, GNAL and HPCA), shows 
the highest expression in the putamen and this brain structure has an established role in 
the pathogenesis of dystonia. I therefore focused the analysis on the putamen module 
including KCTD17.  
This module contains 179 transcripts (equating to 172 genes; see Figure 5-8 for a 
graphic representation of the module).  
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Figure 5-8 Network representation of the putamen KCTD17-containing gene module 
Shown are all genes in the putamen KCTD17-containing module connected with a topological overlap 
measure exceeding 0.03. The dystonia genes in the module (KCDT17 and HPCA) and all the direct 
connections of KCTD17, based on topological overlap values, are highlighted in red. Larger circles 
represent the most interconnected genes in the module, including KCTD17. 
 
I first assessed if the module was enriched for genes linked to Mendelian forms of 
dystonia. The analysis focused on the nine genes known to be associated with dystonia 
(TOR1A, THAP1, SGCE, TUBB4A, CIZ1, ANO3, GNAL, ATP1A3, HPCA). I did not 
include in the analysis genes causing DOPA-responsive dystonia (GCH1, TH, and SPR) 
as their established functional role in nigrostriatal dopamine synthesis, together with the 
specificity of the clinical presentation, clearly identifies them as a separate entity. 
Importantly, the putamen KCTD17-module showed significant clustering of dystonia 
genes (KCTD17 and HPCA; Fisher’s exact test P = 5x10-3), suggesting the relevance of 
this gene network to the molecular pathogenesis of dystonia. The module was poorly 
preserved across other brain regions, indicating its specificity to the putamen (Figure 
5-9).  
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Figure 5-9 Putamen KCTD17-containing module preservation across other brain regions 
Module preservation statistics were calculated (z score) to assess how well modules from one tissue are 
reproducible (or preserved) in another brain region (Langfelder et al., 2011). Previously proposed 
thresholds were considered (z score of <2 indicates no evidence of module preservation, z score between 
2 and <10 indicates weak to moderate evidence, and z score of ≥10 indicates strong evidence). The 
module is poorly conserved across other brain regions, indicating its specificity to the putamen 
 
To infer the biological and functional relevance of the putamen KCTD17 gene network, 
functional annotation enrichment analysis was then carried out using the online tool 
g:Profiler (Reimand et al., 2011). This analysis allowed the identification of over-
represented genes assigned to specific Kyoto Encyclopedia of Genes and Genomes 
 KEGG   ath ays, namely “Circadian entrainment”  KEGG:04713; g: rofiler’s custom 
threshold P = 5.13x10
-3  and “Do aminergic syna se”  KEGG:04728; g: rofiler’s 
custom threshold P = 2.71x10
-2
). This suggests the involvement of the genes in the 
module with these molecular pathways.  
Ca
2+
 imaging in Patient Fibroblasts 
Disruption of calcium (Ca
2+
) homeostasis has been recently implicated in the 
pathogenesis of several genetic forms of dystonia (eg. TOR1A, ANO3, HPCA) 
(Charlesworth et al., 2012, Iwabuchi et al., 2013, Charlesworth et al., 2015). As the 
putamen KCTD17-module included HPCA, a gene with an established role in 
intracellular Ca
2+
-dependent signalling (Palmer et al., 2005), I hypothesized that the 
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KCTD17 p.Arg145His substitution may have a significant impact on intracellular Ca
2+
 
homeostasis.  
For this purpose, fibroblasts were isolated from a skin biopsy taken from a subject with 
the KCTD17 p.Arg145His mutation and two unrelated age- and passage-matched 
controls. The expression of KCTD17 in fibroblasts was confirmed by RT-PCR (data not 
shown).   obser ed that stimulation  ith  T   50μM ,  hich stimulates  2Y rece tors 
and releases Ca
2+
 from the ER via IP3 receptors, resulted in significantly reduced and 
delayed cytosolic Ca
2+
 signal (one-way ANOVA P < 0.01; Figure 5-10A and B) in cells 
carrying the p.Arg145His mutation when compared to both control cells, indicating a 
smaller calcium pool within the ER.  
To further prove this finding, a second round of experiments using thapsigargin (1µM) 
in Ca
2+
-free medium (plus 0.5 mM EGTA) was subsequently carried out. Thapsigargin 
is an inhibitor of the ER calcium ATPase (SERCA) and induces the release of calcium 
from the ER to the cytosol, allowing an estimation of the ER Ca
2+
-pool. Ca
2+
 was then 
added at the end of the experiment to stimulate
 
elevation of cytosolic Ca
2+
 through 
opening of store operated calcium channels. Thapsigargin stimulation resulted in a 
significantly smaller Ca
2+
signal in fibroblasts bearing the p.Arg145His mutation when 
compared to controls (one-way ANOVA P < 0.01; Figure 5-10C and D), confirming that 
the Ca
2+ 
pool in the ER of mutation-carrying fibroblasts is reduced. 
Furthermore, stimulation of the store-operated Ca
2+
 channels induced a smaller Ca
2+
 
influx in mutated fibroblasts (Figure 5-10C), possibly suggesting an insufficient Ca
2+
 
influx across the plasma membrane in response to the fall in Ca
2+
 concentration within 
the ER lumen.  
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Figure 5-10 Functional studies showing abnormalities of endoplasmic reticulum calcium signalling 
in KCTD17 p.Arg145His substitution bearing fibroblasts 
 ll ex eriments  ere carried out in tri licate. Data are re resented as the mean ± SEM. ‘‘n’’ indicates the 
total number of cells analysed. The asterisks indicate P < 0.05 (*), P < 0.01 (**) and P < 0.001 (***). (A) 
Typical trace of [Ca2+]c in control and KCTD17-mutant fibroblasts in response to the application of 50 
mM ATP. (B) Histograms showing a significantly decreased [Ca2+]c response upon ATP stimulation in 
mutation-bearing fibroblasts (n=56) versus controls (control 1 n=41; control 2 n=35), as measured by 
changes in Fura-2 fluorescence intensity. (C) Typical trace of [Ca2+]c in control and KCTD17-mutant 
fibroblasts in response to the application of thapsigargin (1 µM), and subsequent Ca2+ challenge (2 mM). 
(D) Histograms demonstrating a significant reduction in ER calcium pool in response to thapsigargin in 
mutation-bearing fibroblasts (n=53) versus controls (control 1 n=51; control 2 n=65), as measured by 
changes in Fura-2 fluorescence intensity. 
 
5.3.5 Discussion 
Several lines of evidence support the pathogenic role of the KCTD17 p.Arg145His.  
1) In the discovery pedigree, the p.Arg145His variant was located within the only 
segregating chromosomal locus and Sanger sequencing confirmed perfectly co-
segregation with dystonia. This was not the case for any other variant identified by WES 
that survived the filtering strategy. These latter variants were either not carried by 
definitely affected subjects (LRRC6) or carried by clinically unaffected subjects (FLG 
and OBSCN). Given the high penetrance of the disease indicated by the pedigree 
structure (no obligate unaffected carriers observed over four generations) and the onset 
of symptoms in the first decade in all affected individuals, we consider extremely 
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unlikely the possibility of the causative mutation for this pedigree being carried by 
unaffected adults. Furthermore the identified FLG and OBSCN variants are located in 
large and polymorphic genes tolerating a high burden of genetic variation (2560 and 
4135 rare [MAF < 0.01] non-synonymous variants spread across FLG and OBSCN, 
respectively, are listed in the ExAC database versus 71 rare variants observed in 
KCTD17), arguing against a pathogenic role of these changes. Moreover, pathogenic 
variants in FLG and OBSCN have been previously linked to diseases unrelated to 
dystonia, respectively skin diseases (Irvine et al., 2011) and cardiomyopathy (Marston 
et al., 2015). 
2) A screening of the KCTD17 gene in a cohort of SGCE-negative M-D cases revealed 
the same nucleotide change in the index case of an additional unrelated pedigree with an 
autosomal dominant pattern of inheritance. In this second pedigree I could not prove 
segregation due to unavailability of the other affected family members. However, given 
the striking clinical similarity between this case and the affected individuals of the index 
family, together with the absence of the variant in over 65,000 internal and publicly 
available controls, it is highly unlikely this variant could merely represent a private 
benign polymorphism.  
Importantly, I demonstrated that the two families with the p.Arg145His mutation did not 
share a common founder haplotype and therefore two independent mutational events 
must have occurred. This is relevant for two reasons; firstly, I can exclude that the 
KCTD17 p.Arg145His variant is in linkage with the actual causative mutation but it is 
not itself pathogenic. Secondly, were the two families to be linked by an ancestral 
common founder, given the high penetrance of the mutation, I would expect a much 
higher prevalence of the p.Arg145His mutation as a cause of familial M-D across the 
British and German population. This is the case, for instance, for the recurrent GOSR2 
G144W mutation, a widespread cause of progressive myoclonus-ataxia syndrome in 
Nordic populations (Boisse Lomax et al., 2013).   
3) KCTD17 is abundantly expressed in all brain regions and the highest expression was 
observed in putamen and thalamus. In light of the current view about the 
neuroanatomical bases of dystonia, seen as a network disorder originating from 
disrupted circuits involving the sensory-motor cortex, the basal ganglia and the 
cerebellum (Neychev et al., 2011), this pattern of expression is highly relevant and 
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supports the pathogenic role of KCTD17 in the pathogenesis of M-D. Furthermore, 
focal ischemic lesions of the thalamic subnuclei have been causally linked to the 
development of a movement disorder that closely resembles M-D (Lehericy et al., 
2001). This strengthens the relevance of high KCTD17 expression in the thalamus and 
supports the hypothesis of a crucial role for disrupted thalamic pathways in the 
pathogenesis of KCTD17-associated M-D. 
KCTD17 encodes for a member of a recently identified family of 26 closely related and 
highly conserved proteins, the potassium channel tetramerisation domain (KCTD)-
containing proteins. KCTD proteins are characterized by the presence of a N-terminal 
bric-a-brack, tram-track, broad complex/poxvirus zinc finger (BTB/POZ) domain, 
homologous to the cytoplasmic domain T1 of voltage-gated potassium channels (Liu et 
al., 2013). The BTB/POZ domain is known to permit protein-protein interactions, either 
promoting self-oligomerisation or facilitating interaction with other biological partners 
(Stogios et al., 2005). KCTDs are small soluble proteins, which are not predicted by 
their structure to form transmembrane domains. Despite the homology reflected in their 
names, a direct interaction with potassium channels has not been shown for most 
members of the family and was explicitly excluded for KCTD5, a paralog 85% identical 
to KCTD17 (Dementieva et al., 2009). 
KCTD proteins, despite the high level of sequence similarity, are involved in a 
surprisingly wide spectrum of cell functions, including regulation of cellular 
proliferation, gene transcription, cytoskeleton organization, protein degradation 
targeting via the ubiquitin-proteasome system, and regulation of G protein-coupled 
receptors (Skoblov et al., 2013). Several members of the KCTD family have a primary 
role in the central nervous system (Schwenk et al., 2010, Matsui et al., 2013) and a 
growing number of neurological diseases have been linked to mutations in KCTD 
genes. KCTD7 (MIM 611725) mutations cause recessive progressive myoclonic 
epilepsy (Van Bogaert et al., 2007, Kousi et al., 2012, Krabichler et al., 2012). Copy 
number variants in KCTD13 (MIM 60894) have been associated with size of the head, 
autism disorder and epilepsy (Golzio et al., 2012). More recently a homozygous 
missense mutation in KCTD3 (MIM 613272) was identified as the likely cause in a 
pedigree with severe psychomotor retardation, seizure, and cerebellar hypoplasia 
(Alazami et al., 2015).  
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The precise cellular localization and function of the KCTD17 protein are largely 
unknown. Recent work has shown that KCTD17 contributes to the ubiquitin-
proteasome machinery, acting as an adaptor for the CUL3-RING E3 ligase and targeting 
substrates for degradation through poly-ubiquitinylation (Kasahara et al., 2014). 
Although most of the KCTD17-CUL3 substrates are currently unknown, CUL3 has 
been implicated in the elaboration of dendrite branching and neurite terminal 
morphogenesis in drosophila models (Zhu et al., 2005, Djagaeva and Doronkin, 2009).  
A number of cellular pathways, encompassing abnormalities of the cell-cycle and 
transcriptional regulation, endoplasmic reticulum and nuclear envelope function and 
control of synaptic function, are thought to underlie molecular pathogenesis of primary 
genetic dystonias (Ledoux et al., 2013).  
How KCTD17 abnormal function could contribute to dystonia disease mechanisms is 
currently not known. WGCNA analysis indicates that KCTD17 may closely interact 
with HPCA, another recently identified dystonia-gene that is involved in calcium 
signalling (Charlesworth et al., 2015). Through live-cell imaging experiments in 
patients fibroblast I showed that the presence of the KCTD17 p.Arg145His mutation 
reduces Ca
2+
 storage in the ER and opening of store-operated calcium channels. 
Importantly, our group recently showed very similar defects of ER Ca
2+
 storage in 
fibroblasts bearing a pathogenic mutation in ANO3, another dystonia gene 
(Charlesworth et al., 2012). This indicates that defective ER calcium signalling may 
represent a converging pathogenic mechanism in genetically unrelated forms of 
dystonia. 
WGCNA also showed that the putamen KCTD17 module is enriched with genes 
involved in dopaminergic signalling, suggests the involvement of the genes in the 
module with these molecular pathway. Recent work in drosophila strongly reinforces 
the results of WGCNA and further suggests a relevant contribution of KCTD17 to 
regulation of dopaminergic transmission in the putamen. Insomniac (the KCTD17 fly 
homolog) is an essential regulator of sleep homeostasis through the control of the 
dopaminergic arousal pathways (Stavropoulos and Young, 2011, Pfeiffenberger and 
Allada, 2012). More specifically, insomniac seems to regulate dopaminergic signalling 
at the post-synaptic level, possibly controlling the turnover of dopamine receptors or 
their downstream effectors (Pfeiffenberger and Allada, 2012).  
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Importantly, abnormal post-synaptic dopaminergic signalling in the basal ganglia is one 
of the main themes in molecular dystonia pathogenesis, a concept recently strengthened 
by the identification of mutations in GNAL causing dystonia (Fuchs et al., 2013). Fitting 
well with this model, all the genes in the putamen KCTD17 module assigned to the 
KEGG “Do aminergic syna se”  ath ay  CACNA1C, PPP1R1B, AKT1, GNAO1, and 
GNB2) localize and act at the post-synaptic level.  
The KCTD17/HPCA putaminal module is not preserved across brain regions, which 
indicates it is a putamen-specific gene network. Importantly, the brain regional 
specificity of this module may suggest why mutations in KCTD17 and HPCA manifest 
purely as a dysfunction of the basal ganglia (i.e. dystonia), in spite of the ubiquitous 
expression in the human brain. 
Finally, the molecular pathogenic mechanism whereby the identified KCTD17 
p.Arg145His mutation could lead to M-D is still unclear. Our data shows that the protein 
stability or subcellular localization is unaltered in presence of the p.Arg145His 
p.Arg145His. The substitution falls outside the BTB/POZ domain. However it lies in an 
extremely highly conserved amino acid motif, which is not only completely conserved 
throughout all species down to Drosophila, but is also identical in human paralogous 
genes (KCTD2 and KCTD5), suggesting an essential role for the protein function.  
Notably, recent studies highlighted that tetramerisation is not a prerogative of the 
BTB/POZ domain but also the C-terminal domain of KCTD proteins may be able to 
promote tetramers assembly (Correale et al., 2013). Hence, it is possible that 
p.Arg145His mutation might prevent a correct oligomerisation or interaction with 
specific protein partners. Alternatively, the KCTD17 p.Arg145His substitution could 
abrogate the interaction with CUL3, resulting in abnormal degradation of specific 
substrates via the ubiquitine-proteasome system. For instance, this mechanism has been 
recently shown for a KCTD7 pathogenic mutations located outside the BTB/POZ 
domain (Staropoli et al., 2012).  
In conclusion, through a combination of genome-wide linkage analysis and WES in 
large British kindred, I showed that the missense mutation p.Arg145His in KCTD17 
represents a novel genetic cause for inherited autosomal dominant M-D. The clinical 
features of the KCTD17-mutated cases, although fully consistent with a clinical 
diagnosis of M-D, were distinct in many ways from the usual phenotype of subjects 
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with SGCE mutations. Dystonia dominated the clinical picture and showed a 
progressive course, worsening over time and spreading to other sites (including speech 
involvement), a course unusual for SGCE-related M-D. Myoclonus, despite being the 
presenting symptom in most cases, was overall mild and not as disabling as in SGCE-
mutated subjects. These phenotypic differences may be explained by the different 
functions of the two genes, but also by the clearly distinct patterns of brain regional 
expression. SGCE is highly expressed in the cerebellum, whereas its expression is low 
to moderate in putamen and globus pallidus (Ritz et al., 2011). On the other hand, 
KCTD17 expression is high in the putamen and thalamus but relatively low in the 
cerebellum. Intriguingly, this could be the explanation for the scarce response to alcohol 
consumption in KCTD17-mutated cases, as alcohol probably exerts its beneficial effect 
in M-D secondary to SGCE mutations by modulating cerebellar activity (Ritz et al., 
2011). 
Preliminary data suggest an involvement of KCTD17 in dopamine synaptic 
transmission regulation and an effect of the p.Arg145His substitution on ER-derived 
Ca
2+
 signalling. Further insight into the physiological role of KCTD17 and a better 
understanding of the pathogenic effect of the p.Arg145His substitution will shed light 
onto the mechanisms leading to abnormal neuronal activity underlying M-D. 
Furthermore, the identification of KCTD17 interactors will possibly highlight new 
potential pharmacological targets for the treatment of dystonia. 
Mutational screening of additional cohorts of M-D cases will help to define the 
frequency and the spectrum of KCTD17 mutations. KCTD17 mutations should be 
considered in cases without mutations in SGCE presenting with myoclonus, dystonia or 
a combination of both, particularly if there is predominant cranio-cervical and laryngeal 
involvement.
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5.4 Tyrosine Hydroxylase Deficiency Causes Autosomal 
Recessive, DOPA-Responsive, Myoclonus-Dystonia 
5.4.1 Statement of Contribution 
Dr Stamelou and I examined the family described in this chapter. I performed all the 
genetic analysis.  
5.4.2 Background 
I describe here the genetic analysis I conducted in a second, highly informative, family 
with SGCE-negative M-D. While the pattern of transmission was autosomal-dominant 
in the pedigree described in the previous chapter, in this family the disease was clearly 
transmitted in an autosomal recessive fashion (see Figure 5-11); three out of four 
siblings presented with a severe, early-onset movement disorders, while both parents 
were undoubtedly unaffected. 
An important clinical clue toward the identification of the underlying genetic 
abnormality in this family was the reported L-DOPA-responsiveness of symptoms in all 
affected subjects, which raised the suspicion of an atypical form of DRD. As discussed 
in the Introduction chapter, mutations in four genes have been convincingly 
demonstrated to cause DRD: GCH1 (GTP Cyclohydrolase 1), TH (Tyrosine 
Hydroxylase) and SPR (Sepiapterin Reductase) and DDC (DOPA decarboxylase).  
Although M-D has only been described once in a single family with DRD due to GTP 
Cyclohydrolase 1-deficieny (Leuzzi et al., 2002), given the strong clinical suspicion of a 
disorder of the dopamine synthesis pathway, after the exclusion of pathogenic SGCE 
mutations, I sequenced the coding regions of the genes mentioned above and identified 
compound-heterozygous mutations in TH.  
5.4.3 Subjects, Materials and Methods 
Index family 
The clinical characteristics of the patients and the family pedigree are described in the 
Results. All living family members from the index family were assessed and recruited. 
Two children of an unaffected individual were not examined. Assessment included a 
detailed medical interview and a full videotaped neurological examination, with focus 
on movement disorders. The University College London Hospitals/University College 
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London ethics committee (University College London Hospitals project ID number 
06/N076) approved the study, and all family members gave their informed consent. 
After obtaining informed consent, a blood sample was collected and DNA was extracted 
from all examined family members. 
 
Figure 5-11 Pedigree of a family with recessive L-DOPA responsive Myoclonus-Dystonia 
 
Genetic analysis  
Sanger sequencing was performed as described in Materials and Methods section. 
Primers were designed to amplify all coding exons and splicing sites of the GCH1 
(ENST00000491895; 6 coding exons), TH (ENST00000381178; 14 coding exons), SPR 
ENST00000234454; 3 coding exons), and DDC (ENST00000444124; 14 coding exons). 
The primers used in this study are listed in the Appendix.  
5.4.4 Results 
Clinical description 
Patient II-2, the index case, is a 27-year-old, female, who had normal birth. At the age 
of 6 months she was floppy with poor head control, and subsequently never properly 
reached normal motor milestones. She then went on and developed prominent and 
violent myoclonic jerks in all four limbs, trunk and neck. She also developed dystonia, 
which was most prominent on the upper limbs and face without diurnal fluctuation. She 
would also have intermittently painful spasms, with extension of all four limbs and 
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trunk that occurred several times daily, lasted up to several hours, and were 
accompanied by oculogyric crises and double incontinence and exacerbated by fever, 
infections or tiredness. Magnetic resonance imaging (MRI) brain and dopamine 
transporters imaging were normal. TOR1A genetic testing was performed and resulted 
negative.  
At the age of 13, she first tried L-DOPA, initially at a dose of 100 mg and subsequently 
increased up to 800 mg over about 5 years. This led to a gradual but significant 
improvement of dystonia and myoclonic jerks. She also started speaking and became 
able to control the electric wheelchair with her left hand, but she could still not use her 
right hand due to myoclonic jerks. The spasms improved in frequency and severity (5-7 
times a week). After the introduction of L-DOPA, cognition improved and she was able 
to attend a special school and later college. Given the marked response to L-DOPA, the 
suspicion of dopamine synthesis defect was raised. A phenyalalanine loading test was 
normal. Lumbar puncture was performed under treatment with L-DOPA since the 
patient refused to stop treatment for investigations and consequently; CSF showed 
normal pterins; homovallinic acid (HVA) was in the lower normal range 71 nmol/L 
(normal range: 71-565) and 5-hydroxyindoleacetic acid (5-HIAA) was lower than 
normal 28 nmol/L (normal range: 58-220) and 3-methyl DOPA was markedly elevated, 
due to L-DOPA treatment.  
She was first seen at the NHNN at age 18. On examination eye movements were normal, 
she had dystonic grimacing and dysarthria; she had generalized dystonia more 
prominent on the upper limbs with occasionally choreo-athetoid movements; 
generalized non-stimulus sensitive, spontaneous and action-induced myoclonus was 
more prominent in the right side, mostly in the right leg. There was slowing in finger-
tapping but not true bradykinesia. She could walk some steps with help. The rest of the 
examination was unrevealing. Follow-up over the next 9 years revealed no progression 
of the symptoms. She is still taking 800 mg L-DOPA/daily and occasionally up to 
1000/mg, when the spasms are more severe. She has no dyskinesias or further side 
effects from L-DOPA.  
Two of her siblings were similarly affected; case II-3 is a 24 year-old female with an 
identical picture to patient II-2. She was started on L-DOPA at age 8 years with similar 
improvement to patient II-2, but significantly better improvement of the jerks. On 
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examination she had similar findings to the index case, but less myoclonic jerks. Patient 
II-4 is now 19 and is the youngest sibling. He developed similar symptoms at the same 
age as II-2 and II-3, with generalized dystonia and prominent myoclonus, but he was 
treated earlier on L-DOPA at the age of 4. The jerks nearly disappeared.  Both II-2 and 
II-3 are treated with 800 mg L-DOPA/daily (occasionally up to 1000 mg), with no 
dyskinesias or other side effects. 
The older sister, aged 29 and who has two healthy children aged 6 and 8, is unaffected. 
The father (originally from Nigeria) and the mother (British Caucasian) are 
asymptomatic and did not show any neurological sign upon detailed examination.  
Given the results of the phenyalalanine loading test and CSF analysis, a diagnosis of 
GCH1-related DRD was considered unlikely. The presence of the DYT1 mutations was 
excluded. However, the analysis of SGCE revealed the presence of the splice-site 
variant c.391-3T>C in the index case, which was interpreted as the likely cause of the 
disease (Valente et al., 2005). Therefore, when I first started working on this project, the 
consensus was that this was a family with an atypical, particularly severe, form of 
SGCE-related M-D. 
Identification of the Causative Mutation 
As a detailed analysis of the segregation of the SGCE splice-site variant had not been 
performed in all available family members, I first checked whether the variant 
segregated in the remaining subjects (both parents, the affected brother II-4, and the 
healthy sister II-1). Sequencing of the variant was performed using primers previously 
designed and used by our own diagnostics laboratory.  
Importantly, I showed that the variant did not segregate, being present in the father, the 
unaffected sister and absent in the affected subject II-4. Furthermore, the variant is 
reported at a MAF of 0.2786 in African subjects (as per the ExAC database), thus 
completely ruling out a pathogenic role and the initial diagnosis of SGCE-related M-D 
was incorrect. 
Subsequently, based on the marked L-DOPA responsiveness, we decided to direct the 
genetic analysis based on the clinical suspicion of a disorder of the monoamine 
synthesis pathway. Although the CSF analysis was not indicative of any specific 
neurotransmitter deficiency, this was performed while the patient was on L-DOPA 
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treatment, thus making unreliable the dosage of dopamine degradation products.   
Analysis of GCH1, SPR and DCC genes did not reveal any pathogenic change. 
However, TH analysis revealed that all three affected siblings carried two mutations: a 
previously described point mutation (c.1-71 C>T) in the promoter region (Ribases et al., 
2007, Verbeek et al., 2007) and a novel missense mutation in exon 12 (c.1282G>A, 
p.Gly428Arg). The chromatograms of the mutations are shown in Figure 5-12A. 
 
Figure 5-12 Genetic results 
(A) Chromatograms of TH mutations identified in the present study. (B) Amino acid alignment of TH 
protein showing conservation of the p.Gly428Arg residue in different species. 
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Segregation analysis confirmed that the patients were compound heterozygotes, being 
the c.1-71 C>T mutation inherited from the mother and the c.1282G>A inherited from 
the father. The unaffected sister was heterozygote for the latter mutation. The identified 
mutation in the gene promoter lies in the Cyclic Adenosine Monophosphate Response 
Element (CRE), a highly conserved octomer (TGACGTCATGATGTCA) located at -
74 to -68 upstream the transcription initial codon. The novel variant identified in 
exon12 p.Gly428Arg is not reported in the ExAC database (containing WES data from 
more than 10,000 subjects of African ethnical background) and it affects an amino acid 
highly conserved throughout species. It is consistently predicted by both SIFT, 
Polyphen-2 and MutationTaster to have a deleterious effect. 
5.4.5 Discussion 
I report here three members of a family Tyrosine hydroxylase deficiency (THD) who 
presented with severe myoclonus accompanied by dystonia, consistent with a diagnosis 
of M-D, as the predominant feature.  
It is important that this unusual THD phenotype is recognised and considered in the 
differential diagnosis of early-onset M-D, as early treatment with L-DOPA is crucial for 
the final motor outcome in THD (Willemsen et al., 2010). This may be reflected here by 
the fact that although all three patients were similarly affected before the introduction of 
L-DOPA, and were subsequently treated with the same L-DOPA dose, the motor 
outcome is significantly different; the patient that was treated earliest (II-4, 4 years old) 
showed better response with regard to both the myoclonus and the dystonia than the one 
that was treated at age 9 years (II-3), and both of them showed a better outcome than the 
index case (II-2), who was first treated at the age of 13. 
Due to presence of a splice-site variant in SGCE, this pedigree was initially labelled as 
atypical SGCE-related M-D. When the variant was first found in this family, it was not 
observed in 384 control chromosomes and therefore the variant was interpreted as likely 
pathogenic and responsible for the phenotype (Valente et al., 2005). Furthermore, L-
DOPA-responsiveness has been reported before in cases with M-D (Luciano et al., 
2009). Hence, this feature did not put off the treating clinicians from the diagnosis.  
However, in spite of its rarity in European population controls (MAF in EXAC 0.001), 
the variant is common in African controls. This element, together with the complete 
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analysis of the variant segregation in all family members, completely ruled out the 
pathogenic role for the variant and discarded the initial diagnosis of SGCE-related M-D.  
THD is a rare autosomal recessive, DRD secondary to mutations in TH (Iwata et al., 
1992, Brautigam et al., 1998). Tyrosine hydroxylase is the enzyme responsible for 
catalysing the conversion of the amino acid L-tyrosine to L-DOPA and therefore TH 
loss-of-function mutations result in reduced production L-DOPA and dopamine in 
nigrostriatal neurons.  
The phenotype of THD is thought to be a spectrum with overlap of clinical features 
between two main phenotypes (Willemsen et al., 2010); on the one hand, a progressive 
hypokinetic-rigid syndrome with onset of symptoms in the first year, usually presenting 
with a combination of generalized dystonia and parkinsonism and a good response to L-
DOPA; on the other a more ‘com lex ence halo athy’,  ith earlier onset and featuring 
perinatal abnormalities, diurnal fluctuations, autonomic disturbances and less 
pronounced response to L-DOPA (Willemsen et al., 2010) (Brautigam et al., 1999, De 
Lonlay et al., 2000, de Rijk-van Andel et al., 2000, Diepold et al., 2005, Zafeiriou et al., 
2009, Yeung et al., 2011).  
Despite the large phenotypic variability of THD (Willemsen et al., 2010), prominent 
myoclonus is not considered classically to belong to THD phenotype. There is one case 
 ith ‘jerks’ re orted, ho e er, those  resented in the conce t of se ere ence halo athy, 
rigidity, spasticity, no response to L-DOPA and death at the age of 9 (Hoffmann et al., 
2003).  
A recent review of all genetically confirmed THD cases, revealed no phenotype-
genotype correlations (Willemsen et al., 2010). Our family showed compound 
heterozygosity of a point mutation in the promoter region (c.1-71 C>T) and a novel 
non-synonymous substitution in exon 12 (c.1282G>A, p.Gly428Arg). Mutations in the 
promoter region of the TH gene have been reported previously; mutagenesis studies in 
rats and cell lines clearly point out that each nucleotides substitution in the CRE of the 
TH gene results in a drastic reduction of the basal transcription (Lazaroff et al., 1995, 
Nagamoto-Combs et al., 1997).  The c.1-71 C>T mutation has been found to cause a 
reduction of 90% of basal transcription of the TH promoter (Tinti et al., 1997) allowing 
a residual activity, which explains the good response to L-DOPA. This variant has been 
reported previously in two cases, one in the homozygous and one in the compound 
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heterozygous state (Verbeek et al., 2007). The novel variant detected in exon 12 
p.Gly428Arg is highly unlikely to be benign: it is absent in all publicly available 
databases (over 130,000 chromosomes studied), it affects an amino acid completely 
conserved throughout species down to invertebrates, and it is predicted by all in silico 
tools to have a deleterious effect.  
TH pathogenic variants reported up to now are often private mutations confined to 
single or small number of pedigrees and, apart from a common mutation (c.698G>A, 
p.Arg233His) in the Dutch population (van den Heuvel et al., 1998), and one reported in 
three Greek families (c.707T>C, p.L236P) (Pons et al., 2010), no other founder effects 
have been described. Consequently, despite most of THD having been reported in 
Western Europe, the disease is expected to occur worldwide (Willemsen et al., 2010) 
and the novel mutation described here is the first pathogenic TH mutation in patients of 
African ancestry. 
In conclusion, THD should be included in the differential diagnosis of early-onset M-D. 
This is crucial for an early initiation of L-DOPA treatment, which could influence the 
motor and cognitive outcome of patients.  
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5.5 Assessment of The Role Of The CACNA1B Arg1389His 
Variant In a large Myoclonus-Dystonia Cohort  
5.5.1 Statement of Contribution 
I performed all the genetic analysis described in this chapter. 
5.5.2 Background 
Recently Groen and colleagues identified the missense variant c.4166G>A; 
p.Arg1389His (rs184841813) in CACNA1B as the likely causative mutation in a Dutch 
pedigree with five subjects affected by autosomal dominant M-D lacking mutations in 
SGCE (Groen et al., 2015). Unique features in the pedigree were lower limb orthostatic 
high-frequency myoclonus, attacks of limb painful cramps and cardiac arrhythmias in 3 
of the affected subjects (Groen et al., 2011). As CACNA1B mutations have not bee 
identified in other unrelated pedigrees, the implication of mutations in this gene as a 
cause for M-D is not confirmed. 
In this study, we assessed the frequency of the CACNA1B c.4166G>A; p.Arg1389His 
variant in a large multicentric cohort of M-D cases without mutations in SGCE. The 
results of this analysis do not support a causal association between the variant and M-D. 
5.5.3 Subjects, Materials and methods 
Patients 
A total of 520 M-D cases of British, German and Italian origin were recruited for this 
study in four tertiary movement disorders centres (London, Lübeck, Tübingen and 
Milan). This cohort is the same described in the previous chapter, with some additional 
samples recruited by the Tubingen centre. 146 cases (28%) had a positive family history 
of M-D. 489 white healthy controls of UK and US origin were provided by the 
 nternational  arkinson’s Disease Genomic Consortium    DGC .  ll  artici ants 
provided written informed consent. Additionally, I assessed the frequency of the variant 
in European cases listed in publicly available datasets of genetic variation (1000 
Genomes, Exome Variant Server and Exome Aggregation Consortium).  
Genetic analysis 
Given the large size of the entire CACNA1B open-reading frame (47 coding exons) and 
that only one variant has been described to date in M-D, I decided to perform Sanger 
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sequencing only of the coding exon (exon 28; RefSeq NM_000718.3), which contains 
the c.4166G>A; p.Arg1389His variant. Primers used for this study are listed in the 
Appendix. 
5.5.4 Results 
None of the 146 probands with familial M-D carried the CACNA1B c.4166G>A; 
p.Arg1389His variant. However, the variant was detected only in a single female case of 
UK origin with sporadic M-D (Figure 5-13). The clinical features of this case are an 
onset in her mid 30s of tremulous cervical dystonia and myoclonic jerks in the upper 
limbs. She had no family history for M-D or any other movement disorder. No other 
family members were available for segregation analysis of the variant. 
The total carrier frequency in our M-D cohort, including familial and sporadic cases, is 
0.19% (1/520 cases). Surprisingly, the variant was found at a similar frequency in our 
healthy controls (0.2%; 1/489 individuals). The control carrier of the variant is a 38-year 
old male without any neurological disease and with no relevant family history of 
movement disorders. 
The variant was found at similar frequencies in the 1000 genome project (0.26%; 1/379 
individuals) and Exome Variant Server (0.28%; 12/4,203 individuals) databases. In the 
Exome Aggregation Consortium database, c.4166G>A; p.Arg1389His is present in 0.11% 
(38/33,367) of the European subjects (difference to M-D cases not significant; Fisher’s 
exact test p = 0.4). 
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Figure 5-13 Chromatograms showing the CACNA1B c.4166G>A; p.Arg1389His variant (A) and a control sequence (B).
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5.5.5 Discussion 
The c.4166G>A; p.Arg1389His variant was identified by Groen and colleagues 
combining WES and linkage analysis (13 chromosomal regions identified, with a 
maximum LOD score of 1.2) in a single dominant M-D pedigree. Sanger sequencing of 
the CACNA1B exons coding for the protein portion spanning from III-S5 to III-S6 failed 
to reveal other mutations in a further 47 M-D cases.  
CACNA1B encodes neuronal voltage-gated calcium channels CaV2.2, which have a key 
role in controlling synaptic neurotransmitter release (Beuckmann et al., 2003). 
Furthermore CACNA1A mutations in the homologous region of the gene cause familial 
hemiplegic migraine (Carrera et al., 1999) and episodic ataxia type 2 (Jen et al., 2001).  
The CACNA1B p.Arg1389His substitution represents therefore an excellent candidate as 
a disease-causing mutation for M-D.  
While assessment of co-segregation with disease of the candidate variant represents the 
first requirement to prove causality in family-based studies, co-segregation in a single 
pedigree does not establish with certainty its pathogenic role, especially if other co-
segregating coding variants and the possibility of a separate undetected pathogenic 
variant in linkage disequilibrium cannot be convincingly ruled out. This is the case in 
the pedigree reported by Groen et al., where two other rare missense changes, 
c.10355A>G; p.Gln3452Arg in VPS13D and c.5308C>T; p.Arg1770Cys in SPTAN1, 
perfectly co-segregated with the disease. However, given the clinical presentation 
pointing towards a possible channelopathy, the authors assumed that the causative 
variant was the one in CACNA1B. 
De novo mutations in SPTAN1 have been shown to cause a neurological phenotype 
(West syndrome with severe cerebral hypomyelination, spastic quadriplegia, and 
developmental delay) (Saitsu et al., 2010) and more recently a microdeletion 
encompassing SPTAN1 was detected in a child with epileptic encephalopathy and severe 
dystonia (Matsumoto et al., 2014). Furthermore, its frequency in the ExAC database is 
significantly lower (2/33,360 European subjects) than the CACNA1B p.Arg1389His. 
Therefore, the SPTAN1 could also represent a good candidate gene responsible for M-D. 
A candidate variant responsible for a rare disease should be found at a low frequency in 
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population controls, consistent with the proposed model of inheritance and disease 
prevalence. As previously mentioned, M-D is a very rare disorder with a suggested 
prevalence of around 2 per million in Europe (Asmus and Gasser, 2010). I would 
therefore anticipate highly penetrant mutations causing dominant forms of M-D to be 
absent or extremely rare in the general population. Yet, this is not the case for 
p.Arg1389His, which is present at a considerable frequency in our healthy controls and 
all publicly available databases (∼0.1-0.3%). According to the Exome Aggregation 
Consortium database, the carrier frequency of this variant in Europeans is ~4 times 
higher than the TOR1A c.904_906delGAG deletion (0.026%), which is by far the most 
common single mutation responsible for dystonia described to date (Valente et al., 
1998). Given this frequency, if c.4166G>A; p.Arg1389His were a pathogenic variant, it 
would be expected to be responsible for a large proportion of familial M-D cases. 
However, in our cohort not only was the variant not identified in any of the probands 
with familial M-D, but the overall frequency of the variant did not differ between M-D 
cases and healthy controls. This does not support a pathogenic effect of the variant even 
assuming a reduced penetrance.  
These results strongly question the pathogenic role of the CACNA1B variant 
p.Arg1389His as a cause for M-D. Despite its compelling biological role, fitting very 
well with the current themes in dystonia pathogenesis (i.e. abnormal calcium signalling), 
further genetic evidence is needed before designating CACNA1B mutations as a cause 
for dominant M-D. In the era of NGS, the rate of identification of rare genetic variants 
has hugely increased. Hence, to avoid false assignment of pathogenicity, a close 
scrutiny is necessary before causally linking a candidate variant to a disease.  
Groen and colleagues performed functional work (whole-cell and single-channel patch 
recording studies) showing that the identified CACNA1B variant affected the normal 
activity of the channel (i.e. the mutant channel carried less current when open). 
However, the frequency of this variant in controls is simply incompatible with a 
dominant variant causing a disease with an aggregate frequency of 1 per 500,000, even 
if incomplete penetrance is posited. As such there is no remaining support for 
CACNA1B as a causal gene for M-D. 
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Chapter 6. Exploring the Genetics of Benign 
Hereditary Chorea 
6.1 Outline of chapter 
This chapter describes the work I performed to characterise the genetic aetiology, and 
where possible to identify novel genetic causes, in a cohort of patients with benign 
hereditary chorea (BHC). As discussed below, NKX2-1 represents the only gene that has 
been incontrovertibly associated with familial BHC.  
The chapter begins with an overview on BHC. The specific aims of the study were:  
1) To define the frequency of NKX2-1 mutations in the BHC Queen Square cohort 
2) To evaluate whether mutations in ADCY5, the gene responsible for the condition 
Familial Dyskinesias with Facial Myokymia, are a cause of BHC  
3) Identify novel genetic causes of BHC 
6.2 Benign Hereditary Chorea  
The term BHC was first introduced in the medical literature in 1967. The authors 
described a “non-progressive syndrome of inherited childhood-onset chorea with a good 
outcome in the absence of an underlying  rogressi e disease” affecting 14 indi iduals, 
members of a large autosomal dominant 5-generation African American pedigree 
(Haerer et al., 1967). A similar presentation, with different patterns of inheritance, was 
subsequently observed in a number of other families, (Nutting et al., 1969, Chun et al., 
1973, Bird et al., 1976, Burns et al., 1976).  
A single epidemiological study in the Welsh population has tried to establish the 
frequency of BHC (Harper, 1978).  BHC appears to be a very rare syndrome with an 
estimated prevalence of 1 in 500,000, although this figure is likely to be an 
underestimate due to poor recognition of the syndrome. 
Based on the analysis of 42 individuals with BHC reported in the medical literature 
since 1967, Kleiner-Fisman and Lang outlined the phenotype of BHC. BHC is mainly 
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characterized by the onset during infancy or early childhood of a choreic syndrome, 
often preceded by hypotonia and delay in reaching motor milestones. Affected children 
are often described as clumsy and report several falls. BHC cases, differently for 
neurodegenerative forms of choreas, present relatively scarce progression of symptoms 
and the absence of other major neurological deficits, in particular severe mental 
retardation or cognitive decline. In some families improvement of chorea can be 
observed over time (Kleiner-Fisman and Lang, 2007). 
After mapping the disease locus to chromosome 14q (de Vries et al., 2000, Fernandez et 
al., 2001), mutations in the NKX2-1 gene, encoding the thyroid transcription factor 1 
(TTF-1), were recognized in 2002 as a major cause for autosomal dominant BHC 
(Breedveld et al., 2002). At the same time, a second independent group also identified 
NKX2-1 point mutations in cases with congenital hypothyroidism and who also suffered 
from choreoathetosis, muscular hypotonia, and pulmonary problems (Krude et al., 
2002). This discovery represented a major breakthrough in the recognition and 
diagnosis of this condition. To date ~190 cases and ~100 NKX2-1 mutations (both point 
mutations and large deletions; Figure 6-1) have been reported, allowing a better 
definition and an expansion of the phenotype associated with mutations in this gene 
(Inzelberg et al., 2011, Gras et al., 2012, Thorwarth et al., 2014). It is now well 
recognized that NKX2-1 mutations often lead to a complex multisystem disease, defined 
brain-lung-thyroid syndrome, which features hypothyroidism, pulmonary defects and a 
variety of neurological symptoms (including not only chorea, but also hypotonia, 
neurodevelopmental delay, learning disabilities, behavioural problems, dystonia, 
myoclonus, tics and ataxia; Figure 6-2) (Gras et al., 2012). In particular, a series of 
clinical observations have consistently pointed out that dystonic features and EMG-
confirmed myoclonic jerks are often present in carriers of NKX2.1 mutations (Asmus et 
al., 2007, Armstrong et al., 2011, Gras et al., 2012). Importantly, as chorea tends to 
improve during adulthood, myoclonus-dystonia (M-D) symptoms may become the most 
prominent features in adult individuals with NKX2.1 mutations, leading to significant 
diagnostic difficulties in differentiating BHC from M-D secondary to SGCE mutations. 
Around 97% of cases reported in the literature present neurological symptoms, with 
only a minority of cases presenting with isolated lung involvement (Devriendt et al., 
1998, Iwatani et al., 2000, Hamvas et al., 2013). However, it is important to 
acknowledge that this figure may reflect an ascertainment bias due to selection of cases 
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to be screened for NKX2.1 mutations mainly based on the presence of neurological 
involvement. The two larger case series reported to date have demonstrated the presence 
of thyroid dysfunction in ~70% of mutation positive cases and slightly lower frequency 
of pulmonary involvement (Gras et al., 2012, Thorwarth et al., 2014). The full triad of 
brain, thyroid and lung involvement is observed in ~30% of patients, whereas isolated 
chorea in observed in only ~20% of mutation carriers. Pathogenic NKX2.1 are often 
loss-of-function and lead to haploinsufficiency. Missense mutations affect the ability of 
the protein to bind to DNA (Provenzano et al., 2016). 
 
Figure 6-1 Schematic representation of NKX2-1 point mutations reported to date.  
Reproduced from (Peall and Kurian, 2015) 
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NKX2.1 is a transcription factor gene essential for a correct early development of lungs, 
thyroid, and forebrain regions, in particular the basal ganglia. NKX2-1 is expressed in 
brain, especially in striatal cholinergic neurons. Pathological analysis in one case with 
genetically confirmed NKX2-1 associated BHC showed normal gross macroscopic and 
microscopic appearances, though with reduced count of striatal interneurons (Kleiner-
Fisman et al., 2003, Kleiner-Fisman et al., 2005). In mice, homozygous Nkx2-1 gene 
deletion results in a lethal phenotype, featuring pulmonary hypoplasia, absence of 
functional thyroid tissue and complex malformations of brain structures, including the 
basal ganglia (Kimura et al., 1996).  
 
Figure 6-2 Clinical features described in cases with NKX2-1 mutations 
Reproduced from (Peall and Kurian, 2015) 
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Importantly, a significant number of BHC families do not carry mutations affecting the 
coding sequence of NKX2-1. Breedveld et al. failed to demonstrate linkage to 
chromosome 14 in four dominant BHC families (Breedveld et al., 2002). Bauer and 
colleagues did not identify NKX2-1 mutations in 18 patients with chorea of unknown 
origin, including the index cases of three families with dominant benign chorea (Bauer 
et al., 2006). Genetic linkage analysis mapped an alternative disease associated locus on 
chromosome 8 (8q21.3-q23.3; locus named benign hereditary chorea 2 - BHC2) in two 
unrelated Japanese families with autosomal dominant non-progressive chorea 
(Shimohata et al., 2007). However, the clinical phenotype in these pedigrees differed 
from that of classic BHC, as the disease onset was in adult years and not in childhood. 
Finally, Thorwarth and colleagues recently completed an extensive clinical and genetic 
study in a large cohort of 101 cases with suspected BHC cases, clinically ascertained 
based on the presence of a variable combination of chorea, thyroid and lung 
disturbances. They identified NKX2-1 point mutations in 17 cases and large deletions in 
10 cases (Thorwarth et al., 2014). Of 74 cases without NKX2-1 mutations, 15 presented 
the full triad of brain-thyroid-lung involvement, 34 had brain-thyroid involvement and 8 
brain-lung involvement (Figure 6-3), suggesting the existence of variants in NKX2-1 
enhancer and/or promoter region or mutations in other yet unknown genes. 
 
Figure 6-3 Brain, thyroid and lung involvement in index patients and family members, with and 
without NKX2-1 mutations, in the largest cohort of Benign Hereditary Chorea cases screened to 
date 
Reproduced from (Thorwarth et al., 2014).  
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Intriguingly, 2 of the deletions detected in BHC cases were neighboring but not 
including the NKX2-1 coding region. One deletion was de novo, while the other 
segregated in a large pedigree with chorea of dominant inheritance. This finding 
confirms previous isolated observations of chromosomal deletions neighboring but not 
including NKX2-1 in 2 other BHC cases (Barnett et al., 2012, Dale et al., 2012). The 
pathogenic mechanism of such deletions is currently not clear. The deletions may 
remove essential regulatory elements downstream of NKX2-1 and critically affect 
NKX2-1 gene expression. The only coding gene encompassed by all deletions not 
NKX2-1 reported to date is MBIP, which encodes MAP3K12 binding inhibitory protein, 
a histone acetyltransferase complex involved into chromatin modifications (Suganuma 
et al., 2010). In situ hybridisation of MBIP in early mice embryos revealed the same 
expression pattern of NKX2-1, including the basal ganglia, forebrain, thyroid and lung, 
making MBIP a plausible cause of a NKX2-1 deficiency like phenotype (Thorwarth et 
al., 2014).  
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6.3 NKX2-1 Mutational Analysis in the Queen Square Benign 
Hereditary Chorea Cohort 
6.3.1 Statement of Contribution 
All participants to this study were clinically characterized and diagnosed by Professor 
Niall Quinn and Professor Kailash P. Bhatia. Dr Liana Veneziano and I performed the 
NKX2.1 mutational analysis.  
6.3.2 Background 
The Queen square cohort of BHC, consisting of ten families (7 dominant and 3 
recessive) and four sporadic cases, was first characterised and published in 2000 
(Schrag et al., 2000), before the identification of NKX2-1 mutations as the underlying 
genetic cause of BHC. Surprisingly, a systematic mutational analysis of NKX2-1 was 
never performed. In this section, I describe the NKX2-1 analysis performed in the BHC 
Queen Square cohort. 
6.3.3 Subjects, Materials and Methods 
Selection of cases for the project 
Of the 14 cases reported by Schrag and colleagues, DNA was available for only seven 
subjects (five familial and two sporadic cases). 
A search of the NHNN Neurogenetics database revealed an additional 16 cases, 
recruited after the publication of the initial series, with a clinical description consistent 
with BHC. These cases were clinically diagnosed as BHC based on the presence of a 
movement disorder, with onset prior to the age of 20, predominantly characterized by 
chorea in the absence of other major neurological features. In particular, none of the 
selected cases presented significant cognitive decline. Amongst these six had a positive 
family history for a similar disorder consistent with an autosomal dominant 
transmission, whereas ten cases were sporadic. In total, 23 cases (11 familial cases and 
12 sporadic) were included in the study. Amongst these, four familial cases and one 
sporadic case had evidence of extra-neural involvement, namely thyroid and lung 
defects. 
All these cases had been extensively investigated for acquired causes of chorea, without 
reaching a conclusive diagnosis. All cases had previously tested negative for the HD 
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triplet repeat expansion. Furthermore, given the reported clinical overlap with 
Myoclonus-Dystonia, all cases had been screened for SGCE mutations and were 
negative. All cases included in this study were recruited at the Movement disorder 
center of the National Hospital for Neurology and Neurosurgery, Queen Square, London 
and had given written consent and formal ethical approval by the relevant research 
ethics committee. 
Genetic Analysis 
I performed direct Sanger sequencing of the NKX2-1 coding exons (3 coding exons; 
transcript ENST00000354822) in all 23 BHC cases, as described in the Materials and 
Methods section. MLPA analysis to detect NKX2-1 copy-number variants was 
performed by Dr Liana Veneziano at the Institute of Translational Pharmacology in 
Rome.  
6.3.4 Results 
NKX2-1 mutational analysis 
This analysis revealed a total of five different heterozygous NKX2-1 mutations in five 
out of 23 BHC cases (21.7%). All mutations were found in cases with familial 
autosomal dominant BHC (5/11; 45.4%). The identified mutations were a missense 
mutation (c.605A>G; p.Gln202Arg), two STOP-gain mutations (c.622C>T;p.Arg208* 
and c.817A>T; Lys241*), one splice-site mutation (c.463+1G>C;p?), and one intronic 
variant (c.464-24A>C). Two point mutations (c.463+1G>C and p.Arg208*) have been 
previously described in BHC cases and are therefore established pathogenic variants, 
whereas the other variants are reported here for the first time. All variants are absent in 
all publicly available datasets (including ExAC). Segregation analysis supported a 
pathogenic role for all the identified variants as they were all found in other affected 
family members (see below). The missense change Gln202Arg is predicted pathogenic 
by Polyphen-2, SIFT and MutationTaster, and affects an amino acid completely 
conserved down to invertebrates. The effect of the two intronic mutations on splicing 
was evaluated in silico using Human Splicing finder (http://www.umd.be/HSF3/). The 
software predicted a highly detrimental effect for the c.463+1G>C (i.e. broken wild-
type donor site, most probably affecting splicing). Conversely, the in silico prediction 
tool did not highlight any significant splicing motif alteration determined by the c.464-
24A>C variant, suggesting that this mutation may not have any impact on splicing. 
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However, the variant segregated in other two affected family members and is 
completely absent in all publicly available datasets. As we did not have access to RNA 
to test experimentally the effect of the mutation on splicing, the pathogenic role of this 
variant remains uncertain. 
Transmitted and de novo large deletions neighbouring, but not encompassing, the 
NKX2-1 coding region have been recently described in cases with familial and sporadic 
BHC (Thorwarth et al., 2014). Thus, all cases without NKX2-1 point mutations or large 
deletion were genotyped using a dense array HumanOmni 2.5 (Illumina). However, no 
deletions were detected (Figure 6-4). 
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Figure 6-4. Array data of patient with BHC showing no deletions either encompassing or neighbouring the NKX2-1 locus 
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Clinical presentations of cases with NKX2-1 mutations 
Family-1 
This pedigree has been reported before (Robinson and Thornett, 1985) and represents 
family 7 in the paper of Schrag and colleagues. 
The proband, aged 46 when last examined, is the product of a normal pregnancy and his 
birth was uncomplicated. His motor milestones were delayed and as a child he suffered 
with several falls per day. He developed involuntary movements and upper limb jerks 
early in childhood, which progressed until age 11. After that, the movement disorder 
began to improve. When last assessed, the involuntary movements would still represent 
a source of social embarrassment, but they were not functionally invalidating. He had 
no cognitive difficulties. On examination he had generalised dystonia affecting the face, 
hands and feet, with super-imposed myoclonic jerks, mainly distributed in the upper 
body. He had a dystonic gait. Dystonia dramatically improved with a small dose of 
trihexyphenidyl (4 mg/day) combined with a small dose of L-DOPA (600 mg/day), with 
an almost complete resolution of symptoms.  
His son, who carried the same mutation, reported a similar medical history, with delayed 
motor milestones, frequent falls in childhood and an onset of the movement disorder 
very early in life. On examination, at age 22, he displayed generalised chorea, frequent 
stutter and gasps. He was not on any treatment when last assessed. Nobody else in the 
family was affected. The available medical notes did not mention any lung or thyroid 
involvement. Both cases carried the pathogenic splice site mutation c.463+1G>C.  
Family-2 
This family represents family 8 in the paper of Schrag et al. This 38-year-old woman 
was the product of a normal pregnancy and delivery. She had delayed reaching of motor 
milestones, with walking independently only at 3 and ½ years. As a child she would 
have multiple falls per day and she was clumsy and poorly coordinated. She was unable 
to run or ride a bicycle. Involuntary movements appeared at a very early age and these 
would affect mainly lower limbs, making her balance worse. Over the years the 
condition worsened, forcing her to use a wheelchair outdoors to prevent falls. Due to the 
presence of significant learning difficulties she had to attend special schools. 
Her examination showed mild jerky choreic movements affecting the face, the trunk and 
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the four limbs. Her speech was slurred, but the rest of the cranial nerve examination was 
unremarkable, including eye movements. There was mild posturing of hands and feet. 
Gait was choreic with superimposed elements of ataxia. A trial of L-DOPA up to 
600mg/day was not beneficial and therefore trihexyphenidyl was prescribed, though no 
information about the res onse to this treatment is a ailable in the  atient’s notes. 
She carried the pathogenic mutation p.Arg208*, which was also carried by her similarly 
affected mother and brother. 
Family-3 
This family represents family 10 in the paper of Schrag and colleagues 
Unfortunately, I was not able to retrieve any relevant clinical information for this 
pedigree. The pedigree consists of two siblings and their mother, all affected. They all 
had onset of symptoms in the first two years of life and all had delayed motor 
milestones and experienced many falls per day during childhood. Intellectual 
functioning was reported to be low average. The disease symptoms slightly improved 
with age in all family members. They all carried the intronic variant c.464-24A>C, of 
uncertain clinical significance.  
Family-4 
The proband is a 49-year old lady born via an uncomplicated delivery after a normal 
pregnancy. She  as a ‘flo  y’ baby. Her motor milestones  ere delayed,  ith delayed 
independent walking. At age 2 she was diagnosed with cerebellar ataxia. She 
experienced lifelong balance problems and, at around age 16, the balance worsened due 
to the appearance of choreic movements. Benztropine was then started resulting in 
improved symptoms. Hypothyroidism was diagnosed around age 40 and treated 
successfully with levothryoxine. She took no medications for the movement disorder. 
On examination, her gait was mildly ataxic and she had clear chorea and dystonic 
movements of her head and shoulders and dystonic posturing of the hands while 
walking. Eye movement examination revealed ocular apraxia with difficulty initiating 
saccades, broken pursuit movements, hypometric saccades and gaze impersistence. She 
had mild dysarthria. Here daughter was also affected and both cases carried the 
p.Lys248* mutation, which was not found in her parents, brothers and sisters (all 
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unaffected). After identifying the NKX2-1 variant in this case, I was informed that a 
genetic diagnosis had actually already been reached and the clinical description of this 
case had already been published (Veneziano et al., 2014). 
Family-5 
This case, aged 35 when last assessed, was born 3 weeks premature and initially fed 
with difficulty. She had a chest infection as a new-born and her initial motor milestones 
were delayed. Twitching choreic movements in here limbs were noticed since birth and, 
as soon as she started walking, she began to experience several falls per day. Her 
symptoms gradually improved with age. On examination she had a mix of chorea and 
dystonic posturing affecting the four limbs. She was not taking any medication for the 
movement disorder. Her daughter was similarly affected and both carried the novel 
missense change p.Gln202Arg.  
6.3.5 Discussion 
While several studies are available in the literature describing ~ 200 BHC cases caused 
by NKX2-1 mutations (recently reviewed in [Peall and Kurian, 2015]), surprisingly few 
studies have systematically assessed the contribution of NKX2-1 mutations in cohorts of 
clinically defined BHC cases.  
In this chapter I report the results of a detailed screening of NKX2-1, by means of 
Sanger sequencing and MLPA analysis, of the BHC Queen Square cohort. All these 
cases fully met the current clinical definition of BHC, as they all presented in childhood 
with a non-acute onset, predominantly choreic, movement disorder, which was scarcely 
progressive and did not include prominent additional neurological features, in particular 
cognitive decline. As dystonia, in combination with chorea, has been observed in 
genetically proven NKX2-1–mutation cases (Fung et al., 2006, Armstrong et al., 2011), 
this feature was not considered as an exclusion criterion for the study. 
The study included both familial and sporadic cases as it has been recently shown that a 
high proportion of mutated cases carry de novo mutations and therefore the absence of a 
positive family history should not excluded a diagnosis of NKX2-1–related disease 
(Gras et al., 2012). All sporadic cases had all been extensively investigated for acquired 
causes of chorea. 
Importantly, I show that only five out of 23 BHC cases carried variants in the gene. All 
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cases had a positive family history for the condition and mutations were shown to 
segregate in additional affected family members, strongly supporting their pathogenic 
role. Four of the five identified mutations are either established pathogenic changes or 
are clear loss-of-function variants, and therefore pathogenic by definition. More 
controversial is the role of the intronic variant found in family 3, as in silico tools did 
not predict an obvious effect on splicing and I did not have access to patients’ RN  to 
establish experimentally the effect on splicing. However, in support of its pathogenic 
effect, the mutation is completely absent in all publicly available datasets and 
segregated in the three available family members. Furthermore, the role of deep intronic 
mutations in Mendelian diseases is increasingly recognised (Akman et al., 2015, 
Stepensky et al., 2016). 
Although the yield of mutation positive cases (21.7%) of this study could look 
surprisingly low, it is actually in line with what has been reported by other groups. In 
particular, Thorwarth and colleagues have recently completed an extensive clinical and 
genetic study in a large cohort of 101 cases with clinically suspected BHC cases and 
found that 74 cases (73% of the cohort), of which 15 presented with the full triad of 
brain-thyroid-lung involvement, actually did not carry mutations in NKX2-1 (Thorwarth 
et al., 2014). Similarly, in our cohort, three out five cases with brain-thyroid-lung 
disease, two of which with a clear autosomal dominant family history, did not carry 
NKX2-1 point mutations or deletions, or the recently described deletions of the 
chromosomal region neighbouring NKX2-1. These results clearly indicate the existence 
of either undetected variants in NKX2-1 (e.g. in the enhancer and/or promoter region or 
deep intronic mutations) or mutations in other yet unknown genes that critically interact 
with NKX2-1 for the correct development of striatal neurons and of thyroidal and 
pulmonary tissues. 
Interestingly, part of this cohort (and three of NKX2-1-mutated cases; family 1,2, and 3) 
had been reported back in 2000, before the discovery of NKX2-1 mutations (Schrag et 
al., 2000). While all three families had at some point been labelled as affected with 
typical BHC, several cases from all three families, when clinically reappraised for the 
paper of Schrag and colleagues, were re-assigned to other diagnostic categories, such as 
M-D or generalised dystonia. This element clearly suggests the difficulty of recognising 
genetic entities on clinical grounds alone. Furthermore, it highlights the broad clinical 
heterogeneity associated with mutations in NKX2-1. 
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In conclusion, while the term BHC is often used to imply the presence of NKX2-1 
mutations, a significant number of sporadic cases and families with BHC do not carry 
mutations in this gene. Furthermore, NKX2.1-mutated cases can frequently present with 
movement disorders other than chorea. 
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6.4 ADCY5 Mutational Analysis in a Cohort of Benign 
Hereditary Chorea Cases 
6.4.1 Statement of Contribution 
I performed all the genetic analysis described in this section.  
6.4.2 Introduction 
In 2001 Fernandez and colleagues described a North American 5-generation pedigree of 
German origin with 18 members affected with a childhood-onset autosomal dominant 
movement disorder. The clinical presentation in this family was that of a hyperkinetic 
movement disorder featuring predominantly chorea and dystonia involving the limbs, 
neck, and face. Perioral and periorbital twitching was also observed in some family 
members and needle electromyogram (EMG) in two individuals revealed what was 
initially thought to be myokymia (Fernandez et al., 2001). The disease was 
consequently named Familial Dyskinesia with Facial Myokymia (FDFM). 
In 2009 the disease locus was subsequently mapped to chromosome 3p21-3q21 
(Raskind et al., 2009), but only recently Chen and colleagues identified using WES a 
missense variant in ADCY5, encoding adenyl cyclase 5 (AC5), as the causative mutation 
(Chen et al., 2012). Prior to the identification of facial myokymia as one of the core 
features, individuals from the original FDFM kindred had been described as affected 
 ith familial essential  “benign”  chorea (Bird et al., 1976). Hence, given the large 
phenotypic overlap between FDFM and BHC, I hypothesised that ADCY5 mutations 
could be responsible for BHC in cases lacking mutations in NKX2-1.  
I therefore performed a mutational analysis of ADCY5 in the Queen Square cohort of 
NKX2-1-negative BHC cases and in a second cohort of NKX2-1-negative BHC cases of 
Italian origin. 
6.4.3 Subjects, Materials and Methods 
Samples 
The eighteen BHC cases that did not carry NKX2-1 mutations (see previous section), 
including six with an autosomal dominant family history and 12 sporadic, were initially 
selected for this study. An additional cohort of 35 cases of Italian origin, clinically 
diagnosed by  rof Nardo Nardocci’s and Dr Carlo Fusco’s grou s,  as subsequently 
  211 
studied. Dr Liana Veneziano and Dr Barbara Gara aglia’s laboratories had  re iously 
performed the NKX2-1 analysis in the Italian cohort, including Sanger sequencing and 
MLPA analysis. 
Genetic Analysis 
WES was performed in ten of the BHC cases. Cases were prioritised for WES if they 
had an autosomal dominant family history (five cases) and/or an age at onset < 10 years 
(five cases), assuming that a genetic aetiology would be more likely for these cases.  
In the Queen Square BHC cohort, the search for ADCY5 mutations was performed 
either by interrogating WES data or by Sanger sequencing of the ADCY5 coding region 
(21 exons; transcript ENST00000462833). As WES poorly covered exon 1 due to its 
high GC content, Sanger was used to sequence exon 1 in all cases. Visual inspection 
revealed that all other exons were adequately covered by WES. 
In the Italian cohort I screened by Sanger sequencing only ADCY5 exons 2 and 10. This 
strategy was undertaken as these two exons are likely to represent mutational hotspots.  
WES and Sanger sequencing were performed as described in the Materials and Methods 
chapter. The primers used to amplify the coding exons and splice sites of ADCY5 are 
listed in the appendix.  
Segregation analysis was performed in all available relatives of mutation positive-cases. 
Expression Profiling of ADCY5 and NKX2-1 in Brain Tissue  
Brain ADCY5 and NKX2-1 mRNA regional distribution and expression in the normal 
adult human brain and longitudinal expression changes during the course of human 
brain development were determined using microarray analysis of human post-mortem 
brain tissue from the UK Human Brain Expression Consortium and the Human Brain 
Transcriptome database, as previously detailed in the Materials and Methods chapter.  
6.4.4 Results 
Genetic Analysis 
The search for mutations in the entire ADCY5 coding region in the Queen square BHC 
cohort revealed the presence of five different heterozygous mutations.  
The c.1252C>T; p.Arg418Trp variant was identified in two unrelated cases. This amino 
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acid change has been previously reported in association with FDFM (Chen et al., 2014) 
and is absent in all publicly available datasets of population controls (dbSNP, 
1000genome project, NHLBI exome variant server and Exome Aggregation 
Consortium). All in silico prediction tools (Polyphen-2, SIFT and Mutation Taster) 
consistently predict a deleterious effect of the mutation.  
Another missense variant (c.2117C>T; p.A706V) was detected in the index case of a 
pedigree with autosomal dominant BHC (brain-lung-thyroid syndrome). This variant is 
novel, as it is not reported in any of the databases of genetic variations. 
The variant was predicted benign and tolerated respectively by Polyphen-2 and SIFT, 
but disease causing by MutationTaster. Segregation analysis in the family showed that 
the mutation was absent in the affected mother and was inherited by the unaffected 
father, thus ruling out any pathogenic relevance. A non-coding  ariant in the 5’ UTR 
(c.1-5G>C; rs566725675) together with the missense variant c.29C>T; p.P10L 
(rs143905423) (phase of the mutation not know) were detected in a sporadic case of 
African ancestry. The phase of the two mutations is not known. Both variants are 
reported with a MAF ≥ 1% in control indi iduals of  frican ancestry as re orted by the 
ExAC, thus excluding a pathogenic role.  
In total 2/18 probands (11.1%) from the Queen Square cohort carried pathogenic 
ADCY5 variants, both located in exon 2. 
The analysis of exons 2 and 10 in the Italian BHC cohort revealed that three probands 
(3/35; 8.5%) carried pathogenic ADCY5 missense mutations, all involving the same 
amino acid residue, Arg418. The variant c.1252C>T; p.Arg418Trp, the same change 
identified in the two Queen Square cases, was also found in one Italian sporadic case. 
Two novel variants, c.1253G>A; p.Arg418Gln and c.1252C>G; p.Arg418Gly were 
found in a sporadic and in a familial case, respectively. Both variants are absent in all 
publicly available datasets and are predicted pathogenic by Polyphen-2, SIFT and 
MutationTaster.  
Clinical Presentations of Cases with Pathogenic ADCY5 Mutations 
Clinical information of the patients with pathogenic ADCY5 mutations identified in this 
study is summarized in Table 6-1. 
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Family-1 
The clinical description of this pedigree has been previously published in 1981, as part 
of a report describing a series of families with benign (non-paroxysmal) familial chorea 
(Sleigh and Lindenbaum, 1981). The index case is a British 36-year old man. His birth 
and early development throughout infancy were normal. In the first year of life he 
progressively developed brief choreic movements at rest, involving the face and the four 
limbs. Movements were markedly worsened by excitement, stress or tiredness. Around 
the age of 18 he also developed painful spasms of the four limbs, particularly frequent 
and severe upon awakening. Symptoms progressed over the years and neurological 
examination at the age of 28 revealed dysarthric speech and severe abnormal 
involuntary movements comprising generalized chorea with facial grimacing and 
marked dystonic features. Both chorea and dystonia were present at rest, but action 
significantly exacerbated movements in the limbs. Eye movements were abnormal with 
gaze impersistence and use of head thrust to initiate saccades. Gait was unsteady with 
both choreic and dystonic features, but cerebellar testing was otherwise normal. He 
never displayed facial myokymia and EMG of periorbital and perioral regions failed to 
show either myokymia or other signs of motor neuron hyperexcitability. Over the years 
different medications were tried without major improvements, including 
trihexyphenidyl, tetrabenazine, baclofen, L-DOPA and clonazepam. He is currently on a 
combination of trihexyphenidyl (3 mg/day) and tetrabenazine (75 mg/day), which he 
finds helpful in reducing the intensity and frequency of the spasms. His 64-year old 
father also developed hyperkinetic movements in the first year of life. His neurological 
examination mainly consisted of generalized chorea, but no dystonic posturing. Overall, 
his clinical  resentation  as much milder than his son’s one. Besides chorea, on 
examination he had marked ocular and motor impersistence and tandem walking 
difficulties. Cerebellar testing was otherwise normal. At the last follow-up, when he was 
61, occasional twitches were observed in the periorbital areas, but an EMG performed 
on the same day did not show myokymia. A low dose of tetrabenazine was tried but was 
not tolerated due to the developed of depression. He is currently taking trihexyphenidyl 
(7.5 mg/day), with satisfactory control of the dyskinesias. Higher doses were not 
tolerated due to the occurrence of cognitive difficulties. There was no history of 
movement disorders in other family members, including both paternal grandparents of 
the index case. 
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The heterozygous ADCY5 c.1252C>T; p.Arg418Trp mutation was found by WES and 
confirmed by Sanger sequencing in subject III-1. However, Sanger sequencing 
surprisingly failed to detect the mutation in the affected father (Figure 6-5). Mosaicism 
has been previously reported in patients with mild presentation of Mendelian disorders 
(Beicht et al., 2013). We therefore suspected that Sanger sequencing might have missed 
the mutation in the father due to low-grade somatic mosaicism.  
As next-generation sequencing has been shown to be a more sensitive method to detect 
this type of mutations (Beicht et al., 2013; Miyatake et al., 2014), WES was 
subsequently performed also in subject II-1. Interestingly, this disclosed the presence of 
the mutated allele in 9/110 of the sequence reads (~8% versus ~40% in his son; Figure 
6-5), confirming the presence of low-level somatic mosaicism. This suggests that the 
mutation arose in the father during early stages of embryogenesis. Sanger sequencing 
analysis showed that the unaffected mother and sister of the index case did not carry the 
mutation.  
Family-2 
This is a 22-year-old man of Pakistani ethnicity. He is the son of a consanguineous 
marriage (parents are first degree cousins) and he is the first of four siblings. He is the 
only affected member in the family. He had delayed motor milestones with walking at 
approximately 20 months. Since then his gait has always been abnormal, being mainly 
characterized by arching of the trunk, walking on tiptoes and inversion of both feet. 
Around the age of 2 he developed constant involuntary movements involving all four 
limbs and trunk, which became progressively more evident over the years. Movements 
were largely exacerbated by stress and anxiety.  round the age of 10, he de elo ed “fits” 
of violent hyperkinetic movements and painful spasms of all four limbs, mainly 
occurring at night. A polysomnographic study performed to investigate their nature 
excluded any epileptic activity and showed that the attacks occurred when the patient 
was awake. Neurological examination showed he had moderate generalized chorea at 
rest, and intermittent distal dystonic posturing in the four limbs. The hyperkinetic 
movements were dramatically increased by action. Gait was unsteady, but cerebellar 
testing was otherwise normal. Cranial nerve examination showed ocular impersistence 
and frequent facial choreic movements were also observed. The patient declined an 
EMG of the facial muscles. 
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He is currently taking trihexyphenidyl (30 mg/day) and tetrabenazine (50 mg/day), 
which partially reduced the intensity of the dyskinesias and the frequency of the spasms. 
WES and subsequent Sanger sequencing analysis showed the presence of the ADCY5 
c.1252C>T; p.Arg418Trp change in the heterozygous state in the affected. The mutation 
was de novo, as Sanger sequencing showed its absence in both healthy parents and in 
the three unaffected siblings.  
Family-3 
The proband is a 14-year-old Italian girl born pre-term (38
th
 week) from healthy parents. 
She presented with psychomotor delay and could walk independently at around age 3. 
At age 4, she developed a generalized hyperkinetic movement disorder featuring a 
combination of chorea and dystonia, which made ambulation difficult and caused 
frequent falls. Pyramidal signs were present in the lower limbs together with a bilateral 
foot dystonia, requiring splints and regular botulinum toxin injections. Since the first 
months of life, this patient presented severe paroxysmal worsening of chorea upon 
falling asleep, which could happen in clusters of 2-10 attacks lasting up to 30 seconds 
each with spontaneous remission. In addition, she later presented two different kinds of 
paroxysms, one occurring mainly during sleep (generalized dystonia and dyskinesias 
with facial grimacing and no sleep interruption, with onset around age 4), and one 
during the day (multiple sudden falls due to give-way of legs without premonitory 
sensation, with onset around age 11). All the types of attacks were favored by tiredness 
and emotions, but no clear triggering factors were reported.  
Examination at age 14 showed generalized chorea involving also the perioral muscles, 
upper and lower limbs dystonic posturing and fixed dystonia (in turning and plantar 
flexion) of the left foot. Scissoring gait with pyramidal signs in the lower limbs were 
present and speech was markedly dysarthric.  
 
  216 
 
Figure 6-5 Pedigree and genetic results of family 1 
On the left the visual output of the WES data and Sanger sequencing results in the affected individuals carrying the p.Arg418Trp mutation. In the top section of each box the read 
depth of the exonic portion of ADCY5 involved by the mutation is shown. In the bottom part of each box, samples of the reads carrying the mismatching allele are displayed. The 
mutant T replacing a C is highlighted in red. Sanger sequencing failed to show the mutation in individual II-1.  
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Overall, the severity of movement disorder was reduced as compared to infancy, and so 
was the frequency of nocturnal paroxysms; however, diurnal paroxysms were very 
disabling and could occur several times per day. She was on Trihexyphenidyl 32 mg/day.  
Sanger sequencing showed she carried the p.Arg418Trp change, which was 
demonstrated to be de novo. 
Family-4 
The proband is an 18-year-old boy of Italian origin born from healthy parents. He 
presented with delayed motor milestones and a tendency to tiptoe walking around the 
age of 18 months. Since his first months of life, nocturnal paroxysms characterized by 
generalized dystonia with inconsolable crying, lasting for hours, disrupted his sleep. 
During infancy he developed generalized chorea and myoclonic jerks also involving 
facial muscles. Episodic worsening of dyskinesias without specific triggers 
accompanied by hyperventilation was noticed during childhood with a weekly 
frequency. Examination at age 17 showed generalized asynchronous, non-stimulus 
sensitive myoclonic jerks at rest, mild dysarthria, scissoring gait with pyramidal signs in 
the lower limbs and dystonia of upper limbs and the trunk. Diurnal and nocturnal 
paroxysms were still present, albeit at a decreased frequency (one episode per year). 
Overall no progression in the severity of his movement disorder was noticed as 
compared to infancy, though choreic movements decreased and myoclonic and dystonic 
aspects became more prominent. He carried the novel p.Arg418Gln substitution, which 
was not found in both his parents and therefore confirmed to be a de novo mutation. 
Family-5 
The proband is a 2-year-old-boy of Italian origin. He was born normally after a normal 
pregnancy. Generalised choreic and myoclonic movements appeared in the first months 
of life. Motor and language development were severely delayed. He is currently able to 
sit, but not to stand without support. The neurological examination showed axial 
hypotonia, diffuse chorea and myoclonic jerks and dystonic posturing in the four limbs. 
A tendency to tiptoe walking was noted. A trial with trihexyphenidyl was unsuccessful.  
His father, currently aged 47, is affected with generalised dystonia mixed with choreic 
elements, started around age 3. Differently from his child, his motor and language 
development were entirely normal. He presented frequent facial twitches and severe 
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dysarthria. The dyskinesias are markedly worsened by action, emotions and stress. 
Paroxysmal episodes of severe and painful dyskinesias are triggered by strong emotions 
and sleep. Several pharmacological trials (including trihexyphenidyl, L-DOPA and 
tetrabenazine) were ineffective. Both father and son have recently started a therapeutical 
trial with acetazolamide. 
Both cases were found to carry the novel change p.Arg418Gly. Interestingly visual 
inspection of the chromatograms shows an imbalanced ratio between the wild-type and 
the mutated allele, with the latter significantly less represented (Figure 6-6). This was 
not observed in the son, suggesting that the father could be mosaic for the mutation. 
 
 
Figure 6-6. Pedigree of family 5 with the novel Arg418Gly mutation 
The electropherogram of the affected father clearly shows an unbalance ratio between the wild-type and 
the mutant allele (top panel), with the wild-type significantly more represented and suggesting somatic 
mosaicism. This was not observed in the proband where the chromatograms of the normal and mutated 
allele are equivalently represented (bottom panel). 
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Table 6-1 Clinical features of cases with pathogenic ADCY5 mutations 
 
Family-1 - 
Father 
Family-1 Son Family-2 Family-3 Family-4 Family-5 - Father Family-5 - Son 
Ethnic origin UK-Caucasian UK-Caucasian UK-Pakistani Italian-Caucasian Italian-Caucasian Italian-Caucasian Italian-Caucasian 
Age at onset (y) 1 1 2 4 1 3 1 
Age at 
examination(y) 
64 36 22 14 18 47 2 
Mutation 
c.1252C>T; 
p.Arg418Trp 
(low-level 
mosaicism) 
c.1252C>T; 
p.Arg418Trp 
c.1252C>T; 
p.Arg418Trp 
c.1252C>T; 
p.Arg418Trp 
c.1253G>A; 
p.Arg418Gln 
c.1252C>G; 
p.Arg418Gly 
(mosaicism) 
c.1252C>G; 
p.Arg418Gly 
Symptoms at 
onset 
Chorea Chorea 
Chorea and lower 
limb dystonia 
Violent 
dyskinesias upon 
falling asleep 
Chorea, dystonia Chorea, dystonia Chorea 
Developmental 
milestones 
Normal Delayed Delayed Delayed Delayed Normal Delayed 
Dysarthria No Yes Yes Yes Yes Yes Not applicable 
Facial dyskinesias Yes Yes Yes Yes Yes Yes No 
Chorea Yes, mild 
Yes, severe and 
worsened by 
action and 
anxiety 
Yes, severe and 
worsened by 
action and anxiety 
Yes Yes, mild 
Yes, worsened by 
action 
Yes 
Dystonia No Yes Yes Yes, severe Yes, Yes, severe Yes 
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Other features 
Gaze 
impersistence, 
difficulty 
initiating 
saccades 
Gaze 
impersistence, 
difficulty 
initiating 
saccades 
Gaze 
impersistence 
Pyramidal signs 
in the lower limbs 
Frequent myoclonic 
jerks and pyramidal 
signs in the lower 
limbs 
No 
Severe language 
development 
Paroxysmal events 
Ballistic 
episodes and 
spasms upon 
awakening 
Ballistic episodes 
and spasms upon 
awakening 
Ballistic episodes 
and spasms at 
night 
Triggered by 
sleep, favoured by 
emotions 
Triggered by stress 
and sleep 
Triggered by 
stress and sleep 
No 
Gait 
Mild difficulty 
on tandem 
walking 
Abnormal due to 
lower limb 
choreo-dystonia 
Abnormal due to 
lower limb 
choreo-dystonia 
Dystonic and 
pyramidal 
features, frequent 
falls 
Mildly affected 
with dystonic 
features 
Dystonic Not applicable 
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Brain expression data 
In order to investigate the differences in the phenotype and clinical course between 
BHC due to ADCY5 and NKX2-1 mutations, the expression of the two genes across 
multiple brain regions and during the course of development was compared. 
Consistent with the observed phenotype, mainly characterized by chorea and dystonia 
with preserved cognition and no other major neurological features, both ADCY5 and 
NKX2-1 mRNA expression profiling in 10 brain regions showed the highest regional 
expression in the putamen (Figure 6-7 and Figure 6-8). When comparing ADCY5 to 
NKX2-1 expression, ADCY5 had a much higher expression in adult striatum. 
Furthermore, longitudinal analysis of mRNA expression during brain development 
showed opposite trends for ADCY5 and NKX2-1, with ADCY5 expression progressively 
increasing in the striatum from 50 to 500 days post-conceptualization and NKX2-1 
progressively decreasing (Figure 6-7 and Figure 6-8). 
6.4.5 Discussion 
I report here the results of the ADCY5 mutational analysis in a cohort of NKX2-1 
negative BHC cases and show that transmitted and de novo heterozygous ADCY5 
mutations are an important cause of familial and sporadic BHC. Overall, in this study 
pathogenic mutations were identified in 5/53 (9.4%) of cases.   
The heterozygous mutation p.Ala726Thr in ADCY5 was identified as the genetic cause 
in the original FDFM pedigree (Chen et al., 2012). The presentation of the affected 
members of this family was that of a hyperkinetic choreo-dystonic movement disorder 
starting from early childhood to late adolescence. A distinctive feature of this disorder 
was initially thought to be the presence of prominent periorbital and perioral facial 
myokymia (Fernandez et al., 2001). After the identification of ADCY5 as the 
responsible gene in the original FDFM pedigree, the same group identified a second 
pathogenic missense variant in ADCY5 (c.1252C>T; p.Arg418Trp), which occurred de 
novo in two unrelated individuals with a sporadic complex hyperkinetic movement 
disorder (Chen et al., 2014). The phenotype of these cases shared some features with the 
original FDFM pedigree, but it was more severe and further encompassed delayed 
motor milestones, axial hypotonia and progressive gait difficulties in one case.  
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Figure 6-7 Graphical Summary of ADCY5 Brain Expression Data 
On the left box plots representing ADCY5 mRNA expression levels. The expression levels are based on exon array experiments and are plotted on a log2 scale (y axis). ADCY5 
mRNA expression is higher in the putamen than in all other brain regions. Oh the right, graphs to show ADCY5 longitudinal mRNA expression in six brain regions during the course 
of human brain development. The expression levels are based on exon array experiments and are plotted on a log2 scale (y axis). The plots show increasing expression of ADCY5 
mRNA during human brain development, particularly in the striatum, from 50 to 500 days post-conceptualization. 
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Figure 6-8 Graphical Summary of NKX2-1 Brain Expression Data 
On the left box plots representing NKX2-1mRNA expression levels. The expression levels are based on exon array experiments and are plotted on a log2 scale (y axis). NKX2-
1mRNA expression is higher in the putamen than in all other brain regions. However NKX2-1 expression in the putamen is significantly lower than ADCY5. On the right, graphs to 
show NKX2-1 longitudinal mRNA expression in six brain regions during the course of human brain development. The expression levels are based on exon array experiments and are 
plotted on a log2 scale (y axis). The plots show decreasing expression of NKX2-1mRNA during human brain development, particularly in the striatum, from 50 to 500 days post-
conceptualization, an opposite trend compared to ADCY5. 
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In this chapter, I report seven cases from five unrelated pedigrees bearing pathogenic 
ADCY5 mutations. Importantly, all the mutations that I identified involved the same 
amino acid p.Arg418, highlighting a particular relevance of this residue in the disease 
mechanisms. Three unrelated cases carried the previously reported Arg418Trp mutation, 
whereas two others carried the novel mutations Arg418Gln and Arg418Gly. 
The clinical phenotype of these cases predominantly featured generalized chorea, 
though with significant intra- and inter-familial phenotypic variability.  
As previously described, three of the four mutated subjects with the ADCY5 
p.Arg418Trp mutation were more severely affected than subjects from the original 
FDFM pedigree and carriers of the p.Arg418Gln and p.Arg418Gly. The phenotype of 
these cases with the p.Arg418Trp included axial hypotonia, delayed motor milestones, 
and disabling choreo-dystonic dyskinesias.  
Conversely, subject II-1 from family 1 had a much milder presentation, with very little 
functional impact from the dyskinesias. Furthermore, he had isolated chorea and no 
dystonic features. Interestingly, low-level somatic mosaicism is the likely mechanism 
for the observed milder phenotype. Indeed, WES data showed a significantly reduced 
number of reads carrying the mutated allele in the latter case, indicating the presence 
low-level somatic mosaicism. Somatic mosaicism was likely present also in cases II-1 
from family 5 (carrier of the p.Arg418Gly), who, differently from his son, had a 
predominantly dystonic phenotype and normal motor and language development.  
Mosaicism has been recently described in two further cases with ADCY5 mutations and 
a milder phenotype, suggesting that somatic mosaicism may represent a common 
explanation for inter- and intra-familial phenotypic variability in ADCY5 mutation 
carriers (Chen et al., 2015).  
The clinical presentation of the subject with the Arg418Gln mutation, who initially 
presented in childhood with BHC, is now consistent with a diagnosis of myoclonus-
dystonia. A similar evolution was also observed in subject III-1 from family I (with the 
p.Arg418Trp), who predominantly showed chorea during childhood, while dystonic 
elements became more prominent over the years. 
In some of the previously described cases with ADCY5 mutations, dyskinesias are 
  225 
reported as paroxysmal in the initial phase of the disease (Fernandez et al., 2001)
 
(Chen 
et al., 2014). In contrast, in all the cases described herein, dyskinesias were constantly 
present from the onset of symptoms, albeit markedly influenced by emotional states and 
action. However, two subjects developed superimposed diurnal episodic worsening of 
dyskinesias, triggered by intense emotional stress. Furthermore, six subjects (excluding 
individual III-2 from family 5, who is currently only 18 months old) presented 
exacerbations of hyperkinesias at night, sometimes evolving into episodes of violent 
ballistic movements and painful spasms. The episodes were particularly frequent at 
night, either upon falling asleep or awakening. Similar episodes have been described in 
several other cases with ADCY5 mutations (Chen et al., 2015), indicating that this could 
be a specific feature of ADCY5-related movement disorders.  
Facial myokymia was initially highlighted as a distinctive feature of ADCY5-related 
disorder. However, an EMG study of the facial muscles performed in both affected 
subjects from family 1 (both presenting facial involuntary movements) excluded the 
presence of myokymia or other signs of motorneuron hyperexcitability. Although EMG 
was not performed in the other cases, who all reported facial dyskinesias, these were 
clinically deemed to be choreic and/or myoclonic in nature. This indicates that patients 
with ADCY5 mutations present prominent facial hyperkinetic movements in the absence 
of myokymia. Consistent with this, neither facial myokymia was described in all 
affected members from the original FDFM kindred nor was recognized as a prominent 
feature in the other ADCY5 mutation carriers that were subsequently reported. 
Importantly, a subsequent EMG study, performed in the same members of the FDFM 
family in whom myokymia was initially described, failed to confirm the presence of 
myokymia (Chen et al., 2015).  
Importantly, even though the clinical presentation of patients with ADCY5 mutations is 
consistent with the clinical definition of BHC, there are several differences that 
differentiate ADCY5-mutation carriers from BHC secondary to variants in NKX2-1.  
Firstly, although both conditions can have extra-neural involvement, NKX2-1 carriers 
often present pulmonary symptoms or evidence of endocrine defects (Inzelberg et al., 
2011), whereas cardiac heart failure has been observed in some affected individuals 
from the original FDFM pedigree (Chen et al., 2012). ADCY5 overexpression has also 
been shown to lead to cardiomyopathy in a mouse model (Ho et al., 2010).  
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Secondly, the clinical progression between the two disorders seems to be different; BHC 
cases secondary to NKX2-1 mutations tend to remain relatively mildly affected and 
often improve after childhood, while we show here that ADCY5 mutation carriers are 
often severely affected by the dyskinesias, and may present significant progression of 
symptoms, at least until the adult age. This difference in the clinical progression is 
nicely mirrored by the brain transcriptome data. The analysis and comparison of ADCY5 
and NKX2-1 mRNA regional brain expression showed that, although both genes are 
most highly expressed in the adult striatum, ADCY5 levels progressively increase during 
brain development whereas NKX2-1 levels show an opposite trend. Thirdly, prominent 
dystonic and myoclonic features are present in several affected cases with ADCY5 
mutations and may dominate the clinical picture as the disease progresses. Dystonic 
features can be also observed in some NKX2-1 cases (Armstrong et al., 2011, Peall et al., 
2014), but they are generally not as severe as we observed in ADCY5 mutation carriers. 
Lastly, ADCY5-related dyskinesias are dramatically worsened by action, excitement or 
stress. Furthermore, some patients may present frank episodic worsening of the 
dyskinesias, closely mimicking paroxysmal movement disorders. This feature likely 
reflects the biological role of AC5. This enzyme catalyzes the formation of cyclic 
adenosine monophosphate (cAMP) u on β-adrenergic receptor stimulation via G-
proteins in striatal cells and pathogenic mutations seem to increase the cyclase activity 
(Chen et al., 2014).  
In conclusion, this study contributes to expand and delineate the phenotype associated 
with ADCY5 mutations. I suggest the term FDMD should not be used to refer to 
ADCY5-related movement disorder, as facial myokymias are not part of the phenotype. 
A diagnosis of ADCY5-related disorder should be always suspected when assessing 
patients with a choreic disorder with onset in childhood, in particular if neuroimaging is 
normal and a fluctuating course with severe dyskinetic attacks triggered by drowsiness 
are described. Differences in the clinical presentation between ADCY5 mutation carriers 
may be attributed to distinct molecular effects of different mutations, though somatic 
mosaicism may explain intra-familial phenotypic variability, as shown in family 1 and 5. 
Given the possible reported association of ADCY5 mutations with cardiac involvement, 
it will be fundamental to closely follow-up ADCY5 mutation carriers in order to prevent 
or adequately treat potential cardiac complications. 
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Importantly, the majority of the BHC cases included in this project did not carry 
mutations in either NKX2-1 or ADCY5, including four cases with clear autosomal 
dominant family history. This indicates that more genes responsible for BHC have yet to 
be identified. 
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6.5 De novo Mutations in PDE10A Cause Childhood-Onset 
Chorea with Bilateral Striatal Lesions 
6.5.1 Statement of Contribution 
I performed all the genetic analysis performed in this chapter. I performed the in silico 
modelling of the mutations. Dr Haruhide Kimura’s team  Takeda  harmaceutical 
Company Limited) performed the in vitro functional characterisation of the identified 
PDE10A substitution.  
6.5.2 Background 
WES can be used to identify the disease-causing gene in series of unrelated cases with a 
very rare and homogenous phenotype, under the assumption that only few causative 
genes are involved. For example, this strategy has been successful for the identification 
of TUBB4A (MIM 602662) mutations in cases with hypomyelination with atrophy of 
the basal ganglia and cerebellum (Simons et al., 2013) or WDR45 (MIM 300526) 
mutations in an X-linked form of neurodegeneration with brain iron accumulation 
(Haack et al., 2012). 
In this study I identified de novo dominant missense mutations in PDE10A as a novel 
disease-associated additional genetic cause in three subjects without a family history 
who presented with a similar childhood-onset movement disorder predominantly 
characterized by chorea and striking bilateral striatal abnormalities on cerebral magnetic 
resonance imaging (MRI). 
6.5.3 Subjects, Materials and Methods 
Subjects 
I initially analysed WES data from the eight unrelated BHC cases without pathogenic 
variants in NKX2-1 and ADCY5, including four with autosomal dominant family history 
and four sporadic cases. The ascertainment criteria of this cohort have been described in 
the previous sections of this chapter. For three of the familial cases, DNA and WES 
from at least another affected relative (1
st
 degree relative in one case and 2
nd
 degree in 
the other two) were available for segregation analysis.  
An additional cohort of 60 cases with BHC of Italian, Dutch and UK origin, negative 
for mutations in NKX2-1 and ADCY5, was included to replicate the finding made in the 
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initial cohort. The cases of Italian origin are the same subjects described in the previous 
section of the chapter. Additional cases were recruited by Dr Manju Kurian at UCL 
Great Ormond Street Hospital, London (United Kingdom) and Dr Lisenka Visser and 
Dr Michel Willemsen at Radboud University Medical Center, Nijmegen (Netherlands). 
Genetic analysis 
WES, alignment, variant calling and annotation were performed as previously described 
in the Materials and Methods chapter. The average read depth of targeted regions was 
84.29 and all samples had >95% of the target bases were covered at a read depth of 2x 
and >90% at a depth of 10x, ensuring high-confidence variant detection. The variant 
filtration strategy that led to the identification of the PDE10A variants is described in 
the results section. 
Expression profiling in brain tissue  
Brain mRNA regional distribution and expression in the normal adult human brain were 
determined using microarray analysis of human post-mortem brain tissue from the UK 
Human Brain Expression Consortium, as previously detailed in the Materials and 
Methods chapter.  
In silico modelling of the identified PDE10A mutations 
In silico modelling of the 3-D structure of the PDE10A GAF-B domain binding pocket 
and its interaction with the cAMP, was generated with the software PyMol (Schrodinger) 
using the PDB-file 2ZMF (downloaded from http://www.rcsb.org/pdb/home/home.do). 
In vitro functional analysis of the identified PDE10A mutations 
Materials 
1-NO-cAMP was purchased from Biolog Life Science Institute (Bremen, Germany). 
cAMP and cyclic guanosine monophosphate (cGMP) were purchased from Sigma–
Aldrich (St. Louis, MO). The [
3
H]-labeled nucleotides, [
3
H]cAMP (25.9 Ci/mmol) and 
[
3
H]cGMP (7.1 Ci/mmol), were purchased from PerkinElmer (Waltham, MA). 
Cloning and Expression of Constructs 
cDNA for human PDE10A2 (GenBank: NM_001130690) was used as a template and 
the mutants (c.898T>C; p.Phe300Leu and c.1000T>C; p.Phe334Leu) were constructed 
by site-directed point mutation. All constructs were cloned into the pcDNA3.1(+)neo 
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vector (Thermo Fisher Scientific, Inc., Waltham, MA) and transfected into COS-7 cells 
(ECACC, Salisbury, UK). The membrane fractions were used for the enzyme assay. 
In Vitro Phosphodiesterase Enzyme Assay 
Phosphodiesterase (PDE) activities were measured using scintillation proximity assay 
(SPA)-based method
 
(Matthiesen and Nielsen, 2009). In this assay, the product of the 
PDE reaction, either [
3
H]AMP or [
3
H]GMP, can bind directly to yttrium silicate PDE 
SPA beads (GE Healthcare Ltd. UK), leading to light emission from the scintillant in the 
beads. The enzyme assays were conducted in a buffer (50 mM HEPES-NaOH, 8.3 mM 
MgCl2, 1.7 mM EGTA, 0.1% bovine serum albumin (pH 7.4)) in 96-well half-area 
plates (Corning Inc., Corning NY). For kinetic studies, reaction was conducted at 
presence of the indicated concentrations of substrate using mixture (20 L) of [3H]-
labelled and unlabelled cAMP or [
3
H]-labelled and unlabelled cGMP with the 20 L of 
membrane fractions of PDE10A-expressing COS-7 cells at room temperature, followed 
by reaction termination by SPA beads addition (20 μL of 20 mg/mL). The plates were 
counted for 1 min in a scintillation counter (PerkinElmer). For the purpose of 
determination of baseline counts, every tested concentration of labelled and unlabelled 
cyclic nucleotides was run with matching controls having the identical reagent 
concentrations except for the addition of buffer alone in place of enzyme. Specific 
enzyme activity was then calculated by subtracting the baseline counts.  
To obtain the Michaelis–Menten constants (Km), the initial rates of the reaction were 
fitted to the following equations using GraphPad Prism (GraphPad Software, Inc., La 
Jolla, CA): V = Vmax [S] / (Km + [S]), where V is the initial velocity of the enzyme-
catalyzed reaction, [S] is the substrate concentration, Vmax is the limiting reaction 
velocity at saturating substrate concentrations, and Km is the Michaelis–Menten 
constant (concentration of substrate at 1/2 of Vmax).  
The effects of cAMP or its analogue, 1-NO-cAMP, on PDE10A enzyme activity were 
assessed using [
3
H]cGMP as a substrate. The indicated concentrations of unlabelled 
nucleotide (cAMP or 1-NO-cAMP, 10 L) and 70 nM [3H]cGMP (10 L) were added to 
the 20 L buffer containing membrane fractions of PDE10A-expressing COS-7 cells at 
37
o
C. After 40-min incubation, the reaction was terminated by addition of SPA beads  
(20 μL of 20 mg/mL) and the plates were counted in a scintillation counter. Activity 
rates were calculated on the basis of 100% control wells without unlabelled nucleotides 
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and 0% control wells without enzyme.  
6.5.4 Results 
Identification of PDE10A mutations in the discovery cohort 
A total of 26,387 unique variants were detected in eight exomes of unrelated BHC cases. 
I excluded from the analysis (i) UTR and intergenic variants outside of canonical splice 
sites as well as variants that are synonymous, non-frameshift insertions and deletions; (ii) 
variants that lie in segmental duplication regions, as these are prone to produce false-
 ositi e  ariant calls due to ma  ing errors;  iii   oor quality  ariants  quality scores ≤ 
50 or read de th ≤ 5 .  
Given a dominant family history in four out of eight cases and the fact that mutations in 
the two currently known BHC genes, NKX2-1 and ADCY5, exert a pathogenic effect in 
the dominant state, I decided to initially focus the analysis only on single heterozygous 
changes. Furthermore, based on the extreme rarity of BHC in the general population, I 
assumed that causative variants would be absent in dbSNP version 137 (provided they 
were not know disease-associated mutations) and in the publicly available datasets of 
genetic variations (1000 genome project, EVS, ExAC and CG69). I also excluded novel 
variants that were observed more than five times in our in-house exome database 
(~1000) from individuals with unrelated diseases, as these are likely to represent 
sequencing or alignment artefacts. Variants present in the familial cases that did not 
segregate in the affected relatives were filtered out. 
After applying this filtering strategy, I was left with a list of individual variants that 
included 18 frameshift indels, 11 nonsense mutations, four mutations affecting 
canonical splice-sites, and 212 missense variants.  
I subsequently focused only the genes that contained at least a variant in more than one 
sample. This filtering strategy left us with only three candidate genes (see Table 6-2), 
each containing a variant in two unrelated samples, PDE10A (phosphodiesterase 10A) 
on chromosome 6, THSD1 (thrombospondin, type I, domain containing 1) located on 
chromosome 13, and PRMT7 (protein arginine n-methyltransferase 7) on chromosome 
16.  
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I then explored the regional expression of these three genes in the normal adult human 
brain. This analysis showed that PDE10A expression is exceptionally high in the 
striatum (Figure 6-9A), whereas this is not the case for THSD1 and PRMT7 (see Figure 
6-10). These data are consistent with the data available on the Allen Mouse Brain Atlas 
(Lein et al., 2007) (see Figure 6-9B and C) and previous work in the literature, 
demonstrating high and selective expression of PDE10A in the striatum (Fujishige et al., 
1999), particularly in MSNs (Seeger et al., 2003), which makes PDE10A an excellent 
candidate gene for chorea. 
The two cases with PDE10A mutations carriers were both sporadic and carried the exact 
same heterozygous change, c.898T>C; p.Phe300Leu.  
Sanger sequencing confirmed the presence of the mutation in both cases. The mutation 
was demonstrated to be de novo in the first case, as it was absent in both parents and in 
the unaffected 19-year old sister. To confirm that no other variants could be responsible 
for chorea in this subject, WES was performed in all family members, including the two 
parents and the healthy sister. Importantly, I could not identify other putatively 
damaging mutations (defined as nonsense, frameshift, canonical splice site, predicted 
damaging missense mutations based on CADD scores >20; with a MAF <1% in ExAC), 
assuming either a de novo or a recessive pattern of transmission. 
Parents of the second individual were both deceased and therefore not available for 
DNA analysis. However, DNA analysis in six siblings, all unaffected with chorea, 
demonstrated that they were all homozygous for the reference allele. Furthermore, 
haplotype analysis using three microsatellites (Marker 1 – chr6:166069747-166069785; 
Marker 2 – chr6:165862198-165862227; Marker 3 - chr6:165839259-165839288) 
spanning the PDE10A locus identified the four parental haplotypes and revealed that the 
individual carrying the mutation shared one of the haplotypes with two siblings and the 
other with three other siblings, strongly indicative of the de novo occurrence of the 
mutation also in this case (Figure 6-11). Analysis of the same three microsatellites in the 
family of case 1, who carries the same de novo PDE10A change, indicates the mutation 
arose on a different background haplotype. 
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Table 6-2 Summary of variants detected by whole-exome sequencing that survived the filtering strategy. 
Gene 
(Transcript) 
Chr 
Position 
(hg19) 
Variant 
GERP 
score
a
 
CADD 
C-score
b
 
SIFT PolyPhen-2 
Mutation 
Taster 
ExAC constraint 
metrics 
Number of 
unrelated 
probands with 
the variant 
PDE10A 
(NM_001130690) 
6 165832223 
c.898T>C; 
p.(Phe300Leu) 
4.47 28.7 
D 
(0) 
D 
(0.98) 
D 
(0.99) 
Missense: z
c
 3.78 
LoF: pLi
d
 1.00 
2 (both sporadic)  
THSD1 
(NM_199263) 
13 52952435 
c.1669_1670del;
p.(Ser557fs)
d
 
NA NA NA NA NA 
 
Missense: z
a
 0.75 
LoF: pLi
b
 0.00 
1 (familial)
e
 
 13 52952567 
c.1379G>A; 
p.Ser460Asn 
5.62 12.16 
T 
(0.57) 
B 
(0.02) 
D 
(0.99) 
 1sporadic 
PRMT7 
(NM_001184824) 
16 68373391 
c.522dupT; 
p.(Ser174fs)
d
 
NA NA NA NA NA 
 
Missense: z
a
0.23 
LoF: pLi
b
 0.00 
1 (familial)
e
 
 16 68382285 
c.1214T>C; 
p.(Ile405Thr) 
5.6 24.2 
D 
(0.01) 
B 
(0.03) 
D 
(0.99) 
 1 (familial) 
Chr=chromosome; B=benign; D=deleterious/damaging/disease-causing; B=benign; T=tolerated; NA=not applicable; fs=frameshift; LoF:loss-of-function; pLI= probability of loss-
of-function intolerance 
a
Positive scores represent a substitution deficit and indicate that a site may be under evolutionary constraint. Negative scores indicate that a site is probably evolving neutrally. 
Positive scores scale with the level of constraint, such that the greater the score, the greater the level of evolutionary constraint inferred to be acting on that site. 
b
C-scores greater or equal 10 indicates that the variant is predicted to be the among the 10% most deleterious substitutions that you can do to the human genome; a score of greater or 
equal 20 indicates the 1% most deleterious. 
c
z-missense scores reflect expected mutation probabilities and are based on deviation of observed standing variation patterns (higher values = more constrained [fewer variants 
observed than expected]).  
d
The closer pLI is to 1, the more LoF intolerant the gene appears to be. 
e
The two frameshift variants in THSD1 and PRMT7 were found in the same individual 
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De novo mutations in PDE10A have not been observed in control individuals (Rauch et 
al., 2012, Xu et al., 2012, Gulsuner et al., 2013, Genome of the Netherlands Consortium, 
2014, Iossifov et al., 2014) and the p.Phe300Leu is neither listed in ExAC, nor in our 
in-house exomes with unrelated diseases (~1,000), and in 500 exomes from ethnically 
matched healthy controls. All used in silico tools consistently predicted a highly 
deleterious effect of the substitution. Interspecies alignment of protein sequences 
revealed that the amino acid substitution lies in an acid motif that is completely 
conserved down to invertebrate species (see Figure 6-12). Constraint metrics reported in 
ExAC indicate that PDE10A is highly intolerant to both loss-of-function and missense 
mutations (Samocha et al., 2014).  
The frameshift mutations in THSD1 (p.Ser557fs) and PRMT7 (p.Ser174fs) were both 
found in the same subject with a dominant family history of BHC and were present also 
in the similarly affected sister (the DNA of the affected father was not available). The 
missense heterozygous changes in THSD1 and PRMT7 were carried by a sporadic case 
and a familial case, respectively. No family members of the carrier of the THSD1 
missense mutation were available for segregation analysis, whereas the PRMT7 
missense change were inherited from the affected mother and grandmother of the 
proband. Prediction tools displayed contrasting results for both missense mutations. 
Importantly, although a pathogenic role for this variant cannot be excluded, the ExAC 
constraint metrics indicate that both THSD1 and PRMT7 are tolerant to missense and 
loss-of-function variation (see Table 6-2), suggesting it is unlikely that heterozygous 
mutations in these two genes could be responsible for the phenotype.  
Finally, bi-allelic variant variants in PRMT7 have been recently detected in three 
pedigree with a recessive condition called Albright hereditary osteodystrophy, which 
feature mild intellectual disability with obesity and symmetrical shortening of the digits 
and posterior metacarpals and metatarsals (Akawi et al., 2015). This element further 
argues against any pathogenic role for the heterozygous PRMT7 variants I identified in 
patients with BHC. 
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Figure 6-9 Summary of human and mouse brain PDE10A mRNA expression data 
(A) Box plots of PDE10A mRNA expression levels in 10 adult brain regions. The expression levels are based on exon array experiments and are plotted on a log2 scale (y axis). This 
plot shows significant variation in PDE10A expression across the 10 brain regions analysed, with expression higher in the putamen than in any other region. PDE10A expression in 
mouse brain in (B) sagittal and (C) coronal sections. PDE10A is very highly and selectively expressed in the striata and in the olfactory tubercula. Images were obtained from the 
Allen Mouse Brain Atlas website (© 2015 Allen Institute for Brain Science). Expression intensity is color-coded, ranging from blue (low intensity) through green and yellow to red 
(high intensity). 
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Figure 6-10 Summary of human brain expression of PRMT7 and THDS1 
Box plots of mRNA expression levels in 10 adult brain regions showing that the expression in the putamen of PRMT7 (A) and THDS1 (B) is significantly lower than PDE10A 
  237 
 
Figure 6-11 Pedigree and haplotype analysis in the families of cases 1 and 2 
The four parental haplotypes were reconstructed in both families (each haplotype defined by a different 
colour). Cases 1 and 2 did not share the haplotype encompassing the c.898C>T variant, suggesting the 
mutations arose on different haplotype backgrounds. Furthermore, haplotype analysis indicates that case 
2, who carries the PDE10A c.898T>C variant, shares one of the allele (marked in yellow) with two 
unaffected siblings (II-2, II-7) whereas the other allele (marked in red) is shared with three unaffected 
siblings (II-1, II-4 and II-7). 
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Figure 6-12 Interspecies alignment of the identified pathogenic PDE10A mutations 
Interspecies alignment showing the complete conservation down to invertebrates of the amino acid residues involved by the substitutions. Asterisks indicate invariant 
residues (full conservation), whereas a colon (:) and period (.) represent strong and moderate similarities, respectively. 
  239 
Sanger Sequencing of PDE10A in a Cohort of Childhood-Onset Chorea Cases 
As these results outlined in the previous section strongly support the pathogenic role of 
the PDE10A c.898T>C; p.Phe300Leu mutation, I then Sanger sequenced the entire 
coding  sequence and the exon-intron boundaries of PDE10A in a further 60 cases with 
BHC without mutations in NKX2-1 and ADCY5.  
Importantly, this analysis revealed the presence of two additional variants: the 
unreported c.1000T>C; p.Phe334Leu was found in a Dutch case, and the c.1459C>G; 
the p.Pro487Ala (rs61733392) was found in an Italian case.  
Sequencing in the parents of the carrier of the c.1000T>C; p.Phe334Leu variant showed 
that it was absent in both subjects, demonstrating the de novo occurrence of the 
mutation and highly supporting its pathogenic role. WES was performed also in this 
family and no other possibly pathogenic mutations, de novo or bi-allelic, were found. 
This mutation is absent in all publicly available datasets, in all our exomes from healthy 
controls and in all exomes from cases with unrelated diseases. Furthermore, the change 
is predicted pathogenic by all in silico tools  (Polyphen-2, SIFT and MutationTaster) 
and has a CADD score of 31. Interspecies alignment showed complete interspecies 
conservation (see Figure 6-12).  
The p.Pro487Ala is a rare benign coding polymorphism, present in 478 European alleles 
reported in ExAC (MAF 0.007; two subjects are homozygotes) and is predicted benign 
by both Polyphen-2 and SIFT.  
Clinical and Neuroradiological Features of Carriers of Pathogenic PDE10A 
mutations 
Case 1, carrier of the Phe300Leu substitution, is a 22-year-old woman who developed 
generalized chorea around the age of 8. Although developmental motor milestones were 
reached normally, she had mild difficulties with speech and coordination during 
childhood. She now suffers from anxiety with some obsessive features. On examination 
she showed selective upgaze hypometric saccades and a mixed movement disorder 
consisting mainly of generalised chorea associated with some myoclonic jerks. 
Case 2, carrier of the Phe300Leu substitution, is a 60-year-old woman who developed 
chorea around the age of 5. She had a normal birth and normal developmental 
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milestones. The chorea remained stable over the years, with parkinsonian symptoms 
becoming apparent in her fifth decade with freezing and falls. Striatal dopamine 
reuptake transporter density imaging was bilaterally abnormal, consistent with 
nigrostriatal dopaminergic denervation. On her last examination, there was generalised 
chorea, most prominently in the orofacial area, with motor and gaze impersistence and 
severe dysarthria. She also had generalised bradykinesia, more prominent in the lower 
than in upper limbs, and marked axial parkinsonian symptoms (freezing and postural 
instability), which responded well to a L-DOPA treatment (600 mg/day), without 
worsening of the choreic movements. 
Case 3, carrier of the p.Phe334Leu substitution, is an 11-year-old, who developed an 
isolated non-progressive choreic disorder at around age 5. He had normal motor and 
language development.  
Very importantly, brain MRI consistently showed striking bilateral T2 hyperintensity 
within the striatum in all three cases (Figure 6-13). It is noteworthy that the MRI images 
of case 3 (aged 11 when scanned) showed slight swelling of the striata (Figure 6-13A), 
together with restricted diffusion (Figure 6-13B and C), suggesting an active disease 
process. Conversely, MRI of case 1 (aged 22 when scanned) demonstrated modest 
atrophy of the putamina (Figure Figure 6-13D) and normal diffusion (Figure Figure 
6-13 E and 1F), suggesting a more advanced stage of disease. The MRI of case 3 (aged 
53 when scanned) was markedly degraded by movement artefacts, but also showed T2 
bilateral hyperintensities within the posterolateral putamina, albeit less dramatic than in 
the two younger cases. 
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Figure 6-13 MRI features associated with de novo dominant PDE10A mutations 
Axial MR images of case 3 (A-C) and 1 (D-F). There is increased signal intensity within the striatum on 
T2-weighted images (A, D) and diffusion-weighted images (DWI) (B, E). In case 3, the putamen and 
caudate nucleus appear slightly swollen (A) and high signal on DWI (B) is confirmed to represent 
abnormal restricted diffusion on the ADC map (C). In case 1, the abnormal signal is principally located in 
the postero-lateral putamina, which also appear atrophic (D). There is no corresponding restriction of 
diffusion on the ADC map (F), and appearances suggest a more chronic disease stage. 
 
Overall, the three individuals presented with a very similar and unique clinical 
presentation of childhood-onset chorea and characteristic brain MRI (Table 6-3), 
strongly supporting PDE10A mutations as the unitary aetiology underlying all three 
cases.
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Table 6-3 Clinical and genetic features of cases with PDE10A mutations 
     Case 3 Case 1 Case 2 
Age at most recent clinical examination (years) 11 22 60 
Gender    Male Female Female 
Descent    European (Dutch) European (British) European (British) 
PDE10A mutation  Genomic
a
  Chr 6:165829768 A>G Chr 6:165832223 A>G Chr 6:165832223 A>G 
   cDNA
b
         c.1000T>C                      c.898T>C c.898T>C  
   Protein         p.Phe334Leu  p.Phe300Leu  p.Phe300Leu 
   Inheritance       de novo de novo                         de novo
d
  
CADD score
c
           31.0 28.7                           28.7  
        
Neurology       
 Developmental milestones     Normal Normal Normal 
 Cognition       Normal Normal Normal 
 Chorea (age of onset, yrs)     + (5) + (8) + (5) 
 Other        No Anxiety  
 
Adult-onset parkinsonism 
MRI        
 Bilateral striatal hyperintensities  + + + 
 Bilateral striatal swelling + - - 
 Restriction of diffusion + - N.A. 
 Bilateral striatal atrophy - + + 
+=present; N.A.=not available  
a
(GRCh37)  
b
Ref Seq ID: NM_001130690.2 
 
c
Haplotype analysis in unaffected siblings suggests the de novo occurrence of the mutation in case 3 
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In silico Modelling of the Identified PDE10A Mutations 
PDE10A encodes a member of the cyclic nucleotide (cNMP) phosphodiesterase (PDE) 
family, consisting of 21 different genes, grouped into 11 sub-families based on their 
affinity for the type of cNMP (cAMP and/or cGMP), cellular regulation, expression and 
tissue distribution (Lakics et al., 2010). cNMPs are ubiquitously expressed intracellular 
second messengers, which modulate a broad range of cellular functions and pathways 
(Beavo and Brunton, 2002). The intracellular concentration of cNMPs is tightly 
regulated through a fine balance between their synthesis, controlled by the activity of 
adenylyl/guanylyl cyclases (Koesling et al., 1991, Steegborn, 2014), and degradation, 
mediated by PDEs which hydrolyse the cNMPs into their corresponding 
monophosphate nucleoside (Soderling and Beavo, 2000).  
PDEs function as homodimers, with the dimer interface extending over the entire length 
of the molecule, and all share a highly similar catalytic domain located in the C-terminal 
portion of the protein. Conversely, the N-terminal portion, which contains the regulatory 
domains, is variable and differs between different PDE families (Bender and Beavo, 
2006).  
PDE10A contains two N-terminal domains, GAF-A and GAF-B, of which the latter 
binds to cAMP (Figure 6-14A) (Gross-Langenhoff et al., 2006, Heikaus et al., 2009). 
cAMP binding increases the enzyme activity of the PDE10A catalytic domain (Jäger et 
al., 2012). Although details of the GAF-B dependent modulation of PDE10A enzyme 
activity are currently unclear, a general mechanism for the regulation of all PDEs has 
been postulated. In the non-activated state the dimerised catalytic domains are packed 
against each other at the dimer interface, occluding the catalytic pockets. The binding of 
cAMP to the GAF-B domain induces a rotating movement of the catalytic domains, 
enabling substrate access to the catalytic pockets and a consequent increase of cNMP 
hydrolysis (Pandit et al., 2009). 
The crystal structure of the PDE10A-GAF-B domain and its interaction with cAMP has 
been elucidated and consists of six stranded anti- arallel β-sheet  β3, β2, β1, β6, β5, β4 , 
sandwiched between a three-helix bundle  α1, α2, and α5  on one side and three short 
helices  α3, α4, 310) on the other side (Handa et al., 2008). The cAMP molecule is 
almost completely buried deep into a tight binding pocket, the floor of which is formed 
by the β-sheets and the roof by t o α-helices  α3 and α4 .  m ortantly, the amino acids 
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p.Phe300 and p. he334 are located in the β1 and β3 sheets,  ositioned dee  into the 
cAMP binding pocket of GAF-B and in very close proximity to the cAMP molecule 
(Figure 6-14B). It is therefore postulated that the substitutions severely affect the 
morphology of the GAF-B binding pocket and/or alter its affinity for cAMP. 
 
Figure 6-14 Schematic representation of the PDE10A protein and in silico modelling of the 3D 
structure of the PDE10A GAF-B domain 
(A) A schematic representation of the PDE10A protein showing its organization in three domains, the 
regulatory GAF-A and GAF-B domains located in the N-terminal portion of the protein and the catalytic 
domain located in the C-terminus. (B) In silico modelling of the 3-D structure of the GAF-B domain 
binding pocket and its interaction with the cyclic adenosine monophosphate (cAMP; shown in blue). The 
mutated residues p.Phe300 and p. he334 and their aromatic side chains, located in the β1 and β3 sheets 
forming the floor of the cAMP binding pocket, are shown in red and cyan respectively. Both mutated 
residues (in magenta) are located in very close proximity to the cAMP molecule and are therefore likely 
to play an essential role in nucleotide binding. 
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In vitro Functional Analysis of the Identified PDE10A Mutations 
To assess in vitro the functional effect of the identified PDE10A substitutions, we 
investigated whether they affect (i) PDE basal enzyme activity and/or (ii) the 
stimulatory effect on PDE catalytic activity mediated by cAMP binding to the GAF-B 
domain.  
Reactions for kinetic studies were performed using a mixture of [
3
H]-labelled and 
unlabelled cAMP or cGMP together with either WT or mutant PDE10A-expressing 
COS-7 cell membrane fractions.  Km values for cAMP and cGMP in wild-type PDE10A 
were 152.5 ± 17.1 nM and 1.7 ± 0.3 M, respectively. There were no statistically 
significant differences in Km values among the wild-type and the mutant PDE10As 
(Figure 6-15), suggesting that both p.Phe300Leu and p.Phe334Leu do not affect 
substantially basal PDE10A enzyme activity. 
We then explored whether the identified substitutions affect the stimulatory properties 
of cAMP binding to the GAF-B domain. Experiments were conducted using only 
[
3
H]cGMP as a substrate to avoid the binding of [
3
H]cAMP substrate to the GAF-B 
domain and the cAMP analogue 1-NO-cAMP, which has a higher selectivity for the 
GAF-B domain over the catalytic site compared to cAMP (247-fold for 1-NO-cAMP vs. 
8.7-fold for cAMP). These experimental conditions were chosen as, on the one hand, 
cAMP activates PDE10A enzyme activity via its binding to GAF-B and, on the other 
hand, competes at the catalytic domain with radio-labelled substrates and thus inhibits 
their degradation.  
Wild-type and mutant PDE10As were incubated in the presence of various 
concentrations of 1-NO-cAMP with 70 nM [
3
H]cGMP, and then catalytic activities were 
measured. 1-NO-cAMP markedly increased (approximately 2.7-fold over the basal 
levels) the enzyme activity of WT PDE10A, whereas this effect was almost completely 
abolished for both mutant PDE10As (Figure 6-16). These experiments demonstrate that 
p.Phe300Leu and p.Phe334Leu severely affect the positive regulatory mechanism of 
cAMP binding to the GAF-B domain on PDE catalytic activity. 
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Figure 6-15 Enzyme Kinetics of Wild-Type and Mutant PDE10As. 
PDE10A enzymes was incubated at presence of mixture of unlabelled cAMP and [3H]cAMP (A) or unlabelled cGMP and [3H]cGMP (B) with the total concentration as indicated. 
The velocity was divided by each Vmax value. Km values for cAMP (A) and cGMP (B) were determined by fitting to the Michaelis-Menten equation using GraphPad Prism. Each 
data point represented as mean ± SEM of five (for cAMP) or four (for cGMP) independent experiments. There was no statistically significant difference in Km values among the 
wildtype and the mutant PDE10As (p > 0.05 by Dunnett's test compared with wild-type). 
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Figure 6-16 Effects of PDE10A substitutions on the modulatory activity of the GAF-B domain 
Effect of 1-NO-cAMP on the PDE activity of a wild-type and mutants of PDE10A. Various concentrations of a cAMP analogue, 1-NO-cAMP, was added and catalytic activity of 
wild-type and mutant PDE10A, p.(Phe300Leu) and p.(Phe334Leu), at presence of 70 nM [3H]cGMP was determined. Each data point represents the means ± SEM for three 
independent experiments. 
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6.5.5 Discussion 
Strong genetic evidence, fulfilling the recently proposed criteria for inferring causality 
of genetic variants (MacArthur et al., 2014), supports the pathogenic role of the 
identified PDE10A mutations: (i) segregation analysis confirmed that both variants 
arose de novo in the three mutation carriers; (ii) the changes are otherwise absent in all 
interrogated public databases and in-house exomes from healthy controls or subjects 
with unrelated conditions (including more than 70,000 exomes); (iii) the mutations are 
consistently predicted pathogenic by all in silico prediction tools and affect amino acid 
residues completely conserved in all species homologs; (iv) the substitutions are located 
in a functionally important regulatory domain of the protein and in vitro functional data 
show that they disrupt the regulatory effect of the GAF-B domain; (v) PDE10A is very 
highly (and almost selectively) expressed in the striatum, the brain area most closely 
involved in the pathogenesis of choreic movements. 
PDEs have previously been implicated in the pathogenesis of neurodegenerative 
disorders, such as PD and HD (Bollen and Prickaerts, 2012). Mutations in PDE8B, a 
gene highly expressed in the brain and especially in the putamen, causes autosomal 
dominant striatal degeneration (ADSD, MIM 609161), a disease that clinically presents 
with adult-onset parkinsonism (Appenzeller et al., 2010, Barsottini et al., 2015). 
Although the reported MRI abnormalities observed in subjects with ADSD are slightly 
different from those observed in our cases, it is striking that both diseases are caused by 
mutations in PDEs leading to clearly visible, largely symmetric, striatal MRI signal 
abnormalities. Furthermore, the fact that two PDEs are now directly linked to a basal 
ganglia disease may point towards a crucial role of PDEs in these types of disorders. 
The latter is of great interest given the pharmacological potential to manipulate PDE 
activity. Given its high and selective expression in striatal MSNs, PDE10A is a primary 
target in pharmacological research for diseases where dysregulation of striatal circuits is 
believed to be crucial (e.g. psychosis, HD, substance abuse and PD) (Chappie et al., 
2012). 
According to the classic model of basal ganglia motor circuits, chorea may result from 
dysregulation of the activity of the striatal MSNs (Marsden, 1984). Based on different 
anatomical projections and biochemical features, MSNs are divided into two classes 
that constitute two parallel and segregated pathways exiting the striatum;  i  the ‘direct 
 ath ay’, formed by MSNs ex ressing high le els of the D1 do amine rece tors 
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(D1DR) and projecting directly to the basal ganglia output nuclei (the substantia nigra 
 ars reticulata and the globus  allidus internal segment ;  ii  the ‘indirect  ath ay’, 
mainly formed by MSNs expressing both D2 dopamine receptors (D2DR) and 
adenosine 2 receptors (A2AR) and projecting indirectly to the globus pallidus internal 
segment via the globus pallidus external segment and the subthalamic nucleus (Gerfen, 
1992).  
The t o  ath ays control striatal out ut in an antagonistic  ay, the ‘direct  ath ay’ 
being in ol ed in action  roduction and the ‘indirect  ath ay’ in action su  ression 
(DeLong and Wichmann, 2007). According to the classic model of basal ganglia motor 
circuits, chorea mainly results from disruption of the indirect pathway with consequent 
overactivity of the direct pathway (Marsden, 1984). 
Importantly, modulation of MSN activity is largely dependent on cAMP signalling 
(Threlfell and West, 2013). cAMP synthesis, and thus indirectly its signalling, is 
promoted by the stimulation of the G protein-coupled receptors D1DR and A2AR, 
whereas synthesis is inhibited by dopamine stimulation of D2DR (Herve, 2011). The G 
 rotein Gαolf positively couples D1DR and A2AR to the activation of AC5, the main 
molecule responsible for cAMP production in MSNs (Lee et al., 2002). Interestingly, 
the genes encoding Gαolf (GNAL) and AC5 (ADCY5) have both been identified as cause 
of primary dystonia (Fuchs et al., 2013) and chorea (Chen et al., 2012) respectively.   
Mechanistically, ADCY5 mutations seem to increase the AC5 activity with consequent 
raised intracellular cAMP levels in cellular models (Chen et al., 2014). As both 
PDE10A and ADCY5 pathogenic mutations cause chorea, but with PDE10A exerting an 
opposite effect to AC5 on cAMP levels, one would expect that the p.Phe300Leu and 
p.Phe334Leu variants exert a deleterious effect on the PDE enzyme activity. Recent 
studies suggest that PDE10A has two functional states; `active` and `super-active`(Jäger 
et al., 2012, Russwurm et al., 2015). In presence of high intracellular levels of cAMP, 
its binding to the GAF-B domain would stimulate the PDE catalytic activity, switching 
 DE10  from the ‘acti e’ to the ‘su er-acti e’ state. In light of this, PDE10A may 
function as a ‘brake’ for MSN acti ation. Our functional studies sho  that  athogenic 
PDE10A mutations located in the GAF-B domain severely disrupt this positive 
regulatory mechanism without affecting the basal PDE enzyme activity. These 
mutations may therefore have a strong impact on the in vivo regulation of MSN activity, 
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especially when MSNs are activated by high levels of cAMP. Given the homodimerised 
structure of PDE10A, the mutant proteins could exert a dominant negative effect on the 
activity of the WT protein. Intriguingly, the PDE10A knockout mouse does not show a 
movement disorder reminiscent of chorea, but conversely presents reduced exploratory 
activity, more consistent with a parkinsonian phenotype (Siuciak et al., 2006, Siuciak et 
al., 2008).  
In conclusion, I demonstrate here that de novo dominant mutations in PDE10A are a 
novel cause of a unique movement disorder characterized by benign childhood-onset 
chorea and typical MRI abnormalities of the striatum. Of note, PDE10A mutations were 
not found in cases with a BHC syndrome but with normal brain MRI. This suggests that 
PDE10A-related chorea may represent a distinct genetic clinico-radiological entity. 
Mutational screening of additional cohorts of cases with such MRI abnormalities is 
warranted to further define the clinical spectrum associated with PDE10A mutations.  
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Chapter 7. Conclusions 
This thesis describes the work I conducted during my PhD to investigate the genetic 
bases of a range of movement disorders, including PD, dystonia, and chorea, and gain 
novel insights into the biological mechanisms of these conditions.  
I used various combinations of genetic technologies (i.e. Sanger sequencing, WES and 
linkage analysis) and strategies (i.e. linkage mapping in combination with WES, 
interrogation of WES data searching for mutations in candidate genes, and analysis of 
WES from a series of unrelated cases with a specific clinical and radiological 
presentation).  
My research has resulted in the identification of several novel genetic causes for these 
conditions, including genes harbouring high-risk fully penetrant mutations responsible 
for Mendelian forms of disease (e.g. KCTD17 mutations in M-D and PDE10A 
mutations in chorea) and rare variants associated with intermediate risks (e.g. GCH1 
mutations in PD). I also expanded the phenotype associated with known Mendelian 
genes. I recognised that deficiency of tyrosine hydroxylase is a novel, treatable cause of 
M-D and mutations in ADCY5 are not simply responsible for the unique condition 
Familial Dyskinesias with Facial Myokyimia, but actually represent a frequent cause of 
chorea with onset in childhood. 
The main findings of this thesis are summarised below, together with the implications 
deriving from this work, both concerning clinical practice and future research into 
disease mechanisms. 
7.1 Genetics of Parkinson Disease 
GBA Mutations Are Common in Early-Onset Parkinson Disease and Influence the 
disease course 
I showed that GBA mutations are the most common genetic abnormality, not only in 
patients with the classic late-onset form of the disease, but also in patients with early-
onset PD. The frequency of GBA mutations in the latter group is actually significantly 
higher than in patients with classic PD.  
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This finding possesses an important clinical corollary. GBA should be systematically 
assessed in patients with an early onset of symptoms, as information regarding the 
mutational status may have crucial implications in terms of prognosis and response to 
pharmacological or surgical treatments (i.e. DBS). It is thought that patients with early-
onset PD, and in particular those carrying mutations in the recessive genes PARK2 or 
PINK1, tend to have a more indolent and benign disease course, in particular with 
regard to the risk of developing cognitive decline (Schrag and Schott, 2006).  
However, this seems not to be true for GBA carriers, both from a motor and cognitive 
point of view. In our study, PD patients carrying GBA mutations, compared to patients 
with mutations in PARK2, LRRK2 and no mutations, needed DBS significantly earlier in 
their disease, suggesting a more aggressive form of the disease in PD patients with GBA 
mutations. Furthermore, although the motor response to DBS treatment was comparable 
to that of the other patients, patients with GBA mutations presented a more rapid 
cognitive impairment following DBS implantation. Although this aspect should be 
carefully assessed in larger cohorts, these data overall indicate the genetics may be a 
powerful tool in recognizing and predicting clinical heterogeneity in PD. 
The GBA E326K variant predisposes to Parkinson disease  
I established incontrovertibly the pathogenic role of the GBA E326K variant, which, to 
date, represents the single most common genetic risk factor for PD with significant 
clinical relevance (7.5% of the PD cases screened in our study were carriers of the 
variant; odds ratio ~3). Notably, these results approximately double the proportion of 
PD patients with GBA-related disease, a fact that will have tremendous implications as 
soon as treatments for addressing GBA dysfunction in PD become available.  
Confirming my finding, Nalls and colleagues recently demonstrated the association of 
the E326K with PD-dementia complex and Dementia with LBs (Nalls et al., 2013). 
Moreover, it has been shown that the presence of the E326K negatively influences both 
motor disease progression (Winder-Rhodes et al., 2013) and the risk of progression to 
dementia (Mata et al., 2015). 
Finally, the E326K predisposes to PD but does not cause GD (even when inherited in 
the homozygous state), clearly indicating that other molecular mechanisms, in addition 
to reduced GBA activity, may contribute to the development of PD disease in the 
presence of GBA dysfunction. 
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Beyond DOPA-responsive dystonia; GCH1 mutations: a novel risk for Parkinson 
disease 
Through the analysis of WES data in a large cohort of PD cases and controls, I have 
identified rare coding GCH1 as a novel risk locus for PD. Interestingly, as it was the 
case for the discovery of GBA mutations, this association was first suspected on clinical 
grounds, thanks to the observation in pedigrees with DRD of striatal dopaminergic 
denervation in GCH1 pathogenic variant carriers with a clinical diagnosis of PD.  
Interestingly, to date, no genes containing rare variants conferring intermediate risk for 
PD have been identified through unbiased large NGS studies. Therefore, astute clinical 
observations remain crucial for driving and inspiring genetic studies. 
Since the appearance of this study in the literature, several other reports of DRD 
families with members affected by PD have been published (Lewthwaite et al., 2015, 
Terbeek et al., 2015, Someko et al., 2016) and many others have been presented at 
scientific conferences (personal communication).  
Furthermore, a recent study performed within the Canadian population confirmed that 
rare GCH1 coding mutations are enriched in PD. The authors identified two variants, 
the known pathogenic p.Lys224Arg (x2) and the novel variant p.Ala99Asp (likely 
pathogenic according to in silico prediction tools and interspecies conservation) in three 
unrelated cases with PD, while no pathogenic changes were found in controls (Guella et 
al., 2015). The mutational frequency was 0.56% (3/528) in cases versus 0% (0/290) in 
controls, consistent with the frequency we observed in our study (0.75% in cases versus 
0.1% in controls).  
The finding that GCH1 loss-of-function variants are not only responsible for DRD, but 
are also associated with adult-onset neurodegenerative PD, is strengthened by the recent 
identification that GCH1 has also been identified as a low-risk susceptibility locus for 
PD in the latest GWAS meta-analysis (Nalls et al., 2014). This finding potentially 
extends the role of GTPCH deficiency in the pathogenesis of PD beyond the rare 
carriers of deleterious coding mutations.  
An outstanding and crucial question remains as to whether patients with DRD 
eventually develop nigral neurodegeneration, or whether neurodegeneration can be 
avoided by dopaminergic replacement therapy. This could indeed support a central role 
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of dopamine deficiency in favouring nigral degeneration, with important therapeutic 
implications for asymptomatic carriers of pathogenic variants.  
To date, no DRD cases treated with L-DOPA since childhood have been shown to 
develop frank nigral cell loss (Snow et al., 1993, Turjanski et al., 1993, Jeon et al., 
1998). This is consistent with post mortem analysis of few cases showing normal nigral 
cell count and absence of LBs (Furukawa et al., 1999, Grotzsch et al., 2002, Segawa et 
al., 2013). However, Sawle and colleagues report in six cases with DOPA-responsive 
dystonia modest but significant reduction in the uptake of 
18
F-fluorodopa into both 
caudates and putamen (Sawle et al., 1991). Tadic and colleagues describe that 
parkinsonian signs are present in DOPA-responsive dystonia cases as a relatively 
common residual motor sign following treatment, possibly hinting at underlying 
neurodegeneration (Tadic et al., 2012). Terbeek et al. recently described a 41-year-old 
patient carrying a known pathogenic GCH1 variant (p.Tyr75Ser) with onset of classic 
DRD at age 9 (Terbeek et al., 2015). He was treated with L-DOPA from the age of 11 
with good and sustained response. At age 41 dopaminergic imaging (123I-FP-CIT 
SPECT) was performed showing severe bilateral and asymmetric reduction of 
putaminal tracer uptake, a pattern typical of idiopathic PD, arguing against a 
neuroprotective role of dopamine replacement. 
I anticipate that post mortem analysis and longitudinal clinical, neuroimaging, and 
metabolic studies of GCH1 mutation carriers—including asymptomatic carriers, 
individuals with classic DRD and cases with adult-onset parkinsonism - will facilitate 
the understanding of the pathogenesis of GCH1–associated PD.  
Finally, more work is needed to understand the biological relevance of the GWAS signal 
in the GCH1 locus. A functional haplotype at the GCH1 genomic locus associated with 
reduced plasma GTPCH activity and BH4 levels has been previously recognised 
(Antoniades et al., 2008). Interestingly, the most-associated GCH1 SNP (rs11158026) 
detected in the GWAS is in moderate linkage disequilibrium (r
2 
0.457; D’ 0.932) with 
the SNPs constituting the functional haplotype, suggesting a potential functional basis 
for the association of this SNP with increased PD risk. 
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7.2 Genetics of Myoclonus-Dystonia 
Mutations in KCTD17 and TH are Novel Genetic Causes for SGCE-negative 
Myoclonus-Dystonia. 
Through a combination of linkage analysis and WES, I identified that a dominant 
missense mutation in KCTD17 causes autosomal dominant M-D in families without 
SGCE.  
The clinical presentation of the KCTD17-mutated cases differs from the phenotype 
usually observed in SGCE-related M-D. All cases initially presented with mild 
myoclonus affecting the upper limbs. Dystonia showed a progressive course, with 
increasing severity of symptoms and spreading from the cranio-cervical region to other 
sites. 
Like many other dystonia genes (e.g. ANO3, GNAL, HPCA), KCTD17 is most highly 
expressed in the putamen, confirming an essential role of this brain structure in the 
pathogenesis of primary dystonias. Furthermore, a system biology analysis indicates 
that KCTD17 is part of a striatal gene network significantly enriched for other dystonia-
associated genes and genes involved in post-synaptic dopaminergic signalling in striatal 
cells. Intriguingly, knock-out of the KCTD17 homologue in Drosophila leads to hyper-
arousability and lack of sleep due to increased signaling downstream of the 
dopaminergic receptors (Stavropoulos and Young, 2011, Pfeiffenberger and Allada, 
2012), suggesting that KCTD17 may interact mechanistically with molecules within the 
dopaminergic signaling pathway in striatal cells. KCTD17 is known to contribute to the 
ubiquitin-proteasome machinery, acting as an adaptor for the CUL3-RING-E3 ligase 
and regulating turnover of substrates (Kasahara et al., 2014). Functional work is 
warranted to identify the precise substrates of KCTD17 in striatal neurons and the 
mechanism whereby KCTD17 may regulate post-synaptic dopaminergic signalling. 
Despite its rarity, the discovery of KCTD17 mutations as a cause of dystonia may help 
to elucidate pivotal molecular pathways and novel pharmacological targets to improve 
treatment of dystonia and other movement disorders. 
Finally, the identification of family with tyrosine hydroxylase deficiency presenting 
with predominant myoclonus-dystonia highlight the importance of consider this 
treatable condition in the differential diagnosis of M-D, as early treatment with L-DOPA 
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is crucial for the motor and cognitive outcome of these patients. 
The CACNA1B p.Arg1389His Variant Does Not Cause Myoclonus-Dystonia  
Through sequencing in a large multi-centric cohort of M-D cases and controls, I show 
that the CACNA1B p.Arg1389His does not a disease-causing mutation for M-D.  
The advent of next generation sequencing has led to an extraordinary acceleration in the 
discovery rate of rare genetic variants, the majority of which are of uncertain clinical 
significance. Hence, a close scrutiny is necessary before causally linking a candidate 
variant to a disease. To avoid false assignment of pathogenicity, MacArthur and 
colleagues have recently proposed guidelines for implicating causality of rare variants 
in human disease (MacArthur et al., 2014). However, co-segregation of a variant with 
disease in a single pedigree does not establish with certainty its pathogenic role, 
especially if other co-segregating coding variants and the possibility of a separate 
undetected pathogenic variant in linkage disequilibrium cannot be convincingly ruled 
out (as it was the case in the pedigree where the p.Arg1389His was identified). In 
addition, a candidate variant responsible for a rare disease should be found at a low 
frequency in population controls, consistent with the proposed model of inheritance and 
disease prevalence.  
M-D is an exceedingly rare condition. Although CACNA1B, by a biological point of 
view, could be a very plausible candidate gene for M-D and functional work performed 
by the authors shows that the mutation might affect the properties of encoded channel, 
the frequency of the CACNA1B p.Arg1389His in controls is simply too high to support 
its role in the pathogenesis of M-D. 
7.3 Genetics of Chorea 
Benign Hereditary Chorea is Not a Genetic Entity 
Surprisingly, a thorough genetic screen of NKX2-1 in the BHC Queen Square cohort 
revealed that only five probands (~20% of cohort) carried pathogenic mutations in this 
gene. A search for the recently described chromosomal deletions neighbouring but not 
encompassing NKX2-1 (Thorwarth et al., 2014), did not identify any further mutation 
carrier.  
Importantly, I did not detect mutations in three cases with a clinical presentation fully 
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consistent with NKX2-1-related disease (i.e. presenting the full picture of brain-lung-
thyroid disease), of which two had a clear autosomal dominant family history.  
These results clearly indicate the existence of other undetected pathogenic variants, 
either in the NKX2-1 non-coding regions (e.g. in the promoter, in intronic regulatory 
regions or in yet uncharacterised deep-intronic splice-site) or in other closely 
functionally related genes. In the future, WGS analysis in these cases will be potentially 
revealing for the identification of deep intronic mutations in the NKX2-1 locus. 
Currently, WES analysis of the familial cases is ongoing in order to identify coding 
variants in novel genes responsible for the phenotype. Identification of such genes may 
shed light on the biological mechanisms essential for the correct development of striatal 
neurons, lungs and thyroid tissue.  
A last remark regards the use of the term BHC. Importantly, the work presented in this 
thesis, in agreement with previous publications (Thorwarth et al., 2014), demonstrates 
that ~70% of the cases with a clinical diagnosis of BHC do not carry mutations in this 
gene. Furthermore, NKX2-1 mutations have been identified in patients with a range of 
movement disorders other than chorea, encouraging, overall, to abandon the use of the 
term BHC to label patients with NKX2-1 mutations.  
The identification of ADCY5 and PDE10A mutations crucially implicates cAMP 
metabolism in striatal neurons in the pathogenesis of chorea 
I describe the identification of pathogenic dominant mutations (both de novo and 
transmitted) in ADCY5 and PDE10A as important novel genetic causes of chorea with 
onset in childhood.  
From a clinical point of view, ADCY5 mutations appear to be a relatively common cause 
of chorea with onset in childhood (~9.4% of the cases I studied here). Importantly, 
while preparing this thesis, several other papers have appeared in the literature 
confirming the important clinical role of ADCY5 mutations and further broadening the 
phenotype associated with ADCY5 mutations to also include variable combinations of 
dystonia, myoclonus and paroxysmal dyskinesias (Carapito et al., 2015, Chen et al., 
2015, Chang et al., 2016, Friedman et al., 2016). 
Furthermore, a manuscript detailing the identification of recessive PDE10A mutations 
in patients with childhood-onset chorea has been recently published (Diggle et al., 
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2016). Therein, the authors describe the identification of two homozygous mutations 
(p.Tyr107Cys and p.Ala116Pro), located in the GAF-A domain, in two consanguineous 
pedigrees. The phenotype of these cases was more severe than that of the patients I 
describe. Patients with recessive PDE10A mutations showed a much earlier age at onset 
of chorea (< 1 year), severe dysarthria, axial hypotonia, cognitive and language 
development delay. The authors also showed that both mutations lead to a reduction in 
PDE10A levels both in patients and in cellular models. Furthermore, a knock-in mouse 
model had decreased striatal PDE10A. Interestingly, despite a more severe neurological 
involvement, the MRI of the cases with recessive mutations did not show the same 
abnormal signal we observed in the cases with dominant mutations.  
ADCY5 and PDE10A are almost exclusively expressed in the striatum, the brain region 
most closely involved in the pathogenesis of chorea and dystonia, and encode the two 
main enzymes that regulate the synthesis (ADCY5) and degradation (PDE10A) of cAMP 
in striatal neurons.  
Additionally, mutations in GNAL (Fuchs et al., 2013) and GPR88 (Alkufri et al., 2016), 
coding for G proteins almost exclusively expressed in striatal neurons that couple 
dopamine receptors to AC5 activation, have been recently linked to dystonia and chorea. 
Overall, these results strongly suggest that intracellular cAMP signalling in striatal 
neurons is crucial for normal activity of basal ganglia circuitry, and that disruptions 
thereof play an important role in the pathophysiology of hyperkinetic movement 
disorders. Modulation of the striatal cAMP levels may therefore represent a very 
attractive target for the development of novel treatments targeting striatal post-
receptorial dopaminergic dysregulation in a range of hyperkinetic disorders.  
Importantly, modulation of PDE10A activity is already a primary target in 
pharmacological research of basal ganglia disorders, including HD and PD (Chappie et 
al., 2012). More specifically, a phase II clinical study (the Amaryllis study) of a 
PDE10A inhibitor is currently ongoing in HD. Importantly, the identification of loss-of-
function PDE10A mutations as a cause of chorea suggests that pharmacological 
inhibition of PDE10A may not be the best option for the treatment of chorea and other 
hyperkinetic movement disorders. In support of this notion, it has been recently shown 
that asymptomatic carriers of the HD triplet expansion have reduced striatal levels of 
PDE10A (Niccolini et al., 2015).  
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Finally, it will be important to establish whether the observation of EOPD in one of the 
cases I identified with a de novo PDE10A mutation is coincidental or whether 
individuals with de novo PDE10A mutations are also at an increased risk of developing 
degeneration of nigral neurons. In this regard, recent work has demonstrated that striatal 
loss of PDE10A expression is associated with PD duration and severity (Niccolini et al., 
2015).  
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Appendix- Sequences of primers used in this thesis 
ADCY5_exon1_1_FOR GCGGATCCTCAGCTACTTCT 
ADCY5_exon1_1_REV GCTCCTCCAGACCCACCT 
ADCY5_exon1_2_FOR CAGCTTCCGCTCCAAGTC 
ADCY5_exon1_2_REV GATGAGGATCACGCCGAC 
ADCY5_exon1_3_FOR CTACTTCTTCCGCCTGAACC 
ADCY5_exon1_3_REV TCTTTGGAGTCCAGCTGAGG 
ADCY5_exon10_FOR ACGGCTTAGGCTTCTGGTCT 
ADCY5_exon10_REV GGAAGCCTCCCTAGAACTCG 
ADCY5_exon11_FOR CTGTCTCAACTGCCCTCTCC 
ADCY5_exon11_REV AAACTTCTCTCCGTGCCTGA 
ADCY5_exon12_FOR CTGAAGCTGTGAGGATGG 
ADCY5_exon12_REV TGCCAAGCACAATACTCG 
ADCY5_exon13_FOR CTCCTGGTCAGCTGCAGAAT 
ADCY5_exon13_REV ACCCAGGTGCGAAACAAATA 
ADCY5_exon14_FOR TTTTGTCCCCATCAGTGTCA 
ADCY5_exon14_REV GTGAGCTGGTGAGACCCTGT 
ADCY5_exon15_FOR ACCAGGGCCCTTCACTTTAT 
ADCY5_exon15_REV AACAAGGCCGTTTTCCAGAT 
ADCY5_exon16_FOR CCCTGAAAATGTCGTTGGAT 
ADCY5_exon16_REV GGCCTTCTCCTTCACTACCC 
ADCY5_exon17_FOR AGGAAGGCTTTCTGGAGGAG 
ADCY5_exon17_REV CAGAGTGCAGGGAGCAGAC 
ADCY5_exon18_FOR GCGTGACTGGTGCTTTTTCT 
ADCY5_exon18_REV AGCTCCCATCATCACTGCTT 
ADCY5_exon19_FOR TGAAGAGCGGACACATGAAG 
ADCY5_exon19_REV CAGGGAACACACCACATCAG 
ADCY5_exon2_FOR CCAGGTGTGAGTTTGCTGAG 
ADCY5_exon2_REV GGACTCTCTCCAGGGGAAAC 
ADCY5_exon20_FOR AGGCTCCTTGTGTCTTGCAT 
ADCY5_exon20_REV CTTCCAAGACATCAGCGTCA 
ADCY5_exon21_FOR GCTCTACCCCACAGCAGTTC 
ADCY5_exon21_REV CTGCTTCCATGCCTCTGG 
ADCY5_exon3_FOR GGGAGAGCCTGAGAGGTTTT 
ADCY5_exon3_REV TCCATGGGACACCATGATAA 
ADCY5_exon4_FOR CCTTGATCACACCACTGCAC 
ADCY5_exon4_REV CAGTGCTGAAAGCAACTCCA 
ADCY5_exon5_FOR GCACGGGGTGAATCTTTTT 
ADCY5_exon5_REV TGCTGTAGGGAACAGGAACC 
ADCY5_exon6_FOR TTGGACTCTAGGGCTGGATG 
ADCY5_exon6_REV GCACAGGTGATTTGGCAAG 
ADCY5_exon7_FOR TGTGCCAGGATGTTCAGTGT 
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ADCY5_exon7_REV AGGAACCGCAACTGCATAAG 
ADCY5_exon8_FOR TGGCATTAGGGAGTTTGGAG 
ADCY5_exon8_REV TAGTCCAAAGTTGGGGCAAA 
ADCY5_exon9_FOR CACGTCCTTTGGGAGACTGT 
ADCY5_exon9_REV GTGCTGAGGCTCTGTCCTTC 
CACNA1B_exon28_FOR TGTGGTGCAGGTCTTGAGTT 
CACNA1B_exon28_REV ATTTGTGTGCAGGAGGGAAG 
DDC_exon 10_FOR GAGGTGGTCCAGTCTAGGGTAC 
DDC_exon 10_REV CAAGACCAGAAACAGTCCACAG 
DDC_exon 11_FOR GCGTGTGATCAACAAACCTG 
DDC_exon 11_REV GGGAGGAGATGTGTGACAGC 
DDC_exon 12_FOR AAATAGGCGAGCCGGTGAG 
DDC_exon 12_REV TCTAAAGTCCCGAAAGACCTCC 
DDC_exon 13_FOR ATTGCCAAGAGCGTCTAAATG 
DDC_exon 13_REV GCATGGAGGTAATGAACAACAC 
DDC_exon 14_FOR GCACTGTCTTTCCTACATGACC 
DDC_exon 14_REV CTCCAGGAGGACACTCTTGC 
DDC_exon 2_FOR ACGGCTTGCTTGGTATCC 
DDC_exon 2_REV AAATTTCTCTCCAACCTGACTG 
DDC_exon 3_FOR CTCTTGAGGCCTGGCTTTC 
DDC_exon 3_REV TGCATAGGTACCGTGTCCC 
DDC_exon 4_FOR CCAAATTCTGCAATGCCTG 
DDC_exon 4_REV GCATGAGTGCCTCTTTCCC 
DDC_exon 5_FOR GGTACCAATGCCTTCGCTATG 
DDC_exon 5_REV CCAAACATTCGGGTCTTGAAG 
DDC_exon 6_FOR GGCCTGGTAATAACTGCATG 
DDC_exon 6_REV GAGACGGAGTTTCACCTTATTG 
DDC_exon 7_FOR GAGGTTACAGCGGTGACTGG 
DDC_exon 7_REV ACGAGGAAGGTTTGCTAAATTC 
DDC_exon 8_FOR AAGAAGGTGCTCAGACAGGG 
DDC_exon 8_REV TGAAGGGAGAGGTCAATAACAG 
DDC_exon 9_FOR ACCACTGTGGATTAGTTGTGCC 
DDC_exon 9_REV TTCTTTCACTGTCACCTCGGAC 
GBA_PCR_fragment 1(ex.1-4)_FOR CCTAAAGTTGTCACCCATAC 
GBA_PCR_fragment 1(ex.1-4)_REV AGCAGACCTACCCTACAGTTT 
GBA_PCR_fragment 2(ex.5-7)_FOR GACCTCAAATGATATACCTG 
GBA_PCR_fragment 2(ex.5-7)_REV AGTTTGGGAGCCAGTCATTT 
GBA_PCR_fragment 3 (ex.8-11)_REV ACCACCTAGAGGGGAAAGTG 
GBA_PCR_fragment 3(ex.8-11)_FOR TGTGTGCAAGGTCCAGGATCAG 
GBA_sequencing_exon1_FOR CTGTGTCATGTGACGCTCCT 
GBA_sequencing_exon1_REV CAGTGCCAGGATTCCAGAAG 
GBA_sequencing_exon10-11_FOR 5-GGGTCCGTGGGTGGGT 
  326 
GBA_sequencing_exon10-11_REV 5-TGCTGTGCCCTCTTTAGTCA 
GBA_sequencing_exon2_FOR 5-CCTGCCCAGGAGAGTAGTTG 
GBA_sequencing_exon2_REV 5-CTCTGTGCTACCTCCCCACT 
GBA_sequencing_exon3_FOR 5-CAAGGGGTGAGGAATTTTGA 
GBA_sequencing_exon3_REV 5-TATCAGTACCCAGCGGGAAA 
GBA_sequencing_exon4_FOR   
GBA_sequencing_exon4_REV 5-GACAGAATGGGCAGAGTGAGA 
GBA_sequencing_exon5_FOR 5-CAGGAGCCCAAGTTCCC 
GBA_sequencing_exon5_REV 5-TGTCTGTACAAGCAGACCTACCC 
GBA_sequencing_exon6_FOR 5-GCTGAACCGGATGCACTG 
GBA_sequencing_exon6_REV 5-GCTAAATGGGAGGCCAGTC 
GBA_sequencing_exon7_FOR 5-ACACCCAGCTGGTCTGGTC 
GBA_sequencing_exon7_REV 5-TGGATGCTGGATTTGAAGGT 
GBA_sequencing_exon8_FOR   
GBA_sequencing_exon8_REV 5-CTTCTGTCAGTCTTTGGTGAAA 
GBA_sequencing_exon9_FOR 5-CCCACATGTGACCCTTACCT 
GBA_sequencing_exon9_REV 5-TGTAGGAGATGATAGGCCTGGT 
GCH1_exon 1_FOR CCGGGCCATAAAAAGGAG 
GCH1_exon 1_REV CGCCAAAAGTGAGGCAACTC 
GCH1_exon 2_FOR CTTTCCTCCCTCCGTTCTCC 
GCH1_exon 2_REV ACCTGAGATATCAGCAATTGGCAGC 
GCH1_exon 3_FOR AGATGTTTTCAAGGTAATACATTGTCG 
GCH1_exon 3_REV TAGATTCTCAGCAGATGAGGGCAG 
GCH1_exon 4_FOR GTCCTTTTTGTTTTATGAGGAAGGC 
GCH1_exon 4_REV GGTGATGCACTCTTATAATCTCAGC 
GCH1_exon 5_FOR CTCTGTGGCCCAGTCAGC 
GCH1_exon 5_REV AGGCTCAGGGATGGAAATCT 
GCH1_exon 6_FOR CATTTGTGTAAGAAGGGATATTTCG 
GCH1_exon 6_REV AGTGACAAGGAATAAAGTTCACATC 
KCTD17_exon 1_FOR AGGCGCGGACTACAGCTC 
KCTD17_exon 1_REV CCACGGCAATGGGTACATC 
KCTD17_exon 2_FOR TCTCCCTCCACTCTCCTTC 
KCTD17_exon 2_REV TCCTGGTTGTCCAAATGG 
KCTD17_exon 3_FOR GGAGGGAACAAGAGGAGAATG 
KCTD17_exon 3_REV TCCCAACCTCCTCTGCTTC 
KCTD17_exon 4_FOR TCTTCTTTGGGTATGTTGCG 
KCTD17_exon 4_REV TGGTCAGAGGCTAGGAGGTC 
KCTD17_exon 5_FOR GAGGTCTGTCGTATCCTGCC 
KCTD17_exon 5_REV AGAGGTGGAGGGATGGTG 
KCTD17_exon 6_FOR CTTTCACCTTGCCTGAGACC 
KCTD17_exon 6_REV AGGCAAGTGGCTGAGCTAAC 
KCTD17_exon 7_FOR CAGGGTTAGCTCAGCCACTT 
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KCTD17_exon 7_REV AGGCAGGGTGCAGATGAGAT 
KCTD17_exon 8_FOR TCTGTGCCCACTAACCCTG 
KCTD17_exon 8_REV TCAAGAGATGAGCACCCTCC 
KCTD17_exon 9_FOR CACCCGTCAATCTCCTCTC 
KCTD17_exon 9_REV AGGCAGGAGTAAGTCACAGC 
LRRK2_exon41_FOR AGGGACAAAGTGAGCACAGAA 
LRRK2_exon41_REV CACATCTGAGGTCAGTGGTTATC 
NKX2-1_exon 1_FOR GGCAGAAGAGAGGCAGACAG 
NKX2-1_exon 1_REV CGGACAGGTCTTTAGGAG 
NKX2-1_exon 2_FOR   CGGCGTTAAGGTAACACC 
NKX2-1_exon 2_REV AGTGCCTGTTCTTGGACC 
NKX2-1_exon 3_1_FOR  GCTAGGCTGCCTGGGTCA  
NKX2-1_exon 3_1_REV CGCTGTCCTGCTGCAGTT  
NKX2-1_exon 3_2_FOR  GTTCCAGAACCACCGCTACA 
NKX2-1_exon 3_2_REV GTTTGCCGTCTTTCACCAG 
NKX2-1_exon 3_3_FOR  CAACAGGCTCAGCAGCAGT 
NKX2-1_exon 3_3_REV GGTGGATGGTGGTCTGTGT 
PARK2_exon1_FOR GAGGCCTGGAGGATTTAACC 
PARK2_exon1_REV GCCCCGTCATTGACAGTT 
PARK2_exon10_FOR TGTTATTGCCAAATGCAACC 
PARK2_exon10_REV GGAACTCTCCATGACCTCCAG 
PARK2_exon11_FOR ACAGGGAACATAAACTCTGATCC 
PARK2_exon11_REV CAACACACCAGGCACCTTCAGA 
PARK2_exon12_FOR GTTTGGGAATGCGTGTTTT 
PARK2_exon12_REV AGAATTAGAAAATGAAGGTAGACA 
PARK2_exon2_FOR ATGTTGCTATCACCATTTAAGGG 
PARK2_exon2_REV AGATTGGCAGCGCAGGCGGCATG 
PARK2_exon3_FOR TCTCGCATTTCATGTTTGACA 
PARK2_exon3_REV TAAATATGCACCCGGTGAGG 
PARK2_exon4_FOR ACAAGCTTTTAAAGAGTTTCTTGT 
PARK2_exon4_REV AGGCAATGTGTTAGTACACA 
PARK2_exon5_FOR TGGAAACATGTCTTAAGGAGTACA 
PARK2_exon5_REV TTCCTGGCAAACAGTGAAGA 
PARK2_exon6_FOR AGAGATTGTTTACTGTGGAAACA 
PARK2_exon6_REV GTCCGTGGAGGGAAGTGAC 
PARK2_exon7_FOR TGCCTTTCCACACTGACAGGTACT 
PARK2_exon7_REV TCTGTTCTTCATTAGCATTAGAGA 
PARK2_exon8_FOR CAACACTGGCAGTTGATAGTCAT 
PARK2_exon8_REV GGAGCCCAAACTGTCTCATT 
PARK2_exon9_FOR TGCAGTCAGTTTGAAAGCTC 
PARK2_exon9_REV AATATAATCCCAGCCCATGTGCA 
PDE10A_exon1_FOR GTCCCCACCAGCAGTAGTCA 
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PDE10A_exon1_REV CTCCTGCCCCTCCAGAGAA 
PDE10A_exon10_FOR TGCCAAAGCAGAAAAATCAA 
PDE10A_exon10_REV GGTGAATTCCTAAGCCACCA 
PDE10A_exon11_FOR CCAACCAATTAGAGTATAGGACAGC 
PDE10A_exon11_REV TGCAATGTCATTCCCAGAAG 
PDE10A_exon12_FOR CACGCATTTAAGTAAAACAGTGC 
PDE10A_exon12_REV AACTGAATTGGGACGTGGAG 
PDE10A_exon13_FOR TGCAAAGATTGAGGGGAGAT 
PDE10A_exon13_REV CCTTCCAGGGCATTTTATGA 
PDE10A_exon14_FOR TCATGTCTGCACATCCCAGT 
PDE10A_exon14_REV AAGCAGACAATGGCAACACA 
PDE10A_exon15_FOR TGGCTAAGAAGGCAGGAAAA 
PDE10A_exon15_REV CAAACAAAGATCGTGGTGAGG 
PDE10A_exon16_FOR GGATTCAGTCAGGGTGGAAA 
PDE10A_exon16_REV CCATGTCATCAATGTGCTCCT 
PDE10A_exon17_FOR CCAAGATTCCTAAGGGTTTGC 
PDE10A_exon17_REV GCCATAATGATCTTCCTTTTCC 
PDE10A_exon18_FOR CCAAAACGCAGTTTTCGTTA 
PDE10A_exon18_REV TGCCAGCAATCTTGTCAAAC 
PDE10A_exon19_FOR TGTCCTGGCTGTCACTTCTG 
PDE10A_exon19_REV TGACTCACCACAGTTCTCTGAAA 
PDE10A_exon2_FOR AAGCAGTAGCTTCCCCTTCC 
PDE10A_exon2_REV TTAGTCACGGATCTTTCTTTTGT 
PDE10A_exon20_FOR TTGGGTTAACAACCACAAACA 
PDE10A_exon20_REV TCTGCCTGGAATAACCCATT 
PDE10A_exon21_FOR GGCCTCAGAAACAGAACAGTC 
PDE10A_exon21_REV AACCAAAGGGGAGAAGTCGT 
PDE10A_exon22_FOR GTGCCACAGGACTGTTTGGT 
PDE10A_exon22_REV TGGAAAAGTACCCCTTCTGG 
PDE10A_exon3_FOR AAGAGGAAGCATTGCAAAAA 
PDE10A_exon3_REV CCTTCAATTTGCACCCTCTC 
PDE10A_exon4_FOR CATGTGCTATAAAAGCATAATGAATAA 
PDE10A_exon4_REV TTTTAGGTTTGACTCACCTCTGG 
PDE10A_exon5_FOR GACTCACATCTGCCTCTCACC 
PDE10A_exon5_REV ATGCCTAAATGTTGCCATGT 
PDE10A_exon6_FOR ATCATGGCAAAGCACCTTTC 
PDE10A_exon6_REV TGGGTAAAGGGAATTTTCTGA 
PDE10A_exon7_FOR CAAGTATCATGGCAATTTCTGA 
PDE10A_exon7_REV TTTCCTCTCTAAACAGAAACAGGT 
PDE10A_exon8_FOR TCCTTTGTTGAGATGACTACAAGT 
PDE10A_exon8_REV GGCATTGGGTGACTTAACCT 
PDE10A_exon9_FOR CCCAAGTGATTGTGTTAGGC 
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PDE10A_exon9_REV TGGTCTATTTCTGCCACAGG 
SPR_exon 1_FOR ATCCCAAGGGAACCAGCAC 
SPR_exon 1_REV TCTAGGCGTCCTATCTGACCC 
SPR_exon 2_FOR   GATATCTGGAGGAACTTGGGAG 
SPR_exon 2_REV TGTGGGTTGTTTCCTGGAG 
SPR_exon 3_FOR  CAGGGACCTGAAACCTTCTG 
SPR_exon 3_REV TCTATGTGTAAGGCAGGACTGC 
TH_exon 1_FOR TTCCACGGACGAGCCCTTTC 
TH_exon 1_REV TTGCATGGACCCTGAGCCTG 
TH_exon 11_12_FOR CTGCCTCTCCCCATCCTT 
TH_exon 11_12_REV AGGTCCAGGCCTCAGTTTC 
TH_exon 13_FOR TCTACCCAAGGAACCCAC 
TH_exon 13_REV CTCAAGGCCAGAAGGAAG 
TH_exon 14_FOR GAGCTCTGAGCCACTGTGAAG 
TH_exon 14_REV TCACCACAGGCAGCACAAC 
TH_exon 2_FOR CCTTGATTGAAATGTGGTG 
TH_exon 2_REV GCTGAACTCCCAAGAAGG 
TH_exon 3_FOR TGCCTCTGTGTGCCATCAG 
TH_exon 3_REV AGGAACTCAGCCCACACAGC 
TH_exon 4_FOR GAACGGGATCTGTGTGCTG 
TH_exon 4_REV ACGTGGTCACTGTAGGGTCC 
TH_exon 5_6_FOR TCAAGGTGGGTGACACAG 
TH_exon 5_6_REV TGACAAGATGGGTCCTCC 
TH_exon 7_FOR ACCTGTGCCCAGTGAAGCTC 
TH_exon 7_REV TCACACGCCAGGATTCCAG 
TH_exon 8_9_10_FOR AGGCACCCACAGTTCAGGAG 
TH_exon 8_9_10_REV GAGCAGGCAGCACACTTCAC 
 
 
